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As a result of an aging UK population and attendant multi-morbidity, an increasing number 
of medicines are being prescribed for patients, leading to increased risk of unintended side 
effects. The aim of this study was to explore experiences and opinions of patients and the 
public in identifying and managing side effects from medicines. It also sought to develop a 
novel causality scale for use by patients to assess suspected side effects. 
A mixed methods approach with four phases was selected. In Phase One surveys were 
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side effects, to investigate the value of patient reports to pharmacovigilance and to 
compare experiences of Yellow Card reporters to the public. 
This study provided novel insights into the strategies employed by patients to identify and 
manage their side effects. Patients seeking side effect information used a variety of 
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groups, with non-adherence being more prevalent among Yellow Card reporters. Most on-
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Abbreviation Expansion Definition 
ADR Adverse drug reaction  An ADR is a reaction to a drug, or a 
combination of drugs, which is 
harmful and unintended and that 
occurs at a dose normally used for 
prophylaxis, diagnosis or treatment 
ADRWG Committee on safety of 
medicines working group 
An independent advisory committee 
which advised the UK Licensing 
Authority on the quality, efficacy 
and safety of medicines 
CHM Commission on Human 
Medicines  
Advisory body to UK ministers on 




Cancer Information Service Provides up-to-date information on 
cancer incidence, mortality and 
survival rates in UK 
CSM Common Sense Model Leventhal's common sense model 
(CSM) is used to understand 
people's responses to illness. The 
model suggests that illness 
perceptions can influence coping 
strategies and health outcomes 
HCP Healthcare Professional Individual who provides preventive, 
curative or rehabilitative health care 
to people, families or communities 
ICSRs 
 
Individual case safety reports Reports of adverse events for 
individual patients 
IPA Interpretative Phenomenological 
Approach  
An approach to qualitative research 
with an idiographic focus 
MBSS  Miller Behavioral Style Scale 
 
A measure of coping styles that can 
be used in clinical settings 
MeSH Medical Subject Headings (U.S.) National Library of 
Medicine's controlled vocabulary 






Medicine overuse headache Rebound headaches which occur 
when analgesics are overused by 
people to relieve headaches 
NHS  
 
National Health Service Publicly funded health care 
service in the UK 
 
OTC  Over the counter 
 
Medicine available to a consumer 
without a prescription 
Patient YC Patient reporter to YC scheme 
 
The patient who experienced and 
reported the suspected ADR or their 
representative who made the report 
on his or her behalf 
PIL Patient information leaflet  
 
Leaflet containing comprehensive 
information that is accessible to and 
understandable so that patients can 
use their medicine safely 
and appropriately 
PV Pharmacovigilance Pharmacovigilance is the science 
and activities relating to the 
detection, assessment, 
understanding and prevention of 




QDL Quality of Daily Life 
 
An assessment of the quality and 
well-being of an individual's daily 
life 
SE Side Effects  
 
An unintended effect, as a result of 
using medicines which could be 
therapeutic or adverse 
SECope  
 
Side Effect(s) Coping 
Questionnaire 
 
A measure of coping with HIV 
treatment side effects based on the 
Stress and Coping theory 
SO Superordinate 
 
Classification of themes that 
represents a higher order or category  
SPC Summary of Product 
Characteristics 
 
Produced by pharmaceutical 
companies it explains how to use 
and prescribe a medicine used by 
doctors, nurses and pharmacists 
SSRs Spontaneous reporting systems 
 
Established to gather reports of 
suspected ADRs and managed by 
national and international regulatory 
bodies, drug manufacturers and drug 
monitoring programmes 
UMC Uppsala Monitoring Centre (Field 
name for WHO-UMC) 
Collects and assesses information 
about the benefits and risks of 
medicines IURPPHPEHUV¶
pharmacovigilance centres 
WHO World Health Organisation 
 
UN agency dealing with 
international public health 
WHO-PIDM World Health Organisation the 
Programme for International 
Drug Monitoring 
 
Collects and assesses information 





World Health Organization 
Collaborating Centre for 
International Drug Monitoring.  
 
UMC works by collecting, assessing 
and communicating information 
from member countries' national 
pharmacovigilance centres in regard 
to the benefits, harm, effectiveness 
and risks of medicines 
YC Yellow card report 
 
Report made to the MHRA by 
HCPs or patients about problems 
with medicines or medical devices 
YCS Yellow Card Scheme 
 
UK system for collecting 





























1.1 General background  
6LGHHIIHFWVIURPPHGLFLQHVFDQKDYHDFRQVLGHUDEOHLPSDFWRQSHRSOHV¶GDLO\
lives. This impact can be significant and extend into many areas with physical, 
economic, social and/or psychological effects (Anderson et al., 2011; Butt et al., 
2011; De Langen et al., 2008; Dibonaventura et al., 2012;  Krska et al., 2011; Shet 
et al., 2014). Medicines are frequently the most cost effective and least invasive 
medical treatments available to individuals. However, an increasingly aging 
population and attendant multi-morbidity in combination with numerous clinical 
guidelines mean there are an increasing number of medicines being prescribed for 
people by health professionals today. This has led to an increase in the risk of 
unintended harmful effects or adverse drug reactions (ADRs) in the ambulatory 
care setting. Research into these adverse reactions identified risk factors such as 
age, complex medical history and low income status with older patients more 
likely to experience severe ADRs (Wu et al., 2003). These risk factors add to the 
frequent morbidity and mortality associated with ADRs (Mugosa et al., 2016). 
Health researchers and healthcare organisations worldwide have realised that 
ADRs are a public health issue which requires strategic attention and effective 
interventions.   
 
1.2 Adverse Drug Reactions (ADRs)  
1.2.1 Definition and characteristics 
The definition of an adverse drug reaction (ADR) used by the World Health Organisation 
(WHO) is ³DUesponse to a drug that is noxious and unintended and occurs at doses 
normally used in man for the prophylaxis, diagnosis or therapy of disease, or for 
PRGLILFDWLRQRISK\VLRORJLFDOIXQFWLRQ´:+2 An adverse reaction is therefore a 
damaging and unintended response to a medicine. ADRs can be further described in the 
following categories: Augmented effects; Bizarre effects; Continuous effects; Delayed 
effects or End of Use effects (Medicines and Healthcare Products Regulatory Agency, 








Table 1.1: Description of ADR categories (Table adapted from Edwards & Aronson, 2000) 
 
CATEGORIES DESCRIPTION 
A ± Augmented effects $XJPHQWDWLRQRIWKHGUXJ¶VSKDUPDFRG\QDPLFSroperties e.g. 
sedation with muscle-relaxant 
B ± Bizarre effects (IIHFWVXQUHODWHGWRGUXJ¶VSKDUPDFRG\QDPLFSURSHUWLHVHJ
allergic reactions 
 
C ± Continuous effects Effects that persist in the long term e.g. pharmacological 
dependency/ rebound effect 
 
D ± Delayed effects Effects occur after drug discontinuation e.g. cancer/ birth 
defects/impaired fertility 
E ±End of Use effects Effects associated with drug withdrawal e.g. insomnia/anxiety 
 
 
ADRs can also be classified as expected reactions - listed in the Summary of the Product 
Characteristics (SPC) which is produced by manufacturers as part of the licensing process 
for every authorised medicinal product on the market in the UK - or unexpected reactions 
(Montastruc et al., 2006).  ADRs encompass all types of medicine induced effects that are 
undesired or unpredicted. These effects are sometimes referred to as side effects (SE) and 
frequently the terms ADRs and SE are used interchangeably in patient information and 
other contexts. However, there are a number of differences between SE and ADRs:  
 SE can be described as a category of ADRs (category A: Augmented ADRs)  
 SE are often predictable whereas it is not possible to predict ADRs  
 SE occur more frequently in patients than ADRs 
 SE can be positive/beneficial but ADRs are always negative/detrimental 
 SE have high morbidity rates and low mortality rates compared to ADRs 
 SE has strong pharmacological foundation while less is known of the 
pharmacological mechanisms underlying ADRs 
Previous ADR research used inclusive wording to encourage reporting of minor effects and 
defined ADRs as unexpected/unwanted medicine related effects which can sometimes be 
FDOOHGµVLGHHIIHFWV¶'H:LWW	6RURIPDQ; Edwards & Aronson, 2000). Side effects 
can therefore be an imprecise/ambiguous term but was constructed to include beneficial as 
well as harmful therapeutic outcomes. Generally, SE are unintended outcomes that occur at 
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normal dose; go beyond the desired therapeutic effect; can be positive or negative and can 
be linked to the pharmacological properties of the medicine (Edwards & Aronson, 2000). 
 
1.2.2 Prevalence rates 
Research conducted into the frequency of ADRs has varied across studies with prevalence 
rates that range from 0.15% - 30% (Kongkaew et al., 2008). This wide variation can be 
explained in part by insufficient recognition of ADRs by healthcare professionals (HCPs). 
In addition ADR studies have employed different methodologies which could also have led 
to variation in their results. Overall health research indicates that ADRs when combined 
with numerous risk factors can be a common cause of morbidity and mortality (Mugosa et 
al., 2016). ADRs can frequently result in hospital admission particularly in older patients 
(Wu et al 2003). Numerous studies indicate that between 5% and 7% of hospital 
admissions are due to an ADR. In addition, 10% to 20% of all hospital in-patients 
experience an ADR during their stay in hospital (Alhawassi et al., 2014; Dormann et al., 
2003). Up to 6.5% of acute hospital admissions in the UK were due to ADRs (Pirmohamed 
et al., 2004). While the prevalence rates of ADRs have varied across research studies it is 
suggested that these hospital figures may also reflect the rates and severity of ADRs in 
primary care (Pirmohamed et al., 2004). In addition, it has been calculated that 
approximately 50% of ADRs could be prevented (Mugosa et al., 2016). As well as 
statistical data, health research has also provided additional information on the impact of 
ADRs at individual and social levels. 
 
1.3 Impact of ADRs 
Research has established that ADRs can have a significant negative impact on 
healthcare costs, public health, patient safety, as well as on SHRSOHV¶GDLO\OLYHV 
(Anderson et al., 2011; Butt et al., 2011; De Langen et al., 2008; Dibonaventura et 
al., 2012; Krska et al., 2011; Shet et al., 2014; WHO, 2014).  
 
1.3.1 Economic costs to the NHS 
ADRs have a significant impact on public health, placing significant economic 
burden on stretched healthcare services (Avery et al., 2011). Direct economic 
costs of ADRs to the National Health Service (NHS) in the UK was estimated at 
over £450 million annually over ten years ago (Pirmohamed et al., 2004). In 2007 
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the National Patient Safety Agency estimated that ADRs resulted in £770 million 
in costs to the NHS therefore the economic burden is likely to be greater today 
(Berwick review, 2013). The financial burdens of ADRs on the NHS can be 
considerable with increased costs in caring for patients, delays in treatment as 
well as prolonged hospital stays with one in seven hospital inpatients 
experiencing an ADR (Avery et al., 2011).  
 
1.3.2 Patient costs 
ADRs also have notable impact on patient safety in outpatient care settings often 
producing severe symptoms which may require hospitalisation and/or expensive 
visits to Accident & Emergency departments (Wu et al., 2003). ADRs have been 
identified as the fifth most common cause of death in developed countries 
(Edwards, 2012). Health research has established that 6.7% of drug reactions can 
be described as serious ADRs which prove fatal in 0.32% of hospital patients 
(Lazarou et al., 1998; Teo et al., 2016). Even if a severe ADR episode is resolved 
successfully patients can experience numerous long term complications (Teo et al 
2016). Such complications can be multidimensional in nature often with both 
physical and psychological elements. 
 
1.3.3 Psychological and social costs 
Dealing with the effects of ADRs can therefore prove burdensome to patients and 
to healthcare systems. However, ADRs can also have profound social costs 
including loss of productivity; loss of confidence in healthcare systems or reduced 
quality of life because of long-term consequences and anxiety (Avery et al., 2011; 
WHO, 2014; Wu et al., 2003). The impact of ADRs on the quality of peopleV¶
daily lives is a growing area of concern for HCPs. Individuals that experience an 
ADR can develop considerable anxiety and suffer psychological distress in their 
daily life (Reid, 2015). This depletion in their quality of life can have significant 
impact on health behaviours such as reduced adherence to long term treatments 
(Piparva et al., 2011).  
It is clear therefore that there are considerable costs both direct and indirect 
associated with ADRs. This suggests that there is an urgent need for effective 
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health interventions which reduce the impact of ADRs.  It also provides support 
for the argument that continued health research is required which looks at how 




The importance of researching and ensuring awareness of ADRs from the 
perspectives of drug development (manufacturers and licencing authorities) and 
actual use (prescribers and patients) has led to the development of a medical 
discipline known as pharmacovigilance (Singh et al., 2012). Pharmacovigilance 
(PV) is a description of the processes, activities and systems involved in detecting, 
understanding, assessing and preventing ADRs (WHO, 2014). Although all new 
drugs must undergo testing in clinical trials before being made available for use, 
processes for monitoring ADRs after licensing are essential for patient safety as 
most ADRs are not detected through clinical trials. These trials have several 
issues which can compromise ADR detection - such as limited study participants, 
relatively short study duration and selective recruitment of patients which can 
result in narrow heterogeneity amongst the trial participants (Berlin et al., 2008; 
Sultana et al., 2013).  
The devastating effects of the thalidomide disaster in the late 1950s and early 1960s 
established the urgent necessity for national systems which ensured drug safety by 
introducing licensing and monitoring systems. In the UK, this was initially as the Dunlop 
Committee, which became the Committee for the Safety of Medicines and ultimately was 
subsumed into the Medicines and Healthcare products Regulatory Agency (MHRA). An 
international system for monitoring ADRs was established in the 1970s by the WHO - the 
Programme for International Drug Monitoring (PIDM) and the WHO Collaborating Centre 
for International Drug Monitoring was set up in Uppsala, Sweden. There are currently 123 
countries and 28 associate members in the WHO PIDM. These member states submit ADR 
reports ± Individual Case Safety Reports ± to the WHO global database - VigiBaseTM. This 
database is managed by the Uppsala Monitoring Centre (UMC) with over 14 million 
reports of ADRs submitted by member countries since 1968. During 2016 a total of 
1,821,051 reports were entered into the database with 1,059,738 reports entered from Jan 
1st to July 2nd 2017 (³9LJLEDVH´GDWDEDVHQG). 
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This large volume of data facilitates the systematic monitoring of ADRs and assists in 
identifying potential medicinal safety issues. The primary purpose of PV is to contribute to 
patient care and patient safety in relation to medicines. It also seeks to provide reliable 
information for the effective assessment of the risk-benefit profile of medicines as well as 
supporting public health programmes (WHO, 2014).  Monitoring of ADRs can be 
conducted in a variety of ways ± spontaneous reports, prescription event monitoring; 
cohort studies; case reports/series; post marketing surveillance; and investigation of 
electronic data sets (Avery et al., 2011; Singh et al., 2012). 
 
 1.4.1 National system for pharmacovigilance in the UK  
National systems for the spontaneous reporting of adverse reactions have common 
terminologies and classifications and agreed methods of collecting, storing and analysing 
the data. The United Kingdom (UK) was a founding member of the WHO Programme in 
the 1960s and was instrumental in developing the spontaneous reporting system for ADRs. 
In the UK, this is managed through the Yellow Card Scheme (YCS). This scheme 
encourages spontaneous submission of reports of suspected ADRs to the MHRA (and its 
predecessor committees). If a particular symptom occurs in higher numbers than expected 
with a particular drug (drug-reaction pair) this can be investigated further, using case-
control studies or cohort studies. Confirmed ADRs may require changes to the SPC or 
Patient Information Leaflet (PIL) of a product, changes to the use of a product or even 
withdrawal of a product from the market in a country.  
 
1.4.2 Causality assessment of ADRs 
A key element of PV is causality assessment. This is defined by the WHO-80&DV³Whe 
evaluation of the likelihood that a medicine was the causative agent of an observed adverse 
reaction´. Causality assessment is usually carried out on the reports received by regulatory 
authorities E\H[SHUWVWUDLQHGLQ39,QWHJUDOWRDQ\LQYHVWLJDWLRQRISDWLHQWV¶H[SHULHQFHRI
ADRs are the cognitive processes employed by them in identifying ADRs. Models of 
health behaviours, such as /HYHQWKDO¶VSelf-Regulation Model of Illness/Common Sense 
Model of Illness, can provide an effective framework to investigate the cognitive processes 
used by individuals in assessing the causality of ADRs (Johnson & Folkman, 2004; De 
6PHGWHWDO3DWLHQWV¶DZDUHQHVVRI$'5VKDVEHHQLQYHVWLJDWHGto determine if a 
specific ADR prototype/model of cognition exists. It was found that patients displayed 
knowledge and accuracy in identifying ADR symptoms. The data also suggested that 
patients may use a prototype/model of cognition to assist in identifying ADRs (DeWitt & 
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Sorofman, 1999). Specific research has also been conducted which investigates the specific 
VWHSVSDWLHQWV¶WDNHLQLGHQWLI\LQJGUXJUHDFWLRQV7KHODUJHstudy of patient reports to the 
YCS conducted in 2011 found that both the timing of events and information sources were 
key factors influencing reSRUWHUV¶LGHQWLILFDWLRQRI$'5VAvery et al., 2011).  Within 
pharmacovigilance many methods for causality assessment of ADRs have been developed 
- with as many as 34 different types being available to experts (Agbabiaka, et al., 2008). 
Each of these methods has its own inherent strengths and weaknesses, however there is 
agreement that there is considerable lack of consistency across current causality 
assessments. These numerous methods can be divided into four categories: global 
introspection (GI); Bayesian approaches, focussed scales and algorithms. 
 
1.4.2.1 Global introspection (GI) 
GI, also known as expert judgement, utilises previous knowledge and experience in the 
field to make assessments of causality. However, this is not a standardised research tool 
and the structures used to generate these judgements can vary widely. Some methods use a 
single evaluator while others use expert groups or compare assessments across expert and 
non-expert groups. Thus, high levels of disagreements between experts often occur. 
 
1.4.2.2 Bayesian approaches 
Bayesian approaches work to transform previous estimations of probability of causality as 
increasing amounts of data become available. The previous estimation is calculated from 
epidemiological information while the later probability estimation uses both this 
background information and individual case evidence to estimate causality. Computer 
programmes which utilise the Bayesian Adverse Reactions Diagnostic Instrument 
%$5',KDYHKHOSHGWRLQFUHDVHWKLVPHWKRG¶VUHOLDELOLW\+RZHYHUWKLVPHWKRGKDVLWV
limitations as it requires significant investment in time and resources.   
 
1.4.2.3 Focused scales 
Further efforts to develop logical/step by step assessments have resulted in 
IRFXVHGDVVHVVPHQWVIRUH[DPSOH6WULFNHU¶VGHFLVLRQWUHHIRUVXVSHFWHGOLYHU
injury events (Stricker, 1992).  Collaboration amongst experts in the field of 
DGYHUVHHYHQWVFRQVHQVXVOHGWRWKHGHYHORSPHQWRIDQHZVFDOHLQWKH¶V- the 
Roussel Uclaf Causality Assessment Method (RUCAM) (Benichou et al., 1993; 
Danan & Benichou., 1993). This is used for disease states such as liver and 
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dermatological injuries. This method gives weighted scores to causality criteria 
and is easy to use. However, it is focused on specific organs and would require 
additional work on classifications and criteria if it were to be applied in other 
medical areas. The Clinical Diagnostic Scale is another focused scale which 
evaluates suspected hepatotoxic drug reactions (Maria & Victorino, 1997). It is 




Algorithms are structured and standardised assessment methods used to identify potential 
ADRs. They are based on criteria such as time to ADR onset, previous medical history, 
previous adverse reaction history and re-challenge. Most algorithms take the form of 
questionnaires that allow sufficient information to be gathered to assess the probability of a 
suspected ADR. Various algorithms have been developed to address problems of validity 
and reliability as well as bias.  
These include the Karch and Lasagna decision-table approach which uses three tables to (i) 
identify potential drug reactions, (ii) assess the certainty of the link between the drug and 
the event and (iii) evaluate the underlying causes of the adverse events (Karch and Lasagna 
1977). This diagnostic tool is considered easy to use, however there are issues concerning 
its reliability.  It cannot identify new/novel ADRs to a drug that has no history of ADRs 
and this tool requires a high level of subjective judgements which can result in bias 
(García-Cortéz et al., 2011).    
Another decision table was designed by Blanc et al which assessed the nature of the 
relationship between the drug and the adverse event. It considers three factors: the role of 
underlying disease(s), time onset and response pattern (Blanc et al., 1979). However, this 
assessment method also displayed poor internal validity and variation between evaluators 
(Agbabiaka et al., 2008). 
Kramer developed the Karch and Lasagna table into a new set of criteria for assessing 
ADRs (Kramer et al., 1979). The algorithm is made up of six decision tables with a scoring 
system for each axis. It is used to assess an adverse event that occurs after administration 
of a single drug. If a patient receives multiple drugs before experiencing an adverse event, 
then each potential drug is assessed separately (Agbabiaka et al., 2008). This method is 
useful therefore when more than one drug is suspected in the adverse event.  
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Naranjo developed an instrument for assessing ADR probability in numerous clinical 
settings (Naranjo et al., 1981). It is a probability scale of ten questions that can be 
answered as follows³\HV´³QR´³XQNQRZQ´RU³LQDSSOLFDEOH´7KH1DUDQMRVFDOHFDQQRW
address potential adverse reactions that may result from interactions between drugs. It is 
designed to assess the probability of an ADR associated with one drug only. However, it is 
simple to use, not time-consuming and can be applied widely across clinical settings 
(García-Cortéz et al., 2011).    
In general, standardised methods such as algorithms offer greater reliability than GI 
methods. There is high inter-rater agreement in the use of algorithms within the 
pharmacovigilance community, but as a clinical instrument they can lack flexibility. 
Available data which is not required for assessment has no role within this methodology ±
only a finite amount of information can be considered. It is thought that failure to adopt 
consistent operational criteria as well as the role of confounding variables may account for 
the inconsistency and lack of agreement across assessment scales. Overall there is no 
method universally accepted for causality assessment of ADRs. 
 
1.4.3 Yellow Card reports 
As mentioned spontaneous reporting of ADRs within the UK is through the Yellow Card 
Scheme (YCS). When first put in place LQWKH¶VRQO\GRFWRUVFRXOGUHSRUW$'5VWRWKH
Scheme. In 1997, after much evidence had been provided to demonstrate their ability to 
identify and report accurately, this reporting system was extended to pharmacists and in 2002 
it was further extended to allow nurses, health visitors and midwives to report suspected 
ADRs.  
 
1.4.4 Problems with spontaneous reporting of ADRs 
Spontaneous reporting of ADRs is an essential component of PV and is particularly 
important in detecting new, rare and/or serious ADRs (Giezen et al., 2009). Much of modern 
pharmacovigilance practice focuses on individual case safety reports (ICSRs) which are 
supplied by HCPs to national regulatory authorities or through pharmaceutical companies 
(Hazell et al, 2013). ADR reports by HCPs are a key requirement of effective PV practice 
and have created a considerable body of data held at the VigiBaseTM database. However, 
research suggests that under-reporting is a significant problem within spontaneous 
reporting systems (SRSs). There is evidence of notable under-reporting of ADRs by HCPs 
to these systems. Research shows that mild or well-known ADRs are less likely to be 
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reported by HCPs while serious or even fatal ADRs are also under-reported (Hazell et al., 
2006). Explanations for under-reporting by HCPs include lack of clinical experience, poor 
knowledge of over the counter (OTC) medicines and problems identifying the causative 
drug in patients with multiple medicines (Hughes et al., 2002).  Recent research into 
patterns of ADR reports to VigiBase ± over a nine year period - established that there is 
significant variation in reporting rates across high and low income countries (Aagard et al., 
2012). A pattern was identified of highest reporting rates for ADRs in high-income 
countries with lowest reporting rates for low-income countries (Aagard et al., 2012).  
It has been calculated that only between 6-10% of ADRs are reported (Edwards, 2012; 
Elkalmi et al., 2013). A review of ADR reports in 2006 indicated there was significant 
under-reporting of ADRs to SRSs which included serious/severe reactions (Hazell et al., 
2006). A later review in 2009 of ADR reports identified some contributory factors linked 
to under-reporting by HCPs. These professionals feared they would seem ridiculous if they 
reported ADRs which were not proven but merely suspected. There was also a general lack 
of knowledge about the function of ADR reports amongst health professionals (Lopez-
Gonzalez et al., 2009). Research conducted in medical practices in Scotland showed that 
GPs may not record in full all the symptoms that patients reported to them 
(Jarernsiripornkul et al., 2002).  It has been proposed, however, that ADR reports by health 
professionals did not capture all the available information and did not fully reflect patient 
concerns (Edwards, 2012). Research suggested that a significant deficit existed within PV 
systems. An informative and useful source of additional data was being overlooked that of 
direct reporting by patients of ADRs.  
 
1.4.5 Direct patient reports of ADRs 
At this time, patient rights and equality were being promoted within healthcare 
organisations. Initially however, only a limited number of countries ± such as Australia and 
the US ± provided some opportunities for patients to report ADRs themselves within 
national pharmacovigilance systems.  As time progressed and health care policymakers 
focused on ADRs, patient reporting became part of pharmacovigilance systems in several 
countries including the USA, Canada, Australia, New Zealand. An awareness developed - 
supported by the research findings - which highlighted that patient participation could 
prove hugely beneficial to PV systems. In 2003 UK patients could submit a report via 
telephone to NHS Direct, but this reporting was not publicised or genuinely considered as 
a contribution to PV. The Committee on Safety of Medicines formed a working group in 
2004 on patient reporting of ADRs ± the ADRWG. This group was composed of diverse 
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members including patients, patient organisations, pharmacists, general practitioners 
(GPs), clinical pharmacologists and academics. Based on recommendations from the 
ADRWG a patient Yellow Card (YC) for use by the public was created and piloted in 
2005. This was available in electronic format on the MHRA website and a paper version 
Yellow Card was distributed to 4000 general practices. Over a period of nine months over 
650 YC patient reports were submitted to the MHRA. When these reports were evaluated 
by the MHRA, it was found that they provided detailed and potentially valuable 
descriptions of ADRs (Avery et al., 2011). Therefore, the scheme was extended later that 
year and included, as well as paper and on-line systems the opportunity to report by 
telephone. Analysis of the reports received in the first six months was conducted. This 
suggested that the patient reports focused on firmly established drugs and were less 
complete but were of similar standard to HCP reports (Ekins-Daukes et al., 2006). The 
number of reports have since increased and in 2016 67,029 patient/parent/carer reports 
were submitted to the MHRA (MHRA Annual report 2015/2016). The MHRA records, 
manages and analyses the YC reports and combines them with reports from healthcare 
professionals.  
Health research identified limitations and disadvantages of direct patient reporting within 
pharmacovigilance. As stated above, until recently only a limited number of countries had 
systems which provided opportunities for patient reports of ADRs. Over the years steps 
were taken to improve PV systems by facilitating patients in reporting their ADR 
experiences. Sufficient information was collected from countries with patient reporting 
systems to re-examine the potential benefits and limitations of patient reporting of ADRs. 
A key review was conducted in 2006 which considered the value of patient reports to PV 
systems world-wide. It examined published studies and patient reporting systems in six 
countries (Blenkinsopp et al, 2006). This review suggested that patient reports and +&3V¶ 
reports were similar in terms of quality. It found that patient reports identified possible new 
reactions thereby adding value to professional reports of ADRs (Blenkinsopp et al, 2006). 
It concluded that patient reporting could therefore complement HCP reports and contribute 
to SSRs. This indicated an attitudinal change from one where it was assumed that only 
health professionals could iGHQWLI\$'5VWRRQHZKHUHWKHSDWLHQW¶VH[SHULHQFHZDV
viewed as valuable and informative (Van Hunzel et al., 2012).   
,QRUGHUWRH[SORUHWKHSDWLHQW¶VH[SHULHQFHIXUWKHULWLVLPSRUWDQWWRXQGHUVWDQGSDWLHQWV¶





1.5 /HYHQWKDO¶VSelf-Regulation Model of Illness/Common Sense Model of 
Illness  
The central theory of health behaviours ± the biopsychosocial (BPS) model - was 
developed in the 1970s by G Engel.  This model views illness behaviours as a dynamic 
process between biological, psychological and sociocultural factors which interact to shape 
WKHSHUVRQ¶VUHVSRQVHWRSDLQLOOQHVV7Xrk & Flor, 1999). Factors such as beliefs, coping 
strategies, social support, past experiences, education and other aspects can significantly 
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Fig 1.1: Biopsychosocial model of health (Adapted from Natale-Pereira et al., 2011)   
 





















Research was also conducted in the 1970s into the effects of fear on health-related 
behaviours. Leventhal developed a hierarchical model to explain how an individual 
processes a health-related threat.  The original research identified the cognitive domains of 
illness representations through semi-structured interviews (Hale et al., 2007). The self-
regulation aspect of the model highlights individuals¶ attempts to maintain their health 
status equilibrium and/or return their health status to normality.  /HYHQWKDO¶V6HOI-
Regulatory Model (1987) is composed of three main cognitive constructs:  
 Representations ± representations of the health-related threat which interprets the 
experience through cognitive representations such as symptoms, social cues, 
consequences. 
 Coping strategies ± action planning such as avoidance, information seeking, 
seeking medical attention. 
 Appraisal - where the success or failure of coping strategies are assessed.  
(Hale et al., 2007) 
/HYHQWKDO¶V6HOI-Regulation model is also known as the Common Sense Model of self-
regulation (CSM). Overall this model VXJJHVWVWKDWFRJQLWLYHVFKHPDDQGDSDWLHQW¶VLOOQHVV
representations influence how the individual perceives/assesses the illness situation and 
their subsequent health behaviour (Cameron et al., 2003). Such illness representations can 
be divided into five domains: identity; timeline; cause; consequences and control. Each of 
these domains has perceptual and semantic information about an illness threat which can 





















Fig 1.2: Schematic representation of /HYDQWKDO¶V6HOI-regulation model/Common Sense 
model of self-regulation (CSM) 
 
Within the self-regulation model illness cognition is stored in memory in two different 
representations ± concrete and abstract. The illness representation of identity is therefore 
made up of an abstract label and concrete symptoms. There is pressure to connect abstract 
experience to labels known as the symmetry rule. This pressure to link is reciprocal in 
nature as people will seek out labels to explain their symptoms and seek symptoms to 
make sense of their illness/symptom labels (Hill et al., 2007). Research has provided 
support for the symmetry rule and found that patients linked labels and symptoms. Subjects 
in a study reported symptoms when informed that their blood pressure was very high 
(Easterling et al., 1989 as cited in Siegel et al., 2011; Bauman et al., 1989). Recent research 
ZLWKFDQFHUSDWLHQWVLGHQWLILHGFRJQLWLYHVFKHPDDQGSDWLHQWV¶H[SHFWDWLRQVRIVLGHHIIHFWV
as important factors in terms of treatment outcomes in these patients (Von Blackenburg et 
al., 2013). Within the context of the self-regulation model factors such as prior experiences 
with side effects and symptom amplification can lead to misinterpretation of symptoms as 
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side effects of medications. In general, negative events generate more physiological, 
affective, cognitive, and behavioural activity than neutral/positive events. Once the threat 
of a negative event has passed, it has been found that cognitive processes engage in 
counterbalancing activities as they seek to minimise, reverse or undo the initial responses 
to an adverse event. Research using the CSM has investigated the processes employed by 
patients to assess their somatic changes ± in terms of symptoms and daily functioning. The 
CSM stresses the central role that symptom interpretation plays in influencing health 
related coping behaviours. The theory has provided the framework for research into 
effective interventions in managing chronic illnesses such as psoriasis, rheumatoid arthritis 
and multiple sclerosis (Fortune et al., 2000; Scharloo et al., 1999; Vaughan et al., 2003). 
Studies have attempted to describe how patients link these somatic experiences to illness 
UHSUHVHQWDWLRQVDQGKRZWKHVHOLQNVWKHQLQIOXHQFHDQLQGLYLGXDO¶Vhealth outcomes such as 
self-management and care seeking (McAndrew et al., 2008). Researchers have suggested 
that the self-regulation model can also be used in other health-related areas such as ADRs 
(see Chapter Two: Literature Review). 
 
1.6 Sources of information about medicines 
Health research has found that patients require relevant information about their medicines 
with appropriate medicine information often leading to positive adherence and treatment 
outcomes (Nahri, 2007).  Information about medicine can be obtained from a variety of 
sources such as HCPs - particularly doctors and pharmacists. Other sources are PILs, 
pharmaceutical companies and drug regulatory authorities. Medicine information is also 
available from the print and broadcast media and medical books/guides as well as 
family/friends. The mass media which is designed to communicate with the general public 
is an important source of health information and can have a positive effect on public health 
(Moynihan et al., 2000). However, misgivings exist about the quality of coverage which 
medical matters receive. Previous research has identified issues such as inaccuracy and 
sensationalism (Myers, 1996; Schwarz et al., 1999). An abundance of medicine 
information also exists online. Patients often use the Internet to obtain information about 
medicines, however the sheer volume of such information available online can be 
overwhelming for patients (Lee et al., 2014). Reputable health-related UK websites such as 
electronic Medicines Compendium (eMC) and NHS Choices provide regulated up-to -date 
information on licensed medicines and healthcare information. Looking for health-related 
information was the fifth most common UK Internet activity in 2016 and has increased in 
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UK since 2007 by 33 percentage points to 51% in 2016 (Office for National Statistics, 
2016). Evidence-EDVHGNQRZOHGJHDERXWSDWLHQWV¶KHDOWKLQIRUPDWLRQUHquirements and the 
sources of information that patients use could be beneficial to patient-centred care in 
general. Reliable information about medicines could be presented in a structured 
VW\OHIRUPDWWKDWVDWLVILHVWKHSDWLHQWV¶KHDOWKLQIRUPDWLRQQHHGVClarke et al., 2016). 
5HVHDUFKLQWRSDWLHQWV¶KHDOWKinformation needs and sources is reviewed in the following 
chapter - Chapter Two: Literature Review. 
 
1.6.1 Information seeking models  
Models of information seeking were initially developed to address information problems in 
the fields of information science. Models were combined in the 1990s to create six general 
principles of information-seeking behaviour (Harris & Dewdney, 1994). These principles 
are as follows: 
1. Information needs arise from the person¶s situation. 
2. The decision to seek/not seek information is influenced by numerous factors. 
3. People tend to seek the most accessible information. 
4. People tend to first seek information from interpersonal sources, especially from 
people like themselves. 
5. Information seekers expect emotional support. 
6. People follow habitual patterns in seeking information. 
Models of health information seeking behaviour 
Health information seeking models were developed which incorporated these principles 
and which could be applied to patients. Such models describe the cognitive and affective 
processes involved in seeking health information (Clarke et al., 2016; Lalazaryan et al., 
2014).  Information seeking models include the following four models: 
 /D]DUXVDQG)RONPDQ¶V6WUHVV$SSraisal, and Coping theory 
This theory describes coping as a process which can employ different coping mechanisms - 
problem focused or emotion based coping methods. The former method uses planning and 
interpersonal relationships whereas the latter method seeks to pragmatically reduce the 
negative feelings associated with stressful situations. According to this theory personality 
and emotions are key influences on the evaluation and selection of these coping 
mechanisms. People with positive personalities would actively try to deal with the problem 
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while pessimistic people would underestimate their abilities and engage in avoidant 
behaviours. 
 /HQ]¶V,QIRUPDWLRQVHHNLQJPRGHO 
In this model information gathering is described as a six-stage decision making process. It 
begins with internal/external information seeking stimuli; setting information goals; 
decision-making on the necessity to seek information; search behaviours; acquiring and 
evaluation of information. This process will result in cognitive and behavioural changes in 
the information seeker. Factors such as boredom and curiosity contribute to the premature 
ending or extension of the information search.  
 /RQJR¶VH[SDQGHGPRGHORIKHDOWKLQIRUPDWLRQVHHNLQJEHKDYLRurs 
This is a model applied to the sourcing and use of health information in patients with 
chronic disease. This model focuses on the personal and contextual factors that influence 
information seeking behaviours. Personal aspects include anxiety, genetics and health 
history while contextual components could include social support, healthcare delivery and 
information environment. This model describes the effects of information on increases in 
SDWLHQWV¶VDWLVIDFWLRQSHUFHSWLRQVRIFRQWURODVZHOODVLPSURYHGKHDOWKVWDWXV 
 Trans theoretical model (TTM) of health behaviour change (Harris & Wathen, 
2005) 
This is a five-stage health information seeking model, which was initially used in addictive 
behaviours such as smoking. It is described as a spiral shaped process, with 
precontemplation; contemplation; preparation; action and maintenance stages. These stages 
involve intermittent yet linear health behaviours with numerous stops and returns to 
previous stages that can be temporary or permanent. 
 0LOOHU¶V0RQLWRULQJDQGEOXQWLQJK\SRWKHVLV (Miller, 1989).  
This is a key information seeking model which focuses on the impact of information 
behaviours and coping mechanisms. This hypothesis, proposes that people have distinctive 
coping styles/attentional styles when they are faced with threatening situations such as 
ADRs (Miller, 1989). When challenged by threatening conditions active information 
VHHNHUVRUµPRQLWRUV¶HQJDJHLQLQIRUPDWLRQVHHNLQJEHKDYLRXUVUHODWHGWRWKHLUFXUUHQW
situation. In contrast those with a non-DFWLYHFRSLQJVW\OHRUµEOXQWHUV¶XVHGLVWUDFWLRQDQG
re-interpretation techniques to lessen the threat (Miller, 1989). Active information 
seekers/monitors gather a large amount of information about their health status/problems 
and side-effects of medicines and treatments. They are quicker to identify the symptoms of 
diseases and more likely to visit doctors for minor problems (Miller, 1989). Monitors have 
high levels of anxiety and accumulating large amounts of information can help to alleviate 
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this anxiety and stress (Miller, 1989). Patients who do not actively seek information, 
blunters, generally have minimum information related to their health status and potential 
health issues such as ADRs (Miller, 1989). Rigid copers adhere to their coping style using 
either Monitoring or Blunting strategies in both controllable and uncontrollable situations. 
Monitors will be alert and seek information as they attempt to increase the predictability of 
the outcome. Blunters will employ distractive strategies even if they have the potential to 
influence the outcome (Voss et al., 2006). Adaptive copers change their coping style in 
response to different types of situations (Voss et al., 2006). Within this model coping styles 
are an essential component of health information seeking behaviours. Coping as a 
psychological construct can be mediated by factors such as gender, age, education, type 
and severity of illness, social support and health literacy (Lalazaryan et al., 2014). 
 
1.6.2 Information overload 
Information overload can occur when the information which is received is a barrier and not 
beneficial to the patients (Bawden & Robinson, 2009). As mentioned there are numerous 
sources of information about medicines available for patients today. Health information 
can now be obtained from multiple sources which can lead to an increased possibility of 
contradictory information as well as information overload (Carpenter et al., 2010). 
Information can be actively acquired by patients or passively received but both processes 
can result in information burden (Clarke et al., 2016). Excessive information loading can 
lead to delays in processing information; processing information incorrectly; accepting 
poor quality information and ceasing to search for required information (Miller, 1960 as 
cited in Clarke, 2016). Effective patient-centred heath information can be presented to 
patients when factors such as information overload and multiple information sources are 
considered.   
  
1.7 Thesis Outline 
This thesis examines SDWLHQWV¶H[SHULHQFHVLQLGHQWLI\LQJDQGPDQDJLQJside effects from 
medicines. The study seeks to address the lack of information surrounding the following: 
SDWLHQWV¶YLHZVRQ$'5VDQGthe impact ADRs have on their lives and their behaviours. It 
takes a patient-centred approach to ADRs and directs the resHDUFKIRFXVRQWKHLQGLYLGXDO¶V
experience across physical, psychological and social domains. The thesis attempts to 
SURYLGHDXQLTXHDQGLQVLJKWIXOSHUVSHFWLYHRQSDWLHQWV¶SHUVRQDOH[SHULHQFHVRI$'5V
Empirical work was conducted in four phases with these study phases divided as follows:  
 Phase One - Survey development and distribution 
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 Phase Two - In-depth interviews with people who have experienced ADRs 
 Phase Three - Development and validation of Side Effect Assessment tool 
 Phase Four- Investigation of Yellow Card reports 
Chapter Two supplies the context with a review of the relevant literature and research 
evidence in this area. This review identified deficits in knowledge and the chapter 
concludes with the research questions and study aims which were formulated to address 
these shortfalls.  
Chapter Three provides a rationale for the methodological approach that has been 
undertaken - a mixed methods study. Each phase of the study is outlined, starting with the 
surveys, followed by the interviews, the assessment tool and YC study. In addition, 
corresponding support is offered for the inclusion of each stage of this research. 
Chapter Four describes the first phase of the study: a cross-sectional survey distributed 
amongst pharmacy customers, exploring experiences of using information sources for 
finding out about ADRs. 
Chapter Five reports on the second phase of the study: semi-structured interviews 
with survey participants from the first phase who had experienced an ADR. 
Chapter Six describes the third phase of the study: the development and validation 
of a causality assessment tool for patients to use in identifying suspected side 
effects. 
Chapter Seven reports on the fourth phase of the study: an investigation of a large 
sample of YC reports submitted by patients/the public. 
Chapter Eight discusses the findings from the four phases of the study and how 
the research questions have been addressed. It also examines the strengths and 
limitations of the study, its contributions to knowledge and the implications for 







































As part of this thesis, a literature review was conducted which examined the current 
UHVHDUFKOLWHUDWXUHRQSDWLHQWV¶LGHQWLILFDWLRQDnd management of ADRs. This chapter 
presents an overview of the research literature connected with the subject areas that inform 
this research. These subject areas included adverse drug reactions (ADRs); patient 
reporting of ADRs; cognitive processes involved in identifying ADRs; type of information 
sources used to identify ADRs and ADR causality assessment tools. A series of structured 
literature searches were carried out to identify the key issues and deficits in knowledge 
connected to identifying and managing ADRs. A review of these results led to 
development of the research questions and subsequent study design.  
 
2.2 Aim of literature review 
The literature review was undertaken to answer the search questions which were generated 
by initial investigation of the subject area of ADRs. These questions were as follows: 
1. What cognitive processes do patients use to identify and manage ADRs?  
2. What information sources do patients use to identify ADRs? 
3. How do patients cope when they experience ADRs? 
4. What are the characteristics of patient reporting of ADRs and is there any evidence 
that such reports are beneficial?  
5. What motivates patients to report their ADRs? 
6. What benefits would accrue from the development of a reliable ADR 
assessment tool specifically developed for patient use? 
 
2.3 Search terms and methods 
 A broad literature search of ADR research was initially conducted using the following 
databases EBSCO, MEDLINE/Pubmed and PsychINFO. These databases were identified 
as useful resources within the Sciences and Social Sciences fields. The search terms which 
were initially used were broad in scope terms and generated many articles. The search 
terms were amended to generate project specific research articles and included Medical 
Subject Headings terms (MeSH) such aVµSKDUPDFRYLJLODQFH¶DQGµFDXVDOLW\¶A structured 
literature search of ADR research from 1994 to 2017 was conducted across a wider range 
of electronic national and international bibliographical databases. The amended search 
terms included the following words/phrases:  
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 adverse drug reactions 
 side effects 
 pharmacovigilance  
 patients 
 reporting 
 patient reporting 
 information sources 
 causality assessment 
 patient experience 
In addition, the 0H6+WHUPVµFRQVXPHUSDUWLFLSDWLRQ¶DQGµ$'5UHSRUWLQJV\VWHPV¶ZHUH
also used. 
Details of these searches, the revised search terms and the paper selection process are 
presented in Appendix 1.  The search was conducted in two phases which examined the 
following:  
1. Relevant research publications that related to the identification and management of 
ADRs  
2. Research publications which addressed the other search questions 
Multiple databases were searched: Cochrane Database of Systematic Reviews (CDSR); 
EBSCO Host database (MEDLINE, PsychARTICLES, PsychINFO) PubMed, SAGE 
Journals online and ScienceDirect. This conventional search of the databases was further 
developed by following-up studies cited in bibliographies of relevant research papers and 
general internet searches. A filter which limited the search to publications from 1994 to 
2017 was applied and duplicated research studies were omitted. 
 
2.4 Inclusion and exclusion criteria  
Searches were limited to article titles and abstracts and only articles which met the 
inclusion criteria were included in the review. See Table 2.1 on the following page for 









Table 2.1: Inclusion and exclusion criteria used for literature search  
 
Inclusion Criteria 
Quantitative, qualitative or mixed methods research studies  
Description of the research relating to the identification and management of ADRs 




ADR research relating to children   
 ADR research relating to non-human subjects  
 
2.5 Selection method and data extraction  
As part of the initial selection process titles and abstracts were reviewed and studies which 
did not meet the inclusion criteria were omitted. Studies which appeared to meet the 
inclusion criteria were examined in full before they were selected for review. A record of 
the selected studies was created which categorised each study according to the following: 
 Study setting  
 Study population - number of participants, demographic information  
 Methodology 
 Outcomes 
 Summary of results 
 
2.6 Literature review  
The literature search identified papers which described qualitative, quantitative and mixed 
method research. This literature review has been divided into six sections with each section 
related to a specific research area and to the search questions outlined above (section 2.2).  
 
2.6.1 What cognitive processes do patients use to identify and manage ADRs?  
The Self-Regulation model of health behaviour/CSM 
Research has suggested that the Self-Regulation model of health behaviour/CSM can be 
used as a framework for understanding ADRs. Within this model the five cognitive 
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domains ± identity; timeline; cause; consequences and control -  are used by patients to 
assist them in identifying ADRs (De Witt & Sorofman, 1999; Johnson & Folkman, 2004).  
Over the years extensive research has been conducted into health behaviours and illness 
representations. This research has focused on the recall, evaluation and labelling of somatic 
changes. It found that patients process information about physical symptoms according to 
their prototypical perceptions about associations between diseases and particular 
symptoms. These prototypes are composed of cognitive processes which assist the patient 
to organise and evaluate information. Patients use their previous personal health 
experiences or knowledge of the experiences of others to identify symptoms (Bishop & 
Converse, 1986 as cited in De Witt & Sorofman, 1999).  
Researchers considered it plausible that patients would use such preconceived perceptions 
about side effects to assist them in labelling and interpreting symptoms linked to adverse 
effects. A cognitive schema or prototype could be developed by patients which facilitates 
evaluation and identification of the symptoms that indicate an ADR. The elements of this 
prototype were described as identity (symptoms/label); cause; timeline; consequences and 
cure (Bishop et al., 1987 as cited in DeWitt & Sorofman, 1999).  
A study was conducted to investigate if such an ADR prototype existed (De Witt & 
Sorofman, 1999). Self-administered questionnaires were distributed amongst 338 patients 
LQD*3FOLQLFWRH[SORUHSDWLHQWV¶SHUFHSWLRQVDQGNQRZOHGJHRI$'5V$PDMRULW\RIWKH
participants were found to have previously experienced an ADR and described the reaction 
with reference to the five prototype elements (cause; symptom; time; consequence and 
cure). Results indicated that patients displayed largely accurate knowledge of ADRs and 
may use a prototype to assist in identification of symptoms as ADRs (De Witt & 
Sorofman, 1999). This study suggested that previous research into illness representations 
could be extended to ADRs. A specific ADR prototype existed which was composed of 
five elements or cognitive domains (see Figure 2.1 on the following page). These cognitive 
schemas were multidirectional in nature and constructed by patients to assist in organising 












     
 
 
     
      
 
 
Fig 2.1: Five elements of ADR prototype used by patients to assist in recognition and 
evaluation of symptoms that indicate an ADR 
 
Researchers have investigated how cognitive representations can influence coping 
strategies and illness outcomes in a wide range of chronic illnesses (Hale et al., 2007). A 
sample of 233 chronic fatigue syndrome sufferers were assessed and relationships between 
illness perceptions, coping, disability and psychological well-being were investigated 
(Moss-Morris et al., 1996). Patients who had a strong illness identity; perceived the illness 
to be caused by stress; as outside of their control with very severe consequences had high 
levels of disability and psychological impairments. These components of illness 
representations ± identity; consequences and cure/controllability -were therefore linked to 
negative outcomes. In addition, disengaged coping strategies were also associated with 
greater disability and less psychological well-being (Moss-Morris et al., 1996). Another 
study was conducted among 140 UK patients with psoriasis which examined the cognitive 
model of their disorder. High levels of pathological worrying were associated with illness 
representations which perceived psoriasis as having severe consequences and being 
triggered by emotions (Fortune et al., 2000). A later study investigated the illness 
representations of 99 patients with multiple sclerosis. The relationships between these 
perceptions and outcomes such as depression, anxiety and levels of illness intrusion were 
examined (Vaughan et al., 2003). As in earlier research components of illness 
representations were identified which included a strong illness identity; perceived lack of 
Identity  
    (symptoms/labels) 
 
Timeline 







control over an illness; beliefs concerning the acute time-line and severe consequences of 
the illness. These illness cognitions were associated with negative outcomes such as higher 
levels of depression, anxiety and deficits in physical functioning (Vaughan et al., 2003). 
Longitudinal research was also conducted with 71 patients with rheumatoid arthritis (RA) 
to examine if illness perceptions and coping strategies could reliably predict health 
outcomes (Scharloo et al., 1999). Beliefs in adverse consequences were associated with 
higher anxiety, more trips to outpatient clinics and tiredness. Perceived lack of control was 
linked to more hospital admissions. Passive or avoidant coping strategies were connected 
with higher levels of anxiety, more tiredness and greater disability. Overall these research 
findings indicated that coping strategies and illness perceptions could significantly 
influence health outcomes in patients with RA (Scharloo et al., 1999).   
 It would be beneficial to develop this research from the broad parameters of chronic 
illness and focus on the specific category of ADRs.  The concrete language and 
classifications that define ADRs could provide a solid base for research of incremental 
value. The CSM can therefore be used in research as a framework to investigate the 
cognitive processes used by individuals to identify and respond to ADRs (De Witt & 
Sorofman, 1999; Johnson & Folkman, 2004; De Smedt et al., 2012).  
A study of 109 Human Immunodeficiency Virus patients on antiretroviral medicines 
suggests that the CSM can provide a useful framework to assess side effects (Johnson & 
Neilands, 2007). The findings indicate that patients use similar cognitive and emotional 
representations to evaluate side effects and symptoms related to their disease. The 
researchers propose that investigating these processes can provide important insight into 
the impact side effHFWVFDQKDYHRQWKHTXDOLW\RISDWLHQWV¶OLYHVDQGDGKHUHQFH to treatment 
(Johnson & Neilands, 2007).  
Research has been conducted which investigates the cognitive processes that patients 
utilise to identify ADRs (Hughes et al., 2002; Krska et al., 2011; Uchaipichit et al., 2012). 
This research has found that overall patients displayed knowledge and accuracy in 
identifying ADR symptoms. The majority of patients employ temporal associations to link 
symptoms to medication. A proportion of patient reporters use additional information from 
a range of sources - such as PILs ± to confirm suspected ADRs. Research has shown that 
reading about side effects in PILs does not create a bias in patients or encourage them to 
report experiences of ADRs (Krska & Morecroft, 2013). These processes for assessing 
causality of ADRs parallel those employed by healthcare professionals (Krska et al., 2011). 
These findings suggest that a standardised assessment method could be effectively used by 




2.6.2. What information sources do patients use to identify ADRs? 
2.6.2.1 Use of information sources 
Research into the use of information sources by patients into ADRs has been limited. In the 
past health-related information was frequently passively received by patients from 
WUDGLWLRQDOVRXUFHVVXFKDV+&3V7KLVµWRS-GRZQ¶SURFHVVIHDWXUHG+&3VDVWKHµH[SHUW¶
who dispersed the information to patients. Now patients can actively seek information 
about medicines from a variety of sources (Nähri, 2007). A recent review of health 
information needs of patients indicated that useful and up-to-date medicine information 
can help patients to identify suspected ADRs (Clarke et al., 2016). However, the quality of 
information about medicine can YDU\ZLGHO\DQGSDWLHQWV¶LQIRUPDWLRQQHHGVDUHQRWVWDWLF
and can change over time (Van Geffen et al., 2011). While information about medicines 
can be beneficial for patients, research with cancer patients has found that not all patients 
want information )DOORZILHOG,QJHQHUDOVWXGLHVKDYHIRXQGSDWLHQWV¶NQRZOHGJH
about SE and medicine toxicity to be poor even for those with chronic conditions 
(Gilbertson et al., 1996 as cited in Hughes et al., 2002). However, research has shown that 
PILs can addUHVVWKLVNQRZOHGJHGHILFLWDQGFDQLQFUHDVHSDWLHQWV¶NQRZOHGJHDERXW
possible SE (Gibbs et al., 1989; Gibbs et al., 1990 as cited in Hughes et al., 2002). 
Research also investigated how much information patients want from their physicians 
regarding adverse effects from their medicines.  A US study was conducted with 2500 out-
patients in 2001 (Ziegler et al., 2001) which concluded that over 70% of patients wanted 
all the available information regarding possible adverse effects. They expected their 
physicians to supply complete health information about the risk of adverse effects and 
were reluctant to relinquish control in this area to the physician (Ziegler et al., 2001).   
 
2.6.2.2 HCPs and PILs as information sources 
A UK study in 2002 investigated patienWV¶NQRZOHGJHDERXW6(DQGWKHLQIRUPDWLRQ
sources they used (Hughes et al., 2002). Interviews and focus groups were conducted with 
32 pharmacy customers who purchased any of the following: antihistamine, decongestant 
or ibuprofen (Hughes et al., 2002). The findings suggested that patients accessed 
information about medicines from many sources including HCPs, family/friends, the 
media, books and the Internet (Hughes et al., 2002). Previous research proposed that 
patients were competent in identifying ADRs as the majority of ADRs were identified 
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through spontaneous patient reports to HCPs (Fisher et al., 1994; Houghton et al., 199 as 
cited in Hughes et al., 2002). PILs were widely accessible but rarely used by patients ± 
unless a SE occurred or if the medicine was new (Hughes et al., 2002). This profile of PIL 
use by patients only after effects had occurred is supported by later studies.  A Finnish 
VWXG\RIPHGLFLQHXVHUV¶VRXUFHVRIPHGLFLQHLQIRUPDWLRQZDVFRQGXFWHGLQ1lKUL
2007). Over 1000 respondents were interviewed and the most common information sources 
used were PILs - 74% - followed by doctors - 68% -  and pharmacists - 60%. Forty percent 
of respondents used television, 40% used print media, 24% used family/friends and 
medicine books were used by 22%. The Internet was used by 20% with the greatest 
Internet use reported amongst respondents aged 15-34 years (Nähri, 2007). However more 
recent research has focused on the aspects of health information websites which facilitate 
beneficial use. A study used a User Test and interviews with fifteen participants, who took 
medicine in the previous year, to examine the readability of information and ease of use of 
five websites (Nicolson et al., 2011). The design and content of the sites affected the ease 
with which participants located and understood the information. Web pages with too much 
text and/or links were considered distracting and hard to navigate. The trustworthiness of 
the site was frequently determined by its professional appearance (Nicolson et al., 2011). A 
study of 65 patients experiencing medication overuse headache (MOH) was conducted in 
Italy, Denmark and Germany in 2011 (Munksgaard et al., 2011). It investigated the 
information needs and preferences of patients beginning an MOH program of treatment. 
The majority ± over 70% - selected personal verbal information from their HCP as their 
primary preference with 33% selecting PILs and 41% selecting the Internet (Munksgaard 
et al., 2011).  
Hospital patients in six UK hospitals were surveyed in a later study regarding use of PILs 
and other information sources (Krska & Morecroft, 2013). Overall 1218 questionnaires 
were completed and it was found that 6.5% of patients only read PILs if unexpected effects 
occurred. However, using the PILs was beneficial for a majority of patients, helping over 
80% to identify their suspected ADRs (Krska & Morecroft, 2013). A more recent study of 
1044 out-patients in Thailand investigated the information sources used by patients to 
assess suspected ADRs respondents (Jarernsiripornkul et al., 2015). Findings indicated that 
the major source of information about ADRs were HCPs ±  used by 35.5% of respondents 
(Jarernsiripornkul et al., 2015).  However, PILs are not widely available in Thailand and 
patients seldom receive information leaflets (Jarernsiripornkul et al., 2015).  
The format of PILs has changed over time with increased use of consistent risk descriptors. 
A recent review compared the format of PILs for 100 licensed medicines in 2012 with 
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PILs in 2006 (Harris et al., 2015). More recent PILs are more likely to display a consistent 
structure and use the format recommended by the European Medicines Agency (EMA) ± 
combined verbal and frequency information. Recent PILs are also more likely to include 
frequency information about SE risk (Harris et al., 2015). However, a recent study which 
assessed the EMA recommendations found that combined verbal and numerical 
information can lead to notable over-estimation of risk when compared with information 
presented as numerical frequency bands (Knapp et al., 2015). 
 
2.6.2.3 Trust in information sources  
In general, PILs and HCPs such as doctors and pharmacists are viewed across all age 
groups as trustworthy sources of information (Nähri, 2007). Trust in HCPs is associated 
with greater inclination in patients to follow medical recommendations. Viewing HCPs as 
reliable information sources can also be linked to improved attitudes in patients about their 
medicines (Nähri et al.,2001; Trachtenberg et al., 2005). However, research has also found 
that differences can exist between HCPs and patients about the type of information that is 
required. The types of information patients wanted to receive from their GPs about their 
prescribed medicines were categorised. Information about possible SE was the information 
category most frequently requested by patients (Berry et al., 1995 as cited in Berry et al., 
2002). A later study followed on from this research and asked GPs to assess all the 
categories in order of importance when explaining prescription medicine to patients (Berry 
et al., 1997 as cited in Berry et al., 2002). A significant discrepancy was identified between 
the information patients wanted on possible SE and the importance GPs attached to this 
type of information. As stated patients often requested such information, however SE 
information was not considered similarly important by GPs. Inclusion of information about 
possible SE was not prioritised by GPs and received very low ratings from them (Berry et 
al., 1997 as cited in Berry et al., 2002). When such differences occur between the views of 
patients and GPs, the information needs of patients may not be met (Gordon et al., 2007).  
In addition to HCPs and PILs the news media is considered an important source of 
information about medicines. The media can play a positive role in public health and 
increase patient awareness of potential risks and benefits of medical treatments (Moynihan 
et al., 2000). However, there is some concern about the trustworthiness of media coverage 
as the quality of reporting on health can vary greatly (Kennedy & Bero, 1999; Gill et al., 
2002).  Research has identified issues with health reporting within news media such as 
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inaccuracy, an overemphasis on adverse effects/risks and sensationalism (Myers, 1996; 
Moynihan et al., 2000; Schwartz, 1999). 
 
2.6.2.4 Effects of providing information 
High quality health information was found to facilitate informed healthcare decision 
making (Clarke et al., 2016). To make such informed decisions patients need to understand 
the benefits and risks associated with medicines5HVHDUFKLQWRSDWLHQWV¶LQIRUPDWLRQQHHGV
has indicated that they want to be informed about the possible side effects of their 
prescribed medicines (Berry et al., 1995; Enlund et al., 1991; Stevenson et al., 1999 as 
cited in Berry et al., 2002). Multiple studies have been conducted to examine the effects of 
supplying patients with information about side effects with mixed results (Berry et al., 
1997; Gibbs et al., 1990; Myers et al., 1987 as cited in Berry et al., 2002). A study which 
informed patients about possible gastrointestinal SE resulted in a significant increase in 
reports of these SE (Myers et al., 1987). However, a later study found no evidence that 
supplying patients with information leaflets that described SE lead to increased reporting 
of SE (Gibbs et al., 1990).  A study conducted by Berry et al., 2002 was composed of three 
experiments with 976 participants from the general public. Experiment One manipulated 
information about SE to observe its effects oQSHRSOHV¶VDWLVIDFWLRQDGKHUHQFHWRPHGLFLQH
and their perception of risk. Experiments Two and Three examined the effects of 
information about negative SE and how it interacts with the perceived benefits of the 
PHGLFLQHDQGWKHSHRSOHV¶SHUFHLYHGOHYHORf control over SE. It found that people were 
less likely to take medicine associated with a small number of severe side effects than  
medicine linked to a large number of mild SE. Overall providing people with information 
on how to reduce potential SE had beneficial effects. These included increasing both 
SHRSOHV¶SHUFHLYHGOHYHORIFRQWUROLQSUHYHQWLQJUHGXFLQJ6(DQGWKHLULQWHQWLRQWRDGKHUH
to the medicine (Berry et al., 2002). This is supported by earlier research which found that 
supplying patients with information about possible SE ± such as PILs ± does not lead to 
increased reporting of SE (Howland et al., 1990; Myers & Calvert, 1976 as cited in Krska 
& Morecroft 2013).  
 
2.6.2.5 Types of information 
Research indicates that information about medicines and SE influence how people take 
their medicines. It is essential therefore that the information provided is both accurate and 
easy to understand. Studies have found that patients can misinterpret verbal and numerical 
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descriptors of SE and commonly overestimate the risk of SE (Berry & Hochhauser, 2006; 
Carrigan et al., 2008). There are advantages to using verbal descriptors which include 
making the information more manageable and providing a coherent picture to patients of 
the variation that can occur in incidence rates during clinical trials. Verbal descriptors are 
also a format which people find more agreeable than numerical information (Berry et al., 
2003; Carrigan et al., 2008; Dickinson et al., 2016; Knapp et al., 2009). It has been 
suggested that giving frequency information to people about SE could address this 
overestimation of SE (Knapp et al., 2009). A study was conducted with 134 Cancer 
Research UK website users which investigated the effectiveness of SE risk information in 
numerical, verbal and mixed formats (Knapp et al., 2010). It found that patients generally 
overestimated the risk of SE and were less accurate when estimating uncommon SE. 
Frequencies could increase the accuracy of risk assessments and patients preferred 
frequencies to frequency bands (Knapp et al., 2010).  A more recent study with 129 Cancer 
Help UK website users assessed SE risk information on tamoxifen in numerical formats 
alone - frequency, percentage and combined formats. The findings indicated that the type 
of format did QRWDIIHFWSDWLHQWV¶LQWHUSUHWDWLRQVRIWKHLQIRUPDWLRQ2YHUDOOSDWLHQWV
preferred the combined ± frequency and percentage ± format (Knapp et al., 2013).   
Research has also indicated that patients frequently use multiple sources of information 
(Nähri, 2007). However, as described in Chapter One, multiple sources of information can 
have disadvantages for patients. There is an increased possibility of contradictory 
information leading to information overload (Carpenter et al., 2010). A study of over 200 
patients with vasculitis found that conflicting medical information can have negative 
LPSDFWRQSDWLHQWV¶DGKHUHQFHWRWKHLUPHGLFLQHV&DUSHQWHUHWDO 
 
2.6.3 What coping strategies do people use when they experience ADRs? 
As mentioned in Chapter OnHDQLQGLYLGXDO¶VSHUFHSWLRQRIDQHJDWLYHHYHQW- such as an 
ADR - can be influenced by their cognitive processes and generate specific coping 
strategies (Kaptein & Weinman, 2004). Coping strategies have been extensively studied in 
health research and can be assessed by using psychological scales such as the Miller 
Behavioural Style Scale (MBSS).  The MBSS was developed to identify the coping 
styles/strategies that people use when responding to uncontrollable stressful/threatening 
situations (Miller et al, 1989). The scale divides people into monitors and blunters - 
monitoring is an information-seeking behaviour while blunting describes distraction 
behaviours (Miller, 1989). A review of research which used the MBSS indicated that 
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cancer patients with a monitoring coping style have a high degree of knowledge about their 
medical situation, are more anxious about their cancer risk and can experience more 
frequent and more severe SE from their treatment compared with blunters (Miller, 1995). 
Monitors in general ZHUHIRXQGWRIROORZWKHLU+&3V¶UHFRPPHQGDWLRQVDQGUHVSRQGHGWR
their health-related threats with greater psychological morbidity (Miller, 1995). Health 
research which used the MBSS also indicated that monitors can feel culpable in their 
health problems and responsible for the progression of the disease (Miller et al., 1995). 
When the MBSS was used to assess cancer patients it indicated that patients identified as 
monitors adapt to their situation and focus on managing their health by seeking 
information about prevention methods and potential outcomes (Lalazaryan et al., 2014; 
Miller et al., 1995; 1996; 1999; Muris et al., 1994). Cancer patients experienced better 
health outcomes when the information they received about their medical condition was 
specifically designed for their coping style (Miller, 1995; 2005). Generally, monitors cope 
better when given more information while blunters progress better if they receive less 
information (Miller, 1995; 2005). This early research was supported with later findings 
which found that monitors acquire a large amount of detailed information when diagnosed 
with cancer (Kola et al., 2013; Mancini et al., 2006; Williams-Piehota et al., 2005). 
However, a study in 2006 did not support the characteristics of monitors established by 
earlier MBSS research. Two groups of patients were examined - 217 patients from three 
hospital clinics (rheumatology departments/pain clinics); and 262 patients taking 
antihypertensive medicines from 40 community pharmacies. Monitors wanted written 
medical information but were not prepared to actively seek this information themselves 
(Koo et al., 2006). 7KLVILQGLQJPD\EHH[SODLQHGE\WKHIDFWWKDWWKHUHVSRQGHQWV¶KHDOWK
condition was well established and was not a new diagnosis (Koo et al., 2006). Research 
was also conducted across patient populations and found similar associations between the 
desire for information and monitoring styles of coping (Janssen et al., 2009; Meulenkamp 
et al., 2010; Sie et al., 2013). Monitoring is therefore associated with a desire for detailed 
health information as well as a desire for detailed knowledge of imminent medical 
procedures. Research proposes that seeking information can help to reassure monitors by 
reducing uncertainty (Bouckenooghe et al., 2007; Krohne & Hock, 2011; Rosen & 
Knauper, 2009). Monitors find information has cognitive and affective value for them and 
consider accessible information to be a comforting resource (Shiloh & Orgler-Shoob, 
2006).  The MBSS has been used with different patient groups to identify coping styles 
however it has not been used in research relating to ADRs to date.  
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2.6.4 What are the distinctive aspects of patient reporting of ADRs and is there any 
evidence that such reports are beneficial?  
2.6.4.1 Benefits of patient reports 
Patient reporting systems created datasets that could be examined to identify the potential 
benefits and/or limitations of patient reports and much research has been conducted in 
recent years on this topic. Early research in the 1980s was conducted which investigated 
SDWLHQWV¶SURILFLHQF\LQSURGXFLQJXVHIXOUHSRUWVRQ$'5VWRWZRVHOHFWHGDQWLELRWLFV7KH
researchers suggested that large scale reporting by patients could prove valuable in early 
detection of ADRs (Mitchell et al., 1988 as cited in Blenkinsopp et al., 2006). Later 
research compared the time profile of ADRs reports related to paroxetine by both patients 
and health care professionals. It was suggested that reporting by patients could assist in 
earlier detection of ADRs. These researchers suggest that optimum detection rates might 
be achieved by combining the information from both patients and health care professionals 
(Egberts et al., 1996). A later study in 2003 compared health professional reports submitted 
through the YCS to patient reports of suspected ADRs to paroxetine, collected via e-mails 
(Medawar et al., 2004). The research found that overall patient reports were more 
descriptive and provided greater understanding of the significance and consequences of 
ADRs (Medawar et al., 2004). Patients, in contrast to HCPs, provided more comprehensive 
explanations of their ADRs and their impact on their social and personal lives (Medawar et 
al., 2004). However, researchers were uncertain of the merits of direct patient reports with 
some in PV arguing for the desirability and value of an intermediary role for HCPs in 
µILOWHULQJ¶SDWLHQWUHSRUWV9DQ*URRWKHHVWHWDO 
Several later studies highlighted the benefits that can result from patient reporting of ADRs 
(De Langen et al., 2008; Hazell et al., 2013). These studies found that overall patient 
reports could contribute to drug safety and compliment reports by HCPs (Basch et al., 
2009; Hazell et al., 2013).  Patient reports were found to contain valuable information with 
similarities to heatKSURIHVVLRQDOV¶UHSRUWVLQWHUPVRIWKH$'5VWKDWZHUHPRVWIUHTXHQWO\
reported and most frequently reported drugs (De Langen et al., 2008; Hazell et al., 2013). 
Researchers suggested that patient reports could be considered as pertinent sources of 
information sources which provided complimentary perspectives (Basch et al., 2009). 
3DWLHQWUHSRUWVDOVRSURYLGHGH[SOLFLWGHWDLORIWKHHIIHFWVRI$'5VRQWKHSDWLHQW¶VOLIH
family and/or carers. These additional details created a richer narrative and help to form a 
PRUHFRPSUHKHQVLYHSLFWXUHRIWKHLQGLYLGXDO¶VH[SHULHQFHVRI$'5V(Avery et al., 2011; 
McLernon et al., 2010; Medawar et al., 2004). Despite this, a study carried out in 2011 
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found that 25% of community pharmacists in the UK believed that reporting of ADRs 
should be limited to HCPs (Krska, 2012). 
A review of patient reporting of ADRs in 11 countries was conducted in 2012 (Van Hunzel 
et al., 2012). Most of the countries had three methods for patients to report ADRs ± paper; 
electronic or telephone. The survey identified that personalised feedback was not offered 
by all countries and only the UK and The Netherlands have actively evaluated their patient 
reporting schemes. However all countries recognised the importance of facilitating the 
public in reporting ADRs and the scientific value of this data (Van Hunzel et al.,2012).  
$QRWKHUUHYLHZFRPSDUHGSDWLHQWUHSRUWVWRKHDOWKFDUHSURIHVVLRQDOV¶UHSRUWVIURPWKUHH
studies of the pharmacovigilance systems in Denmark, the UK and the Netherlands (Inch et 
al., 2012). This review highlighted both similarities and differences between patient reports 
DQG+&3V¶UHSRUWV7KHUHZHUHVLJQLILFDQWVLPLODULWLHVLQWKHFDWHJRU\RIWKH$'5VDQGWKH
symptoms of ADRs that were reported by patients and HCPs. Both reported similar 
numbers of serious ADRs and similar types of causative drugs were reported in the 
Netherlands and UK studies. However significant differences were apparent between 
SDWLHQWDQG+&3V¶UHSRUWVLQWKHERG\V\VWHPVWKDWZHUHDIIHFWHGE\$'5VLQWKH8.DQG 
Danish studies (Inch et al., 2012). Research which compares reports across 
pharmacovigilance systems in this manner is problematic. Recent research in Sweden of 
over 7000 members of the public suggested that the public experience large numbers of 
ADRs that are not captured by studies of hospital in-patients (Hakkarinen et al., 2013). 
Self-reports of ADRs from the public displayed a characteristic profile ± ADRs commonly 
resulted in gastrointestinal symptoms with the causative drugs related to nervous system, 
dermatological or psychiatric disorders (Hakkarinen et al., 2013).  
 EU-funded reviews of patient reports identified them as valuable tools ± these reports can 
provide information on causality, provide more detail in general and patients frequently 
report different types of drugs and types of reactions than healthcare professionals. The 
SUHVFULEHU¶VLQWHUSUHWDWLRQRIHIIHFWV± ZKLFKFDQGLIIHUIURPWKHSDWLHQWV¶RSLQLRQV- are not 
FRQVLGHUHGE\SDWLHQWVZKHQUHSRUWLQJDQGGRQRWLQIOXHQFHWKHSDWLHQWV¶Ueport. Many 
SDWLHQWUHSRUWVGHVFULEHLQGHWDLOWKHLPSDFWRI$'5VRQWKHLQGLYLGXDO¶VOLIHIDPLO\DQGRU
carers (Herxheimer, 2012). These additional details create a richer narrative and help to 
IRUPDPRUHFRPSUHKHQVLYHSLFWXUHRIWKHLQGLYLGXDO¶VH[SHULHnces of ADRs.   
 
2.6.4.2  Evaluation of patient reporting to the Yellow Card Scheme in the UK 
The reporting of ADRs has benefit in increasing knowledge and understanding of such 
drug effects. Patient reports can be viewed as a key component of effective PV processes. 
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Monitoring and evaluating patient reporting can aid in the assessment and prevention of 
adverse effects (Wiktorowicz et al., 2012). The MHRA has facilitated research into patient 
reporting by providing access to the YC dataset. A large study which reported in 2011 
compared patient reports with HCP reports and evaluated the impact that direct patient 
reporting had on pharmacovigilance. It examined all reports to the YCS between 2005 and 
2007 and also sought the opinions of the reporters and the public to patient reporting of 
ADRs (Avery et al., 2011). This research found that patient reports could be considered a 
valuable element of PV as they provided detailed descriptions of suspected ADRs; were 
likely to extend knowledge as they reported different drug types and reactions to HCPs and 
provided useful information about how they identified ADRs, the information sources they 
used as well as the impact of ADRs on their lives (Avery et al., 2011; Krska et al., 2011). 
YC reporting forms include free-text questions that seek information on the following: 
symptoms and how the ADR happened; details of the outcome including use of medicines 
and other information considered relevant. As part of this study the free-text data were 
analysed qualitatively and it was found that YC reports frequently provide explicit detail of 
WKHHIIHFWVRI$'5VRQWKHSDWLHQW¶VOLIHIDPLO\DQGRUFDUHUVZKLFKFRXOGEHXVHGWR
FUHDWHDULFKQDUUDWLYHHQDEOLQJDFRPSUHKHQVLYHSLFWXUHRIHDFKLQGLYLGXDO¶VH[SHULHQFHV
of their ADR and their subsequent use of medicines (Avery et al., 2011). However, this 
qualitative work used a small, purposively selected sample of YC reports ± approximately 
270 patient reports. Recommendations for future study were made as part of the evaluation 




(Avery et al., 2011). 
 
2.6.5 What motivates patients to report their ADR experiences? 
Research has also focused on the motivations ± conscious and unconscious ± which induce 
patients to report ADRs. A study was conducted in the Netherlands with approximately 
1300 patients who had reported an ADR (Van Hunsel et al.,2010). A web-based 
questionnaiUHZDVVHQWWRFDQYDVVSDWLHQWV¶opinions and motivations for reporting ADRs.  
The main motives for reporting ADRs were related to the severity of the ADR and 
SDWLHQWV¶ altruistic desire to share their experiences. Over 90% of reporters felt that 
reporting an ADR could prevent the adverse reaction happening to others (Van Hunsel et 
al., 2010). This finding of altruistic motivation is supported by later research which looked 
at patient reporting to the YCS and found the primary motivatioQIRUSDWLHQWV¶UHSRUWLQJ
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was to describe their experiences for the benefit of others (Avery et al., 2011). The scheme 
allowed reporters to contribute in a significant way to PV by providing the patient 
perspective to manufacturers and regulators. This type of meaningful participation in 
improving patient safety was highlighted by reporters as an important motivating factor 
(Avery et al., 2011). However, another study was conducted which investigated altruistic 
motives for reporting ADRs amongst non-reporting patients. This examined the impact of 
ADRs on fifteen hospital patients and their views on reporting ADRs (Lorimer et al., 
2012). Hospital patients admitted for ADRs were interviewed and asked to relate their 
experience of an ADR. The negative impact of an ADR ± anger, fear, isolation ± was 
apparent amongst all the patients. Patients who experienced a severe ADR following acute 
illness displayed negative emotions towards their HCPs. Patients with a chronic health 
condition coped better and experienced less negative emotions. None of these patients ± 
acute illness or chronic illness ± felt responsibility to report their ADR.  Experience of a 
severe ADR - even if accompanied by potential motivating factors such as anger ± did not 
routinely result in a desire in patients to report the reaction. These study findings suggest 
that patients who do report ADRs may not be representative of the general patient 
population (Lorimer et al., 2012).    
 
2.6.6 What benefits would accrue from the development of a reliable ADR assessment 
tool for patients? 
$VRXWOLQHGLQ6HFWLRQSDWLHQWV¶FRJQLWLYHSURFHVVHVLQFOXGHJDWKHULQJDUDQJHRI
information from various sources to identify ADRs and attribute causality, in an 
unstructured way. In contrast pharmacovigilance centres use standardised, often highly 
structured methods for assessing causality, as described in Chapter 1. All the instruments 
available for assessing causality of ADRs are designed for use by professionals working in 
pharmacovigilance centres. These scales can be described as limited in their design and 
application as they were not created for use by general clinicians or patients (Agbabiaka et 
al., 2008; Théophile et al., 2013) This lack of a standardized, structured assessment 
WRRODOJRULWKPIRUSDWLHQWV¶XVHFRXOGEHFRQVLGHUHGDVDFRQVLGHUDEOHOLPLWDWLRQRISDWLHQW
reporting to pharmacovigilance centres. However, some assessment tools for assessing 
causality are available for patients. Recent research was conducted in Thailand which 
developed and tested an instrument for patient self-assessment of ADRs (Jarernsiripornkul 
et al., 2015). This novel instrument displayed reliable psychometric properties in its 
preliminary testing and received positive evaluations from patients. A patient-reported 
adverse drug event (ADE) questionnaire was also developed and validated by researchers 
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in the Netherlands (De Vries et al., 2013). The questionnaire was based on checklists and it 
was intended to be used in clinical trials and postmarketing studies. An assessment tool - 
the RxISK Report - is also available on the Canadian RxISK drug safety website 
(htpp://rxisk.org) which helps patients establish if their side effects are linked to their 
medicines. Generic assessment tools could have multiple benefits and aid patients in their 
decisions in terms of reporting ADRs. If patients do decide to report to regulatory 
authorities an assessment tool specifically developed for patient use could enhance the 
quality of these reports. In addition, a suitable assessment tool for patient use could 
facilitate a productive partnership between patients and healthcare professionals. This is 
increasingly important, given the trend towards patient-centred consultations and their 
involvement in decision-making around treatments, including medicines. 
 
2.7 Discussion 
Health research has slowly come to recognise the potential of a patient-centred approach 
which moves past the clinical aspect of ADRs. There is genuine value to be gained by 
exploring the alternative viewpoint that patients can provide to ADR reporting. As part of 
this thesis, a literature review was conducted which examined the current research 
OLWHUDWXUHRQSDWLHQWV¶LGHQWLILFDWLRQDQGPDQDJHPHQWRI$'5V 
It is clear from this research literature that there is a lack of knowledge surrounding how 
people cope with and manage ADRs. This review has identified key areas that merit further 
H[SORUDWLRQKRZSDWLHQWV¶H[SHULHQFH$'5VDQGWKHSHUVSHFWLYHVRISDWLHQWUHSRUWVKRZ
ADRs LPSDFWRQSDWLHQWV¶OLYHVKRZSDWLHQWV¶FRSHZLWK$'5VZKDWLQIRUPDWLRQVRXUFHV
are used by patients to identify ADRs; and finally, the value of an ADR causality 
assessment tool for patients. This thesis sought to address these areas.  
 
2.8 Aim 
This research study sought to explore how people identified and managed ADRs and 
develop a reliable tool for patients to use to assess ADRs. 
 
2.9 Research question 
How do people identify and manage ADRs from their medicines and what impact 
and consequences do these ADRs have in their lives? 
This central research question was developed into four sub-questions: 
1. What are the personal experiences of people in managing ADRs? 
40 
 
a. What are the impact and consequences of their ADR experiences? 
b. What coping strategies do people use when they experience ADRs? 
2. What types of information sources do people use to find out about ADRs? 
a. What are the factors contributing to the use of these different 
information sources? 
3. What would be the essential characteristics of a reliable assessment tool 
for patients to use to assess ADRs? 
a. Would patients consider such an assessment tool to be valuable and 
useful to them?    
4. What is the value of patient reports within pharmacovigilance?  
a. Are there differences between people who report ADRs and the 













































3.1 General Introduction to methodology 
The purpose of this research is to address the lack of knowledge surrounding how 
people cope with and manage ADRs. A variety of research methods are utilised 
within health research and each methodological technique presents its own 
inherent advantages and disadvantages. This study sought to explore the personal 
experiences and opinions of the general public in identifying and managing side 
effects from medication. It also sought to develop a novel causality scale for use 
by the general public to assess suspected ADRs. The Literature Review which is 
described in Chapter Two identified gaps in knowledge surrounding how people 
cope with and manage side effects. These knowledge deficits informed the 
research questions and the subsequent study design. A pragmatic approach to the 
research methodology was selected as the most beneficial way to address the 
research questions. This approach ensured that the most appropriate methodology 
was chosen for each of the four phases of the research. A mixed methods study 
model was therefore employed which allowed the researcher the flexibility to use 
any quantitative and qualitative methodological techniques that were deemed 
suitable. This chapter will present the alternative options that existed and the 
rationale for the methodological choices that were made within this study.  
 
3.2 Justification for research 
Research has established that side effects from medicines can have a significant 
QHJDWLYHLPSDFWRQSHRSOHV¶GDLO\OLYHV7KLVLPSDFWFDQEHPXOWLGLPHQVLRQDOLQ
QDWXUHH[WHQGLQJLQWRPDQ\DUHDVRISHRSOHV¶OLYHVZLWKSK\VLFDOHFRQRPLFVRFLDO
and/or psychological effects. The literature review described in Chapter Two 
identified gaps in the research into patient experiences of ADRs with researchers 
being divided on the merits of direct patient reports. Research tended to compare 
health professional and patient reports of ADRs across pharmacovigilance 
systems or reports related to specific medicines - such as antidepressants. 
However recent research has highlighted the benefits that can result from patient 
reports in increasing knowledge and understanding of ADRs. The gaps identified 
in the ADR research confirm the necessity of further exploration of the personal 
experiences and opinions of people in identifying and managing side effects from 
medicines. They also support the development of a reliable assessment tool for 
assessing ADRs, specifically designed for patient use. A comprehensive study 
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was therefore needed to address the central research question set out in Chapter 
Two:  
How do people identify and manage side effects from their medicines and what 
impact and consequences do these ADRs have in their lives? 
 
3.3  Factors influencing the methodological approach 
As described in Chapter Two the central research question was developed into 
four sub-questions. Given the range of these research questions the study design 
had to be structured in a manner which enabled all the required data to be 
collected and the following sub- questions to be fully investigated:  
1. What are the personal experiences of people in managing ADRs? 
a. What are the impact(s) and consequences of their ADR experiences? 
b. What coping strategies do people use when they experience ADRs? 
2. What types of information sources do people use to find out about ADRs? 
a. What are the factors contributing to the use of these different 
information sources? 
3. What would be the essential characteristics of a reliable assessment tool 
for patients to use to assess ADRs? 
a. Would patients consider such an assessment tool to be valuable and 
useful to them?    
4. What is the value of patient reports within pharmacovigilance?  
a. Are there differences between people who report ADRs and the 
general public in terms of impact of ADRs and information sources 
used? 
 
3.4 Traditional qualitative and quantitative research 
Debate between supporters of quantitative and qualitative research paradigms has 
existed for decades. Quantitative purists have a positivist philosophy which 
maintains that research should be objective with the observer separate from their 
observations. This ensures the researcher is without bias and can achieve stylistic 
neutrality (Maxwell, 2004). Qualitative purists known as 
constructivists/interpretivists reject this positivism approach. They contend that 
research is value laden with the existence of multiple-constructed realities. 
Explanations are generated inductively from the data and a detailed, direct 
informal stylistic approach is key (Smith, 1983). Both quantitative and qualitative 
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research approaches have many benefits as well as many disadvantages (Johnson 
et al., 2004). However, beyond quantitative and qualitative research arguments 
mixed methods research offers an additional useful research paradigm.  
 
3.5 Mixed methods research 
The combination of quantitative and qualitative research methods in a mixed 
methods research study can enhance the strengths of each of these approaches 
(Howe, 1992). The eclectic nature of the methodology is a key element of mixed 
methods research which can regularly result in superior research (Johnson et al., 
2004). A central principle of mixed methods research is that study design is a 
deliberate, considered and flexible process. The key objective is to answer the 
research questions and not to be limited to a prescriptive list of design options 
(Johnson & Onwuegbuzie, 2004). It is felt that the philosophical challenges of 
mixed methods research can be addressed by employing pragmatist approaches 
(Bishop, 2015; Dures et al., 2011; Tashakkori et al., 2010). It has been argued that 
an optimum researcher is a pragmatic researcher who uses a needs-driven 
approach when selecting research methods (Johnson & Onwuegbuzie, 2004). In 
general pragmatist approaches accept the epistemological differences that exist 
between qualitative and quantitative research but suggest they are commensurable 
within the common aim of all research ± to effect positive change in the world 
(Bishop, 2015). Several important features influence the procedures that are 
selected for a mixed methods study. These include timing, weighting, mixing and 
theorizing (Creswell et al., 1994; 2009).  The researcher can decide to collect their 
quantitative and qualitative data either sequentially or concurrently. In some 
mixed methods studies equal priority may be given to quantitative and qualitative 
research or one type of research may be prioritised over the other. Mixing of the 
data can occur at several stages of the research. The researcher can decide to 
connect, integrate, or embed the databases. Finally, theoretical perspectives may 
be explicit or implicit within mixed methods studies (Creswell et al., 1994; 2004). 
Creswell and Clarke proposed six major mixed methods designs in 2011. These 
include exploratory, explanatory, triangulation, embedded, transformative and 
multiphase designs (Bishop, 2015). These can be seen in Figure 3.1. The 
transformative design describes any combination of methods used within a 
comprehensive transformative framework while the multiphase design describes 
45 
 
any combination of methods carried out within more complicated research 









*d Note. QUAN indicates quantitative component; QUAL indicates qualitative component; Capitals indicate component is typically 
emphasised or prioritised in this design. Lower case indicates component is typically used in supportive capacity. 
           (Bishop, 2015) 





This study sought to explore the experiences of people and the impact of their 
experiences on their physical, social and psychological environments. There are 
five main reasons for selecting a mixed methods design: (i) triangulation - using 
different methods and designs to find corroboration and convergence in results;                    
(ii) complementarity - finding clarification, enhancement and elaboration of 
results from one method with the results of another method; (iii) initiation - 
discovering any contradictions or anomalies; (iv) development - using the results 
from one method to inform another method and (v) expansion - expanding the 
width and range of the research study through the use of different methods for 
different elements of the research (Mark et al., 1997). In order to meet the study 
objectives diverse research areas needed to be covered and varied study 
populations investigated. It was therefore decided that an explanatory mixed 
method design that combined the strengths of both qualitative and quantitative 
research was appropriate for this study. 
 
3.6 Study design 
There is limited knowledge surrounding how people cope with and manage 
ADRs. This exploratory study proposed to address this deficit as well as 
developing a reliable assessment tool for assessing ADRs, specifically designed 
for patient use. Initially a mixed methods approach was selected as appropriate as 
both quantitative and qualitative data were required. When the study aims were 
considered a mixed methods design was chosen so that data could be generated 
from different sources and subjected to different analysis which addressed the 
range of research questions in varied ways (Creswell, 2004). This design also 
enabled the triangulation and confirmation of results across methods. The study 
was divided into four phases as follows:  
 Phase One - Survey development and distribution 
 Phase Two - In-depth interviews with people who have experienced ADRs 
 Phase Three - Development and validation of Side Effect Assessment tool 
 Phase Four- Investigation of Yellow Card reports 
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A broad outline of the methods employed in each phase follows as an overview of 
the study before discussion of the rationale. Full detail of the methods for each 
phase is provided at the appropriate chapter within the thesis. Phase One is fully 
described in Chapter Four: Survey; Phase Two in Chapter Five: Interviews; Phase 
Three in Chapter Six: Side effects Assessment tool and Phase Four in Chapter 
Seven: Yellow Card reports. Phase One of the study involved the development of 
DTXHVWLRQQDLUHWRJDWKHUJHQHUDOLQIRUPDWLRQRQSHRSOHV¶ experiences of ADRs 
and recruit potential interviewees for Phase Two. Survey research was chosen as 
an appropriate technique to gather general information from a large study 
population and to help prepare for the more in-depth second phase of the study. 
The instrument was piloted in the Medway area and amongst people known to 
have experienced an ADR. The results of the piloting were used to develop the 
final version of the Side Effects survey. These surveys were distributed to 
pharmacy customers in selected independent and small to medium sized multiple 
pharmacies within Kent and the West Midlands urban centres. Initial survey 
results were used to inform the Topic Guide for the interviews in the second 
phase. For Phase Two a phenomenological approach was selected to explore the 
opinions and experiences of people who had recently experienced an ADR, 
through in-depth interviews. Phase One and Phase Two of the study overlapped 
and were followed by Phase Three. Analysis of the interviews from Phase Two 
informed Phase Three of the research and was used to develop a causality 
assessment tool for the general public to use to assess suspected side effects. This 
phase also involved the validation of the novel assessment tool amongst members 
of the general public known to have experienced side effect(s) and in a larger 
population. Finally, an explanatory strategy was developed from the results of 
Phase One which informed Phase Four. In Phase Four a large sample of YC 
reports - submitted to the YCS by patients, parents and carers - were examined to 
IXUWKHUOHDUQDERXWSHRSOHV¶H[SHULHQFHVRI$'5VWRinvestigate the potential 
value of data within YC reports from non-HCPs and to compare YC reporters and 
the wider general public. A flow diagram presents the overall methodology in 






AIM STUDY DESIGN PARTICIPANTS (N) 
Phase 
One 
To investigate how people use information sources 
to help them identify ADRs DQGWRH[SORUHSHRSOHV¶
experiences of ADRs 
Cross-sectional survey Pharmacy customers in Kent & 
Medway & Birmingham from 
February-November 2015 (230) 
Phase 
Two 
To explore the opinions/experiences of people who 
had recently experienced an ADR 
 
In-depth interviews People in Kent area who recently 
experienced an ADR from June-





To develop and validate a causality assessment tool 












People who had experienced ADRs 
(Total 31: 11 Phase two 
interviewees & 20 novel 
participants) 
Online reports from people who 




To examine and evaluate YC reports and to 
compare how YC reporters and the general public 
identify and manage ADRs 
 
Quantitative analysis & 
qualitative content 
analysis of free text 
comments in YC reports 
YC reports from July-Dec 2015 
(2285) 
 







3.7 Rationale/Justification for study design 
3.7.1 Phase One: SE Survey  
It was apparent that the first phase of the research required a research technique 
which could gather general information from a large pre-selected study population 
in an effective manner and provide the researcher with access to potential 
interview participants for Phase Two. The survey method potentially allowed a 
large amount of data to be collected from a large sample, prompted by coherent 
questions and allowing respondents sufficient time to respond. Consideration was 
given to the problem of low survey response rates in health research as well as the 
time and resources available to the researcher (Edwards, 2002; Sax et al., 2003). 
Distribution of surveys in pharmacies was included in the study design to 
counteract anticipated low survey response rates. It was decided to distribute 
surveys in pharmacies, within Kent and Birmingham, amongst pharmacy 
customers who had used prescription medicines or non-prescribed medicines in 
the past six months and who satisfied the other inclusion criteria. This method of 
distribution was selected as the most appropriate method to gather information 
from a large number of people who regularly used medicines and therefore might 
be considered likely to frequent pharmacies, likely to have personal experience of 
an ADR or likely to have opinions on ADRs in general. Personal distribution of 
the surveys in pharmacies also afforded the researcher with opportunities not 
available with more blanket methods of distribution. These included the chance to 
initially screen the customers; to fully engage with the customers; to describe the 
research and its relevance in a clear manner which encouraged the customers to 
participate. This distribution method therefore had the potential to increase 
response rates and recruitment of interviewees while avoiding the necessity of 
accessing medical records. Development and piloting of the instrument, the final 
structure of the survey as well as survey distribution are described in full in 
Chapter 4. A sequential explanatory strategy within the mixed methods design 
was employed at this stage of the study. 
 A sequential explanatory strategy can be described as a two-phase process which 
initially sees the collection and analysis of quantitative data followed by the 
collection and analysis of qualitative data. The initial quantitative results inform 
the secondary qualitative phase. The two forms of data can therefore be 
51 
 
considered as connected yet also separate (Johnson & Onwuegbuzie, 2004). The 
sequential explanatory strategy that was employed during this study began with a 
quantitative stage - the SE survey. Analysis of this survey data was used to 
identify people who had recently experienced a suspected ADR. Identification of 
this cohort can be difficult and therefore survey data which facilitates such 
identification can be considered both significant and useful. This in turn led to the 
identification of potential participants for qualitative data collection in the 
secondary stage - the interviews. Because of time and resource factors the request 
to participate in these interviews was limited to pharmacy customers in the Kent 
area only. Analysis of the returned surveys was conducted to develop a Topic 
Guide for the secondary stage interviews.  
 
3.7.2 Phase Two: Interviews 
For Phase Two a phenomenological approach was selected as most appropriate to 
explore the opinions and experiences of people who had recently experienced an 
ADR. Interpretative Phenomenological Analysis (IPA) is an approach to 
qualitative research which is extensively used in psychology and based on the 
three key areas of phenomenology, hermeneutics and idiography (Smith, 2011). 
Phenomenology focuses RQWKHµOLYHGH[SHULHQFH¶DQG,3$LVEDVHGRQWKH
H[DPLQDWLRQRISHUVRQDOµOLYHGH[SHULHQFH¶WKHPHDQLQJRIH[SHULHQFHWR
participants and the manner in which participants make sense of their experience 
(Smith, 2011). Within an IPA perspective this examination is an explicit 
interpretative process. IPA requires the researcher to employ a dual hermeneutic 
process of engagement with and interpretation of the data (Smith et al., 2008). It 
can be considered idiographic in its detailed analysis of each case/text. IPA is 
WKHUHIRUHDSURFHVVRILQYHVWLJDWLQJLQGHWDLOWKHKXPDQµOLYHGH[SHULHQFH¶ZLWKDQ
iterative analytical process (Smith et al., 2008). This process is an interpretative 
one which situates the participants in their particular contexts and explores their 
personal perspectives (Smith et al., 2008). IPA involves the in-depth analysis of 
the personal accounts of participants and the most commonly used method of 
collecting these accounts is through in-depth interviews (Smith et al., 2011). 
While quantitative methods can be informative they cannot provide the 




(Smith et al., 2008). As mentioned in Chapter Two the overall research aims of 
this phase of the study was to focus on the personal experience and sense-making 
of people who had recently experienced ADRs. Therefore, IPA was chosen as a 
suitable approach over other qualitative methods because it was evidently 
consistent with these proposed research aims (Smith et al., 2008). The difficulties 
that exist in identifying people who have experienced ADRs result in problems 
recruiting this population for research studies. Therefore, only limited qualitative 
research had been conducted amongst this population to date. This suggested that 
WKHUHZDVDQHHGWRLQFUHDVHEDVLFXQGHUVWDQGLQJRIWKHLUµOLYHGH[SHULHQFH¶7KH
IPA approach was therefore considered a particularly appropriate method to 
address this research deficit and also increase understanding of this particular 
SKHQRPHQRQIURPWKHSDUWLFLSDQWV¶SHUVSHFWLYH 
 
3.7.3 Phase Three: Side Effects Assessment Tool 
The aim of this phase of the study was to develop a causality assessment tool for 
the general public to use to assess suspected side effects. The Side Effects -Patient 
Assessment tool (SE-PAST) was developed based on the findings of the research 
conducted in Phases One and Two. Phase Three also involved the validation of 
the SE-PAST amongst members of the general public known to have experienced 
side effects (see Appendix 2). A cross-sectional mixed methods study was 
selected as most appropriate as it can provide flexibility and allow the integration 
of complimentary perspectives (Creswell et al., 2004; Johnson & Onwuegbuzie, 
2004). This research design allows the traditional objective/positivist paradigms 
and subjective/constructivist paradigms to be combined in research that is 
composed of both quantitative and qualitative research methods. This combination 
of quantitative and qualitative data is the key strength of mixed methods and will 
ensure that patient experiences will support the statistical analysis inherent in the 
process of developing instruments (Onwuegbuzie et al., 2010). Recent health-
related research has evolved and numerous studies have used a pragmatic mixed 
methods approach in developing instruments (Durham et al., 2011; Onwuegbuzie 
et al., 2010; Willgoss et al., 2011). In the present study, initial validation of the 
instrument developed was sought through telephone interviews with people 
known to have experienced side effect(s). This was followed by placing the SE-
PAST online enabling additional validation in a larger population. This helped to 
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increase the claims for validity and reliability, both essential components in 
developing a scale.  
 
3.7.4 Phase Four: Analysis of Yellow Card reports  
The aim of Phase Four was to investigate the value of YC reports as a means of 
confirming how people use information sources to help them identify ADRs and 
to further explore the experiences of ADRs among a population of people who 
choose to report this to the regulatory authority. The YC data included free-text 
comments and responses to closed questions from a large sample of Yellow Card 
reports. A mixed methods design was selected as the most appropriate approach to 
take in this exploratory stage of the study. This exploration involved an in-depth 
µSHUVRQ-FHQWUHG¶IRFXVWKDWZDVDIXQGDPHQWDODVSHFWRIWKHVWXG\RYHUDOO$FFHVV
to the YC reports facilitated this focus. These reports provided the researcher with 
the opportunity to create the personal narratives of individual experiences and 
combine them with quantitative data. The reports obtained included both 
qualitative and quantitative data and therefore analysis primarily involved both 
YC free-text data and content from other data fields. Using qualitative and 
quantitative components in a mixed methods design provided complementary 
insights helping to create a more comprehensive understandiQJRIUHSRUWHUV¶
experiences of ADRs. A mixed methods approach was therefore consistent with 
the research aims.  
 
3.8 Ethical considerations  
Overall this study had some ethical issues to consider as it involved people who may have 
experienced an ADR. This experience could have left them sensitive to the subject and 
distressed by recalling the details for the researcher. However, each phase of the study was 
granted ethical approval as appropriate to the population involved. This was obtained from 
an NHS Research Ethics Committee (REC) which approved Phases One and Two, the 
Medway School of Pharmacy Research Ethics Committee (MSoP REC) which approved 
Phases Three, and the Independent Scientific Advisory Committee for MHRA database 
research (ISAC) which approved Phase Four (See Appendix 3 for approval letters: REC ref 
14/NE/1053; MSoP ref 0116/2; ISAC ref GENQ-00097958). 
54 
 
Detailed protocols were submitted at each stage, which outlined clear research 
aims and objectives and comprehensive methodology. Any inherent ethical 
considerations were declared and robust strategies were created which ensured 
ethical compliance. It is incumbent for researchers to be aware when engaging 
with human participants if sensitivity to the research topic is displayed and 
participation may be a distressing process for them. In such a situation, a rigorous 
case for the value of such research must be made by the researcher. In this 
particular study, it would not have been possible to conduct research into ADRs 
without including participants who had experienced ADRs. The benefits of 
creating a more comprehensive picture of their ADR experiences outweighed any 
concerns about possible distress in recalling negative experiences. The 
UHVHDUFKHU¶VEDFNJURXQGLQSV\FKRORJ\SURYHGWREHRIFRQVLGHrable benefit 
GXULQJWKLVVWXG\7KHUHVHDUFKHU¶VH[SHULHQFHRIZRUNLQJDVDSV\FKRORJLVW
facilitated the survey distribution and facilitated the collection of rich narratives 
from interview participants. The researcher has taken care to be consistent and 
ethically rigorous in ensuring the confidentiality and consent of the participants. 
Processes and procedures dealing with participant confidentiality and consent in 
each of the four phases of this study are described in detail in Chapters Four-
Seven.   
 
3.9 Summary 
It should be noted then that the development and approach to the study as well as 
the analysis and interpretation of results was shaped by the personal 
characteristics and previous experiences, knowledge, and general background of 
the researcher. Three key premises inform the study: that ADR research has been 
limited by focusing on clinical aspects of these effects; that ADRs can have 
VLJQLILFDQWLPSDFWDQGFRQVHTXHQFHVLQSHRSOHV¶OLYHVDQGWKDWLQGLYLGXDOVFDQ

































4.1 General introduction 
Chapter Two: Literature Review provided evidence of the existence of a 
knowledge deficit in health research in ADRs. The purpose of this study was to 
address the lack of knowledge surrounding how people cope with and manage 
ADRs. The aim of this phase ± Phase One - of the research, as described in 
Chapter Three: General Methods, was to investigate how people use information 
sources to help them identify ADRs and to explore pHRSOHV¶H[SHULHQFHVRI$'5V. 
To address some of the research questions which arose as a result of the literature 
review, JHQHUDOLQIRUPDWLRQRQSHRSOHV¶H[SHULHQFHVRI$'5VZDVUHTXLUHGIURP
a large study population. These research questions included the following:  
1. What are the personal experiences of people in managing their ADRs? 
a. What are the impact and consequences of their ADR experiences? 
b. What coping strategies do people use when they experience 
ADRs? 
2. What types of information sources do people use to find out about ADRs? 
a. What are the factors contributing to the use of these different 
information sources? 
Phase One gathered details about these issues through a purposely designed 
survey which collected the required information. This survey was used as a 




The rationale which guided the design for this phase of the study was provided in 
Chapter Two. This phase ± Phase One ± sought to contribute to ADR research by 
collecting information through surveys on how people identify and manage their 
ADRs. As mentioned in the General Introduction survey data from this phase of 
the study was used in Phase Two to recruit interview participants and structure the 
subsequent interviews. This chapter will describe the instrument development and 
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distribution procedures, recruitment and data collection processes, the strategies 
for data analysis, the results and a discussion of these results. 
 
4.2.2 Aims and objectives 
The aim of this phase of the study was to investigate how people use information 
VRXUFHVWRKHOSWKHPLGHQWLI\$'5VDQGWRH[SORUHSHRSOHV¶H[SHULHQFHVRI$'5V. 
The objectives are as follows:  
 To identify the types and value of different sources of information that 
people use to find out about ADRs 
 To identify the factors that influence what sources of information people 
use to find out about ADRs 
 To explore the personal experiences of people in managing their ADRs 
 To investigate the LPSDFWDQGFRQVHTXHQFHVRISHRSOHV¶$'5H[SHULHQFHV 
 To investigate the coping strategies that people use when they experience 
ADRs 
 7RDVVHVVUHODWLRQVKLSVEHWZHHQSHRSOHV¶FRSLQJVWUDWHJLHs and their 
experiences of ADRs 
 
4.2.3 Ethical approval 
An application was made to the NHS/HSC Research and Development (R&D) 
offices and the Research Ethics Committee through the Integrated Research 
Application System (IRAS).  (See Appendix 4). A favourable opinion was 
obtained from the Proportionate Review Sub-committee of the NRES Committee 
North East - Newcastle & North Tyneside 1. However considerable delays in the 
research governance approval process then ensued which in turn caused 
significant delays to the research overall. These delays were a result of conflicting 
information given by the Kent and Medway Research Management and 
Governance (RM&G) Consortium. It was stated - incorrectly - that a research 
passport for the researcher with full Occupational Health (OH) and Disclosure and 
Barring Service (DBS) checks were required before R&D would issue a Letter of 
Access for the study (See Appendix 5). The delays were unnecessary and 
incredibly frustrating occurring at a critical time period and significantly delayed 
data collection. This situation continued for over three months until notification 
was received from Kent and Medway R&D that a research passport was not 
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required to distribute questionnaires and local approval for the researcher to 
access the pharmacy premises would now be sufficient (see Appendix 5). As part 
of this application process potential ethical issues that might arise during this 
research were identified. Key amongst these were issues of confidentiality and 
anonymity. The researcher structured the study as indicated below to address 
these crucial areas.       
 
4.2.4 Confidentiality and Anonymity  
All participating pharmacies as well as survey respondents remained anonymous. 
All participants were informed that the research was confidential. Lists of the 
pharmacies visited were generated with unique identifying numbers. These lists 
were written on paper and locked in a secure filing cabinet. Access to these lists 
was limited to named members of the research team. At the end of this study these 
lists will be held for period of one month and subsequently destroyed by 
shredding. The returned surveys were assigned unique study numbers ensuring 
anonymity. Consent forms which contain contact details were also assigned 
unique identifying numbers and stored separately from the returned surveys. All 
survey data collected was stored on password protected computers and memory 
sticks. These digital records will be destroyed five years after the final thesis has 
been written. 
 
4.2.5 Instrument development 
A survey was developed iteratively within the research team to gather general 
LQIRUPDWLRQRQSHRSOHV¶H[Seriences of ADRs (See Appendix 6). Its structure was 
based on the research objectives and an effective framework was provided by 
previous research instruments. These surveys/questionnaires included the 
following: the Yellow Card Scheme Questionnaire, 2005; Side Effects Coping 
Questionnaire, 2012; the Hospital Inpatient Survey, 2013). Two validated 
instruments were also included - the MBSS abbreviated and the SECope 
abbreviated. Permission was obtained from the developers of these instruments to 
use the MBSS and SECope (see Appendix 7). These scales were included to 
provide additional information on the coping styles and coping behaviours of 




4.2.5.1 Justification for using MBSS and SECope scales 
$QLQGLYLGXDO¶VSHUFHSWLRQRIDQHJDWLYHHYHQW- such as an ADR - can be 
influenced by cognitive processes such as coping strategies (Kaptein & Weinman, 
2004). These coping strategies can be assessed by using psychological scales. 
Monitoring and blunting are defined as two response modes that are utilised in 
stressful/threatening situations. Monitoring is an information-seeking approach 
while blunting describes distraction and re-interpretation of the inhibiting aspects 
of the situation. Most individuals will use either Monitoring or Blunting strategies 
in stressful situations. Monitors will be alert and seek information as they attempt 
to increase the predictability of the outcome. Blunters will employ distractive 
strategies even if they have the potential to influence the outcome (Voss et al., 
2006). The abbreviated version of the Miller Behavioural Style Scale (MBSS) 
(Miller 1987; Steptoe, 1989) has been extensively used in psychological research 
to identify coping styles in stressful situations. It was used in this study to assess if 
coping styles influence whether and how, people with recent experience of an 
ADR, access information sources. The MBSS (abbreviated) consists of two 
controllable scenarios ± going to the dentist and the threat of potential job loss. 
Controllability is defined as the possibility that active interventions in the 
situation may change the outcome. Each scenario offers the respondent eight 
possible behavioural choices ± four will describe monitoring behaviours/styles of 
coping with aversive situations while the other four will describe blunting 
behaviours/styles of coping with aversive situations. Respondents are required to 
visualise the scenarios and assess if the proposed responses correspond to what 
they would do or think if they were in this situation. It was hypothesised that 
individuals that sought out information about their ADR would be assessed by the 
MBSS as monitors, while survey respondents that did not utilise sources of 
information such as PILs would be identified as blunters.  
The Side Effect Coping Questionnaire (SECope) (Johnson & NHLODQG¶V is 
DQLQVWUXPHQWXVHGLQKHDOWKEHKDYLRXUUHVHDUFKWRPHDVXUHSHRSOHV¶FRSLQJ
strategies and behaviours with treatment side effects. A revised version of the 
SECope questionnaire was developed composed of 16 items with four behavioural 
subscales - social support seeking, information seeking, non-adherence and taking 
additional medication (DeSmedt et al., 2011).  Respondents indicate their level of 
agreement with statements within each of these subscales. This SECope (revised) 
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was further amended to 10 items, in this phase of the study, after piloting, to aid 
instrument clarity and reduce repetition. This amended 10 item SECope was used 
in this study to assess the coping behaviours of people who experience ADRs and 
identify potential associations between these coping strategies.  
 
4.2.5.2 Survey structure 
The survey was structured as follows (See Appendix 6):  
Section A ± UHVSRQGHQWV¶XVHRIVRXUFHVRILQIRUPDWLRQ 
This section asked respondents how they might use information on medicines and 
was composed of two questions with tick box responses. Question One asked 
respondents about their hypothetical use of information sources if they 
experienced side effects. Ten potential sources of information were listed for 
respondents, divided into three categories: 
 HCPs ± GPs; Hospital doctors; Pharmacists and Nurses 
 Formal sources of information ± PILs; Print and Broadcast Media 
and Medicine books/guides  
 Informal sources of information - Relatives/friends; Internet and 
Other 
Respondents were asked to choose which of these sources they would use and 
could choose multiple sources by ticking multiple boxes. Question Two asked 





 Relevance  
Respondents were asked to consider each of the information sources and indicate 
if they considered them easy to access; trustworthy; easy to understand and/or 
relevant to them by ticking response boxes.  
Section B ± UHVSRQGHQWV¶SHUVRQDOH[SHULHQFHVRIVLGHHIIHFWV 
7KLVVHFWLRQDVNHGUHVSRQGHQWVIRUGHWDLOVDQGGHVFULSWLRQVRIWKHLUVLGHHIIHFWV¶
experience. It was composed of 12 questions in total with ten questions requiring 
tick box responses and two text box questions requiring free text comments. 
Questions Three to Six asked respondents if they had experienced a SE, as well as 
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the timing and consequences of their SE. 7KHWHUPµVLGHHIIHFWV¶ZDVVHOHFWHGas 
inclusive wording that would be more familiar to respondents than ADR and that 
would encourage reporting of minor effects. Question 7 asked respondents to rate 
the severity of their SE on a four-point scale ranging from Mild; Unpleasant; 
Serious to Very serious. Question 8 required respondents to assess the impact of 
the SE on their daily lives on a four-point scale ranging from No impact, Mild 
impact, Moderate impact to Severe impact. Question 10 also required respondents 
to rate their confidence that the SE was caused by their medicine on a four-point 
scale ranging from Not at all confident, Not very confident, Fairly confident to 
Very confident.  Questions Nine and 11 were free text questions asking 
respondents to describe in their own words the impact of the SE on their daily 
lives and how they concluded that the medicine had caused the SE. Question 12 
asked what information sources respondents used to confirm their SE. The same 
ten potential sources of information given in Section A in three categories were 
again listed for respondents. Respondents were asked to choose which of these 
sources they used and again could choose multiple sources by ticking multiple 
boxes. Questions 13 and 14 required tick box responses and sought information 
on adherence to medicines.  
Respondents were asked if they stopped taking their medicines and if they did was 
it their decision to stop or the result of advice from HCPs or relatives and/or 
friends. 
Section C ± UHVSRQGHQWV¶FRSLQJVWUDWHJLHVDPHQGHG6(&RSH  
This section sought information on how respondents cope with SE. Coping 
behaviours were assessed using an amended version of the SECope questionnaire 
(De Smedt et al., 2011), which contained 10 items in four subscales: 
 Information seeking  
 Taking medicines  
 Social support  
 Non-adherence  
7KHVWDWHPHQWVUHODWHGWRSHRSOHV¶EHKDYLRXUVZKHQWKH\H[SHULHQFHG6(
Respondents were asked how closely these behavioural statements corresponded 
with their own behaviours if they experienced a SE. They were asked to rate their 
possible responses on a five-point Likert-type scale ranging from Never; Rarely; 
Sometimes; Often to Always. 
Section D ± UHVSRQGHQWV¶FRSLQJZLWKVWUHVVIXOVLWXDWLRQV0%66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This section assessed the coping styles of respondents in stressful situations using 
the abbreviated MBSS. The abbreviated MBSS in this section consists of two 
scenarios: 
 Question 16 - going to the dentist  
 Question 17 - threat of job loss.  
Each question has eight possible behavioural choices for these aversive situations 
± four statements of monitoring behaviours and four statements of blunting 
behaviours. Respondents are asked to visualise the scenarios and choose which of 
the statements corresponded to what they would do or think in that situation. 
Respondents ticked boxes to indicate their agreement with behaviours/statements 
and could choose multiple responses by ticking multiple boxes.  
Section E ± demographic information. 
This section asked respondents to provide information on their gender, age range, 
employment status, education level and ethnicity. They were also asked to 
indicate the number of prescription medicines they regularly used. In addition, 
they were asked to provide their postcode. These postcodes distinguished between 
respondents from Birmingham and Kent and Medway. 
Section F - invitation to participate in interviews and Contact details form  
Surveys distributed in Kent and Medway contained an additional section. This 
section sought to recruit interview participants who had experienced a SE in the 
past six months. People were invited to provide their contact details for the 
researcher if they were willing to talk about their SE experience.  
 
4.2.5.3  Inclusion criteria 
The inclusion criteria for survey participants were as follows: 
 Adults aged 18 or over 
 Resident in the UK 
 Competency in written and spoken English 
 People who used prescription medicines or OTC medicines in the past 6 
months 
 
4.2.5.4 First pilot  
Piloting of questionnaire 
Twenty people known personally to the research team, who were known to have 
experienced an ADR, were asked to complete and assess the questionnaire. They 
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were posted an envelope which contained a questionnaire, Participant Information 
Sheet, a pre-paid envelope, and a Feedback form (See Appendix 8). They were 
asked to assess the questionnaire in terms of clarity, ease of completion, face 
validity and overall functionality. Based on the feedback received and discussions 
amongst the research team, several modifications were made to the questionnaire. 
Question Two, which asked respondents to assess a list of information sources for 
their accessibility, trustworthiness, understanding and relevance, was reformatted 
with clearly labelled tick boxes to aid clarity. The instructions section of the SE 
Cope Questionnaire was re-written to enhance coherence. In addition, the 
perceived repetition within the SECope was addressed and the initial 16 item scale 
was abbreviated to 10 items which focused on the important subscales 
information seeking behaviours and social support seeking behaviours. A second 
pilot was conducted to assess the impact of these amendments. 
Piloting of the distribution method 
As mentioned in Chapter Three, pharmacies were selected as distribution sites for 
this phase - Phase One ± of the study. Surveys were distributed amongst pharmacy 
customers who had used prescription medicines or non-prescribed medicines in 
the past six months. This method of distribution was selected as the most 
appropriate method to gather information from a large number of people who 
regularly used medicines. Personal distribution of the surveys in pharmacies 
enabled the researcher to screen and fully engage with the customers. This 
personal distribution method had the potential to increase response rates and 
recruitment of interviewees. Distribution of the initial version of the questionnaire 
was piloted in a local pharmacy in the Medway area. The owner of this pharmacy 
was known personally to the research team and was willing to participate in the 
pilot. Envelopes were prepared in advance and contained a questionnaire, a 
Participant Information Sheet and a pre-paid envelope to return completed 
questionnaires (See Appendix 8). During the pilot pharmacy customers were 
approached by the researcher who introduced herself and displayed her University 
ID. The researcher outlined the study and invited people to participate. If the 
individual indicated their willingness to participate they were asked questions to 
determine if they satisfied the inclusion criteria for the study. They were asked to 
complete the questionnaire at their leisure and return the completed questionnaire 
in the pre-paid envelope provided. The researcher took note of the following - the 
number of customers in the pharmacy over a four-hour period; the number of 
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customers who were approached by the researcher over this time period and the 
reasons given by people for refusing to take a questionnaire. This piloting of the 
distribution enabled the researcher to rehearse her approach to customers and 
calculate likely recruitment rates for the main study. 
 
4.2.5.5  Second pilot 
A novel group of people personally known to the research team and known to 
have experienced an ADR were contacted by the researcher. They were asked by 
phone or email if they were willing to participate. Those who agreed were asked 
to participate in the second pilot by assessing the revised questionnaire and 
providing feedback. Snowballing recruitment techniques were used as the pilot 
progressed to identify and recruit additional participants. The survey was 
distributed by post and included the questionnaire, a Participant Information 
Sheet, a pre-paid envelope and a Feedback form. This pilot enabled a final version 
of the survey to be developed for Phase One of the study (See Appendix 6). The 




4.2.6 Main study design 
This paragraph will describe the following stages: 
 Sample size 
 Recruitment of pharmacies 
 Recruitment of survey participants 
 Analysis of survey data 
 
Sample size 
The statistical power of a study provides a measure of the probability that its 
results are statistically significant. A study with good statistical power will 
produce accurate/precise findings which can be considered as representative of the 
population as a whole. Statistical power is influenced by sample size and it is 
good practice to estimate how many participants will be needed to achieve 
statistical significance. Considering sample size helps to control for Type II error 
and to estimate the accuracy/precision of the results. (Brace et al., 2016).    
The sample size for the survey was calculated using the following equation.  
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Ss = Z² x (p) x (1-p)      
                    C² 
 
where Ss= sample size; Z = 1.96 (95% confidence level); p = % accuracy expressed in 
decimals and C-squared = confidence interval or margin of error expressed as a decimal. 
C-squared is an estimate of the deviation between survey and general population 
parameters.  Confidence intervals define the range of values which are likely to include the 
population parameters - margin of error set at 5% estimates that 95% of survey respondents 
will include the population parameter. 
The calculation was based on an estimated figure for the prevalence of experiencing an 
ADR of 26% (/Alhawassi et al, 2014). Thus for a confidence level of 95%, a confidence 
interval/margin of error of 5%, the sample size required was: 
Ss = (1.96)² x (0.26) x (1-0.3) 
                 (0.05)² 
 
Ss = 3.84 x 0.26 x 0.7     =      0.698  
            0.0025                          0.0025    
 
Ss = 279.5 
 
The study therefore aimed to recruit approximately 300 participants. A previous study in 
the Kent area utilising similar methodology which sought experiences of using long-term 
medicines among the general public using community pharmacies found a response rate of 
40%. Therefore, based on this rate, it was decided to distribute approximately 700 
questionnaires (750*0.40 = 300).   
 
4.2.6.1 Recruitment of pharmacies 
This phase of the study aimed to survey members of the public through 
distribution of surveys in independent and small to medium sized multiple 
pharmacies within Kent & Medway and the West Midlands urban centres.  
Contacts amongst the research team (study collaborators) were used to facilitate 
the identification of potential small chains of pharmacies which may be willing to 
allow the study to take place on their premises. Large multiples were not 
approached as it was envisaged that seeking permission to access these premises 
would be too time consuming. A list of pharmacies with their contact details was 
compiled from the NHS Choices website. A letter of invitation to participate in 
the study was sent to these pharmacies and, if they could be identified, to named 
managers within these pharmacies (See Appendix 9). The envelope included an 
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information sheet for the pharmacist explaining the study and the survey (See 
Appendix 10). The initial postal contact was followed a week later by a telephone 
call to each pharmacy. The researcher asked the pharmacies for permission to 
access their premises to distribute surveys to the general public. The inclusion 
criteria for pharmacies were as follows:  
  Independent pharmacies 
 Small to medium sized multiples 
 Pharmacies within the following geographical areas ± Medway, Kent and 
the West Midlands 
 
4.2.6.2 Recruitment of survey participants 
Potential survey participants were identified by the researcher as pharmacy 
customers who had used prescription medicines or non-prescribed medicines in 
the past six months and satisfied the remaining inclusion criteria (see above). The 
researcher arrived at the pharmacy premises with prepared envelopes to distribute 
to the general public. Each envelope contained the following: participant 
information sheet, consent form, survey and a prepaid envelope to return the 
questionnaires. The researcher approached potential participants and outlined the 
study, asked questions to determine if they met the inclusion criteria and, if so, 
invited participation by completing the questionnaires and returning them at their 
leisure.  
This phase ± Phase One ± overlapped with Phase Two of the study. Survey data 
continued to be collected and analysed, as interviews for Phase Two were arranged 
and conducted. The data collection was enhanced by the involvement of MSoP 
undergraduate students who contributed by distributing the survey as part of their 
MPharm undergraduate Research Project. 
 
4.3 Data management 
The data from the returned surveys were entered into and analysed using SPSS for 
Windows Statistics 23. The data were checked and cleaned - errors and inconsistencies 
were identified and removed and data entry quality assured through comparison with 
original paper surveys. For validation purposes, a 10% (n=230) sample was checked for 




values were reported and the Kruskal-Wallis test was using to compare groups. 
&RQWLQJHQF\WDEOHVDQG3HDUVRQ¶VFKL-squared test was used to investigate associations 
between the following: 
Box 4.1: List of associations investigated with contingency tables and chi-squared tests 
5HVSRQGHQWV¶GHPRJUDSKLFVDQG6( history, gender 
5HVSRQGHQWV¶GHPRJUDSKLFVDQG6(H[SHULHQFH6(RXWFRPHV 
8VHRILQIRUPDWLRQVRXUFHVDQGUHVSRQGHQWV¶GHPRJUDSKLFVFRQILGHQFHLQFDXVDOLW\ 
Assessment and use of information sources 
Actual use of information sources and coping styles 
Coping styles and SE experience and SE outcomes 
 Predicted coping behaviours and gender, coping styles  
 
A significance value of p 05 was set to control for type I error DµIDOVH
SRVLWLYH¶LQFRUUHFWUHMHFWLRQRIWKHQXOOK\SRWKHVLV. A Bonferroni correction was 
applied for several analyses due to the large number of multiple comparisons 
being made. This resulted in a lower p value which reduced the occurrence of type 
I errors (adjusted p value=Į/n). Responses to survey text box questions nine and 
11 were entered in Excel and content analysis was carried out. Commonalities 
were identified and categories were created. The number of answers per category 
was noted and a frequency table was created. Then the free text responses for 
Survey questions were recorded in SPSS and into the data management 
programme NVivo (QSR NVivo 10). The responses were analysed using an 
iterative thematic approach. 
The MBSS and SECope scale scores were analysed using the methods specified 
by the authors of these instruments (see EHORZWRDVVHVVUHVSRQGHQWV¶FRSLQJ
styles and behaviours.  Factor analysis was used to investigate the underlying 
structure of the revised 10 item SECope. Survey data was subjected to regression 
analysis to examine relationships between variables and used to develop a Topic 
Guide for the interviews in Phase Two of the study (See Appendix 11). 
 
4.3.1 Analysis of SECope 
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The SECope was scored by assigning the numerical values 1-5 to the Likert scale 
responses as follows: very often = 5, often = 4, sometimes = 3, rarely = 2, and never = 1. 
All items were positively weighted except item 8 ± µAccept the side effect and take the 
PHGLFDWLRQDVSUHVFULEHG¶- which was reverse scored.  
The revised 10 item SECope was subjected to Principal Component Analysis 
(PCA) using direct oblimin rotation with Kaiser normalisation. The internal 
UHOLDELOLW\ZDVGHWHUPLQHGZLWK&URQEDFK¶VDOSKDĮ,WHPV with loadings values 
greater than 0.5 on a factor were considered strong loadings and assigned to that 
factor. If items displayed strong loadings on more than one factor they were 
further examined as cross loadings components.  
The amended 16 item SECope had four subscales ± Information seeking subscale; 
Taking medicines subscale; Social support subscale and Non-adherence subscale. 
Positive and negatively weighted items in each subscale were scored and an 
average of these scores was then calculated. The percentage of individuals who 
engaged in information seeking behaviours; social support seeking behaviours; 
taking medicines and non-adherence behaviours was thus calculated. A mean 
percentage of each of the SECope subscales was then calculated by summing the 
scores for the individual items that made up the subscale and dividing by the 
number of items. Scores above this mean value were labelled as positive coping 
strategies within the subscale while those below the value were considered 
negative coping strategies. This further distinguished the SECope subscale results 
and generated percentages for positive and negative coping behaviours/strategies.  
Contingency tables and 3HDUVRQ¶VFKL-squared test was then used to investigate 








4.3.2 Analysis of MBSS 
Coping styles were assessed by the abbreviated MBSS. The MBSS scoring key 
presents several scoring options. For this study, it was decided to calculate the 
total monitoring and blunting scores for each respondent. Each of the two 
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scenarios had eight possible responses - four monitoring and four blunting 
responses. Monitoring items are marked "M" on the MBSS Scoring Key and the 
Blunting items are marked "B" on the MBSS Scoring Key (See Appendix 12). An 
overall monitoring score was generated by summing endorsed monitoring items 
across the two scenarios. An overall blunting score was generated by summing the 
endorsed blunting items across the two scenarios. Subjects with a total score on 
the monitoring subscale of the MBSS which is greater than the median were 
classified as high monitors and those with scores less than the median value were 
classified as low monitors. Contingency tables and 3HDUVRQ¶VFKL-squared test was 
used to investigate associations between the following: 







4.4.1  Pilot Studies 
Two pilots were conducted: the first was designed to test the distribution method as 
well as the initial instrument, thus was intentionally large, the second was required 
as the instrument underwent major changes after the first pilot, thus was 
intentionally smaller, as there was no requirement to test the distribution method 
again. For the first pilot, 48 surveys were dispersed with 28 returned indicating a 
response rate of 58%. Approximately 40 customers were approached over four 
hours indicating that a 5-minute engagement with each customer was required to 
generate this response. The second pilot, using the amended instrument ±involved 
the distribution of 16 surveys with 12 returned, indicating a response rate of 75%. 
Overall 64 surveys were distributed with 40 returned a response rate of 63%.  
 
4.4.2 Main survey - survey distribution 
In total 935 surveys were distributed to pharmacy customers - 80 distributed in 
pharmacies in the Birmingham region and 214 distributed in pharmacies in Kent 
and Medway over seven months February-July 2015. Undergraduate students 
distributed 641 surveys over three months from October-December 2016. An 
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overall response rate of 25% was achieved with 230 surveys returned. Pilot 
responses were not included in these totals as respondents may have differed from 
those in the main study, hence creating selection bias. It is generally regarded as 
good practice not to combine data from pilot studies with data from the main study 
(Lancaster et al., 2004; Peat et al., 2002).  
 
4.4.3 Main study - Respondent characteristics 
From 230 returned surveys the UHVSRQGHQWV¶PHGLDQ,45DJH was 61 years (51 to 70 
Years), majority (141; 62%) were female and 164 (72%) were of white ethnicity. The 
highest proportion of respondents (102; 45%) were retired with 72 (32%) educated to 
University level. Demographics from pilots and main study are presented on the following 
page in Table 4.1. Comparison of pilots and main studies indicate similar demographics. 
The main differences were (a) education with more students in the pilots and (b) 100% of 
pilot respondents used medicines but 15% of survey respondents used no medicine. This 
was a result of recruiting people for the pilots who were known to the researcher and 
known to have experienced SE from their medicines. Overall 20 surveys (9%) were 
assessed as incomplete with item nonresponse dealt with by the conventional method of 
pairwise exclusion of missing data from analysis (Soley-Bori, 2013). The frequency of 





Table 4.1: Demographic characteristics of respondents to pilots and main survey  
 
Demographics Frequency (f) Percentage (%) 
 





8                               2                                 87 
20                             10                               141 
 
29                            17                         38 









 9                               1                                44 
 7                               3                                29 
 7                               3                                49 
 5                               3                                50 
 0                               2                                44 
 0                               0                                12 
 
32                              8                         19 
25                             25                        13 
25                             25                        21 
18                             25                        22 
0                               17                        19 








  11                             5                              46 
  11                             6                              82 
   6                              0                              53 
   0                              1                             12 
   0                              0                             35 
 
39                             42                         20 
39                             50                         36 
21                              0                          23 
0                                8                           5 
0                                0                         15 
Education 
6FKRRO/HDYHU 
School Leaver=17/18           
Further education                 
University                             
 
 6                                 2                            61 
 6                                 1                            36 
 6                                 7                            60 
10                                2                            72 
  
 
21                              17                       27 
21                               8                        16 
21                              58                       26 








 10                              3                             64 
   5                              3                             28 
   8                              5                             102 
   5                              1                             10 
   0                              0                             12 
 
36                               25                       28 
18                               25                       12 
29                               42                       44 
18                                 8                         4 
 0                                  0                         5 
Ethnicity 
White 
Asian/Asian Br    
Black/Black Br 
 
13                              8                               164 
 5                               3                                36 
10                              1                                11 
 
 
 46                               67                      71 
 18                               25                      16 
















Q1 Predicted info 
use 
2 Q13 Stopped meds 6 
Q2 Assessment of 
info sources 
 
1 Q14 Advice on 
stopping meds 
4 
Q3 SE experience 
 
2 Q15 SECope 20 
Q4 SE timing 2 
 
Q16 & Q17 MBSS 6 
Q5 G.P. visit 
 
2 Q18 Medicine use 2 
Q6 Hospitalisation 
 
2 Q19 Gender 2 
Q7 SE Severity 
 
2 Q20 Age 2 
Q8 SE Impact 
 
3 Q21 Employment 2 
Q9 Text box 
Impact on QoL 
 
20 Q22 Education 1 
Q10 Confidence on 
causality 
 
3 Q23 Ethnicity 3 
Q11 Text box 
causality 
 




2   
QoL = quality of daily life; MBSS= Miller behavioural style scale; SECope =  Side effects Coping 
 
4.4.4 Main study - findings 
Findings relating to SHRSOHV¶ H[SHULHQFHV RI $'5V are presented under three 
headings: The experience of SE; Identifying SE and Managing SE. 
 
4.4.5 Side effect experience  
The overall SE experience was composed of SE history; SE timing and SE 
outcomes. Outcomes were categorised for analysis by the reported severity, 
impact and consequences of SE. 
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Overall 192(85%) respondents used prescribed medicines regularly - a similar 
proportion of females 121(86%) and males 71(83%). The highest proportion of 
respondents 82(36%) took two to four medicines -   31(36%) of males and 
51(36%) of females. In total 12(5%) respondents used more than eight medicines. 
Overall 159 respondents had experienced a SE with the timing of the SE a year 
ago or longer for 77(49%) respondents; past six months for 34(22%); past three 
months for 23(15%) and in the past month for 24(15%) of respondents. 
4.4.5.1 Associations between Gender, SE history DQGUHVSRQGHQWV¶GHPRJUDSKLFV 
Gender and Employment 
Analysis was conducted to examine associations between Gender, SE experience 
DQGUHVSRQGHQWV¶GHPRJUDSKLFVAnalysis indicated that there was an association 
between gender and employment with a higher proportion of males 32(37%) in 
full time work than females 32(23%). The difference was not statistically 
significant at the Bonferroni adjusted probability level (p=0.005). (See Table 4.3).  
Gender and SE history 
Crosstabulation indicated that female respondents experienced more SE from their 
medicines than males, but the difference was not statistically significant.  Overall 
159 respondents ± 106 females and 53 males - had experienced a SE. (Sixty eight 
respondents had no history of side effects). It was indicated that females 42(40%) 
had experienced SE once compared to 28(53%) of males. A majority of female 
respondents 64(60%) experienced SE more than once compared to 25(47%) of 
males. (See Table 4.3).  
SE history and Age 
A relationship was identified between SE history and age with a greater 
proportion of respondents with a history of SE 36(23%) in the 61-70 age range. 
The difference was not statistically significant at the Bonferroni adjusted 
probability level (adjusted p=0.004). Of these 26(30%) had more than one SE 
experience. A similar proportion of respondents 25(16%) below 40 and 41-50 
years had a history of SE. However, in later age ranges there was increases in the 
incidence of SE to 33(21%) in those aged 51-60; 36(23%) in those 61-70 years 




SE history and medicine use 
Analysis indicated an association between SE history and medicine use. However 
the association was not statistically significant at the Bonferroni adjusted 
probability level (adjusted p=0.005). Regular use of multiple prescribed medicines 
was linked to more than one SE experience. Overall the highest proportion of 
respondents 56(35%) with a history of SE used two-four medicines regularly. 
Over half of respondents 88(55.3%) had more than one SE experience. Amongst 
respondents who had experienced SE more than once 33(59%) used two-four 
medicines; 28(32%) used five-eight medicines and 9(10%) used more than eight 
medicines. (See Table 4.3).  
SE history and Education, Employment  
Overall retired respondents and those educated to further education levels had a 
more extensive SE history. The highest proportion of overall respondents with a 
history of SE were University educated 50(31%) and Retired 76(48%). A total of 
89(56%) had experienced SE more than once. The highest proportion of these 





*Not significant at Bonferroni adjusted alpha levels 
 
Table 4.3: Respondent characteristics 
by Gender/SE history n=230  
    
Respondent characteristics  
 
        Gender f (%) n=227 
Male               Female      
p-value SE history f (%) n=159 










16(18.4)                   28(20) 
13(14.9)                   16(11.4)                     
15(17.2)                   34(24.3) 
22(25.3)                   28(20) 
13(14.9)                   31(22.1) 
 8(9.2)                        3(2.1) 
0.09       
 15(21.1)       10(11.4) 
 12(16.9)       13(14.8) 
 15(21.1)       18(20.5) 
 10(14.1)        26(29.5)  
 12(16.9)        19(21.6) 









15(17.4)                   20(14.2) 
15(17.4)                   30(21.3) 
31(36)                      51(36.2) 
21(24.4)                   32(22.7) 
 4(4.7)                        8(5.7) 
 
0.93  
12(16.9)           8(9.1) 
18(25.4)         10(11.4) 
23(32.4)         33(37.5) 
15(21.1)         28(31.8) 




School Leaver=17/18           
Further education                 
University                             
 
24(27.6)                     36(25.5)   
11(12.6)                     25(17.7) 
21(24.1)                     39(27.7) 
31(35.6)                     41(29.1) 
0.58  
20(28.2)        23(25.8) 
11(15.5)        12(13.5) 
15(21.1)        29(32.6) 







32(37.2)                     32(22.7) 
 9(10.5)                      19(13.5) 
40(46.5)                     62(44) 
 
0.03*  
20(28.2)         17(19.1) 
10(14.1)          9(10.1) 
28(39.4)         48(53.9) 










57(65.5)                    106(76.3) 
20(23)                        16(11.5) 
  4(4.6)                        7(5) 
 
N/A                             N/A                      
N/A                             N/A 
                                                                 
0.35  
54(77.1)         66(75) 
10(14.3)         14(15.9) 
  1(1.4)             4(4.5) 
   
  28(52.8)           25(47.2)                      








Age and medicine use  
 
Analysis indicated an association between the age range of respondents and their medicine 
use. Overall as the age ranges increase so too does medicine use. The highest proportion of 
respondents used two to four medicines 82(36%) followed by 52(23%) who used five-eight 
medicines. A high proportion of those who used two-four medicines were aged 51-60 and 
61-70 years; 25(51%) and 23(46%) respectively. The proportion of respondents who use 
five-eight medicines increased from 18(36%) in those aged 61-70 to 20(46%) in 71-80 
years and 6(50%) in those over 80. Half of respondents aged over 80 6(50%) use five-eight 
medicines. The percentages RIUHVSRQGHQWV¶PHGLFLQHXVHLQHDFKDJHUDQJHLVpresented 
graphically see Figure 4.1. The association between age and medicine use was not 





















# missing data (n=3) 
 













































more than 8 freq
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4.4.5.2 Associations between SE severity and respoQGHQWV¶FKDUDFWHULVWLFV 
7KHHIIHFWVRIUHVSRQGHQWV¶FKDUDFWHULVWLFVRQ6(VHYHULW\ZHUHLQYHVWLJDWHG7KHVH
characteristics included demographics such as gender and medicine use. 
SE severity and Gender 
Analysis indicated an association between SE severity and gender of respondents. 




4.4.5.3 Associations between SE consequences and respondents¶characteristics 
The effects of demographics and medicine use on SE outcomes such as SE 
severity, SE impact and SE consequences were investigated. These consequences 
included a GP visit and hospital admission. A GP visit was associated with 
gender; age and medicine use as well as employment and education. (See Table 
4.4) 
GP visit and Gender   
Analysis indicated a relationship between gender and SE consequences. Gender 
effects were evident as 103(65%) of respondents saw a GP with the majority 
76(72%) females. Overall 14(9%) respondents required hospitalisation with a 
higher proportion of females 11(10%) than males 3(6%).  The relationship 
between SE consequences (GP visit) and gender was significant: X2 (1, N = 159) = 
6.01, p = 0.01. The negative association was of moderate strength: ĭ = -0.2, 
gender accounted for just 4% of the variation in SE severity.  
GP visit and age 
A relationship was identified between age and SE consequences. As the age ranges 
increased from 41-50 to 71-80 the proportion of respondents who saw a GP also increased. 
The majority of respondents within these age ranges - 15(60%) of respondents aged 41-50 
years; 22(67%) aged 51-60; 23(64%) aged 61-70 and 28(90%) aged 71-80 saw a GP. The 
highest proportion of respondents who saw a GP across the age ranges were aged 71-80 
years 28(90%). The association between age and GP visits was not statistically significant 
at the Bonferroni adjusted probability level (adjusted p=0.004). 
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GP visit and medicine use 
Analysis indicated an association between medicine use and SE consequences. A higher 
proportion of respondents using two-eight medicines saw a GP compared to other 
respondents. Those taking two-four medicines 43(77%) and five-eight medicines 31(74%) 
were compared to 17(17%) taking one medicine and 7(58%) who were using more than 
eight medicines. Analysis showed that one cell had expected count less than 5 so an exact 
VLJQLILFDQFHWHVWZDVVHOHFWHGIRU3HDUVRQ¶VFKL-square. The relationship between SE 
consequences (GP visit) and number of prescribed medicines was significant at the 
Bonferroni adjusted probability level (adjusted p=0.005): X2 (4, N = 158) = 16.22, p = 
0.002. The association was of moderate strength: ĭ = 0.3 with medicines accounting for 
10% of the variation in SE consequences (GP visit).  
GP visit and Employment and Education 
Retirees and those in full time employment were more likely to see a GP because 
of their SE when compared other respondents. Overall 104(65%) saw a GP with a 
higher proportion 57(76%) of these retired respondents and 23(62%) in full time 
employment.  Early school leavers were more likely to see a GP compared to 
other respondents. A higher proportion of school leavers under 16 years 32(76%) 
and at 17/18 years 19(83%) saw a GP than other respondents.  
Hospital admission and age, medicine use, employment and education 
Crosstabulation indicated that those aged 41-50 (4;16%); those using 5-8 
medicines (5;11.9%); retirees(5;7%); school leavers under 16 (5;12%) and 
University educated respondents (5;10%) experienced more hospital admissions 
as a consequence of their SE. However the difference was not statistically 
significant. 
 
4.4.5.4 Predicting SE experience  
As mentioned previously overall SE experience was composed of SE history; SE 
timing and SE outcomes. Outcomes were categorised for analysis by the reported 
severity, impact and consequences of SE. 
Regression analysis was conducted to determine if SE experience could be 
predicted by demographic variables and medicine use. Multinomial logistic 
regressions were performed on 224 cases to assess the relationship between the 
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predictor variables - age, gender, employment status, education and number of 
medicines ± and the dependent variable, SE experience.  
It was found that age and gender significantly predicted SE history (chi-square = 25.58, df 
= 12, p =0.012) and SE consequences such as GP visits (chi-square = 29.2, df = 6, p 
<0.001). Males were less likely than females to have had more than one SE and the odds of 
males having had more than one SE was 63% lower than the odds of females.  
Respondents aged below 40 were less likely to have had more than one SE compared to 
those aged over 80. The odds of those aged below 40 having experienced more than one 
SE was 45% lower than those aged over 80. Males were less likely than females to have 
required a GP visit as a result of the SE with the odds of males 74% lower than the odds of 
females. See Table 4.5 on the following page. 
Gender also predicted SE severity (chi-square = 12.36, df = 3, p =0.006) and SE impact 
(chi-square = 5.6, df = 1, p =0.02). Males were less likely than females to describe their SE 
as serious and also less likely to report their SE as having a severe or moderate impact on 
their lives. Analysis indicated that the odds of males having a serious SE was 76% lower 
than that of females. When compared to females the odds of males reporting the impact of 






















































    Gender f (%) n=159 
 Male                   Female  
p-value Prescribed medicines f (%) n= 
None            One             2-4          5-8             >8 
 
p-value 
SE severity  
Mild 
 Unpleasant  
Serious  
Very serious                   
 
14(26.4)              11(10.4)  
26(49.1)              47(44.3) 
13(24.5)              43(40.6) 




4(15.4)          6(23.8)        8(30.8)       8(30.8)         0    
9(12.5)          8(11.1)       30(41.7)    15(20.8)      10(13.9) 
7(12.5)         12(21.4)      17(30.4)    18(32.1)        2(3.6) 









11(21.2)               11(10.5) 
25(48.1)               41(39) 
13(25)                  37(35.2) 
3(5.8)                   16(15.2) 
 
0.07  
 4(18.2)           7(31.8)        7(31.8)     4(18.2)         0 
10(14.9)          8(11.9)      24(35.8)    15(22.4)      10(14.9) 
 4(8.2)             6(12.2)      18(36.7)    19(38.8)        2(4.1) 





GP visit  
Hospital visit 
 
27(51.9%)           76(71.7%) 





6(5.8)              17(16.3)     43(41.3)    31(29.8)     7(6.7) 





#Not significant at Bonferroni adjusted alpha levels 
*Significant at p=0.05 probability level 








Table 4.5: Multinomial regression analysis identifying predictors of SE history (n=224) and GP visits (n=156) 
Predictor 
Variables 
                     B 
SE history*     GP 
visitx 
 
               df 




SE history*     GP visitx 
 
Sig 





   
 
-0.9                  -0.897 
0                          0 
 
1                    1 
0                    0 
 
 
0.4           0.408       
0                0 
 
0.009**        0.021** 









- 0.593          -2.87 
1.362            -1.63 
0.136           -1.41 
0.853           -1.38 
0.463           0.09 
0                  0 




1                    1 
1                    1 
1                    1 
1                    1 
1                    1 
0                    0 
 
0.553        0.06 
3.905        0.2 
1.146        0.24 
2.348       0.25 
1.589       1.09 
0               0 
          
 
 
0.559          0.02** 
0.212          0.17 
0.892          0.23 
0.388          0.23 
0.646          0.94 
0                 0 
*Reference category no SE 
x Reference category no visit 
#Parameter set to 0 










Table 4.6: Multinomial regression analysis identifying predictors of SE severity (n=159) 
 
*Reference category = mild 
#Parameter set to 0 
**Significant at p<0.05 level 
 
 





         B 
Severe/Moderate*  
             
           df 
Severe/Moderate*  
 
          Exp(B) 
Severe/Moderate*  
 






    
 
-0.83                 
0                            
 
1      
0      
 
 
0.44      
0      
 
0.02**      
0       
*Reference category mild/no impact 
#Parameter set to 0 





    B 
Serious SE* 
 





















4.4.6 Identifying SE  
4.4.6.1. Information sources  
Predicted use vs actual use of information sources 
In response to question 1, all survey respondents indicated the sources of 
information they thought they would use to find out about SE. Those who 
indicated they had experienced a SE also provided details of the sources they 
DFWXDOO\XVHGZKHQWKLVRFFXUUHG5HVSRQGHQWV¶DFWXDOXVHRILQIRUPDWLRQVRXUFHV
to confirm their SE differed from their predicted use of these sources. Analysis 
indicated that GPs 194(85%); PILs 192(84%) and pharmacists 153(67%) would 
be the information sources most likely used by respondents. In actual use GPs and 
PILs were the most utilised sources; 109(69%) and 106(67%) respectively. 
However, a higher proportion of respondents used the Internet 60(38%) than 
pharmacists to confirm their SE 44(28%). Overall medicine books/guides and the 
print/broadcast media were the least used sources across both predicted use - 





















PILs-=Patient Information Leaflet; GPs=General Practitioners 
 




















































 4.4.6.2 Assessment of Information sources 
Analysis was condXFWHGRQUHVSRQGHQWV¶assessments of information sources for 
ease of access; ease of understanding; trustworthiness and relevance (n=229). 
Overall PILs were considered the most accessible source 180(79%) with medicine 
books/guides identified as the least accessible 45(20%). GPs were identified as the 
most trustworthy information source 181(79%) with the Internet considered the 
least trustworthy 34(15%). A similar proportion of respondents identified GPs and 
pharmacists as sources that were easy to understand; 150(66%) and 151(66%) 
respectively. However, medicine books/guides were viewed as the least 
understandable source 30(13%). Respondents identified GPs as the most relevant 
information source 149(65%) with print/broadcast media the least relevant 









Rel/Fr=Relatives/Friends; Med bks=Medicine books; Print & Broadcast media; PILs=Patient Information Leaflets; Pharm=Pharmacists; Hsp D=Hospital Doctors; GPs=General 
Practicioners;  
*Sources assessed by respondents as most accessible; trustworthy; easy to understand and relevant 



































































5HVSRQGHQWV¶DVVHVVPHQWDQGDFWXDOuse of information sources 
A logistical regression was performed to predict the actual use of information 
VRXUFHVDJDLQVWUHVSRQGHQWV¶DVVHVVPHQWRIWKHVHLQIRUPDWLRQVRXUFHV6HHTable 
4.8. Use of information sources to confirm SE was the dependent variable with 
accessibility, trustworthiness, ease of understanding and relevance as predictor 
variabOHV7KLVSUHGLFWLYHDQDO\VLVRIFDVHVLQGLFDWHGWKDWUHVSRQGHQWV¶
perceptions of two information sources - GPs and the Internet - could be 
associated with actual use of these information sources.   
GPs 
Assessment of GPs as easy to access and relevant information sources 
significantly predicted whether GPs were used to confirm SE. Accessibility 
variable; b = 0.89, Wald X2 (1) = 4.94, p = 0.03 and relevance variable; b = 1.02, 
Wald X2 (1) = 4.17, p = 0.04. The odds of respondents using GPs to confirm SE 
was 2.42 times higher and 2.77 times higher respectively if they perceived GPs as 
accessible and relevant (with a 95% CI 1.11-5.29; 95% CI 1.04 -7.36). 
Internet 
Assessment of the Internet as an accessible information source reliably predicted 
its use to confirm SE. Accessibility variable; b = 1., Wald X2 (1) = 6.6, p = 0.01. 
The odds of respondents using the Internet to confirm SE was 3.97 times higher if 








Table 4.8: Logistic regression analysis identifying predictors of actual use of information sources. 
















B= coefficient; Wald= Wald chi-square test; df=  degrees of freedom; Exp(B)=  exponentiation of the B coefficient; Sig=significance 
GPs=General Practitioners; PILs=Patient Information Leaflets 















Ease of Access 
   GPs 
   Pharmacists 
   PILs 




































   GPs 
   Pharmacists 
   PILs 



































Easy to Understand 
   GPs 
   Pharmacists 
   PILs 





































  GPs 
   Pharmacists 
   PILs 

























4.4.6.4 Use of information sRXUFHVDQGUHVSRQGHQWV¶FRQILGHQFHOHYHOV 








Type of sources 
The types of sources used to confirm SE varied across respondents, but overall use of 
multiple sources or combining HCPs and PILs led to increased levels of confidence in 
respondents. Over half of respondents 82(52%) used multiple sources ± HCPs, 
formal/informal sources - and 51(64%) of these were very confident that the SE was due to 
their medicine. Respondents who combined HCPs and PILs 37(24%) to confirm their SE 








































Number of information sources
Not at all confident freq











































Not at all confident freq





4.4.6.5 Number and types of information sources and coping styles 
Of 224 respondents 164(73%) respondents had monitoring coping styles with 
28(13%) identified as Blunters and 32(14%) with neutral coping styles. Analysis 
was conducted on the number of information sources by respondents across these 
coping styles. The top three sources used by Monitors were GPs (79;72%), 
followed by PILs (72;66%) and the Internet (44;40%); Blunters used PILs 
(16;84%), GPs (11;58%) and pharmacists (8;42%). Those with neutral coping 
styles used PILs (16;67%) followed by GPs (14;58%) and the Internet (8;33%). 
See Table 4.9. 
 
Table 4.9: Type of information sources used by Coping styles 
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     Hospital doctors 
     Pharmacists 





















   PILs 
   Pr & Br Media 
   Medicine books/guides 

















   Relatives/friends 
   Internet 
    
















Figures shown are n(%) 




4.4.7     Management of SE  
4.4.7.1 Coping Styles and SE experience  
Data were analysed to identify any patterns between MBSS coping styles and 
FKDUDFWHULVWLFVRIUHVSRQGHQWV¶6(H[SHULHQFH7KHRYHUDOO6(H[SHULHQFHZDV
composed of SE history; SE timing and SE outcomes. Outcomes were further 
categorised as the reported severity, impact and consequences of SE. 
 
4.4.7.2 Coping styles and SE history and timing 
A total of 160 respondents had experienced SE - 71 (44%) indicated they had experienced 
SE once with 89(56%) having more than one SE experience. Of those who completed the 
MBSS similar proportions of Monitors (49;44%) and Blunters (9;50%) had experienced a 
SE. The timing of SE was similar in Monitors and Blunters ± 55;50% and 7;42% 
respectively. See Table 4.10. 
 
4.4.7.3 Coping styles and SE severity 
2YHUDOOUHVSRQGHQWVUHSRUWHGWKHLU6(DVµXQSOHDVDQW¶ DQGDVµVHULRXV¶
Monitors reported theiU6(DVµXQSOHDVDQW¶RUµVHULRXV¶%) compared to Blunters 
(15;79%) and Neutrals (16;67%). Thirty-six Monitors reported µVHULRXV¶HIIects compared 
to eight Blunters (42%) and nine neutrals (38%). Associations between coping styles and 
the reported severity of SE were examined. Five cells had expected count less than 5 so an 
H[DFWVLJQLILFDQFHWHVWZDVVHOHFWHGIRU3HDUVRQ¶VFKL-square. There was a relationship 
between coping styles and SE severity: X2 (6, N = 154) = 13.97, p = 0.033. The association 
was of moderate strength: ĭ = 0.3 coping styles accounted for 9% of the variation in SE 
severity. See Table 4.10.  
 
4.4.7.4 Coping styles and SE impact and consequences    
$QDO\VLVRIWKHLPSDFWRI6(LQGLFDWHGWKDWUHVSRQGHQWVH[SHULHQFHGµPLOG¶RU
µPRGHUDWH¶LPSDct. The highest proportion of Monitors experienced either 
µPRGHUDWH¶RUµPLOG¶LPSDFW7KHKLJKHVWSURSRUWLRQRI%OXQWHUV
DQG1HXWUDOVUHSRUWHGWKHLULPSDFWDVµPLOG¶6HYHQWHHQUHVSRQGHQWV
UHSRUWHGDµVHYHUH¶LPSDFW± 13(12%) of these were identified as Monitors. Overall a 
majority of respondents (104;65%) required a GP visit while 14(9%) required 
hospitalisation. The majority of Monitors (71;65%) and 13 Blunters (69%) required a GP 
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Table 4.10: SE experience of respondents by Coping styles (n=154)  
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4.4.7.5 SECope and coping behaviours  
 The revised 10 item SECope was analysed by means of a principal component analysis 
(PCA) with direct oblimin rotation. The various indicators of factorability were good and 
the residuals indicated a good solution. Four components with an eigenvalue greater than 1 
were found See Table 4.11. These components were confirmed by visual inspection of the 
scree plot. See Figure 4.7. Parallel Analysis (PA) was then performed to further establish 
significant components. The same components and rotation methods were used to generate 
a random set of variable loadings. The PCA eigenvalues for the first four components are 
larger than the corresponding PA eigenvalues and are thus significant at p = 0.05. 
Retaining these components for interpretation and subsequent analysis was therefore 
appropriate. See Table 4.12.  
The four extracted components corresponded with the four subscales of the original 16 
item SECope. All loadings were greater than 0.5 and no clear cross-loadings were seen for 
the 10 items. See Table 4.13 for the loadings of Items 1-10. The pattern of loadings 
indicated the following four factors/subscales:  
- information seeking subscale (Items 3, 4, 9 and 10) 
- non-adherence subscale (Items 1 and 8) 
- social support seeking subscale (Items 2 and 6) 
- taking medicines subscale (Items 5 and 7) 
As with the 16 item SECope items 9 and 10 - related to requests for medicines -loaded 
strongly onto the information seeking subscale instead of the taking additional medicines 
subscale. Analysis indicated the revised 10 item scale was reliable - &URQEDFK¶VDOSKD
(Į=0.8). The subscales had acceptable internal reliability: information seeking (Į ; 
non-adherence (Į ); taking additional medicines(Į ) and social support seeking 
subscale (Į=0.5). The exploratory analysis resulted in a 10 item scale with four subscales. 
This model explained 67.3% of the total variance.
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Table 4.11: Eigenvalues and variance for possible Components 1-4 extracted by PCA 
Possible components*  Eigenvalues Variance % 
 
Cumulative loadings %           
Component 1 
Information seeking 




























Social support seeking 









Table 4.12 Comparison of PCA and Parallel Analysis eigenvalues  
 
Possible components* PCA Eigenvalues Parallel Eigenvalues 
Component 1 
Information seeking 























Social support seeking 










































Talk to your doctor or 
health care professional 










Try to get more 
information about the 

















Ask your doctor to prescribe a 
different medication 




Request a medication from your 
doctor to help with the side effect 
0.584* 0.236 -0.051 0.035 
Take another medication to deal 
with the side effect 
0.193 0.787* -0.067 -0.117 
Accept the side effect and take the 
medication as prescribed 
0.102 -0.158 0.801* 0.064 
Reduce the dose of the medication 
that is causing the side effect 
0.013 0.749* 0.273 0.218 
Decide that the benefit from the 
medication is not worth the side 
effect and stop taking it 
-0.078 0.301 0.812* 0.06 
Talk to family friends loved ones 
about the problem 
0.024 -0.026 -0.038 0.886* 
* Strongest loading  
Rotation converged in 6 iterations 
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Analysis of the SECope item responses indicated that a high proportion of 
respondents would engage in information seeking strategies. Predicted strategies 
included information seeking with 104(45%µDOZD\V¶RUµRIWHQ¶
consulting HCPs. 5HVSRQGHQWVZRXOGµDOZD\V¶RUµoften¶ 64 (28%) 
sought more information about the SE/medicine. In terms of social support, a 
TXDUWHURIUHVSRQGHQWVZRXOGµRIWHQ¶JHWVXSSRUWIURPSHRSOHZKLOH
ZRXOGµRIWHQ¶WDONWRIDPLO\IULHQGV1RQ-adherent strategies were 
predicted by almost 40% of respondents -  ZRXOGµRIWHQ¶RUµDOZD\V¶
VWRSWDNLQJWKHPHGLFLQHZKLOHZRXOGµQHYHU¶RUµUDUHO\¶
DFFHSWWKH6(DQGNHHSWDNLQJWKHPHGLFLQHµ2IWHQ¶UHGXFLQJWKHGRVH
was a predicted strategy for 22(10%) whilHZRXOGµDOZD\V¶HQJDJHLQWKLV
EHKDYLRXU$QDO\VLVIXUWKHULQGLFDWHGWKDWZRXOGµRIWHQ¶RUµDOZD\V¶
(32;14%) accept the SE and keep taking the medicine. The responses to individual 







IS =  Information seeking subscale; NA = Non-adherence subscale; Tkmeds =  Taking additional medicines subscale; SS#=Social support seeking behaviours 
 



















































0 10 20 30 40 50 60 70 80
NA: Decide that the benefit from the medication is not worth the side effect and stop taking it
NA: Accept the side effect and take the medication as prescribed
SS#: Get support from other people
SS#: Talk to family friends loved ones about the problem
IS: Talk to your doctor or health care professional about the problem
IS: Try to get more information about the medication or side effect
IS: Request a medication from your doctor to help the side effect
IS: Ask your doctor to prescribe a different medication
Tkmeds: Take another medication to deal with the side effect









Always % Often % Sometimes % Rarely % Never %
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4.4.7.6 Predicted coping behaviours and gender and coping styles  
Overall 210 respondents completed the SECope, mean scores for each of the four 
subscales were calculated see Table 4.14 below:  
Table 4.14: Descriptive statistics of SECope subscales including mean subscale 











Non-adherence    
 
3.03 1.08 2-10 
Information 
seeking    
 








medicines   
 
2.18 1.04 2-10 
# Mean subscale values which range from 1-5 
*Range of item scores per subscale 
 
Analysis identified positive and negative coping strategies within each subscale. 
A higher proportion of respondents indicated they would engage in positive 
information seeking behaviours (111;53%) or seek social support (107;51%). The 
majority of respondents predicted that they would use negative coping strategies 
within non-adherence and taking medicines subscales ± 128(61%) and 120(57%) 
respectively. See Figure 4.9.  
Gender was not a significant factor in predicted coping behaviours. Similar 
proportions of males (42;54%) and females (69;53%) indicated they would 
engage in positive information seeking behaviours. Positive social support seeking 
behaviours were also predicted in both males (39;50%) and females (67;52%). 
Monitors reported they would use positive information seeking strategies 
(81;52%). However they were more likely to engage in negative behaviours in 
relation to non-adherence (95;61%) and in relation to taking medicine(s) to cope 
with the SE (94;60%). A high proportion of Blunters predicted positive social 
support seeking (15;68%) and information seeking behaviours (13;59%). 
Associations between coping behaviours and coping styles were examined. The 
relationship between predicted non-adherent behaviours and coping styles was 
significant: X2 (2, N = 206) = 7.38, p = 0.03. The association was of moderate 
VWUHQJWKĭ FRSLQJVW\OHVDFFRXQWHGIRURI the variation in predicted non-
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adherence. A summary table of predicted coping behaviours by gender and coping 



































Negative strategies Positive strategies
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Table 4.15: Predicted coping strategies vs gender and coping styles 
 
 
Figures shown are n (%) 
+ =positive, - = negative 

































































































































4.4.7.7 Predicted non-adherence and actual non-adherence  
Analysis of the SECope non-adherence subscale and non-adherent behaviours 
were conducted. This indicated that a majority of respondents who stopped taking 
their medicines predicted they would engage in non-adherent behaviours 
(49;58%). The majority of these respondents made their own decision to stop their 
medicines (20;77%). See Figure 4.10. 
Blunters were more likely to engage in non-adherent behaviours as a result of 
HCP advice. A majority of Blunters (11;65%) with 64 Monitors (59%) and 13 
Neutral (54%) stopped their medicines. HCP advice to stop medicines was 
received by 10 Blunters (91%); compared with 39 Monitors (58%) and 10 
Neutrals (77%). Over 30% of Monitors made their own decision to stop medicines 





















































Rel/friends=relatives/friends; HCP=Healthcare professional 































Advised by rel/friends % Advised by HCP % Own decision %
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4.4.7.8   Survey text box responses 
Analysis of the text box responses examined the impact of SE and the factors that aided 
UHVSRQGHQWV¶LQOLQNLQJWKHLUPHGLFLQHVWRWKHLU6($majority of respondents described 
the impact of SE in primarily physical effects (125;85%) followed by 17 (12%) describing 
psychological effects and 15 (10%) social effects. Respondents confirmed the SE with 
HCPs 43(29%) and PILs (38;26%). Factors such as the timing of the side effect, previous 
health experiences and knowledge (from a range of sources) were used to link the medicine 




























Table 4.16: Frequency table of text box responses to survey questions 9&10 
             Examples of responses to questions 9 & 10 (N=148)        Frequency % 
Q9:Please describe in your own words how the side effect(s) affected your daily life. 
  
Physical impact of SE 
³3LQV	QHHGOHVLQP\IHHW	KDQGV,DOVRIHOWDELWVKDN\.´ 
Female, 61-70 yrs, Retired, F ed, 5- meds. 
 
³&RXJKLQJXSEORRGDQGNQHHVZDV>VLF@painful´ 
Male, 61-70 yrs,Retired, SL 17/18, 2-4 meds 
 
125 85 
Psychological impact of SE 
 
³Methotrexate was causing my heart beat to beat faster which made me very DQ[LRXVDQGZDVYHU\XQSOHDVDQW´ 
Female, 41-50, other, F ed,1 med 
  
³Long term meds - was advised that it would take approx 3 wks for my body to get used to them. Side effects were 
drowsiness, confusion, numbness (feelings) woolly, disorientated - this meant I had to take extra care driving & 
undertaking tasks at work.´ 
Female, 41-50 yrs, Part time, SL16, 1 med 
17 12 
Social impact of SE 
 
³6NLQUDVKHVKHDG	IDFHFDXVHGHPEarrassment when going out. Dizziness avoided going out of [sic]P\RZQ´ 
Female, 61-70 yrs, retired, F ed, 1 med 
³3ODQQLQJP\URXWHWRLQFOXGHWRLOHWV:RUULHGDERXWIDLQWLQJ´ 







Table 4.16: Frequency table of text box responses to survey questions 9&10   
Q10:What made you think that the medicine had caused the side effect(s)?   
Timing of the SE  
³I took it about an hour before symptoms´ 
Female, 41-50 yrs, Part time, SL17/18, I med 
 
³A few hours (2) after taking thHPHGLFLQH,IHOWXQFRPIRUWDEOH´ 
Male, 41-50 yrs, Part time, Univ, 1 med 
11 7 
Dechallenge - stopped medicine(s) and SE disappeared 
³Had no symptoms before taking medicine when discontinued medicine symptons [sic]stopped´ 
Female, 71-80 yrs, Retired, SL16, 2-4 meds 
 
³Never had this before & it started after I had taken the tabs for a week. Went away when I stopped´ 
Female, 71-80 yrs, Retired, SL16, 5-8 meds 
23 16 
Onset of symptoms linked to medicine ± symptoms start when begin to take medicines   
³Had just started taking the medication´ 
Female, below 40 yrs, Full time, F ed, 1 med 
 
³%HFDXVHLWVWDUWHGZKHQ,VWDUWHGWKHQHZGUXJ´ 
Male, 61-70 yrs, Retired, SL16, more than 8 meds 
 
20 14 
Recall of prior health experiences ± changes in health linked to medicines 
³Before I started taking the medicine I had none of the effects´. 








Table 4.16: Frequency table of text box responses to survey questions 9&10   
Use of HCPs as information sources ± confirm SE 
³Spoke to my GP and he told me it is a common side effect.´ 
Female, 71-80 yrs, Retired, F ed, 5-8 meds 
 
³Because the pharmacist told me this can happen´ 
Female, 71-80 yrs, Retired, SL18/18, 2-4 meds 
 
43 29 
Use of Relatives/friends as information sources to confirm SE 
³,DVNP\IDPLO\WRORRNLQWRWKHPHGLFDWLRQ´ 
Male, 51-60 yrs, Full time, SL17/18, 2-4 meds 
 
³Talking to others on the same tablet - same side effect´ 
Male, over 80 yrs, Retired, SL16, More than 8 meds 
 
5 3 
Use of PILs as information sources to confirm SE 
³I look in the leaflet of the medication and one of the side effects was stomach upset´ 
Male, 61-70 yrs, Retired, SL17/18, 1 med 
 
³I had read the leaflet and side effect was on the leaflet´ 
Male, 71-80 yrs, Retired, SL16, 5-8 meds 
 
38 26 
Use of the Internet to confirm SE 
³,WZDVFOHDUO\GHWDLOHGLQWKHLQIRUPDWLRQOHDIOHW$OVRFRQILUPHGRQYDULRXVLQWHUQHWVLWHV´ 
Male, below 40 yrs, Full time, Univ, 1 med 
 
³Reading the information leaflet with the medication. Media coverage Internet´ 








This phase of the study has investigated how people use information sources to help them 
identify ADRs and explored SHRSOHV¶H[SHULHQFHVRI$'5V. Overall the survey data that 
were obtained has met these aims. 
SE experience 
The overall SE experience was composed of SE history; SE timing and SE 
outcomes. Outcomes were categorised for analysis by the reported severity, 
impact and consequences of SE.  
*HQGHUGLIIHUHQFHVLQUHVSRQGHQWV¶SE experience  
There were a greater number of females than males amongst the respondents. 
Results suggested that there were clear gender differences in SE experience. More 
females than males had experienced SE and approximately 60% of females who 
took 2-4 medicines had experienced more than one SE. In general females 
reported more SE and frequently described their experiences as both significant 
and negative with lasting consequences.  Over 80% of females reported their SE 
DVµXQSOHDVDQW¶RUµVHULRXV¶7KHRIUHVSRQGHQWVZKRUHSRUWHGWKHLU6(DV
µYHU\VHULRXV¶ZHUHIHPDOH2YHUWZLFHDVPDQ\IHPDOHVDVPDles - 15% - reported 
WKHLPSDFWRIWKHLU6(DVµVHYHUH¶DQGRIWKRVHZKRUHTXLUHGD*3YLVLWZHUH
female. These findings are supported by previous research which found that that 
females are at higher risk of developing ADRs than males (Zopf et al., 2008). 
Studies suggested that older women are particularly susceptible to ADRs and 
reported greater impact on their QoL (Skilving et al., 2014). In addition research 
has indicated that females are more likely to use multiple medicines than males, 
increasing the likelihood that ADRs could occur (Moen et al., 2009). Females are 
also more interested in health information and more likely to engage in health 
information behaviours than males (Ek, 2013; Lorber & Moone., 2002). This 
body of research may explain the gender bias towards females evident in the 
survey respondents.   
Role of age and medicine use in SE experience 
Previous research has identified the prevalence of medicine use in older patients (Qato et 
al., 2008). These older patients have been identified as being at high risk of developing 
ADRs. Factors such as polypharmacy, changes in pharmacokinetics which occur in aging 
patients and multiple health conditions contribute to their risk (Hefner et al., 2015). Data 




increased risk of SE amongst older respondents. SE incidence increased from 16% in those 
below 40/41-50 to over 20% in 51-60; 61-70 and 71-80 age ranges. More than one SE was 
experienced by 30% of those aged 61-70. Over 60% of those aged 41-50; 51-60 and 61-70 
and 90% of those 71-80 required a GP visit. These results suggest that the increased 
incidence of SE in older patients were significant events as older respondents required 
proportionately more GP visits than younger patients. This pattern of GP visits is supported 
by previous research which found that older patients value interactions with their HCPs, 
relying on these HCPs for information and advice on their medicines (Carter et al., 2013; 
Miller, 1987).  
Results suggested that regular use of multiple prescribed medicines were linked to more 
than one SE experience. Overall the highest proportion of respondents 56(35%) with a 
history of SE used two-four medicines regularly. This supports previous research findings 
which found polypharmacy increased the risks of adverse effects. The number of older 
patients who present with complex health conditions that require multiple medicines 
increases as life expectancy rates improve. Such patients are more likely to experience SE 
(Rambhade et al., 2012). 
Retirees and those in full time employment were more likely to see a GP because of their 
SE when compared to other respondents. This may be linked to less time constraints for 
retirees and the pressure to avoid prolonged periods off work for full time workers.   
Identifying SE 
Use and Assessment of Information sources 
The results from this study indicated that respondents¶ predicted use of information sources 
varied from their actual use. Over 80% of respondents indicated they would use GPs and 
PILs with 67% indicating potential use of pharmacists. This pattern of predicted use and 
information preferences is supported by previous research studies (Munksgaard et a., 2011; 
Nähri, 2007) and was maintained in actual use for both GPs and PILs - 69% and 67% 
respectively.  
7KLVPLUURUVWKHUHVSRQGHQWV¶DVVHVVPHQWRI*3VDVWKHPRVWWUXVWZRUWK\DQGHDV\WR
understand information sources; with PILs as the most accessible source. High proportions 
of respondents assessed pharmacists as both trustworthy - 73% - and easy to understand 
information sources. Previous research has similar assessments of GPs and pharmacists as 
reliable and trusted information sources (Hamrosi et al., 2014). However, the positive 
assessments of pharmacists were not reflected in actual use as actual use of pharmacists 
was only 28%. Although 15% of respondents considered the Internet to be the least 
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trustworthy source pharmacists were used less often than the Internet (38%). This is an 
interesting finding and it may suggest that perceptions of information sources can be a key 
factor in actual use of information sources. These perceptions may in turn be mediated by a 
hierarchical order of characteristics. Positive assessments of pharmacists across the four 
source characteristics did not correspond with actual use. However, PILs, which are readily 
available to medicine users, were actually used by a majority of respondents despite the 
mixed assessments they received. If a hierarchy of characteristics exists these parameters 
PD\LQIOXHQFHSHUFHSWLRQVLQYDU\LQJGHJUHHV5HVSRQGHQWV¶SRVLWLYHSHUFHSWLRQRI3,/VDV
an accessible information source seemed to mitigate the influence of the other 
characteristics and resulted in high usage of PILs by respondents. This is supported by the 
principle of information seeking behaviours which proposes an individual will seek the 
most accessible information available (Lalazaryan et al., 2014).  Previous research 
identified tailorability and anonymity as salient characteristics of information sources for 
patients accessing health information, with a variety of factors influencing salience 
(Ruppel & Rains, 2012). This survey data suggested that the source characteristics of 
accessibility and relevance can be significant predictors of use of GPs and the Internet by 
respondents. Further research is required to examine the information source characteristics 
that are essential/relevant in information seeking on medicines. This could aid in 
identifying the predictive factors that are most influential in determining use of information 
sources relating to medicines.  
Use of information sources and confidence in causality 
Data from this study indicated that over 80% of respondents used two or more sources of 
information to confirm their SE - 32% used two, 33% used three and 16% used more than 
three sources. This finding is supported by previous research which found patients obtain 
medicine information from a variety of sources (Clarke et al., 2016; Hughes et al., 2002; 













The proportion of Blunters amongst survey respondents was low (28;13%) compared to 
Monitors (164;73%). However, analysis of the actual use of sources and coping styles 
identified patterns/profiles of information use. The majority of Monitors - over 70% - used 
GPs, followed by PILs - 66% - and the Internet ± 40%. The profile of information use by 
Blunters was PILs (84%), GPs (58%) and pharmacists (42%). Those with neutral coping 
styles used PILs (67%) followed by GPs (58%) and the Internet (33%). These findings 
indicate that PILs and GPs are sources common across coping styles. Research has found 
that providing information to patients which is consistent with their coping style can be 
viewed as effective interventions with beneficial outcomes (Roussi & Miller, 2014). PILs 
and GPs may therefore have a role as mediating factors in the relationship between 
information use and coping styles. The findings of this survey suggest that PILs and GPs 
are influential information sources which are commonly used across different coping 
styles. Focusing on information sources which could have mediating effects on coping 
styles could ensure effective distribution of health information. However research has 
found that monitoring coping styles have specific information preferences and value health 
information (Carter et al., 2013; Roussi & Miller, 2014). This suggests that Monitors are 
more likely to engage with and complete health-related surveys. Additional research with 
equivalent numbers of participants with monitoring, blunting and neutral coping styles is 
therefore required to verify these survey findings.  
Managing SE 
Coping styles and coping behaviours 
The majority of survey respondents who completed the MBSS were identified as Monitors 
± over 70%. Research has identified the specific cognitive, affective and behavioural 
characteristics inherent in cancer patients with monitoring coping styles (Roussi & Miller, 
2014). Monitors have significant knowledge about health-related threats and attach greater 
value to health information then those with other coping styles. Generally, they also tend to 
be less satisfied about the information they receive. Monitors display more negative health 
beliefs, perceive greater risk and experience more negative affective consequences. 
Monitors demand more information and emotional support from HCPs and are more 
forceful in decisions related to their treatment (Rees & Bath, 2000; Roussi & Miller, 2014). 
A similar pattern of characteristics was identified in survey respondents with monitoring 
coping styles. A significant association existed between coping styles and reported severity 




suggests that survey respondents with monitoring coping styles who experienced SE, 
perceived greater risks from their SE and experienced more negative consequences than 
respondents with blunting or neutral coping styles.  
A smaller proportion of respondents ± less than 30% - who completed the MBSS had 
blunting or neutral coping styles. A cautious approach should therefore be taken when 
interpreting survey results linked to the blunting/neutral coping styles. However, a 
significant relationship was identified between coping styles and predicted coping 
behaviours. Similar patterns of predicted coping behaviours were displayed by Monitors 
and Neutrals across the information seeking, social support seeking and non-adherence 
subscales. However more Blunters (21;75%) who completed the SECope, would engage in 
social support seeking behaviours and non-adherence behaviours (17;61%) than either of 
the other coping styles. These findings were not significant but the low number of Blunters 
amongst respondents may have been a contributory factor. Data from this survey also 
suggested that overall more females would employ information seeking strategies than 
males. This finding supports previous research which has identified females as more active 
seekers of information than males (Ek, 2013; Tong et al., 2014).    
Predicted non-adherence behaviours and actual non-adherence behaviours 
Overall predicted non-adherence behaviours were linked to actual non-adherence. Over 
half of respondents who indicated they would engage in these behaviours stopped their 
medicines when they experienced SE. These findings broadly support that of De Smedt et 
al., (2012) which found patients used non-adherent coping strategies to manage adverse 
drug events. The majority of survey respondents received advice on stopping their 
medicines from HCPs ± which is consistent with the finding that almost 70% of 
respondents used GPs to find out about their SE. These findings are also supported by 
previous studies which found that respondents mostly accessed HCPs for medicine 
information (Nahri et al., 2007; Tio et al., 2007). Data from this survey indicated that the 
highest proportion of respondents who made their own decision to stop taking medicines 
had monitoring coping styles. These results confirm the association between monitoring 
coping styles and higher perceptions of risks identified in previous research (Miller & 
Roussi., 2014). In this study more Blunters (65%) stopped their medicines than either 
Monitors (59%) or Neutrals (54%). These findings are supported by previous research 
which found that avoidant/blunting coping styles were associated with non-adherence to 
medicines (Deschamps et al., 2004; Singh et al., 1996 as cited in Zwikker et al., 2014). 
However these findings should be interpreted with caution because of the low numbers of 
Blunters amongst survey respondents. Health research into monitoring coping styles and 
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non-adherence have had mixed results. Some studies have found an active coping style 
associated with medicine adherence (Gremigni et al., 2007; Smalls et al., 2012). However 
other studies with renal and cardiac patients found no relationship (Cholowski et al., 2007; 
Frazier et al., 1994 as cited in Zwikker et al., 2014). An interesting finding from this study 
was that adherence was not the preferred behaviour for Monitors ± a high proportion were 
likely to engage in non-adherent behaviours and stop taking their medicine after 
experiencing SE. A possible explanation for this may be the type of information sources 
that Monitors used to find out about their side effects. The current study found that 
Monitors most commonly used GPs, PILs and the Internet as information sources. 
Research has found that patients who seek medicine information from independent sources 
were more likely to engage in non-adherent behaviours (Carter et al., 2013).  
Analysis of the survey text box comments was examined and used to develop the Topic 
Guide for the following phase of this study - the Phase Two interviews.  
This study contributes to knowledge about coping styles in patients with SE. Identifying 
associations or patterns of information use can assist in the delivery of tailored health 
information to SE patients. The objectives of this phase of the study were to identify the 
types and value of information sources; to identify the factors that influence their use; to 
investigate the SE experience, impact and consequences of SE and the coping strategies 
patients use. Analysis of the survey data suggests these objectives have been met.   
 
4.6 Strengths and Limitations 
This phase of the study added to previous research by exploring the types of information 
sources people use to find out about ADRs. In general surveys are considered to have poor 
validity as they are limited in their scope and do not facilitate in-depth investigation of a 
VXEMHFW+RZHYHURQHRIWKLVVXUYH\¶VVWUHQJWKVZDVWKDWHYHQUHVSRQGHQWVZKRKad not 
experienced a SE could contribute to the research. This was achieved by structuring the 
survey to initially gather data on information sources from all respondents before moving 
to the specific SE experience. In addition the methods added to the strengths of this 
research with two pilots conducted with people known to have used medicines and to have 
experienced a side effect. This assisted in the development of a robust instrument, with 
high content validity. Postal return was selected to reduce any obsequiousness bias ± the 
potential for respondents to indicate they would or had used a pharmacist as an information 




Distributing the surveys in pharmacies was beneficial to the study as it ensured access to a 
pool of pharmacy customers likely to be taking medicines and by extension have 
potentially experienced a SE. However there was a lower response rate for the main study 
compared to the pilots or a previous survey using a similar distribution method. The 
selected distribution method also prevented the use of reminders that may have improved 
response rates. Respondents were required to recall and report on past events so recall bias 
may also have been an issue. However efforts were made to control for such bias by using 
a structured survey with focused questions.  Respondents were also encouraged to 
complete the survey at their leisure, to allow them time to reflect on their past SE 
experiences. 
A limitation of the survey structure was that respondents were not asked for details of the 
suspected causative medicine. This question would have contributed to the survey data and 
enabled investigation of different associations such as drug types and symptoms; drug 
types and symptom severity/impact/consequences and drug type and information use. 
This phase of the study further added to previous research by investigating the coping 
styles of patients with SE. A key strength of the survey was the use of a gold standard 
psychological scale ± the MBSS - to identify these coping styles. This was a novel 
approach as the MBSS had not been previously used in SE research. Its use reflected the 
multidimensional nature of SE with its cognitive, affective and behavioural components. 
However, respondents with a monitoring coping style have explicit preference for 
information and are more likely to respond to surveys. Another issue therefore was the 
likelihood that there would be a high proportion of monitors amongst survey respondents. 
This was borne out by analysis of the surveys which indicated that the majority of survey 
respondents who completed the MBSS were identified, as expected, as Monitors.  
An additional limitation of the survey was the presence of two scales which may have 
proved too onerous for some respondents. Attempts were made at the piloting stage to 
address this limitation. The MBSS short format was used and the SECope was revised for 
clarity and ease of use, by removing some items. However, respondents may still have 
engaged in automatic responding. Efforts were made to control for such biases and 
LQFUHDVHUHVSRQGHQWV¶PRWLYDWLRQ7KHVHLQFOXGHGHQJDJLQJZLWKSRWHQWLDOUHVSRQGHQWV
while distributing the surveys - describing the purpose and value of the research. 
 
4.7 Summary 
A survey was developed for distribution amongst pharmacy customers to collect 
information on how people identify and manage their ADRs. The survey gathered 
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information from respondents on personal ADR experiences; the impact and consequences 
of these ADRs; the information sources and coping strategies people use and their 
demographic characteristics.  
 Analysis of the 230 returned surveys was conducted and the results presented under 
the following headings: SE experience; identifying SE and managing SE. 
 Gender differences were evident in SE history and SE severity. More females then 
males had SE and were more likely to report them as more severe. 
 Age and medicine use were influential factors in SE history. Those using multiple 
medicines were likely to experience SE. Older respondents were more likely to use 
multiple medicines and thus more likely to experience SE. 
 Actual use and predicted use of information sources varied. GPs and PILs were 
most used by respondents and accessed as trustworthy, relevant and accessible sources. 
Pharmacists were easy to understand. Source characteristics of accessibility and relevance 
key to predicting use of GPs and the Internet. GPs and PILs are common sources used 
across coping styles. Using several sources or combining HCPs with PILs increases 
FRQILGHQFHOHYHOVLQUHVSRQGHQWV¶DERXWFDXVDOLW\RI6( 
 Coping styles may be related to reported severity of SE (p = 0.05) and non-adherent 
behaviours/strategies (p = 0.03).  
 
As described earlier in Chapter Three: General Methods, in Phase Two of this research 
interviews were conducted to explore the opinions and experiences of people who had 
recently experienced an ADR. The recruitment procedures, analysis and findings of these 




































5.1 General introduction 
The Literature Review described in Chapter Two provided evidence of the need to 
increase understanding of the personal experiences and opinions of the general 
public in identifying and managing side effects from medicines. Research was 
described which suggested that only limited qualitative research had been 
conducted amongst this population to date. This phase ± Phase Two ± of the study 
sought to address this deficit and thus make a novel contribution to ADR research. 
One of the main purposes of this phase was to form a more comprehensive picture 
RILQGLYLGXDOV¶H[SHULHQFHVRI$'5V, but the findings were also important for 




The rationale which guided the design for this interview phase of the study was 
provided in Chapter Three. This chapter will describe the participant recruitment 
for in-depth interviews, the interview processes, the strategies for data analysis, 
the interview results and a discussion of these results. For this phase - Phase Two 
- a phenomenological approach was selected to explore the opinions and 
experiences of people who had recently experienced an ADR, through in-depth 
interviews. The surveys distributed in Kent during Phase One of the study were 
used to recruit interview participants. Analysis of the returned survey data was 
used to develop the Topic Guide for the Phase Two interviews (See Appendix 11).  
 
5.2.2 Aims & Objectives 
The aim of this phase of the study was to explore the opinions and experiences of 
people who had recently experienced an ADR. Objectives for this phase of the 
study were as follows: 
 To determine how people identified their ADRs 
 7RLQYHVWLJDWHWKHLPSDFWRI$'5VRQSHRSOHV¶GDLO\OLYHV 





5.2.3 Ethical approval 
Approval for this phase of the study was sought from the NHS Research Ethics 
Service and a favourable opinion was received from the Proportionate Review 
Sub-committee of the NRES Committee North East - Newcastle & North 
Tyneside 1 (See Appendix 3: REC ref 14/NE/1053). Potential interviewees were 
supplied with a Participant Information sheet to facilitate their decision to 
participate or not in the research (See Appendix 8). Written consent was obtained 
from interviewees prior to interviews and they were also verbally reminded that 
their participation was entirely voluntary (See Appendix 13). These interviews 
involved participants recollecting a negative event. Sensitive issues could 
potentially arise and participants could become distressed in these circumstances. 
Suitable locations for interview were agreed between researcher and interviewee 
including public settings such as cafes and/or rooms in private dwellings. By 
selecting locations that were agreeable to participants they felt secure and/or 
comfortable and potential distress was avoided. Before the interview began the 
researcher reminded the interviewee that their participation was voluntary and if 
they found a question upsetting they did not have to answer. Procedures were in 
place in the event an interviewee became distressed. These involved an immediate 
suspension of the interview and recommendation that the participant contact their 
G.P. /pharmacist or the Patient Advice and Liaison Service (PALS).  
 
5.2.4 Interview participant recruitment  
Potential participants were identified as respondents to the Phase One survey who 
indicated they had experienced an ADR from their medicines, who had returned 
their contact details and indicated their willingness to be interviewed about their 
ADR experiences.  All potential participants were contacted by phone/email and 
arrangements were made to interview them at a time and location suitable for 
them. Vouchers with a monetary value of £10 were offered to interviewees as an 
incentive to participate. Recruitment for interviewees was limited to the Kent area 
to facilitate ease of access for the interviewer.   
Inclusion criteria were as follows:  
 Pharmacy customers aged 18 years or over 
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 People who suspect they have experienced side effect(s) from their 
medicines 
 Proficiency in English language (reading and speaking). 
 
5.2.5 Study design 
This phase of the study involved off campus interviews with people who had 
experienced an ADR from their medicines. The purpose of the interviews was to 
gather information on how they identified and coped with their ADR and its 
impact on their daily life. The interviews were in-depth and the Topic Guide for 
these interviews was informed by initial survey data (See Appendix 11). 
Interviews were audio-recorded using an Olympus Digital Voice Recorder WS-
852 and were anticipated to last up to an hour. Interviewees provided written and 
verbal consent before the interview began. The interviews were transcribed in the 
Medway School of Pharmacy on the University of Kent campus with an Olympus 
AS-4000 Transcription Kit. Words or phrases emphasised by the interviewee were 
indicated by underlining in the transcripts. The interview data were then entered 
into the data management programme NVivo (QSR NVivo 10) to facilitate 
analysis.  
 
5.2.6 Data analysis 
An Interpretative Phenomenological Approach (IPA) was taken to the analysis of 
the transcripts. A line-by-line analysis of the transcripts was conducted. This 
method of analysis involved repeated readings of the transcripts and making initial 
notes which highlighted key areas of concerns of each participant. Connections 
between emergent themes were then identified through processes of abstraction, 
subsumption and contextualization (Smith, JA., 2008; Smith et al., 2011). See 
Figure 5.1 on the following page for a schematic of the coding process. As 
recommended for larger sample sizes, emergent themes from analysis of initial 







Figure 5.1:  IPA Coding process (Table adapted from Smith et al., 2009)
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Saturation in coding continued until no other emergent themes were being generated at 
which point recruitment of potential participants for interview was discontinued. Analysis 
of the interviews led to the creation of a Master table of themes which is presented in the 
Results section which follows. The main superordinate themes that were identified are 
supported with appropriate quotations from the interview transcripts. These 
distinctive/poignant quotations were selected in line with common research practice and 
were identified as the most representative of the research findings (Anderson, 2010; 




Twenty-two survey participants indicated they had recently experienced an ADR 
and were willing to be interviewed about their experience. They completed the 
Contact details section of the survey supplying their contact details and preferred 
method/times of contact. A response rate for interviews of 9.6% was achieved± 22 
potential participants from 230 returned surveys. One participant supplied an 
incorrect email address and could not be contacted. The remaining 21 were 
contacted by telephone/email at their preferred times. In total 19 confirmed their 
agreement to be interviewed. Subsequently, two were not available for interview - 
one individual was recuperating from a car accident and the other was leaving for 
an extended holiday. Participants were contacted by telephone and arrangements 
for interview dates, times and locations were made. Fifteen participants were 
interviewed, by which time saturation in coding was reached and the interviews 
ceased. The remaining four individuals were contacted, thanked for their 
participation and advised they would not be interviewed. Overall 10:32:42 hours 
of interview data were transcribed with interview times ranging from 20.26 to 
127.02 minutes (M = 42.16; SD ± 29.15).  Interviewee characteristics are 






Table 5.1: Interviewee characteristics 




Int1/Tpt1 Female 41-50 FT F ed Underactive thyroid 5-8 Carbimazole Monitor 25.10 
 
Int2/Tpt2    Female 41-50 FT Univ COPD; Lupus; MS 5-8 Hydroxychloroquine Blunter 60.08 
 
Int3/Tpt3 Female 51-60 Disability SL 16 Rheumatoid 
arthritis 
2-4 Clarithromycin Monitor 77.02 
 
Int4/Tpt4 Male 41-50 FT F ed Cardiac disease 2-4 Lisinopril Monitor 30.23 
 
Int5/Tpt5  Male 61-70 Retired Fed Hypertension 5-8 Simvastatin Monitor 63.35 
 
Int6/Tpt6 Female 51-60 FT Univ Menopause 1 HRT Blunter 25.40 
 
Int7/Tpt7 Male 61-70 Retired SL 16 Chronic pain 2-4 Morphine patches Monitor 36.17 
 
Int8/Tpt8 Male 61-70 Retired F ed Arrhythmia 5-8 Amiodarone Monitor 40.30 
 
Int9/Tpt9 Male 61-70 FT SL 16 Depression 2-4 Mirtazapine Monitor 127.02 
 
Int10/Tpt10 Female Below 40 FT Univ Acne 2-4 Tetracycline Monitor 32.80 
 
Int11/Tpt10 Female 71-80 Retired SL 17/18 Dental infection 2-4 Antibiotic Neutral 24.60 
 
Int12/Tpt12   Female 71-80 Retired Univ Reflux 2-4 Lamsopraole Monitor 27.02 
 
Int13/Tpt13 Female 61-70 Retired Univy Spondylosis 2-4 Co-codamol Monitor 22.01 
 
Int14/Tpt14 Female 61-70 Retired SL 17/18 Asthma 1 Prednisolone Blunter 21.06 
 
Int15/Tpt15 Female 51-60 Disability Univ Fibromyalgia 
syndrome 
More than 8 Multiple medicines Monitor 20.26 
Int =  interviewee; Tpt=transcript;FT =  Full time; Univ =  University; F ed =  Further education 





These characteristics suggest that the interviewees were a reasonably diverse 
group. They displayed a variety of ages, education levels, coping styles and 
medical conditions. In addition they used a variety of medicines and numbers of 
medicines. This demographic information suggests that the overall interview 
findings could be widely applicable.  
 
5.3.2 Themes 
Analysis of the interviews identified six main superordinate (SO) themes, 
illustrated in Figure 5.2 and described below. These were  
1. Side effect experience 
2. Identification 
3. Adherence 
4. Information use 
5. Coping  











5.3.2.1 Side effect experience 
All the participants related the multidimensional nature of their experience of side 
effects. They identified a range of physical symptoms which contributed to the 
somatic experience of side effects: 
 
77UDQVFULSW³they prescribed me another brand I started experiencing a 
IHZVLGHHIIHFWVVKDNLQJEORRGSDOSLWDWLRQV´     
        4.7 (page.line) 
 
77UDQVFULSW³Yeah I mean I was having a job walking up hills..getting 
PRUHDQGPRUHRXWRIEUHDWKZKLFK,ZDVEODPLQJLWRQWKHDVWKPD«DPKDQGLW
ZDVQ¶WMXVWJHWWLQJRXWRIEUHDWKLWZDVP\WKLJKVDQGHYHU\WKLQJZDONLQJD
distance were really KXUWLQJDVLIWKHUHZDVQ¶WHQRXJKR[\JHQWKHUH´ 
                  2.7(page.line) 
 
77UDQVFULSW³the symptoms were like were very much like early pregnancy 
DPKWKDWQDXVHDWKHGL]]LQHVV´ 
           5.23(page.line) 
 
The side effects described also included psychological symptoms: 
T10(Transcript 10):´the one that impacted me the most was the mini-pill 
reaction amh because..I was really I it was the fact it was a hormonal issue and 
my moods were everywhere..it was making me feel even more agitated 
and..depressed and..just all around hRUULEOH´     
                    4.8(page.line) 
 
77UDQVFULSW³Oh the change in my the change in my demeanour was was 
like light and shade black and white it it I went from being..nice which I think I 
am to being quite..not nice at all slamming things around everything was a 
SUREOHP´ 
       20.100(page.line) 
 
Participants described a wide range of symptoms - both physical and 
psychological symptoms ± which had both explicit and implicit impact on their 
lives. 
The explicit impact was primarily related to physical symptomology such as 
stiffness, headaches, or rashes: 
77UDQVFULSW³ZLWKLQDQGDKDOIZHHNV,ZDVEURNHQRXWKHDGWRWRHLQD
rash..that was just massive KRWOXPS\GRWVMXVWFRYHULQJP\HQWLUHERG\´  
                                                                                   
                              4.23(page.line)  
                                                                                      






GRLQJZKDW\RXZDQWLWWRGRWKHQ«´      
        27.46(page.line) 
 
T87UDQVFULSW³,¶PWDNLQJFR-enzyme Q10 therefore this muscle aches 
OHVV«$FWXDOO\DP,LQYHVWLQJZLVHO\SRXQGVHYHU\WKUHHPRQWKV´ 
                                    22.98(page.line) 
 
However, participants also emphasised the implicit impact of side effects. In 
general, these were linked to the psychological symptoms that they were 
experiencing. Most participants described these less obvious symptoms as 
significant in terms of impact on their lives: 
T10(Transcript 10): ³at the same time the faFWWKDW\RX¶UHIHHOLQJWKHVHHPRWLRQV
WKDW\RXGRQ¶WXVXDOO\\RX¶UHQRWXVXDOO\WKDWPXFKLW¶VQRWXVXDOO\WKDWPXFKRI
DUHDFWLRQDQG,GRQ¶WNQRZLWZDVMXVWWKHVZLQJVEHWZHHQLWLWZDVUHDOO\




   
                                                                
 
T77UDQVFULSW³I was really shocked that that just that that little tiny patch 
could do so much to your mental stability and the way that you felt you know the 
ZD\WKDW\RXIHOWLQ\RXUVHOILWZDVMXVWVWUDQJH«<HDKFRVLWZDVLWZDVDWRWDO




                                             
 
Within the side effect experience participants echoed health research findings, 
reporting that attending/attentional biases towards negative symptoms could 
facilitate maintenance or escalation of these symptoms: 
77UDQVFULSW³\RXNQRZDQDVWKPDWLFDWWDFNFDQDOVREHZRUVHif you start to 
SDQLF´  
                        16.98(page.line) 





IHZWLPHVVD\LQJWKDW,WKLQNVRPHWKLQJHOVHLVZURQJ´    
         5.25 (page.line) 
 
Participants also indicated the priming effects which their medication beliefs had 
on their side effects experience. These beliefs were extensive in their range such 
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as positive/negative attitudes towards their medication and their own ability to 
manage side effects:  
T2(TrDQVFULSW³6R,¶PUHDOO\UHDOO\FDUHIXOQRZZRQ¶WHYHQOLNHZRQ¶WHYHQ






          
                               3.9(page.line) 
 
Participants also displayed perceptions about their health status which had 
significant effect on their side effect experience: 
77UDQVFULSW³WKLVZDVQ¶WOLIH-saving medication that I had to be on there  
there were RSWLRQVIRUPH´  
  9.39(page.line) 
 
77UDQVFULSW³\HV,KDYHFRQGLWLRQVZKLFK\HDUVDJR,ZRXOGQ¶WEHKHUH
talking    about....and ah so yes bottom line ah therapeutic doses of nasty toxic   
FKHPLFDOVWKDW\RXJX\VLQYHQWEHWWHUWKDQEHLQJGHDG´    
                                              26.119 (page.line) 
The perceptions of participants towards side effects were also mediated by the 
doctor-patient relationship. In general, a positive relationship has a beneficial 
effect even if side effects occur: 
T27UDQVFULSW³,WKLQNWKDWKHJDYH me WKHRSSRUWXQLW\WRVD\,¶PZLOOLQJWo 
take the risk take this medication because he gave me that opportunity I feel 
WKDW,FDQWUXVWKLPZLWKRWKHUWKLQJVDVZHOOHYHQLIWKHUH¶VVRPHWKLQJGRZQWKH
URDGFDXVHVDQRWKHUUHDFWLRQFRVKH¶VYHU\RSHQDERXWLW\RXNQRZ´  
        33.160(page.line) 
 
Participants also indicated the characteristics of a positive relationship which 
centred on concepts of communication, engagement and accessibility: 
77UDQVFULSW³<HDKGRFWRUWKDW¶VLWHQWLUHO\DPKP\IRUPHUZHZRXOG
discuss we would actually have DGLVFXVVLRQDPKLWZDVQ¶WVRUWRIDQDXWKRULW\
SDWLHQWW\SHRIUHODWLRQVKLSLWZDVPRUHZKDWGR\RXWKLQN",¶OOJLYHKHUHDUHD
IHZIDFWVZKDWGR\RXWKLQN"7KLQNDERXWWKHPWDONDERXWWKHP«VRLWZDVPRUH
OLNHDGLDORJXHDPKZKHUHDVZLWKWKHQHZ*3LW¶VD very different relationship 
LW¶VZHOOWU\WKHVHLIWKH\GRQ¶WZRUNFRPHEDFNLQDPRQWKYHU\GLIIHUHQW´ 











Participants describe different avenues/methods in identifying their side effect. 
However, the system of identification was based on constructed cognitive 
processes. These cognitive processes are common across participants. They are 
constructed by participants and include eliminatory thinking, cognitive linking of 
medicines to symptoms and acquisition of knowledge:  
T6(Transcript 6)³Yeah I sort of pieced it together I mean my initial my initial 
WKRXJKWVZHUHSHUKDSV,¶PLOO,QHHGWRJRVHHWKH*3´    





*3«7KHFRQILUPDWion was the fact that we then stopped my medication of any 
statin for 1 month..and at the end of the month when I went back to see her it was 
fine so it was...The thought analysis took me through..suspicion 
EHOLHIFRQILUPDWLRQ«EXWLWZDVWKHZKROHSURFHVV IURP$WR%´  
21.59(page.line)
  
                                                      
77UDQVFULSW³The reading packet, amh and my GP saying yeah this is what 
it is (laughs) The connection was just that instant..thing of I think it could be your 
medications..that just..That was the bridge just hearing that I was just like mmm 
\HDKLWZDVMXVWSDXVHKHDULQJWKDWWKHUHZDVOLNHDUHPLQGHURIZKDW,¶YH
DOUHDG\UHDG´ 
            21.119(page.line) 
 
77UDQVFULSW³It was new so I had been using my other four medicines and 
WKH\GLGQ¶WJLYHPHDSUREOHPVR,WKLQNWKDW¶VRQHRIWKHWKLQJVWKDWRFFXUWR
me....This is a new medication..And then also...the information on the Internet 
people were also complaining about that. I found quite a number of patients who 
VDLGWKH\KDGWKHVDPHSUREOHP6R,ZDVOLNHWKLVLVGHILQLWHO\LW¶FRV,KDGUHDG
DERXWLWTXLWHDORW´ 
              12.62(page.line) 
 
 
All participants used the timing of the side effect to link the medicine to the side 
effects. The timing of symptoms onset varied but the sequence of medication 
leading to symptoms was common across participants:  
T27UDQVFULSW³$QGZLWKLQDQGDKDOIZHHNV,ZDVEURNHQRXWKHDGWRWRH
LQDUDVK´  
       4.23(page.line)  
                                                                                            
T10(Transcript 10): ³I took the medication..I started to get the tingliness about 
half an hour to an hour later? Amh and then..the really severe swelling and stuff 
and when I woke up that was..SUREDEO\DIWHUDOLWWOHELWRIVOHHS,¶GVD\DERXW
DERXWPD\EHILYHKRXUV´   





just come out in this. He said what was you doing beforehand and I went well just 
sitting there I said I had pains in my st..tummy so I took a couple of para..of co-
codamol and then about five or ten minutes later my face was started coming up 
OLNHWKLV´ 
          6.22(page.line) 
 
Also, common across participants was the use of aids such as PILs and HCPs to 
confirm the side effect: 
T2(Transcript 2)³So I went to my GP and he said well it looks like measles but I 
GRQ¶WWKLQNLWLVODXJKV$QGWKHQ,VWDUWHGKDYLQJPRUHEUHDWKLQJ
problems..about an hour later and he looked through all my medications and he 
VDLGKHORRNHGLWXSDQGVDLGWKLV,¶PSUHWW\VXUHWKLVLVZKDWLWLV´ 
6.32(page.line)  
                                                  
 
T6(Transcript 6)³I re-read the information leaflet just to confLUPRUQRW´ 




The medication beliefs of participants featured as part of the earlier theme of side 
effect experience. However, these beliefs also have a role in the decision-making 
processes surrounding adherence: 
T8(Transcript 8): ³6RHYHU\WKLQJLVVWDWXVTXRHYHU\WKLQJLVZRUNLQJILQH,¶PQRW
going to consider messinJDERXWZLWKP\PHGV´     




get as educated aERXWLWDV,FDQ´      
       19.112(page.line) 
 
77UDQVFULSW³,GRQ¶WWKLQN,UHDOO\UHDOLVHG\RXNQRZ\RX¶UHVRUWRIJLYHQ
this thing that is going to help you..and then you have this strange reaction and I 
think it took me quite a little while to make the connection because you just think 
JLYHQDPHGLFLQHDQGLW¶VJRLQJWRKHOS\RXDQG\RXGRQ¶WUHDOO\H[SHFWWKHRWKHU
VWXIIWRFRPHZLWKLW«$PKEXWRQFHLt does happen then you just want to get it 
VRUWHGRXW,GRQ¶WNQRZZKDWWKHWLPHODJZDVDPKEXW,GRUHPHPEHUWKDW,MXVW
ZDQWHGWRJHWULGRILWEDVLFDOO\´ 
                7.33(page.line) 
 
 
5.3.2.4 Information use 
All the participants used varied information sources both formal and informal to 
find out about their side effects. Participants highlighted these varied sources 
which included healthcare professionals, the Internet as well as family/friends: 
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77UDQVFULSW³ZLWKWKHPLQL-pill amh that was because I went to the 
GRFWRU¶VFRV,ZDVUHDOO\FRQFHUQHGEHFDXVH,ZDVWKHUHOLNH,¶YHEHHQEOHHGLQJ
IRUD\HDUQRZ,GRQ¶WNQRZZKDWWKHSUREOHPLVDQG,¶YHEHHQKDYLQJDOOWKHVH
PRRGVZLQJV´    
                                                                                                 3.6(page.line) 
 
77UDQVFULSW³<HDK,MXVWGHFLGHGWRVWD\RIIWKDWDQGMXVWJRULJKWWRWKH




WKHVWDWLQVDQGKHVDLGDPKZDWFKRXWIRUDFKLQJOLPEV´   
                   9.45(page.line) 
 
Participants described the use of PILs as context-specific in that drug type or drug 
regime could determine its use. Past experiences of side effects also influenced 
SDUWLFLSDQWV¶XVHRI3,/V 
77UDQVFULSW³XQOHVVLWZDVVRPHWKLQJOLNHDQDQWLELRWLFWKDW,¶GEHHQ
prescribed for infection or something and thHQ,ZRXOGQ¶WQHFHVVDULO\ERWKHUEXW
VRPHWKLQJWKDW\RX¶UHWDNLQJUHJXODUO\RYHUDORQJSHULRGRIWLPHWKHQ\HDK,
ZRXOGORRNDWWKHLQIRUPDWLRQOHDIOHW\HDK´     
                   8.15(page.line) 
 
T10(Transcript 10)³DIWHUZKDWKDSSHQHGZLWKWKHWHWUDcycline amh I always 
read them now because I want to be prepared in case something did happen like 




I look for the side effects ahh quite a lot on the leaflets because there are side 
HIIHFWVRQDQ\GUXJVHYHQSDUDFHWDPRO,UHDGWKHOHDIOHWQRZ4XLWH,¶PTXLWH
DYLGODXJKVORRNWRVHHWKHZD\LW¶VJRLQJWRDIIHFWPHPD\EH´ 
                                                                                              14.66(page.line) 
 
Participants also described the role of the Internet in the self-management of side 
effects. All participants approached the Internet with caution. However specific 
sites ± such as NHS Choices - were identified as being quality trustworthy 
information sources. In addition, patient forums were seen by participants as 
useful in offering personal narratives/experiences of medical experiences:   
77UDQVFULSW³WKHRWKHUZDVWKURXJKWKH,QWHUQHW,ZHQWRQOLQHDQG,Wyped 
in..Being sick after having the combi-pill and it came up straight away as this is a 
FRPPRQVLGHHIIHFW\RXVKRXOGFRPHRIIRILW´     
         3.5(page.line) 
 
77UDQVFULSW³WKDWVLPYDVWDWLQZKHQ,VWDUWHGJHWWLQJWKLV,UHDGDOOWKH
leaflets and it said this may happen..so I went onto the website about simvastatin 
DQGWKDWZDVRQD1+6VLWH,IRXQGWKLVRQHRXW´    








              15.74(page.line)  
 
An attentional bias is described as an increased assignment of attentional 
resources towards threatening stimuli relative to neutral stimuli (Cisler & Kostler, 
2010; MacLeod et al., 1986). Participants described the effects of attentional 
biases in Internet use: 
77UDQVFULSW³<HDKDPKEXW,GLGQ¶WJRRQWKHLQWHUQHWFRVHYHU\WLPH,¶YH
JRQHRQWKHLQWHUQHWZLWKDQ\V\PSWRPRKKH¶V dying VR,GLGQ¶WJRUHVHarch 
WKDW´    
13.74(page.line) 
 
77UDQVFULSW³\RXFDQVHOI-diagnose on the internet so easily these days and 
LW¶VDVLPLODUNLQGRIWKLQJ\RXFDQORRNDWSDUWLFXODUO\VRUWRIWKHWKHHQGRIVLGH
effects that are..much more severe you might stop and wooo I was feeling like 
WKDWGR\RXNQRZZKDW,PHDQ"´      
                                                  32.54(page.line) 
 
77UDQVFULSW³What if I wanted to know anything about the tablets or 
whatever? Yeah everybody I think with access to the internet now [indistinct] 
Google. Usually if I do that I come off and phone the local funeral 




5.3.2.5 Coping  
Participants described the coping strategies they used to manage their side effects. 
These included negative thinking, excessive rumination and avoidant behaviours 
in social settings which impacted on the quality of their daily lives: 
77UDQVFULSW³,NQRZWKDW,¶YHJRWDWOHDVWPLQXWHVEHIRUH,¶YHJRWHQRXJK
well 10 minutes to find the loo (smiles) right down to that I look around for loos 
and stuff like that and I know where they are and then I can run to them if need 
WR´     





                                                                                                  22.38(page.line) 





Participants also identified the influential role that symptom interpretation can 
have on coping behaviours: 
77UDQVFULSW³,FDQZDONLQWRDVKRSDQGWKHUH¶VQRDLUFRQGLWLRQLQJRU
something like that and I just feel claustrophobic and then that starts and you 
think to yourself (gasps) god and then the body temperature goes up and then 
KDOIDQKRXUODWHU,¶PUXVKLQJWRWKHORR´ 
          7.36(page.line) 
77UDQVFULSW³6RLI,JHWXSRQHPRUQLQJDQG,GRQ¶WIHHOULJKW,¶OOWKLQN
hold on a minute ZKDWWKHKHOO¶VJRLQJRII,H[SHFWWRKDYHSDLQ,H[SHFWWRKDYH
discomfort I expect to put one leg..down and [indistinct] and I go arse over tip so 
,¶PDOUHDG\DZDUHRIWKRVHWKLQJVDQG,¶OOSUHYHQWLWHYHU\WLPHLWKDSSHQV,






activities anyways. So I listen to what my body is telling me, slow down, ease up 
a little bit, sometimes  ,OLVWHQ,PLVUHDGWKHPDQGWKHQ,WKLQN,¶PJRLQJLQWRD
blown panic but most of the time ,NLQGRIJR\HDK6ORZGRZQGRQ¶WGRVR
much, you know, get a lift rather than walking if you can possibly do it, or catch 
DEXVLI\RXFDQGRLWMXVWVLWGRZQDQGFKLOORXW´ 
          8.23(page.line) 
 
The accounts also captured the disparity which can sometimes exist between 
physician beliefs about side effects versus patient beliefs about side effects:  
77UDQVFULSW³:KHUHLWVDLGDKWKLVFDQEHTXLWHVHYHUHDQGGD-da-da and off 
LWZHQWDQGRIFRXUVHDIWHU,¶GUHDGLWEHLQJWROGE\RQHGRFWRULW¶VLQPLOOLRQ
DQGLW¶VQRWKLQJWRZRUU\DERXW´      




KXPGLQJHURIDSRVVLEOHVLGHHIIHFW´      
                                          21.102(page.line) 
 
5.3.2.6 Body awareness 
The final theme which emerged was linked to body awareness. Participants 
indicated that attending to body signals were positive self-care health behaviours: 
77UDQVFULSW³FRVRYHUWKH\HDUV,¶YHOHDUQHGKRZP\ERG\LVKRZLWZRUNV
KRZLWIHHOVDQG,NQRZLIVRPHWKLQJ¶VQRW,¶PQRWDK\SRFKRQGULDFRUDQ\WKLQJ
OLNHWKDW%XW,NQRZ´        







                                                    8.47(page.line) 
 
5.4 Discussion 
SE experience: physical and psychological effects 
The interviewees described a wide range of physical and psychological symptoms 
which had both explicit and implicit impact on their lives. The explicit impact was 
primarily related to physical symptomology such as stiffness, headaches or rashes. 
Participants described the implicit impact of side effects as significant and linked 
to psychological symptoms. This pattern of symptomatology is supported by 
previous research into patient reports of side effects, which found that these  
generally provide a detailed extensive picture of ADRs and their impact (Dobashi 
et al., 2016; Inch et al.,2012). In patient reports physical effects are generally the 
most frequently reported ADRs, with patients reporting more ADRs than HCPs 
(Aagaard et al., 2011; de Smedt et al.,2012; Gandhi et al., 2003; McLernon et al., 
2010). This is further supported by the survey results in Chapter Four, where 
primarily physical effects were described in free-text comments by a majority of 
230 survey respondents  ± 85%. Research has found that patients can have 
GLIIHULQJOHYHOVRIVXVFHSWLELOLW\WRSV\FKRORJLFDOHIIHFWV2¶1HLOHWDO7KH
interview participants describe psychological effects as having a significant and 
debilitating impact on their lives. This is supported by research into ADRs where 
patients describe these changes in mood, memory and/or behaviour as distressing 
and persistent in nature (Avery et al., 2011; Judd et al., 2014). 
SE experience: economic effects 
Participants also linked their SE experience to explicit economic effects for the 
individual. These included medication costs, costs of treating SE and work 
productivity. This supports other research into ADRs which has also found 
general economic effects with significant costs to healthcare services and loss of 





SE experience: attentional biases to negative symptoms 
Participants reported that attentional biases towards negative symptoms could 
facilitate maintenance or escalation of these symptoms. This is supported by 
health research which has found that excessive patterns of attention to negative 
stimuli play a central role in anxiety and depression disorders (Demeyer et al., 
2012; Price et al., 2011). Research into gastrointestinal disorders has found that 
attentional biases can negatively impact on the subjective appraisal and perception 
RIV\PSWRPV/HY\HWDO0RJRDúHHWDO7KLVFDQOHDGLQWXUQWR
symptom escalation or persistence and resulting avoidant health behaviours. 
These attentional biases allocate attention resources to symptom-related stimuli 
over neutral stimuli. This in turn can lead to impaired cognitive processing of the 
symptom cues, as was experienced by the interview participants.  
SE experience: medication beliefs 
5HVHDUFKKDVH[SORUHGWKHLPSDFWWKDWSDWLHQWV¶SHUFHSWLRQVDQGPHGLFDWLRQEHOLHIV
have on their health behaviours. Studies have found that negative medication 
beliefs can be a factor for non-adherent and information seeking behaviours (de 
Smedt et al., 2012; Johnson et al., 2007; Molloy et al., 2009). Interview 
participants indicated the significant impact which medication beliefs had on their 
side effects experience. These beliefs were extensive in their range and included 
their attitudes towards their medication, their confidence in their own ability to 
manage side effects, as well as their perceptions about their health status. The 
mediating effects of a positive doctor-patient relationship on negative medication 
beliefs were also mentioned by the interviewees. This suggests that current 
measures of medication beliefs such as the Medication Questionnaire (BMQ; 
Horne et al., 1999) may be limited. The BMQ covers personal and general beliefs 
and is widely used in health research, however it may not fully capture the wide 
range of factors inherent in medication beliefs. 
Identification: constructed cognitive processes 
Interview participants described the different processes they use to identify their 
side effect. The system of identification common across participants was based on 
constructed cognitive processes.  They included eliminatory thinking, cognitive 
linking of medicines to symptoms and acquisition of knowledge. These results are 
supported by research which has identified processes where symptoms are filtered 
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DQGDOORFDWHGVLJQLILFDQFHWKURXJKSDWLHQWV¶FRJQLWLYHV\VWHPV(Eysenck et al., 
2000; David et al., 2006; 0RJRDúHHWDOAll interview participants used 
the timing of the side effect to link the medicine to the side effects. Previous 
studies support these findings and have also established that patients use temporal 
associations to assess suspected ADRs (Chaipichit et al., 2014; Krska et al., 2011; 
Lorimer et al., 2012). Also, common across interview participants was the use of 
aids such as PILs and HCPs to confirm the side effect. Other studies also mirror 
this use of PILs (Hughes et al., 2002; Krska et al., 2013). These findings are 
further supported by the survey results in Chapter Four: Survey. Over 80% of 
survey respondents used GPs or pharmacists to confirm their SE and a majority of 
respondents ± over 70% - used PILs to confirm their SE.  
Adherence: medication beliefs 
Previous research investigating medication beliefs and non-adherence have shown 
mixed findings. Associations between medication beliefs and non-adherence have 
been found in a variety of patients ± cardiovascular, HIV and patients with 
epilepsy (Bane et al., 2006; Cha et al., 2008; Nakhutina et al., 2011). However 
research conducted with cardiovascular and asthma patients found medication 
beliefs were not related to adherence (Maguire et al., 2008; Van Steemis et al., 
2014)). Recent research has found that patients with negative medication beliefs 
could misattribute symptoms to a medication and consequently decide to stop 
taking their medication (de Smedt et al., 2012; Heller et al., 2015; Kelly et al., 
2014). The medication beliefs of interview participants had a role in their 
decisions about adherence. These beliefs ranged from self-perceptions on their 
abilities to manage the SE, to considering whether the benefits of controlling a 
chronic condition outweighed the burden of SE and general beliefs that over 
prescribing is a current issue with HCPs. 
Information use: formal and informal 
Interview participants used varied information sources - both formal and informal 
- to find out about their side effects. This mirrors previous research which found 
that the majority of patients used HCPs, PILs or the Internet to find out about their 
SE (Chaipichit et al., 2014; Krska et al., 2013). Past experiences of side effects 
also LQIOXHQFHGSDUWLFLSDQWV¶XVHRI3,/V3DUWLFLSDQWVZHUHDOVRPRUHOLNHO\ to 
read PILs if their medicines were to be taken regularly or for a prolonged period 
of time. All participants considered that the Internet should be used with caution 
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when seeking information on SE. However specific sites ± such as NHS Choices - 
were identified as being trustworthy. Interview participants also specifically 
identified on-line patient forums as useful in offering personal narratives of 
medical experiences. Research has shown that such interactive sites can influence 
patient health behaviours (Masoni et al., 2013; Weaver et al., 2009). Participants 
also described the tendency to over attend to negative information on the Internet. 
These attentional biases to negative stimuli are potential barriers to effective use 
of online resources and have been identified in previous research studies (Cline et 
al., 2001; de Raedt et al.,2010; Lee et al., 2014).  
Coping: information seeking, social support seeking and non-adherent behaviours 
Interview participants described the coping strategies they used to manage their 
side effects.  The interviewees had a variety of coping styles and employed a 
variety of strategies. These strategies included information seeking, social support 
seeking and non-adherent behaviours. Previous research supports this pattern of 
coping, with social support seeking being the most common strategy, followed by 
information seeking (de Smedt et al., 2009; de Smedt et al., 2012). The SECope 
results reported in Chapter Four also support this pattern of coping behaviours. 
Social support seeking and information seeking strategies were most commonly 
reported predicted strategies by survey respondents (47% and 42% respectively). 
In addition, the predicted non-adherence of survey respondents (42%) rose to over 
half of actual non-adherence behaviours (56%). Research has also found that the 
SURFHVVRIREWDLQLQJLQIRUPDWLRQPD\EHLQIOXHQFHGE\DQLQGLYLGXDO¶VFRSLQJ
style (Case et al., 2005; Sawka et al., 2015). The levels of information that 
patients require varies greatly from those who require detailed medical 
information to those whose preference is to reduce discomfort by avoiding detail. 
High scores on the monitoring scale on the MBSS have been associated with 
specific information seeking activities. These include increased use of specialised 
information sources, seeking more detailed information and increased questioning 
of HCPs by patients (Ong et al., 1999; Timmermans et al., 2007). The majority of 
interviewees were monitors and their information seeking activities reflected this 
pattern of seeking information, particularly in accessing specialised sources of 
information. However recent research has found no evidence that obtaining 
detailed information as favoured by monitoring styles resulted in improved 
medical knowledge (Sawka et al., 2015).  
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Coping: negative thinking, excessive rumination and symptom interpretation 
Interview participants also described negative coping strategies which involved 
cognitive factors such as negative expectations and excessive rumination. Health 
research has shown that affective cognitions can have significant impact on health 
outcomes (Taylor, 2013).  Research provides evidence of the significant role that 
cognitive and emotional processes can have in health-protective and health-risk 
behaviours (Case et al., 2005; McSorley et al., 2014; Steptoe, 2006; Cameron et 
al., 2015). Interview participants also identified the influential role that symptom 
interpretation can have on coping behaviours. This central role of symptom 
interpretation in influencing coping behaviours is fundamentally embedded in the 
Self-Regulation model (Hale et al., 2007; Johnson et al., 2004; Levanthal et 
al.,2011). 
Coping: disparity between physician and patient beliefs 
Interview participants also identified the disparity which can exist between 
physician beliefs about side effects versus patient beliefs about side effects. Some 
interviewees described dismissive responses from their HCPs when they 
described their SE. Research studies provide supporting evidence for such 
dismissive attitudes amongst some HCPs. This disparity between HCPs and 
SDWLHQWV¶SHUVSHFWLYHVRQ6(FDQOHDGWRGHFUHDVHG6( reporting from patients 
(Anderson et al., 2007; Golomb et al., 2007; Gordon et al., 2007; Krska et al., 
2013; van Geffen et al., 2011; van Grootheest et al., 2003). 
Body Awareness: positive self-care  
The final theme was linked to body awareness. Interview participants indicated 
that attending to body signals was an essential element of positive self-care health 
behaviours. This is supported by health research which has defined body 
awareness as an active process which involves an awareness of and attentional 
focus on body cues and signals (Mehling et al., 2009). Studies have identified 
body awareness as an adaptive process which can be helpful in managing chronic 
health conditions (Cioffi, 1991; Mehling et al., 2012; Watkins et al., 2004). 
Recent research has found that patients who ignored their bodily signals displayed 
lower levels of physical and psychological health (van Beugen et al., 2015). To 
date research has not specifically identified body awareness as a factor in terms of 
identifying ADRs. However this research found that body awareness and an 
appreciation of how the body reacts in differing circumstances is important in the 
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context of SE from medicines. Research has found that body awareness/sensitivity 
is a complicated construct which can be key to both adaptive and non-adaptive 
health behaviours. Hypochondriac tendency was reduced in those with high 
sensitivity to body symptoms that was combined with a non-catastrophising mode 
of attention (Ginzburg et al., 2014). Adaptive body awareness/sensitivity has been 
identified as occurring in combination with  non-judgemental attention to the 
immediate sensations/effects (Mehling et al., 2009). This suggests that SE could 
be mediated by adopting a self-focus that directs attention to the effects in a 
mindful, non-judgmental manner. 
  
5.5 Strengths and limitations  
One of the main purposes of this interview phase was to address knowledge 
deficits in health research and IRUPDPRUHFRPSUHKHQVLYHSLFWXUHRILQGLYLGXDOV¶
experiences of ADRs. This research makes a novel contribution to ADR research 
and increases both knowledge and understanding of the personal experiences and 
opinions of patients in identifying and managing side effects from medicines. It 
achieved this aim by collecting and investigating the detailed personal experiences 
of people obtained through face to face interviews. Self-selection bias may apply 
to the interviewees as they signalled their desire to participate from a larger 
survey sample. It is possible that the interview participants were particularly 
interested in ADRs as they had experienced significant SE which they regarded as 
being outside of the common SE experience. However the demographic 
information shows that interviewees had differing ages, education, medical 
conditions and number of medicines used, which suggests that participants may be 
likely to have a wide range of opinions and experiences. The medicines used by 
interview participants were also varied which suggests the results obtained could 
be widely applicable. The use of incentives ± vouchers ± may have led to bias in 
recruitment however the vouchers were of small monetary value which reduced 
their significance. Another strength of this research was that saturation in coding 
was reached after 15 interviews. This meant that further recruitment of 
interviewees was not required. A limitation of this phase of the study was the lack 
of independent coding considered best practice for qualitative research. 
Transcripts were checked by supervisor (JK) but not coded separately. This may 
have affected the reliability of the coding process. However the researcher had 
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previous experience of using IPA and had engaged in informal discussions during 
the coding process with an expert mentor with extensive IPA experience in health 
research (AK). The IPA approach to the analysis proved beneficial to this research 
DOORZLQJH[SORUDWLRQRISDUWLFLSDQWV¶VXEMHFWLYHH[SHULHQFHRI$'5V,WVIOH[LEOe 
interpretative processes ensured the interviews were comprehensively coded. A 
key finding of this phase of the research was the identification of body awareness 
DVDNH\SURFHVVLQSDWLHQWV¶H[SHULHQFHRI$'5V7KLVLVDQRYHOUHVHDUFKILQGLQJ




In Phase Two of the study, in-depth interviews were conducted with 15 
participants who had recently experienced an ADR. An IP approach was taken to 
transcript analysis and the following six main superordinate themes were 
identified - side effect experience; identification; adherence; information use; 
coping and body awareness. These themes link to recent health research, 
providing evidence of the significant role they have in ADR experiences. As 
described earlier in Chapter Three: General Methods, in Phase Three of this study 
a side effects assessment tool was developed which was based on the findings 
from these in-depth interviews. The development and validation of this 
assessment tool will be presented in the following chapter ± Chapter Six: Side 
effects Assessment tool. 








































6.1 General Introduction 
Chapter One provided evidence to support the need for development of an 
assessment tool for use by patients to assess suspected ADRs. Scales currently in 
use for assessing causality of ADRs are designed for use by professionals working 
in pharmacovigilance centres. However, there are limited numbers of assessment 
tools for assessing causality available for patients (De Vries et al., 2013; 
Jarernsiripornkul et al., 2015). Research was described in Chapter One which 
suggest that a standardised assessment method could have multiple benefits. A 
generic assessment tool for patient use could facilitate improved reporting of 
ADRs by patients. It could address the current deficits within patient reporting 
and enhance the quality of these reports. In addition, it could empower patients to 
discuss their experiences of suspected ADRs with health professionals. One of the 
aims of this PhD was thus to develop a novel causality scale for use by the general 




The rationale which guided the design for this phase of the study was provided in Chapter 
Three. Phase Three of the research involved the development and validation of the Side 
Effects Patient ASsessment Tool (SE-PAST). This chapter will describe the assessment 
tool development and validation procedures, the data collection processes, the strategies 
for data analysis, the results and a discussion of these results. The Side Effects Patient 
ASsessment Tool (SE-PAST) was developed based on the results obtained from research 
conducted in Phases One and Two ± the Survey and Interview phases described in 
Chapters Four and Five. The Self-Regulation Model/CSM provided a theoretical 
framework to this phase ± Phase Three ± of the research. Criteria data from previous 
research conducted in Thailand (Jarernsiripornkul et al., 2015) and the gold standard 
Naranjo algorithm were used in the development of this assessment tool (Naranjo et al., 
1981). This phase involved the validation of the SE-PAST amongst members of the 





6.2.2 Aims and Objectives 
The aim of this phase of the study was to develop and validate a novel assessment tool for 
the general public to use to assess suspected side effects. Objectives for this phase of the 
study were as follows: 
 To develop an instrument designed to assess suspected side effects 
 To validate the assessment tool amongst people known to have experienced side 
effect(s) 
 To further validate the assessment tool in a larger population by making the 
assessment tool available online through links to relevant websites 
 To determine whether patients consider such an assessment tool to be valuable and 
useful 
 
6.2.3 Ethical approval 
Two approval processes were followed. An amendment to the NHS ethics approval was 
sought to allow interview participants from Phase Two to be involved in the validation of 
the assessment tool. This was supplemented by further participants who were members of 
the public and the online survey also involved members of the public. Approval for the 
amendment to the NHS ethics protocol was obtained, and the other parts of this study 
phase received favourable ethical approval from the Medway School of Pharmacy 
Research Ethics Committee (see Appendix 3 REF 0116/2). For the initial validation stage a 
Participant Information Sheet, Feedback and Consent Forms were created (See Appendix 
15).  The Information Sheet described the aims of the study and explained exactly what 
participants were required to do. It also provided relevant information to participants about 
confidentiality, study funding as well as researcher contact details. The Feedback Forms 
were used to assist the participants in assessing the tool according to its structure, clarity, 
and usability. Consent was obtained in written form by return of completed Consent forms. 
Those who took part in telephone feedback also provided verbal consent at the start of each 
telephone engagement. Implied consent was applied to the online validation of the 
assessment tool. A statement which gained consent through completion of the scale was 





6.2.4 Instrument design and development  
A causality assessment tool was developed based on the Self-Regulation Model of Health 
Behaviours (Leventhal et al.,1980; 2011) as well as the survey and interview data collected 
in the earlier phases of this study. The assessment tool was primarily informed by the data 
and results from the Phase Two in-depth interviews conducted with people who had 
recently experienced an ADR. Findings from previous research, which developed a self-
assessment measure for use by patients, were also used in this instrument development 
(Jarernsiripornkul et al., 2015). The initial tool was a paper based instrument and later an 
electronic version was created for use on a computer platform. The paper based tool was 
structured as follows (See Appendix 17): 
Section A ± background information 
 Respondents were asked to provide detailed descriptions of their SE experience. This 
section was composed of nine questions in total - five questions require tick box responses; 
three open-ended questions require free text comments and one question is composed of 
two parts with tick box response and free text comment options. Questions One to Two 
asked respondents to describe their suspected SE and its timing. Question Three required 
respondents to assess the impact of the SE on their daily lives on a four-point scale ranging 
from No impact, Mild impact, Moderate impact to Severe impact. Questions Four and Five 
required free text responses in which respondents listed their medicines at the time of the 
SE and indicated which medicine they suspected caused their SE. Question Six asked if 
respondents had allergies/pre-existing medical conditions and if they did to list them in the 
text box. Basic demographic information, gender, age group and highest achieved 
education level accounted for the remaining three questions. 
Section B ± Assessment tool 
This section contained the Assessment Tool (AT), Scoring Box and SE Probability Key. 
The AT was composed of ten statements/items. The ten statements related to SE 
experiences and respondents were required to answer all the statements. They were asked 
to select the statements that corresponded most closely with their own SE experience. Each 
statHPHQWKDGIRXUSRVVLEOHUHVSRQVHVµ<HV¶ µ1R¶µ'RQ¶WNQRZ¶RUµ1RWDSSOLFDEOH¶ The 
tool required those completing it to score their responses from 1-10, by filling in the 
Scoring Box with the score assigned to their selected response and then calculating the 
total score. This total score could then be categorised with the SE Probability Key to 
determine the likelihood of causal association (highly probable, probable, possible, 
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unlikely). Weighting of the assessment tool score for each statement was based on the 
widely-used Naranjo algorithm (See Appendix 18). Information about the four causality 
levels ± ranging from unlikely to highly probable - was provided, accompanied by advice 
for respondents to contact a relevant health professional and consider reporting their 
experience to the YC Scheme, for any experience categorised as possibly, probably or 
highly probably a SE from a medicine. The Medway School of Pharmacy public 
engagement group - Public Involvement in Pharmacy Studies Group (PIPS) was 
approached to assess and provide feedback on the tool. Based on their assessment and 
suggestions amendments were made to the SE-PAST tool which was then subjected to 
validation. 
 
 6.2.5 Procedures to validate the instrument 
A cross sectional study design was employed with initial validation by people known to 
have experienced side effect(s). The assessment tool was then placed online to gain 
additional validation in a larger population.  
 
6.2.6 Participant recruitment  
This part of the validation aimed to recruit assessors - approximately 30 people - known to 
have experienced side effect(s). This minimum sample size was selected based on previous 
research (Jarernsiripornkul et al., 2015) and to ensure the previous interview participants 
were balanced by an equal number of new participants.  The initial validation was to be 
provided by the 15 interviewees who had previously participated in Phase Two of the study 
and 15 novel assessors. These participants were members of the general public who were 
known to the research team and known to have experienced SE.  
The participant inclusion criteria were as follows:  
 Adults aged 18 years or over 
 UK residents 
 Participants who suspect they have experienced side effect(s) from their medicines 




6.2.7 Distribution of draft assessment tool 
6.2.7.1 Postal distribution and telephone interviews 
Potential participants were approached via email or phone (See Appendix 19). They were 
invited to participate in the study and provided with a Participant Information Sheet, 
Consent Form, Assessment Tool and Feedback Form. A prepaid envelope was also 
included to return completed forms and tools to the Medway School (See Appendices 15 
and 17). Participants were also offered the option to provide their feedback by telephone if 
they preferred. The Feedback form was used to structure the evaluation of the tool and to 
prompt the telephone interviewees. It provided some demographic information and 
gathered information from the assessors on the structure, clarity, and usability of the tool. 
Assessors were asked for their general opinion/comments on the tool overall and any 
suggestions for improvement. 
 
6.2.7.2 Online distribution of assessment tool 
Online distribution of the assessment tool followed this initial validation. The SE-PAST 
was prepared for online use in Qualtrics®. The assessment tool was mostly structured as 
previously described in 6.2.4 with some additional features.  
This electronic version of the tool included a pre-screening component with appropriate 
questions used to ensure respondents satisfied the inclusion criteria. A Participant 
Information Page accompanied these screening questions (See Appendices 15-16). The on-
line version also differed from the paper instrument as it assigned scores automatically to 
each response and calculated the score, so avoiding the need for respondents to do so 
themselves. The electronic version also requested feedback at the end of the tool. This 
additional feature was included to determine whether participants found the assessment 
tool useful, and if it would encourage them to report their side effect or talk to a HCP about 
it, thus meeting the final objective for this study.  
A list of patient support groups and organisations with a record of encouraging patient 
engagement and supporting health self-management were approached via email (See 
Appendix 20). These organisations were asked to post a recruitment statement with a link 







Robust predictive validity for a tool generally requires a large sample size to generate a 
lower validity coefficient (r) value. The sample size was calculated using the following 
parameters when making the power calculations; 
Using a prevalence estimate of 26% (/Alhawassi et al, 2014) for experiencing an ADR 
A random sample of the general population at a confidence level of 95% 
Confidence interval of  ±1.96 and a margin of error of 5% 
Power equation 
Ss = Z² x (p) x (1-p)      
      C² 
Where Ss= sample size; Z = 1.96 (95% CL); p = % accuracy expressed in decimals;  
Ss = (1.96)² x (0.26) x (1-0.3) 
                 (0.05)² 
 
Ss = 3.84 x 0.26 x 0.7     =      0.699  
            0.0025                      0.0025    
Ss = 279.55  
Therefore it was proposed that the study required a sample size of approximately 300 
completed assessments. 
To facilitate a high response rate, it was decided to maintain an active online link for five 
months. During this time contacts were made with appropriate people within individual 
organisations via email and telephone which ensured a large number of completed reports. 
As sufficient responses had been obtained after five months, the survey was closed.  
 
6.2.8 Confidentiality and anonymity 
All participants in the initial validation stage were informed that the research was 
confidential. Telephone interviewees were informed in writing and verbally of this prior to 
the interview. Contact details were supplied to the researcher by the assessors during the 
initial phone/email contact. These details were stored in paper format only and shredded by 
the researcher following postal and telephone feedback. No personal identifiable 
information was included in postal responses and telephone interviews. The study data 





6.2.9 Methods for data analysis 
6.2.9.1 Initial validation of draft assessment tool 
The postal distribution and telephone interviews generated feedback forms which helped to 
develop the tool. The demographic information and the overall evaluation/assessment of 
the tool obtained from both methods was combined. A frequency table of responses to the 
closed TXHVWLRQVZDVFUHDWHGWRH[SORUHWKHWRRO¶VFODULW\HDVHRIXVHORJLFRIWKHVWUXFWXUH
etc. The free text comments/suggestions for improvement were examined to identify points 
of commonality which needed to be addressed. Amendments were subsequently made to 
the tool to facilitate ease of use such as clarifying the instructions.  
 
6.2.9.2 Online validation of SE-PAST  
The Qualtrics® data were downloaded for analysis into SPSS (Windows Statistics 23) and 
Excel. The dataset was cleaned and checked for errors such as missing values. Missing 
data was dealt with by the conventional method of exclusion and was not included in the 
analysis (Soley-Bori, 2013). Incomplete statements in the AT were assigned a value of 0 
(Brick et al., 1996). Data were then subjected to qualitative and quantitative analysis and 
sWDWLVWLFDOVLJQLILFDQFHZDVVHWWRS. Descriptive statistics and cross-tabulations were 
conducted to investigate statistical differences. Categorical data were described using 
percentages/frequencies and as rHVSRQGHQWV¶DJHZDVnot normally distributed median 
value was reported. The SE experience of the online respondents was characterised 
according to the following parameters: 
 impact and timing of SE 
  list of medicines and causal medicine  
 pre-existing conditions/allergies  
 Multidimensional chi-square tests were then conducted to identify associations between 
UHVSRQGHQWV¶GHPRJUDSKLFVDQGWKHLU6(H[SHULHQFH Responses to the SE-PAST text box 
questions were entered in Excel and the data management program QSR NVivo 10. A 
coding frame was created in an earlier phase of the study during the analysis of the Survey 
free text comments. This frame was applied to the SE-PAST free text data. 
A frequency table of the feedback responses was analysed to assess the value and potential 
usefulness of the AT. Principal Component Analysis (PCA) with direct oblimin rotation 
was conducted on completed ATs to examine the factor structure of the SE-PAST. Four 
factors were retained based on the Eigenvalues > 1 and visual inspection of the scree plot 
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elbow point. An optimum structure was achieved that revealed one item had factor 
loadings below 0.4. This item (statement one) was excluded and PCA conducted again. 
The results are presented in Section 6.3.4.8. AT scores 
 
6.3 Results 
The assessment tool was developed and initially validated by people known to have 
experienced SE before further validation online in a larger population. The results of the 
initial and online validation are presented in the following sections: respondent 
characteristics; their SE experience; their scoring on the AT and their feedback.   
 
6.3.1 Initial validation ± Assessor characteristics 
Overall 31 assessors ± 11 interviewees from Phase Two and 20 novel assessors ± 
completed the AT and supplied feedback. Four previous interviewees were unavailable to 
provide feedback due to illness or holidays. The majority of assessors (21;68%) were 
female, median age 52 years with over half University educated (16;52%). Seventeen 
assessors (55%) had an existing medical condition and experienced their SE a year 
ago/longer. Over half used two-four medicines regularly (16;52%) and 13 (42%) rated SE 
LPSDFWDVµPRGHUDWH¶6HHTable 6.1. A majority (20;65%) scored between 4-7 on the AT 
and thus their experience was categorised as µ3UREDEOH¶on the SE-PAST Probability key.  
 
6.3.2 Initial validation - Assessor feedback 
Assessors provided feedback on the SE-PAST under the following criteria: ease of use; 
clarity; structure; length of AT and difficulties in recalling SE. The time taken to complete 
the SE-PAST ranged from five to forty-five minutes (M=25; SD±12). The majority 
(24;70%) completed it between 5-15 minutes while over 90% thought it was not too long. 
All assessors either agreed /strongly agreed that the SE-PAST was easy to read while a 
majority either agreed (13;45%) or strongly agreed (14;42%) it was easy to understand and 
clearly laid out (16;52% and 14;45%).  Over 80% had no difficulty in recalling their SE 
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Figures show n(%) 
SL=School leaver; F ed= Further education; Univ= University; SE=Side Effects 
 
 




                N (%)  
Disagree      Agree       S Agree   
 
Evaluation criteria 
          N (%) 
    Yes            No 
Easy to read      0                 16(52)      15(48) Too long      1(3)           30(97) 
Easy to understand     4(13)          13(45)      14(42) Recall difficulty    4(13)         26(84) 
Easy to complete     2(7)           13(42)      16(52)   
Clearly laid out    1(3)           16(52)      14(45)    
Logical structure   3(10)         15(48)      13(42)   
Figures show n (%) 




The responses from this initial validation were reviewed and used to guide amendments to 
the SE-PAST. Instructions were clarified to facilitate clarity and ease of use. This initial 
validation data was not included in further analysis.  
 
6.3.3 Online validation 
Overall 761 people accessed the SE-PAST online with 273 completed responses, a 
response rate of 36%. See Table 6.3. 
A majority of online respondents were female (216;69.9%) with 35.8% aged 61-70 years.  
Overall over half were University educated (179;58.1%) and had experienced SE a year 
ago/longer 159(53.7%). A majority had an existing medical condition/allergy 273(89.8%) 
and used between two-four medicines at the time of the SE (122;43.1%). The SE impact 










Table 6.3: Number of responses per question/statement in online SE-PAST  
 
SE-PAST Section A: questions 1-9 Total responses to 
questions 
SE-PAST Section B: 
AT statements 1-10 
Total responses to AT 
statements 
Q1 Description of SE 304 St1 
 
307 
Q2 SE timing 
 
296 St2 252 
Q3 SE impact 
 
300 St3 214 
Q4 Medicine use 292 
 
St4 305 
Q5 Causative med 
 
287 St5  306 
Q6 (i) Medical conditions/allergies 
 
304 St6 306 
Q6 (ii) List of medical 
conditions/allergies 
 
294 St7 286 
Q7 Gender 
 
309 St8 292 
Q8 Age 
 
310 St9 287 
Q9 Education 
 








6.3.3.1 Gender and respondent characteristics  
Over half of males (52;55.9%) and females (126;58.9%) were University educated 
and had experienced SE a year ago/longer - 50;59.5% and 107;51.4% 
respectively.   There were no gender differences in the proportion of medicines 
used by respondents. Similar proportions of males and females used between two-
four medicines 35;42.7% and 88;44% respectively. Analysis indicated an 
association between gender and age with a higher proportion of younger females ± 
below 60 years - than males amongst respondents. Overall the highest proportion 
of each gender were aged 61-70 years ± 39 males (41.9%) and 71 females 
(32.9%). There were a higher proportion of females aged under 40 (25;11.6%) 
than males (2;2.2%) and over twice as many female respondents below 60 years 
(96;44.4%) as males (15;16.13%). An e[DFW3HDUVRQ¶VFKL-square indicated a 
moderate association between gender and age: X2 (5, N = 309) = 31.2, p 
Gender accounted for 10% of the variation in age ranges; ĭ = 0.32. See Table 6.4. 
 
6.3.3.2 Gender and SE impact 
Analysis indicated gender differences in SE impact. Females were more likely to 
describe the impact as moderate (82;39.2%) or severe (87;41.6%) This compared 
to moderate impact for 30 males (34.5%) and severe impact for 28 males (32.2%). 
The relationship between gender and SE impact was significant: X2 (3, N=296) = 
7.7, p = 0.05. The association was moderate: ĭ = 0.2, gender accounted for 4% of 
the variation in SE impact. See Table 6.4. 
 
6.3.3.3 Gender and medical profile  
Analysis indicated a similar medical profile existed amongst respondents. The 
majority of males and females had two or more medical conditions - 28(52%) and 
81(60%) respectively. The same proportion of females 40(71%) and males 







Table 6.4: Online validation of SE-PAST ± gender by respondent characteristics 
and SE experience  
*signLILFDQFHDWSUREDELOLW\OHYHOWZR-tailed) 














        Gender f (%) n=309 










2(2.2)                            25(11.6) 
4(4.3)                            29(13.4)                              
9(9.7)                           42(19.4) 
39(41.9)                       71(32.9) 
29(31.2)                       45(20.8) 
10(10.8)                         4(1.9) 
0.001* 






19(23.2)                       63(31.5) 
35(42.7)                       88(44) 
21(25.6)                       33(16.5) 









8(9.2)                           8(3.8) 
21(24.1)                    32(15.3) 
30(34.5)                     82(39.2) 




School Leaver=17/18     
Further education          
University                      
 
12(12.9)                      25(11.7)   
 8(8.6)                         21(9.8) 
21(22.6)                      42(19.6) 




Past 3 mths 
Past 6 mths 
1 yr/longer 
 
12(14.3)                     45(21.6) 
8(19.5)                       22(22.6) 
14(16.7)                     34(16.3) 
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6.3.3.4 Categories of the top 20 causative medicines  
Medicine(s) believed to have caused the SE were classified according to the British 
National Formulary (BNF). Overall 289 respondents supplied details with 10(3.5%) unsure 
what drug had caused the SE. In addition, 15.2% (44) of respondents reported 
combined/multiple medicines linked to BNF categories. The highest proportion of 
respondents (86;29.8%) reported causative medicines(s) linked to the central nervous 
system (CNS), followed by cardiovascular (CV) (65;22.5%), endocrine system (18;6.2%) 
and 14(4.8%) with gastrointestinal (GI) medicines.  
The 20 most frequent causative medicines suspected of causing SE are presented in Figure 
6.2. These are BNF categorised as follows ± the central nervous system (CNS) and the 






















BNF= British National Formulary; CNS= Central Nervous System; CVS=Cardiovascular system; Endo=Endocrine; GI=Gastrointestinal; Musko=Musculoskeletal 
#excludes combination/multiple medicines, injections, those not sure/none 
*unspecified 
 
































































6.3.3.5. Medicine categories and gender, SE impact 
Analysis indicated an association between gender and the category of the causative 
medicines. Proportionately more females (72;35.8%) identified CNS medicines as causing 
their SE compared to males (13;15.5%). Gastrointestinal medicines were also identified by 
a majority of females (11;5.5%) compared to males (2;2.4%).  Similar proportions of 
females and males identified medicines related to infections - 9;4.5% and 4;4.8% 
respectively. The relationship between gender and causal drug was significant: X2 (3, 
N=176) = 23.6, p < 0.001. The association was strong: ĭ = 0.4, gender accounted for 16% 




(27;25.5%) medicines.  
 
Table 6.5: Categories of causative drugs reported in online validation of SE-PAST by 
gender and SE impact 




















































BNF =  British National Formulary; CNS =  Central Nervous System; CVS=Cardiovascular system; 
GI=Gastrointestinal 
# Four BNF categories GI, CVS, CNS and Infections included in analysis  
 *significant at p<  0.05 significance level 






6.3.3.6 Causality knowledge and medicine use 
Knowledge about causality of SE varied amongst respondents. From 280 
respondents 196(70%) knew the causal medicine, 19(7%) were not sure what 
medicine had caused the SE and 65 (23%) thought more than one medicine was 
responsible. The highest proportion of those who knew the causal medicine 
78(41%) or thought that more than one of their medicines could be responsible 
33(52%) were using between two to four medicines. As medicine use increased, 
from two to four to five to eight medicines, the proportion of respondents who 
could identify one causal medicine dropped to 34(18%) and 18(28%) of these 
respondents thought that more than one medicine could be responsible. The 
relationship between causality knowledge and medicine use was significant: X2 (6, 
N=272) = 24.7, p = 0.001. The association was moderate: ĭ = 0.3, medicine use 



























































1 med %  2-4 % 5-8 % more than 8 %
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6.3.3.7 Description of SE   
A total of 304 responses to the following text box question ZHUHDQDO\VHGµPlease describe 
the suspected side effect(s) you experienced in detail, including any information that you 
think may be relevant¶ 
The number of answers per category was noted and a frequency table was created. This 
suggested that a majority of respondents described the physical effects of the SE 
(255;84%) followed by social effects (74;24%) and psychological effects (46;15%). 
Respondents confirmed the SE with HCPs 35(37%) or PILs (4;1%). Factors such as the 
timing of the side effect and previous health experiences were used to link the medicine to 
SE. See Table 6.6. 
 
Table 6.6: SE-PAST - categories and frequencies of text box responses to Question 1 
 
             Responses (N=304)  
       
Frequency % 
Categories:   
Reported physical effects 
 
255 84 
Reported psychological effects 
 
46 15 
Reported social effects 
 
74 24 
Timing of the SE# 
 
100 33 
Stopped meds & effects disappeared 
 
69 23 
Onset of symptoms linked to start of 
medicines  
19 12 
Recalled previous health experiences ± 
changes in health linked to medicines 
4 1 
Talked to HCPs to confirm SE 35 37 
Talked to relatives/friends to confirm SE 
 
4 1 
Used PILs to confirm SE 
 
4 1 
Used the Internet to confirm SE 
 
2 0.7 
# specific timing of onset of symptoms GHVFULEHGµIHZKRXUV¶¶DQKRXUODWHU¶ 
 
6.3.3.8 AT scores (SE-PAST Section B) 
Overall 307(40.3%) out of 761 persons who accessed the online survey completed some or 
all of the AT. The number of completed statements ranged from two to 10 as some 
respondents failed to answer more than one statement. All ten statements were completed 
by 186 (60.6%) of these respondents with 75(24.4%) completing nine statements. When 
these incomplete statements were examined a pattern was identified - the statements most 
168 
 
RIWHQQRWFRPSOHWHGZHUHVWDWHPHQWµWhen I stopped taking the medicine the effect(s) 
GHFUHDVHGLQVHYHULW\RUGLVDSSHDUHG¶ DQGVWDWHPHQWµI have experienced 
VLPLODUHIIHFWVIURPWKLVPHGLFLQHRUDUHODWHGPHGLFLQH¶ (55;17.9%).  
Based on all those completing any of the AT, the majority  (181; 59%) had scores of 4-7 
(Probable/Likely) followed by 46(15%) who scored 8 or higher (Highly probable/Likely). 
The AT score ranged from -1 to 12 (M = 4.96; SD± 2.76 with skewness of -0.5 (SE=0.1) 
and kurtosis of -0.4 (SE=0.3). Distribution was considered approximately symmetric. A 
similar pattern of probability scores were identified in those who completed all of the AT, 
the majority (119;64%) had scores of 4-7 (Probable/Likely) followed by 38(20.4%) who 
scored 8 or higher (Highly probable/Likely).  The AT completed by respondents were 
analysed using principal component analysis (PCA) with direct oblimin rotation. Sampling 
DGHTXDF\IRUWKH$7ZDVDFFHSWDEOH.02 DQG%DUOHWW¶V7HVWRI6SKHULFLW\p < 


























Table 6.7: Information about factorability of data 
KMO and Bartlett's Test 
 
Kaiser-Meyer-Olkin Measure of Sampling Adequacy. 0.589 







Figure 6.4: Scree plot of eigenvalues generated by PCA  
 
 
The PCA revealed three components which when combined explained 54.93% of the 
variance. Statements 4, 5 and 6 loaded most strongly on Component 1; statements 8, 9 and 
10 on Component 2 and the strongest loadings for Component 3 were statements 3 and 7. 
The component loadings are shown in Table 6.8.  The components represent stages in 
identifying SE: component 1 -sequencing; component 2 ± alternative causes and 
component 3 ± self-directed health behaviours.   
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The overall scale had poor reliability (&URQEDFK¶Vɲ= 0.53); the three factors¶UHOLDELOLW\
ranged from 0.4 - 0.7 and the items had low to moderate correlations (r2 values ranged 

































Table 6.8: PCA components, loading variables and squared multiple correlations (n=183) 
 





                     




                          
                          R2 
 
Component 3 
(Self-directed health behaviours) 
                     
                    R2  
Statement 6:  
When I decreased the 
dose the effect(s) 
became less severe. 
 
0.79             0.36   Statement 9: 
I think an existing medical 
condition or conditions could 
have led to the effect(s). 
0.78                   0.2 Statement 3: 
When I stopped taking the medicine the 
effect(s) decreased in severity or 
disappeared altogether. 
0.85             0.22 
Statement 5; 
When I increased the 
dose the effect(s) 
became more severe. 
 
0.77             0.34 Statement 8: 
I think that something else apart 
from the medicine could have 
caused the effect(s). 
 
 
0.74                  0.2 Statement 7: 
I confirmed the effect(s) with some or all 
of the following information sources ± 
doctors, pharmacists, information leaflets 
with your medicine, the internet or 
medicine books. 
0.74              0.21 
Statement 4: 
When I took the 
medicine again the 
effect(s) reappeared. 
0.59             0.2 Statement 10: 
I think that other medicine(s) 
that I was using at the time 
could have caused the effect(s). 
0.56                   0.2 Statement 2: 
I have experienced similar effect(s) from 
this medicine or a related medicine in the 
past. 
0.4                0.20 
Statement 2: 
I have experienced 
similar effect(s) from 
this medicine or a 
related medicine in the 
past. 
0.47             0.2     







6.3.3.8 Feedback  
Overall 240(91.3%) respondents agreed to provide feedback to the following questions: 
1. Did you find the SE-PAST useful? (n=144) 
2. Would it encourage you to report your SE to the relevant agencies? (n=208) 
3. Would it encourage you to talk to a HCP about your SE? (n=227) 
The 144 (100%) respondents who answered question 1 found the SE-PAST useful; 146 
(70.19%) of those who answered question 2 would be encouraged to report their SE to 
relevant agencies and 170(74.89%) of those who answered question 3 would be motivated 
to discuss their SE with a HCP. See Figure 6.5 below.  
Analysis of the feedback provided by those who fully completed the 10 statements of the 
AT was also conducted. Overall 143 of these respondents provided feedback ± a majority 
of those who completed the AT found the SE-PAST useful (96;67.1%); would be 
encouraged to report their SE (91;63.6%) and would be encouraged to discuss their SE 
with a HCP (105;73.4%).  
 
 
*Number of respondents to feedback questions range from 144-227 
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6.3 Discussion  
SE experience of online respondents 
Results suggested that there were some gender differences in SE experience. There were a 
majority of females amongst the online respondents and females reported greater impact on 
WKHLU4'/2YHURIIHPDOHVUHSRUWHGWKHLPSDFWRIWKH6(DVµPRGHUDWH¶RUµVHYHUH¶
These findings are supported by previous research which identified a higher risk of 
developing SE amongst females than males. The incidence of ADRs in females are 
between 50-75% more likely to occur than in PDOHV'¶,QFDXHWDOLucca et al., 
2017; Montastruc et al., 2002; Zopf et al., 2009). Studies have also found that females 
generally reported greater impact on their QDL than males (Skilving et al., 2014). Most 
online respondents who accessed the AT were aged 61-70 years however there were twice 
as many females as males aged below 60 years. This higher proportion of younger females 
has implications as it could reflect the under-representation of the SE experience of 
younger males in SE research. Females are more likely to experience SE however research 
should be balanced and the experiences of younger males in particular are also necessary to 
create a comprehensive overview of SE.   
As the age ranges of respondents increased this trend was reversed so there were more 
males ± from 71 to over 80 years - than females. These results suggested that older males 
were more prone to engage in online health activities than younger males. This is 
supported by previous research into Internet use amongst older adults which found over 
half of these frequently used the Internet as a source of health information (Medloc et al., 
2015; Tan et al., 2017; Van de Belt et al., 2013). Research suggests that tailored Internet 
health interventions such as the SE-PAST can be effective in reaching older adults and 
support adaptive health behaviours (Nes et al., 2013). 
 Knowledge about SE causality  
The data suggested that causality knowledge amongst online respondents decreased as 
medicine use increased. Over 70% of respondents who took between one-four medicines 
could identify one causal medicine. However when medicine use increased to five-eight 
medicines the proportion who identified one causative medicine dropped to 18%. This 
could indicate that the inability to assign causality to one medicine among this high 
medicine use group is linked to positive health knowledge. This knowledge could include 
an awareness of interaction effects and good health literacy in general. Research has been 
conducted into the relationships between age, cognitive skills and health literacy (Berkman 
et al., 2011; Kiechle et al., 2013; Kobayashi et al., 2014). High medicine use does not 
automatically lead to negative outcomes and could have positive effects on health literacy. 
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An effective assessment of health literacy should include influencing factors such as 
medicine use. Additional research could determine the parameters of a beneficial range of 
medicine use for patients. Identifying when high medicine use becomes high medicine 
burden for patients could prove useful.  
 Most common drug categories 
The data suggested that the most commonly reported causative medicines by online 
respondents were linked to the CNS, cardiovascular system and infection medicines. This 
finding is supported by previous research into YC reports which also found that the CNS 
was the most frequently reported category by patient reporters, followed by cardiovascular 
and anti-infection drugs (Avery et al.,2011).  
The current study found an association between gender and the categories of the causative 
medicines. More females identified CNS medicines as their suspected causative medicine 
than males. Females were also more likely to report gastrointestinal medicines than males. 
Previous research supports these findings with females more likely to take medicines and a 
wider variety of medicines than males (Lucca et al., 2017; Rademaker, 2001). Females are 
therefore more likely to experience SE  however there are fewer females than males that 
participate in phase 1 and 2 clinical trials. There is an awareness amongst researchers that 
the pharmacological status of females needs to be examined (Franconi et al., 2012; Pinnow 
et al., 2009). This current study built on previous research with hospital patients which 
found females using antibacterial and anti-inflammatory drugs experienced more ADRs 
than males (Zopf et al., 2009; Zopf et al., 2014).  The present data were collected from a 
different population and provides a pattern of causative medicines in online female 
respondents.  
SE-PAST validation 
The numbers accessing the instrument were not maintained to completion and response 
rate was 36%. However this response rate reflects previous studies where the response 
rates for internet based health interventions ranged from 28% - 32% (Guttmacher et al., 
2010; Wangberg et al., 2011).    
The feedback from respondents about the SE-PAST was generally positive and the 
majority of respondents found it useful. Over 70% considered that it motivated them to 
report and/or discuss their SE with a HCP. These feedback comments suggest the SE-
PAST has good face validity.  The process of developing the instrument included a high 
degree of engagement by the supervisory team and an initial validation process. This 
ensured there was a high degree of inter-rater agreement that the SE-PAST had good 
content validity.  
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The online SE-PAST proved an effective recruitment tool as the required sample size was 
achieved within the estimated time period. As mentioned the overall response rate for the 
SE-PAST was 36% with varied completion rates across the sections. Section A was 
completed by 36.7% of respondents with a lower proportion - 24.4% - completing all of 
Section B. Previous research of completion rates for online surveys suggest the percentage 
of respondents who participate in full in these surveys have declined over time (Crawford 
et al., 2001; LaRose & Tsai, 2014). The variation in completion rates of the SE-PAST 
supports these research findings.  
Exploratory factor analysis investigated the factor structure of the SE-PAST and the 
correlations between its variables. PCA identified the number of factors/components and 
which variables were linked to these factors/components. The three components that 
emerged during analysis represent stages in identifying SE: component 1 ± sequencing; 
component 2 ± alternative causes and component 3 ±  self-directed health behaviours. 
9DULDEOHVZHUHVWURQJO\ORDGHGRQWRWKHVHFRPSRQHQWVIDFWRUV+RZHYHUWKH&URQEDFK¶V
alpha for the SE-PAST was below the 0.7 required for a reliable scale. This suggests 
SUREOHPVZLWKWKHWRRO¶VFRQVWUXFWYDOLGLW\7KLVYDlidity could be improved by rewriting 
items that have been revealed as inconsistent by the PCA. The validation of a measure is 
an iterative process and further work can be done to continue the development and increase 
the construct validity of the SE-PAST (Fallon et al., 2016).   
 
6.5 Strengths and limitations  
This phase of the study sought to develop and validate a novel assessment tool for the 
general public to use to assess suspected side effects. The online distribution of the SE-
PAST was facilitated by patient support groups and organisations. This method of 
distribution aided the targeting of a specific population likely to have experienced SE. 
However online survey distribution can be limited by problems such as multiple responses 
or incomplete surveys. The SE-PAST was accessed by a large number of people - 761 
persons - however not all these people completed the tool. A limitation of online 
distribution was the reduced opportunities to engage with the respondents, motivating them 
to progress through and complete the tool. Another limitation was the large gender bias 
amongst respondents - 69.9% of respondents were female. Information was gathered on 
causative medicines however these data are limited as it was not possible to validate the 
causality assigned to the individual experiences through review of medical records.  
However just 40% of respondents who accessed the questionnaire completed the SE-
PAST. This was a considerable limitation as a large sample size of approximately 325 
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completed assessments were required to ensure robust predictive validity for the tool. This 
VPDOOHUWKDQDQWLFLSDWHGVDPSOHVL]HPD\KDYHFRQWULEXWHGWRWKHORZ&URQEDFK¶VDOSKD
value for the overall scale. These limitations also extended to the PCA ± the 183 responses 
subjected to PCA did not meet the minimum recommended sample size of 200 
participants. However the requirement of 5-10 respondents per statement for effective PCA 
was met (Brace et al., 2016).  
The structure of the questionnaire can be identified as a possible strength. Section A asked 
for background information from respondents before the assessment tool in Section B was 
presented. This design was intended to aid respondents to fully recall a particular event - 
their SE - before they assessed it using the AT. The SE-PAST was intended to be a 
balanced tool ± simple yet useful. Its fundamental strength is that it has met some of those 
criteria and has the potential to be further developed and improved.  
This phase of the study can be considered to have been of incremental value as it built 
upon previous research. Knowledge about the SE experience was increased and patterns of 
medicine use were identified. The objectives of this phase of the study were to develop and 
validate a novel assessment tool amongst people known to have experienced side effect(s). 
Further validation in a larger population was conducted by placing the assessment tool 
online through links to relevant websites. The following chapter - Chapter 7: YC reports - 
will continue to explore the experiences of people who experience SE and present the 
findings from analysis of the YC reports. 
 
 6.6 Summary 
The SE-PAST was developed and made available online for people who suspected they 
had experienced SE. This assessment tool used a simple 10-item scale to assess the 
probability for respondents that the SE was caused by their medicines. In addition, 
information was collected on the impact of the SE, the suspected causative medicine(s), 
pre-H[LVWLQJPHGLFDOFRQGLWLRQVDOOHUJLHVDQGUHVSRQGHQWV¶ demographic characteristics.  
 Overall 761 respondents accessed the AT with 273 completed responses, a response 
rate of 36%. The majority were female and most online respondents were aged 61-70 
years. 
 Gender differences were evident in SE impact on QDL. Females were more likely 
than males to report the SE impact as severe (p =  0.05). 
 Causality knowledge decreased as medicine use increased. Over 70% of 
respondents who took between two-four medicines could identify one causal medicine. 
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This ability to assign causality to one medicine drops to 18% in those taking five-eight 
medicines.  
 The most commonly reported causative medicines were linked to the CNS, CV 
system, and infection medicines. 



























































7.1 General Introduction 
Chapter One described this PhD study as an investigation of how people cope 
with, identify and manage ADRs as well as the consequences of ADRs - in terms 
of future use of medicines and their impact on daily lives. The public have been 
permitted to report suspected ADRs directly to the YC Scheme since 2005. 
Previous research into patient Yellow Card (YC) reports was described in Chapter 
Two which suggested that analysis of the free-text responses and other content in 
a large unselected sample of patient YC reports was necessary. The analysis of 
existing YC data which was undertaken in this phase of the study can therefore be 
considered important and novel research. It will increase information about the 
content of the free-text data these reports include and could confirm its potential 
value in the field of ADR research.  
 
7.2 Methodology 
7.2.1 Introduction  
Phase One of the study used a survey, distributed to patients using community 
pharmacies, to gather information in how people cope with and manage ADRs. 
Phase Two followed with in-depth interviews with a sample of survey 
respondents to explore their personal experiences of ADRs. These interviews 
informed the development of the SE-PAST in Phase Three of the study. This final 
phase of the study ± Phase Four - involved the analysis of patient YC reports 
received by the MHRA with particular focus on the free-text responses. A 
comparison was made between YC reporters and the wider general public, 
through comparison of the YC reports and the Survey data collected in Phase One 
of the study. The results of this comparison will be discussed in Chapter 8: 
Discussion.    
 
7.2.2 Aim & Objectives 
The aim of this phase of the study was to explore the experiences of ADRs among the 
general public. The YC reports investigated were non-HCP reports from members of the 
general public who have reported their ADRs. The objectives were as follows:  
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 To investigate the free-text content of YC reports. 
 To determine the different sources of information used by YC reporters in finding 
out about ADRs and their perceived value for this purpose.  
 7RDVVHVVWKHLPSDFWRI$'5VRQSHRSOHV¶GDLO\OLYHVDQGWKHFRQVHTXHQFHVRI
ADRs on medicines use in a large sample of YC reporters.  
 
7.2.3 Ethical approval 
This study phase received favourable ethical approval from the Independent Scientific 
Advisory Committee for MHRA database research (ISAC; Ref GENQ-00097958) (see 
Appendix 21). Accessing anonymised YC data was considered to be minimal risk. No 
additional information which could be considered sensitive was sought such as information 
DERXWWKHUHSRUWHURUWKHUHSRUWHU¶VGRFWRU,QDGGLWLRQWKH0HGZD\6FKRRORI3KDUPDF\
Research Ethics Committee was informed of the study and the ISAC approval. 
 
7.2.4 Study Design 
This study involved the analysis of YC reports received by the MHRA during a six-month 
period from July to December 2015. This time period was selected as it was estimated that 
approximately 3000 reports would be available. Vaccination reports were excluded from 
the data set as this sub-sample may contain confounding effects unique to vaccinations. 
These include confounding by indication and healthy vaccine biases which can influence 
vaccine effectiveness (Remschmidt et al., 2015; Jackson et al., 2013). Research has also 
identified associations between increased symptom/effects reports and un-informed 
choices to receive vaccination (Murphy et al., 2012).  The remaining YC reports were 
subjected to qualitative and semi-quantitative analysis. Free-text comments and responses 
to closed questions were examined to explore the overall ADR experiences of YC 
reporters. The information contained in YC reports was used to address the study 
objectives - to establish how YC reporters identify and manage their ADR; to identify the 
information sources used by YC reporters as well as the impact of ADRs on their daily 
lives. 
An application form for Permission for Access to Yellow Card data was submitted to the 
ISAC (See Appendix 22). A Category II request was made to the ISAC as all data fields 
listed in Section D.2 of the ISAC application form (except test results) were required for this 
study. This included both Category Ib data fields which excludes information that can 
identify patient/reporter and Category II data fields which are listed in Table 7.1. All 
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responses to open questions in Sections 1-3 of the YC form were also required. See Table 
7.1 which lists the requested data fields: 
Table 7.1: Required data fields for YC analysis 
 
Inclusion criteria for the YC data were as follows:  
 YC reports from the general public 
 YC reports generated from July ± December 2015 
 Category Ib & Category II data fields as specified in the ISAC application 
MHRA staff extracted and cleaned the YC data, copied it into a series of Excel 
spreadsheets and provided these in a password protected CD format for analysis.  
 
7.2.5 Data Analysis 
All individual reports had a code number which was used to match up the data from the 
separate Excel spreadsheets, enabling a single dataset to be derived (by JK) which 
contained: reporter number, reporter status, age and gender of person experiencing ADR, 
reaction text, all additional free text responses and all drugs listed on the report. All 
individual drugs in each report were classified using BNF number 59 (March 2015) and the 
total number of different drugs and different products were calculated for each report (by 
RMR). This classification system was initially based on BNF chapter headings which were 
related to general body systems for example BNF Chapter 4 Central Nervous System. This 
Category Ib and Category II data fields  
Patient age (Ib) Reaction outcomes (Ib) 
Patient gender (Ib) Reaction start/stop dates (Ib) 
Suspect drug(s) (Ib) Reaction details (Ib) 
Dose of suspect drug(s) (Ib) Past medical history (Ib) 
Route of administration (Ib) Previous drug history  (II) 
Drug start/stop dates (Ib) Other: Where drug(s) were obtained (II) 
Severity of the side effect (II) 
Suspected adverse drug reaction(s) (Ib) Other: Full free text comments provided in 
response to questions covering: symptoms and 
how it happened, more details of the outcome, any 
other relevant information (II) 
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was then further broken down to show the class within the overall chapter for example 
BNF 4.2.1 Antipsychotic drugs. Similar mechanisms of action are usually present in drugs 
in a particular class and therefore these drugs may also have a similar side effect profile. 
The data were transferred from Excel into SPSS and checked using simple frequencies to 
assess completeness of all data fields, remove any duplicate cases, detect and remove any 
errors and account for missing data. The cleaned data were subjected to qualitative and 
quantitative analysis. A significance value of p ZDVVHWWRFRQWUROIRU7\SHHUURU 
Content analysis was used to code the free-text responses and identify points of 
commonality, in addition to a semi-quantitative analysis of coded data. For the latter, free-
text responses were analysed using Excel to develop a coding frame. This coding process 
involved the researcher and supervisor (JK) independently reading 100 different responses 
to identify and agree emergent themes. A further 100 responses were coded with these 
initial themes, to determine the need for further themes. Any differences were resolved by 
discussion. The final agreed themes were then used by the researcher to code the entire 
dataset. In addition, a subset of approximately 100 reports was selected to be coded 
independently by the two coders. This coding was then compared to ensure reliability in 
the coding process. This method has been used previously for quantitative analysis of free-
text responses to questionnaires from YC reporters (Avery et al., 2011).   
The data management program QSR NVivo 10 was used to further analyse the free-text 
responses from individual reporters qualitatively, combining them with responses to closed 
questions, to create narratives of individual experiences. Template analysis is a particular 
style of thematic analysis which focuses on hierarchical coding in a highly structured 
analysis process. The approach is underpinned by an established theory and permits the use 
of a priori themes. Unlike other thematic approaches to analysis coding levels are not 
ordered or set in advance. There is no distinction between descriptive and interpretive 
themes and no particular position assigned for each theme in the coding structure. 
Template analysis was chosen as an appropriate technique to examine the narratives as it 
was a flexible approach which used the richest data to generate themes and focused 
analysis on relevant aspects of the dataset (Braun & Clarke, 2006; Brooks et al., 2015). It 
has been used in previous studies to analyse a variety of datasets including open-ended 
questionnaire responses (Dornan et al., 2002; Kent, 2000). Template analysis of the 
narratives built on existing theory and enabled the identification of key themes relevant to 
the study. 
This analysis involves five phases ± familiarisation with the dataset; initial coding; 
identification and organising of themes into hierarchical clusters; reviewing and defining 
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themes (Braun & Clarke, 2006; Brooks et al., 2015). This is an iterative process generating 
a succession of templates which are refined before a final template is applied to the dataset.  
See Figure 7.1 on the following page for a schematic of the coding process. The final 






Figure 7.1: Thematic analysis coding process
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The free-text responses were read to identify key narrative aspects, focusing on how the 
individual ADR experience was structured and actively reconstructed. The influence of 
social and environmental factors such as family, work, health care systems were also 
considered. The a priori themes focused on the processing of the ADR event and the 
multidimensional impact of ADRs. Narratives were selected according to the following 
criteria: 
- reporter type  
- reports coded with severe effects  
- reports with elaborate narratives 
- reports with a variety of drug classes  
The quantitative data from responses to closed questions within the YC reports were 
analysed using SPSS (Windows Statistics 23). Descriptive statistics were generated 
covering suspect drug, indication, whether or not the drug was stopped after the 
ADR, reported seriousness and outcome, in relation to age and gender. For the 
purposes of analysis age was divided into eight categories: 
1. Infants less than 1 year 
2. 1-20 years 
3. 21-40 years 
4. 41-50 years 
5. 51-60 years 
6. 61-70 years 
7. 71-80 years 
8. Over 80 years  
Reports were divided into the following three categories: 
1. Patient reports/self-reports from those who had experienced the SE. 
2. Carer reports submitted by carer on behalf of another person who had 
experienced the SE. 
3. Parent reports submitted by parent on behalf of children who had 
experienced the SE. 
The outcomes described in YC reports were divided into two categories: 
1. SE outcomes.  
2. Reaction outcomes.  
SE outcomes were the consequences for patients of the reported SE. These were 
labelled as follows: incapacity, hospitalisation and/or life-threatening results. 
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Reaction outcomes were the assignment of categories to the current condition of 
the patient in relation to the SE. There were labelled as follows: effects were 
recovered/resolved; effects were not recovered/resolved; effects were 
recovering/resolving; effects were recovered/resolved with sequelae or effect 
outcomes were unknown.  
Severity levels were divided into three categories: 
1. mild symptoms/effects. 
2. moderate symptoms/effects.  
3. severe symptoms/effects.  
5HSRUWV ZKLFK XVHG WKH WHUPV µPLOG¶ µPRGHUDWH¶ RU µVHYHUH¶ LQ WKHLU IUHH WH[W
comments to describe symptoms/effects were flagged as self-identifying/assessing 
reports. These reports were then coded according to these terms. Otherwise severity 
levels were assessed according to the following criteria: 
- the short term impact of the effects 
- the long term consequences of the effects 
- the number and type of effects 
- the number and type of HCP interactions. 
 The impact of SE were divided into three categories with overlap between these 
classifications: 
1. physical impact. 
2. psychological impact. 
3. social impacts.  
Social impacts were assessed according to the following criteria:  
- the quality of daily life was affected 
- resulted in negative/avoidant social behaviours  
- the result of a combination of physical and psychological impacts. 
Multidimensional chi-squared, Mann-Whitney and Kruskal-Wallis tests were used 








Box 7.1: List of associations between variables investigated in analysis of YC data  
Reported demographics by gender and type of reporter  
Gender and type of reporter by method of reporting and reported severity 
of SE 
Gender and type of reporter by HCP confirmation of effects  
Gender and type of reporter by SE outcomes 
Gender and type of reporter by reaction outcomes 
Number of drugs by gender and age 
Number of drugs by reported severity and outcomes 
BNF classes by gender and age 
 BNF classes by reported severity and outcomes 
 
7.3 Results 
7.3.1 YC sample 
Reports concerning vaccinations (775) were excluded from the initial 3060 reports 
provided by the MHRA. Therefore, 2285 YC reports were analysed. 
The results are presented in three sections: Description of YC reports; SE Causality 
and Managing SE. 
 
7.3.2 Description of the YC reports  
This analysis investigated reports from those who had experienced the SE - 
µSDWLHQW¶UHSRUWVVHOI-reports - and those who submitted the report on behalf of 
another individual - µFDUHU¶DQGµSDUHQW¶UHSRUWVOverall 8792 reactions were 
reported ranging from 1-52 effects (M=3.9; SD±3.63). See Section 7.3.3 SE 
causality for details of these reactions/effects. 
Age and gender 
The reported median age of patients who experienced SE was 43 years (range 0-
91). Age was not normally distributed, with skewness of -0.13 (SE = 0.05) and 
kurtosis of -0.74 (SE = 0.11). The majority of reports were for females (1522; 
67%) compared to 752 (33%) for males. The highest proportions of reports were 
for those aged 21-40 years (675; 31%), followed by 368 (17%) aged 61-70 years. 
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There was a significant difference between gender and reported age of those who 
experienced SE. More younger females and older males were reported to have 
experienced SE. The highest proportion of these females (525; 36%) were 21-40 
years while the highest proportion of males (158; 22%) were aged 61-70 years. A 
Mann-Whitney test indicated a significant relationship between gender and age 
(years): U = 393615, N1=706, N2=1446, p <0.001, two-tailed. 7KH&RKHQ¶VHIIHFW
size value (d
 
= 0.4) suggested a small to moderate practical significance. See 
Table 7.2.  
Type of report and reporting methods 
$PDMRULW\RIWKHUHSRUWVZHUHµSDWLHQW¶UHSRUWVZLWK
µFDUHU¶DQGµSDUHQW¶UHSRUWV$VFDQEHVHHQIURPTable 7.3 the majority 
of SE experienced by both males (656; 87%) and females (1433; 94%) were 
reported via patient/self-reports:X2 (2, N = 2274) = 32.56, p <0.001 with a weak 
association ĭ = 0.12, gender accounting for 1% of the variation in reporter type.  
The majority of reports submitted for all age ranges apart from infants were 
patient reports. The highest proportion of reports for those aged 41-50 (330; 98%) 
and 51-60 years (355; 98%) were patient reports. As expected all reports for 
infants (27; 100%) and many of those aged 1-20 years (53; 36%) were parent 
reports. The highest proportions of carer reports were for those aged over 80 (18; 
29%) followed by those aged 71-80 (17; 10%). A Kruskall-Wallis test indicated a 
significant relationship between reporter type and age (years): X2 (2, N = 2159) = 
263.16, p <0.0017KH&RKHQ¶VHIIHFWVL]HYDOXHd
 
= 0.7) suggested a large 
significance. 
The Internet was the most common method of reporting for all reporters - 1877 
µSDWLHQW¶VHOI-UHSRUWHUVµFDUHUV¶DQGµSDUHQWV¶7KH
Internet was also the most frequently used reporting method across both gender 
and age categories. The majority of SE reports for both males 643 (86%) and 
females 1388 (91%) were submitted via the Internet:  X2 (4, N = 2244) = 18.9, p 
ZLWKDZHDNDVVRFLDWLRQĭ JHQGHUDFFRXQWLQJIRURIWKH
variation in reporting methods. Over 90% of reports submitted for five of the eight 
age categories - 1-20; 21-40; 41-50; 51-60 and 61-70 years ± were Internet 
reports. The lowest proportion of Internet reports were submitted for those over 
80 (41; 66%). 
Reported severity and HCP confirmation of SE 
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Severe reactions/effects were reported in 1621 (71%) reports irrespective of 
reporter type - patient (1481; 71%), carer (72; 73%) and parent (68; 76%) reports. 
The majority of SE were not confirmed with a HCP (2249; 98%). Overall SE 
outcomes in YC reports were as follows: incapacity (106; 5%), hospitalisation 
(185; 8%) and life-threatening outcomes (265; 12%). It can be seen from the data 
in Table 7.3 that there was a relationship between reporter type and two SE 
outcomes - hospitalisation and life-threatening results.  The majority of 
hospitalisation outcomes were reported by parents (19; 21%) and carers (18; 18%) 
with proportionately fewer patients (148; 7%) reporting this consequence: X2 (2, N 
= 2285) = 37.04, p<0.001. There was a weak association: ĭ = 0.13, thus reporter 
type accounted for 2% of the variation in this outcome. The majority of life-
threatening results were reported by carers (13; 13%) with 8 parents (9%) and 85 
patients (4%) reporting this consequence: X2 (2, N = 2285) = 22.43, p<0.001. 
There was a weak association: ĭ = 0.1, thus reporter type accounted for just 1% 
of the variation in life threatening outcomes.  
 
7.3.2.1 Associations between Gender and age, with SE severity and SE outcomes. 
Gender against SE severity and outcomes 
Overall the majority of reports for both females (1113; 73%) and males (501; 
67%) reported serious effects. Analysis indicated an association between gender 
and reported SE severity with severe/serious SE reported for more females than 
males. These assessments of severity were not linked to SE outcomes as a 
majority of both males and females experienced no incapacity (652; 87% and 
1357; 89% respectively) or hospitalisation (684; 91% and 1405; 92% 
respectively). The relationship between gender and SE severity was significant: X2 
(1, N = 2274) = 10.34, p=0.001 with a weak association: ĭ = -0.07, thus gender 
accounted for 0.5% of the variation in SE severity.   
It can be seen from the data in Table 7.2 that there was a relationship between 
gender and life-threatening outcomes. A higher proportion of males (49; 7%) than 
females (55; 4%) experienced life-threatening effects; X2 (1, N = 2274) = 9.7, 
p=0.002 with a weak association: ĭ = 0.07, thus gender accounted for 0.5% of the 
variation in life threatening outcomes. Although not statistically significant, there 
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were also slightly more males who experienced hospitalisation and 
disability/incapacity.  
Age against SE severity and outcomes 
A pattern of reported severity was evident across the older age categories with 
severe effects more likely to be reported for these categories. A majority of the 
following five age categories were reported to have experienced severe effects: 
207 (68%) aged 41-50; 227 (70%) in those 51-60; increasing to 245 (73%) of 
those aged 61-70; 128 (72%) of those between 71-80 years and 37 (73%) aged 
over 80 years. A Mann-Whitney test indicated a significant relationship between 
reporter severity and age (years): U=405010.5, N1=1563, N2=593, p <0.001, two-
tailed. 7KH&RKHQ¶VHIIHFWVL]HYDOXHd = 0.2) suggested low practical 
significance. See Table 7.4. 
Analysis indicated that 11947 reaction outcomes were linked to 2285 reports, with 
older patients more likely to have resolved reactions. The highest proportion of 
resolved effects occurred in those aged 51-60 (64; 18%) and over 80 years (15; 
24%). The highest proportion of unresolved reactions occurred in 61-70 years 
(172; 47%). Similar proportions of reactions had unknown outcomes for infants 



























           Gender freq (%)  
                n=2285 
    














  17(2.4)                                        10(0.7) 
  45(6.4)                                      102(7.1) 
145(20.5)                                    525(36.3) 
  92(13)                                       244(16.9) 
111(15.7)                                    252(17.4)  
158(22.4)                                    210(14.5) 
 97(13.7)                                       82(5.7) 












643(85.5)                                 1388(91.2) 
 32(4.3)                                       48(3.2) 
 69(9.2)                                       75(4.9) 
  5(0.7)                                          8(0.5) 




Reported SE severity 
Considered serious 
Not considered serious 
 
501(66.6)                                1113(73.1) 













100(13.3)                                    165(10.8) 
652(86.7)                                1357(89.2) 
 
68(9.0)                                      117(7.7) 
684(91.0)                                1405(92.3) 
 
49(6.5)                                       55(3.6) 














  14(1.9)                                    21(1.4) 





Table 7.3: Reporter type by reported characteristics and outcomes 
 










                              Reporter type f (%) n=2285 
        
 













        0                                 0                               27(100) 
    92(62.6)                         2(1.4)                        53(36.1) 
  649(96.1)                       19(2.8)                         7(1.0) 
  330(97.9)                         5(1.5)                         2(0.6) 
  355(97.5)                         9(2.5)                          0 
  50(95.1)                         18(4.9)                           0 
  162(90.5)                       17(9.5)                           0 
    44(71.0)                       18(29.0)                         0 
1 





  656(87.3)                       48(6.4)                       47(6.3) 
 1433(94.1)                      48(3.1)                   42(2.8) 
 
   







  1877(89.6)                      83(83.8)                    81(90) 
       70(3.3)                         7(7.1)                       3(3.3) 
     131(6.3)                         8(8.1)                       6(6.7) 
       13(0.6)                         0                               0 
         5(0.2)                         1(1.0)                    0 
 0.42 
      
Reported SE severity 
Considered serious 
Not considered serious 
 
  1481(70.7)                      72(72.7)                     68(75.6) 
    615(29.3)                      27(27.3)                     22(24.4) 
0.56 











   237(11.3)                      12(12.1)                       16(17.8) 
 1859(88.7)                      87(87.9)                       74(82.2) 
 
 148(7.1)                          18(18.2)                        19(21.1) 
1948(92.9)                       81(81.8)                        71(78.9) 
 
  85(4.1)                           13(13.1)                           8(8.9) 
2011(95.9)                       86(86.9)                         82(91.1) 
    0.17 
 










     32(1.5)                          2(2.0)                                2(2.2) 
 2064(98.5)                      97(98)                               88(97.8) 











   
 
#Multiple effects  
Rseq=resolved with sequelae 












 Reported severity f (%) n=2285 
 
Serious                   Not serious      
 
p-value 
Reaction outcomes n=11947# 
 












 123(74.1)                  43(25.9) 
 267(72.6)                101(27.4)          
387(69.2)                172(30.8) 
207(67.6)                 99(32.4) 
227(70.1)                 97(29.9) 
245(73.4)                 89(26.6) 
128(72.3)                 49(27.7) 
 37(72.5)                  14(27.5) 
 
1  
  4(14.8)         12(44.4)                2(7.4)            3(11.1)           6(22.2) 
 23(15.6)        62(42.2)              28(19)           13(8.8)            21(14.3)                       
115(17.0)      312(46.2)           109(16.1)        29(4.3)          110(16.3) 
 54(16.0)       152(45.1)            60(17.8)         11(3.3)             60(17.8) 
 64(17.6)       148(40.7)            68(18.7)         26(7.1)             58(15.9) 
 63(17.1)       172(46.7)            50(13.6)         19(5.2)             64(17.4) 
 31(17.3)         80(44.7)            25(14.0)          13(7.3)             30(16.8) 
 15(24.2)         20(32.3)            10(16.1)           3(4.8)              14(22.6) 
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7.3.2.2 Associations between reported severity by SE outcomes and reaction 
outcomes  
There were relationships between the reported severity of effects and the three SE 
outcomes of incapacity, hospitalisation and life-threatening results. 
Reported severity by SE and reaction outcomes 
The data revealed that many effects which did not result in negative outcomes were still 
reported as severe. The majority of reported severe effects did not lead to incapacity (1356; 
84%); hospitalisation (1436; 89%) or life- threatening outcomes (1515; 94%). However, 
the reports which did describe these SE outcomes always reported effects as severe effects. 
The relationship between reported severity and incapacity was significant with a moderate 
association: X2 (1, N=2285) = 122.8, p <0.001: ĭ = -0.23, severity accounted for 5% of the 
variation in incapacity. 
Analysis indicated the relationship between reported severity and hospitalisation 
outcomes was significant with a moderate association: X2 (1, N=2285) = 82.46, p 
<0.001: ĭ = -0.2, severity accounted for 4% of the variation in hospitalisation 
outcomes. 
The association between reported severity and life threatening outcomes was also 
found to be significant: X2 (1, N=2285) = 45.5, p <0.001: ĭ = -0.1, however 
severity accounted for just 1% of the variation in life threatening outcomes 
Overall reported severity was also not influenced by reaction outcomes. Unresolved 
reactions did not result in increased reporting of severity. Similar proportions of resolved 
(272; 70%), resolving (276; 74%) and unresolved (739; 73%) reactions were all linked to 



































Not serious freq  Serious freq
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7.3.2.4 Section summary  
 Patient reports are the most common reporter type.    
 The Internet is the most common method of reporting.   
 SE were more frequently reported for females and older patients. 
 More severe SE were reported for females and older patients. 
 Reported severity of SE was not influenced by SE outcomes or reaction 
outcomes. 
 
7.3.3 SE causality 
7.3.3.1 Number of reported drugs and effects 
Overall, within the 2285 YC reports, 2472 causative drugs were reported and linked to 
8,792 SE. The number of reported drugs taken by individual patients ranged from 1 to 12; 
M = 1.08 (SD ± 0.45) and mode = 1. As Table 7.5 below shows the vast majority of reports 
cited one drug (2168; 95%) with 79 (4%) citing two drugs.  
 


















No of drugs taken 
 
Frequency % 
1 2168 94.88 




4 11 0.48 




12 1 0.04 
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The number of reported effects per YC ranged from 1 to 52 effects (M = 3.9, SD ± 3.63). 
The most common number of effects reported was one effect (594; 26%) followed by 456 
(20%) who reported two effects.  See Table 7.6 below. 
The most frequently reported effect was pain (1060; 46%) followed by abdominal 
discomfort (467; 20%) headache (389; 17%) and fatigue (326; 14%). See Figure 7.3. 
 


















No of effects 
 
Frequency  %  
1 594 26.00 




4 243 10.63 




7 97 4.25 
8 76 3.33 
9 42 1.84 
10 44 1.93 





Figure 7.3: Top 10 reported effects (n=8792) 
 
7.3.3.2 Reported causative drugs 
Initial classification of the 3060 reports found that 2936 involved drugs which could be 
classified according to the British National Formulary (BNF), however there were also 124 
reports which involved drugs/products which constituted discontinued/unclassified items. 
From 2285 reports, 2472 causative drugs were reported, with the highest proportion of 
drugs linked to the central nervous system (CNS) (544; 22%), infections (406;16.42%) and 
cardiovascular system (CVS) drugs (279;11.29%).  











































#Excludes Vaccinations/Immunological products; 
 *Indicates highest proportions of drugs  
 

















































The 20 most frequently reported individual drugs are presented on the following page in 
Figure 7.5. The top five drugs were as follows:  
Sertaline (60; 2.43%)  ± BNF 4.3 Selective serotonin re-uptake inhibitors  
Clarithroymcin (58; 2.35%) ± BNF 5.1 Antibacterial drugs 
Citalopram (51; 2.06%) - BNF 4.3 Selective serotonin re-uptake inhibitors  
Omeprazole (47; 1.9%) - BNF 1.3 Proton pump inhibitors  






















Po=progesterone only; (BNF classification number) 










































oral po contraceptive (7.3.2)
ramipril (2.5.5)







































10.1.1 Non steroidal anti-inflammatory
10.3.2 Non steroidal anti-inflammatory
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7.3.3.3 Associations between number of drugs and gender, age, reported severity, and 
outcomes  
Analysis was conducted to identify relationships between age, gender, reported 
SE severity and the number of drugs reported to have caused the SE. 
Number of drugs by gender and age, reported severity 
The majority of reports for both males (704; 94%) and females (1453; 96%) 
related to taking one drug. The data revealed a similar pattern across the eight age 
categories with a majority ± over 85% - reporting one causative drug. As Table 
7.7 shows the seriousness of SE did not vary with number of drugs. There were 
similar proportions of severe effects linked to one drug (1539; 71%); two (66; 








































        Number of reported drugs f (%) n=2472 






704(93.6)                 33(4.4)         10(1.3)              4(0.5)         1(0.1)               0                0           













  24(88.9)                   3(11.1)          0                       0                0                    0                0  
 138(93.9)                  6(1.4)            1(0.7)               1(0.7)         0                    1(0.7)        0 
 645(95.6)                 22(3.3)           2(0.3)               2(0.3)         1(0.1)            0                0 
 323(95.8)                 11(3.3)           0                       0                1(0.3)             0               1(0.3) 
 342(94)                    13(3.6)           3(0.8)                3(0.8)        1(0.3)             0               0 
 347(94.3)                 15(4.1)           1(0.3)                1(0.3)         0                    0               0 
 168(93.9)                   6(3.4)           2(1.1)                2(2.1)         0                    1(0.6)       0 
   58(93.5)                   2(3.2)           1(1.6)                1(1.6)         0                    0               0 
0.37 
Reported SE severity 
Considered serious 
Not considered serious 
 
1539(71)                 66(69.6)        15(71.4)              10(63.6)         3(66.7)        0               0          















 252(95.1)                  11 (4.2)          1(0.4)                1(0.4)          0                    0                0 
1916(94.9)                 68(3.4)          20 (1)               10(0.5)          3(0.1)            2(0.1)        1(0) 
 
 
174(94.1)                   6(6.3)            2(1.4)               1(0.5)          1(0.5)            1(0.5)         0 
1994(95.0)                73(3.5)          19(0.9)            10(0.5)          2(0.1)            1(0.5)         1(0.5)    
 
 
104(98.1)                     1(0.9)            0                      0                  0                 1(0.9)           0 
















7.3.3.4 Associations between BNF categories and gender, age, reported severity, 
and outcomes  
Analysis was conducted to identify relationships between BNF chapter categories 
and gender, age, reported severity and outcomes. 
BNF categories by gender and age 
The highest proportions of reports for both males (175; 26%) and females (361; 
25%) were for CNS drugs. A Mann-Whitney test indicated a significant 
relationship between BNF categories and gender: U = 435199.5, N1=685, 
N2=1444, p <0.001, two-tailed. 7KH&RKHQ¶VHIIHFWVL]HYDOXHd = 0.2) suggested 
a small practical significance. See Figure 7.6. Similar proportions of CNS drugs 
were evident across age categories 1-20 (35;26%); those aged 21-40 (223; 35%) 
those aged 41-50 (86; 28%). The proportions of CVS drugs, in contrast, increased 
with age: 21-40 years (21;3%); 51-60 years (62;18%) to those aged over 80 
(16;27%)  A Kruskall-Wallis test indicated a significant relationship between 
BNF categories and age (years): X2 (13, N = 2013) = 252.376, p <0.001. The 
&RKHQ¶VHIIHFWVL]HYDOXHd
 
= 0.7) suggested a moderate to high practical 
significance. 




     BNF   categories# 
 




1-20 35(25.7)                        3(2.2) 
21-40 223(35.2) 21(3.3) 
41-50 86(27.7) 26(8.4) 
51-60 70(20.3) 62(18.0) 
61-70 47(13.8)             87(25.5) 
71-80 34(20.7) 42(25.6) 
>80 8(13.6) 16(27.1) 
# Most frequently occurring categories in age categories 
 
BNF categories and reported severity and outcomes 
Similar proportions of CNS and CVS drugs were linked to serious effects. There 
were 539 effects involving CNS drugs and 412 of these reported serious effects 
(412;76%). Similar proportions of serious effects were reported for CV drugs 
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(205;74%). There were 407 reports of serious effects for infections however a 
lower proportion of these reports were linked to serious effects (280;69%). A 
Kruskall-Wallis test indicated a significant relationship between BNF categories 
and severity: X2 (14, N = 2127) = 46.548, p <0.001. CRKHQ¶VHIIHFWVL]HYalue (d
 
= 
0.3) suggested a small to moderate practical significance. See Figure 7.7.  
The highest proportions of incapacity were reported for CNS drugs (81; 15%) and 
CVS (36; 13%). Similar proportions of GI (12; 9.8%), CNS (51; 9.5%) and CVS 
drugs (26; 9.4%) resulted in hospitalisation. The most life-threatening events 
occurred with CNS drugs (39; 7.3%). Kruskall-Wallis tests indicated significant 
relationships between BNF categories and all the following SE outcomes. 
Incapacity: X2 (14, N = 2127) = 27.784, p =0.015FRKHQ¶VHIIHFWVL]HYDOXHd
 
= 
0.2) suggested low practical significance; hospitalisation: X2 (14, N = 2127) = 
24.965, p=0.035, ZLWKDYDOXHIRUFRKHQ¶VHIIHFWVL]H (d
 
= 0.2) of low practical 
significance; and life-threatening events: X2 (14, N = 2127) = 41.338, p <0.001, 
with FRKHQ¶VHIIHFWVL]HYDOXHd
 
= 0.3) of small to moderate practical significance. 
























































































































Infections freq CVS freq CNS freq GI freq
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7.3.3.5 Section summary 
Most reported drugs were for CNS, CVS and infections 
-12 drugs reported; 95% reports for one drug  
6E severity did not increase with number of drugs 
-52 effects reported; 45% reports for 1/2 effects 
&16GUXJVcommonly reported across gender and age categories 
&96GUXJVUHSRUWs increase for older age categories 
CNS and CVS drugs linked to serious effects and incapacity 
 
7.3.4 Managing SE  
7.3.4.1 Content analysis of YC reports 
The free text comments were subjected to content analysis which systematically 
categorised the data. From 2285 reports four duplicates and 26 blank reports were 
excluded from the analysis leaving 2255 reports. As outlined in the Methods 
chapter a Content Analysis (CA) coding frame was generated with 74 sub-
categories which formed 13 hierarchical categories. These codes were applied to 
the YC reports and the major categories were as follows: 
 SE description 
 identification of SE 
 management of SE 
 impact of SE  
 consequences of SE 
 
See the following page for Table 7.9
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Table 7.9: Content analysis (CA) coding frame applied to YC free text comments 
Coding of sub-categories 
 
Hierarchical categories Coding of sub-categories 
 
Hierarchical categories 
Patient describing SE  
1-Physical symptoms/effects 
1-Description of SE Suspect drug 
2-Patient provides name of suspect drug  
2-Drug details  
 3DWLHQW¶VUHDVRQIRUWDNLQJFDXVDWLYHPHG 
3-Treating long term medical condition 
4-Current medical problem/general health 
3-Reason for drug use  Impact of SE  
5-Physical impact 
6-Psychological impact 
7-Social impact (QDL) 
4-Impact of SE on patient 
 




5-Severity of SE  Strategies employed by patient in 
identification of SE 
11-Timing sequence of side effects 
14-HCP confirmed 
15-Used PILs to identify SE 
16-Used Family/friends to identify SE 
17-Used Internet to identify SE 
18-Prior SE history (medical history) 
19-Change in general health status 
20-Change in brand 
21-Patient makes differential diagnosis 
22-Suspected possible interaction effects 
6-Identification of SE 
 
Knowledge of possible SE  
23-Self informed prior to SE event 
24-HCP informed prior to SE event 
25-No knowledge of possible SE  
7-Prior knowledge of SE  Behaviours 
26-Stopping meds 
27-Adhered to meds 
28-Reducing dose 
29-OTC remedies to counteract 
symptoms 
30-Prescription remedies to counteract 
symptoms 
31-Finished course 
32-Reverting to original brands 
33-HCP consultation 
34-Self directed medicine management 
35-Self directed non medicine 
management 
36-HCP medicine management 
 
8-Patient behaviours  
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Table 7.9: Content analysis (CA) 






Outcome of Patient Behaviours 
37-Dechallenge and SE went away 
38-Took counteracting med and masked SE 
39-Med taken to treat SE leads to more SE  
40-Used CAMs to treat SE 
41-Recorded suspect ADR in medical records (JK) 
42-Used coping strategies to deal with SE  
9-Behavioural Outcomes 
 
Description of interactions with HCPs 
43-Hospital admission 
44-A&E 




49-Reported SE to HCP 
50-Did not report SE to HCP  
51-HCP not aware of SE 
52-Multiple contacts with HCPs 
53-Future HCP consultation 
likely/intended 
10- Interaction with HCPs  
Consequences 
54-Accepts SE 
55-Reluctant to take related med 
56-Will not use med again 
57-Prolonged/persistent physical effects 
58-Prolonged/persistent psychological effect 
59-Prolonged/persistent social effects 
60-Prolonged/persistent work-related effects 
61-Prolonged/persistent economic effects 
62-Prolonged/persistent life-changing effects 
 




64-Issues with Prescribers 
65-Issues with Pharmaceutical industry 
66-Negative experience in HCP 
interaction 
67-Specific concerns about 
quality/suitability of meds 
68-Disagrees with HCP 
diagnosis/treatment 
69-HCP ignored allergy 
70-Perceives themselves as sensitive to 
meds 
12-Patient Concerns 
Characteristics of YC Reporters 
71-Motivation to report described 
72-Supporting documents supplied e.g. medical 
records/consultant letters 
73-Advice requested 








The frequencies of the hierarchical categories (1-13) in the YC reports were calculated. 
The highest proportions of reports described the SE ± (2153;70%) and the impact of the SE 
± (2140;70%). The severity of the SE was described in 1371 reports (44%), patient 
behaviours in 990(32%), details of the drug were given in 751(24%) and interactions with 
HCPs were reported in 739(24%) reports. See Figure 7.9. 
Analysis indicated 17 subcategories (23%) had frequencies greater than 200. These 













































Table 7.10: Subcategories with frequencies greater than 200 created from CA of YC free 
text comments (n=2255) 
 




2- Patient provides name of suspect drug  
 
751 
4- Current medical problem/general health 
 
301 






7- Social impact (QDL) 
 
760 
8- Mild effects 
 
290 
9- Moderate effects 
 
532 
10- Severe effects 
 
559 
11- Timing sequence of side effects 
 
313 
26- Stopping meds 
 
354 
33- HCP consultation 
 
671 






52- Multiple contacts with HCPs 
 
315 
57- Prolonged/persistent physical effects 
 
207 




7.3.4.2 Quantitative analysis and in-depth qualitative analysis of free text 
comments 
A range of extracts have been used to describe the YC reports and demonstrate the 
results of the analysis. These extracts represent different reporters, drugs and 
reactions. Information on the gender, reporter type and method of reporting is 
outlined for each extract (I-Net refers to Internet reports; paper to YC forms; 
telephone to report via phone; MHRA to report via letter/email report). The 
results are based on the 13 hierarchical categories which informed the in-depth 
qualitative analysis. Each category is illustrated by verbatim quotations and the 
extracts are identified by reporter type, patient age, gender, drug type and method 
of reporting. The focus of the analysis is on specific sub-categories and detailed 
quotes are used to emphasise noteworthy themes. The analysis is divided into the 
following six sections: 
 SE description 
 Impact of SE 
 Identification of SE 
 Managing SE 
 Consequences of SE 
 YC reporters and reports 
 
Additional quantitative analysis was conducted to create a fuller picture of the 
reports. Free text comments were described in relation to their characteristics, 
drug classes, SE severity and impact. Comments on identifying SE, HCP 
interactions and non-adherence were also linked to reported characteristics. A 
summary of this analysis is presented at the end of each section. 
 
7.3.4.3  SE description within free text: symptoms, background information, prior 
knowledge of SE and severity of SE 
Descriptions of SE were provided by the majority of reports (2153; 96%) with the 









Table 7.11: Frequency table of reports coded as Subcategories 1-10# 
 




categories 1-5  
Describing SE 
 
2153 95.48 26.44 
Name of suspect drug 
 




167 7.41 35.84 
Current medical problem/general 
health 
 
301 13.35 64.59 
Physical impact 
 
2099 93.08 98.08 
Psychological impact 
 
532 23.59 24.86 
Social impact (QDL) 
 
760 33.70 35.51 
Mild effects 290 12.86 21.15 
Moderate effects 532 23.59 38.08 
Severe effects  
 
559 24.79 40.77 
 
#Includes multiple effects per report 
 
7.3.4.3.1  Physical symptoms/effects 
A large majority of patients (95%; 2153) provided vivid, detailed descriptions of 
the physical symptoms of their SE. These ranged from lengthy lists of symptoms 
to single words or phrases. These frequently included descriptions of the severity, 
timing and consequences of their SE 
 
³Movement and standing gave dragging sensation and very painful back and 
hip..Sleepiness then severe back pain under left shoulder blade, kidney area and 
ULJKWKLSZHHNVDIWHUVWDUWLQJ6HYHUHEDFNDQGKLSSDLQ´ 




of weight, prolonged seizures of total confusion and inability to function or speak 
RUFRPSUHKHQG´ 
Patient, female, 70 years, Symbicort, paper.  
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7.3.4.3.2  Drug details 
It was found that 751 patients (33%) also supplied details of the suspect drug 
within the free-text descriptions:  
³&DQ
WEUHDWK- DVWKPDRXWRIFRQWURO«3UHVFULEHG³Fostair´ instead of 
previous asthma treatment that worked well. Within a few days asthma symptoms 
JRWPXFKZRUVH,
PVLWWLQJLQIURQWRIP\3&DQGVWUXJJOLQJWREUHDWKH´ 
Patient, male, 48 years, Fostair, I-Net.   
 
³7LJKWMDZJULQGLQJRIWHHWKXQDEOHWRUHOD[MDZLQKLELWVVOHHp, ache in jaw. 
Irritating. The patient was taking Sertraline foU$Q[LHW\DQGGHSUHVVLRQ´ 
Patient, female, 23 years, sertraline, I-Net. 
 
 
7.3.4.3.3  Reason for taking drug 
Overall 20% of the reports gave reasons for taking the drug ± 301 patients (13%)   
indicated they had taken this drug to deal with a current medical problem: 
 
³/RZPRRGIDWLJXHWLUHGQHVVFROGV\PSWRPV,ZDVUHJXODUO\WDNLQJLEXSURIHQ
400mg 3 times daily for bunions and shoulder pain for several months. I 
experienced extreme fatigue affecting ability to perform daily tasks, running 
nose, low mood´ 
Patient, male, 47 years, ibuprofen, I-Net. 
 
³Swirling, flashing lights covering the whole of my right visual field. No loss of acuity. 
Reduced vision in right eye in low light. Started spontaneously, increasing over 
approximately 3 days.  Had been on stable dose of 400 mg for 4 years but had increased to 
700mgm due to break through of paiQ´ 
     Patient, female, 65 yrs, carbamazepine,I-Net. 
 
 
 Just 167 patients (7%) reported they took the suspect drug to deal with a long 
term/established medical condition:  
 
³8VXDOO\KDYHDSXUSOHSDFNHW7KLVLVDVLOYHUEDWFK+DYHQRWLFHGP\ROGWULJJHUVLQD
light format starting to breakthrough. Not noticed for years. Medications have worked for 
15 years. First ever symptom. Illnesses: Epilepsy. I was epileptic 20 years. Breakthrough 
symptoms with this silver batch. Never noticed with purple batch.´ 
Patient, unknown, 33 yrs, sodium valproate, I-Net 
 
³,QIHFWLRQ6ZROOHQWHVWLFOHVDQGEORRGLQXULQH9HU\SDLQIXO9LVLWHGJHQHUDOSUDFWLWLRQHU
who prescribed course of ciprofloxacin 500mg to be followed by course of trimethoprim 
200mg. The patient was taking amiodarone for their heart condition following a number of 
FDUGLDFDUUHVWV´ 
     Patient, male, 50 yrs, amiodarone, I-Net. 
 
7.3.4.3.4 Prior knowledge of SE 
Two per cent or 45 patient reports indicated that they had no prior knowledge of a 
possible SE and consequently the effects were both negative and unexpected. 
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They reported their considerable dissatisfaction that they had not been informed 
by their HCP of the possible SE before they used the medicine: 
 
³$FLGUHIOX[EDGZLWKGUDZDOZKHQFRPLQJRIIWKHPHGLFDWLRQ'RFWRUXQDZDUH
of the full details about the medication and its side effects thus risks not explained 
WRPH´ 
Patient, male, 44 years, Lyrica, I-Net.  
 
³6HYHUHIXOOERG\VNLQUDVK%HJDQZLWKKLYHVWKDWPHUJHG$UPVKDQGVOHJVDQG
feet swollen. Large blisters on tops of feet. Skin turned purple and black 
particularly on face, legs and feet. Unable to walk for several days due to 
swelling on feet and legs. Shed skin all over. Felt nauseated and lost 
DSSHWLWH«+DYLQJUHDGWKHPHGLFDOSURGXFWLQIRUPDWLRQDQGDGYLFHDVVRFLDWHG
with Omnipaque after the event, it is clear I should have been warned about side 
effects and asked if I was epileptic, had a brain tumour or had a history of 
allergic reactions to medication. All of which are documented on my medical file. 
I was never asked such questions or offered such advice. If I had been aware of 
the side effect risks, particularly to people with my history, I would have refused 
WRKDYHWKHFRQWUDVW´ 
Patient, male, 49 years, Omnipaque, I-Net.  
 
Just 2 patients (0.1%) were, in contrast, informed of the possibility of SE by their 




absolutely no alcohol from the moment of starting the drug, as was told that it 
KDGVHULRXVVLGHHIIHFWV´ 
Patient, female, 80 years, metronidazole, I-Net. 
 
 
7.3.4.4  Impact of SE 
Descriptions of SE impact were divided into physical, psychological and social impacts as 
follows 
- physical described by 2099 (93%)   
- psychological described by 532 (24%)  
- social described by 760 (34%) 
Physical impact was reported in the majority of reports:  
 
³6HYHUHFUDPSDQGVKRRWLQJSDLQVLQKDQGV´ 
Patient, female, 56 years, prednisolone, I-Net 
 
The SE was described as having psychological impact in 532 reports (24%) and 





Patient, female, 31 years, Gedarel, I-Net 
 
 
³Severe myalgia and exhaustion. Began with severe muscle pain in right calf.  Gradually 
spread, getting worse each day, to most muscles all over body to the point that I could 
hardly walk and trying to lift a knife and fork to eat was an ordeal. Extreme depression 
caused either by medication or difficulty with daily life.´   
Patient, female, 59 years, Januvia, I-Net 
  
 
7.3.4.5  Severity of SE 
Descriptions of the severity of SE were divided into mild, moderate and severe effects as 
follows 
- mild effects described by 290 (21%)   
- moderate effects by 532 (39%)  
- severe effects 559 (41%) 
Severe effects were reported in 559 reports (41%) with 314 of these reports  
(56%) using the term ³VHYHUH´to describe SE within their free text comments:  
 
³+DQGVEHFDPHVZROOHQILUVWDQGIHHWVKRUWO\DIWHU6ZROOHQKDQGVDQGIHHW
causing severe pain when walking, and pain when using hands for anything. 
Doctor prescribed strong pain killers and ibuprofen gHO´ 
Patient, male, 67 years, Januvia, I-Net.  
 
³'U\SDOPVDQGKRDUVHQHVVRIYRLFH+RDUVHQHVVODVWHGVHYHUDOZHHNVDQG
affected ability to carry out school activities. Also think it perhaps led to a severe 
ear infection which was difficult to clear, requiring 4 lots antibiotics. 
Parent, male, 8 years, Oxybutynin hydrochloride, I-Net.  
 
³6LGHHIIHFWV- just like a bad flare up of irritable bowel disease/ irritable bowel 
syndrome - stomach pain/cramps and severe diarrhoea.. one day I was in tears at 
work afWHUEHLQJVWXFNLQWKHUHVWURRPVIRUQHDUO\KRXUV´ 
Patient, female, 30 years, Xeristar, I-Net.  
 
The SE was described as having moderate effects by 532 patients (39%) and 290 
(21%) described having mild side effects: 
 
³,IHHOH[WUHPHO\RGGRQWKLVLQhaler. It has not helped the wheezing and it is 
IULJKWHQLQJWRIHHOIDLQW$OVRP\PRXWKLVYHU\VRUH,IHHODQ[LRXVQRZ´ 








³$SSOLHGRQWKHDUHDRIWKHNQHHWKDWZDVVRUH:LWKLQDERXW-10 minutes the 
knee joint began to get very sore and painful. Continued to suffer it for 15-20 
minutes then washed it off. Gradually the pain subsided but was left with the knee 
MRLQWDEVROXWHO\VWLIIFRXOGKDUGO\EHQGLW7KHMRLQWIHOWORFNHGXS´ 
Patient, male, 83 years, piroxicam, telephone 
 
³/LJKW-headed feeling and slightly numb around lips and face; mild tingling throughout 
body. Unnerving!´   




Patient, female, 35 years, amoxycillin, I-Net. 
 
Associations between free text severity and the following - gender, reporter type, 
drug class and outcomes - were explored. Similar proportions of females (375; 
41%) and males (168; 38%) experienced severe effects. The highest proportion of 
severe effects were linked to CNS drugs (167; 53%) and described by over half of 
carer reports (36; 57%) and parent reports (26; 53%). There was a significant 
relationship between coded severity and reporter type with a weak association: X2 
(6, N=1370) = 16.13, p =0.02: ĭ = 0.11, reporter type accounted for 1% of the 
variation in free text severity. A Kruskal-Wallis test indicated the relationship 
between the coded severity and drug class was significant: X2 (4, N = 842) = 
28.51, p <0.001. 7KH&RKHQ¶VHIIHFWVL]HYDOXHd
 
= 0.4) suggested a small to 
moderate practical significance. Significant relationships were identified between 
coded severity and the outcomes of incapacity: X2 (3, N = 1370) = 97.9, p <0.001; 
hospitalisation: X2 (3, N = 1370) = 103.62, p <0.001; and life threatening 
consequences: X2 (3, N = 1370) = 92.9, p <0.001. The associations were of 
moderate strength: ĭ=0.3 with coded severity accounting for 9% of the variance. 
See Table 7.12. 
Reported severity levels in free-text were compared to coded severity to establish 
if MHRA-assigned severity levels were reflected by the free text descriptions. As 
Figure 7.10 shows the reported severity levels were related to coded severity 
levels. A majority of effects coded as moderate (425; 82%) and severe (520; 95%) 
were reported as serious. Just over half of effects coded as mild (149; 51%) were 


















 Coded severity f (%) n=2255 
Mild                             Moderate                                     Severe                        Moderate & Severe  
 
 






 95(21.5)                   174(39.5)         
192(20.9)                 347(37.7)                                      
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 268(21.3)                 493(39.2)              
    9(14.3)                    18(28.6)                  
  13(26.5)                    10(20.4)         
     
 
487(38.7)   
 36(57.1) 
 26(53.1)                 
                  
                            0.03* 
10(0.8)     
  0 
  0           








 13(21.3)                    28(45.9)              
 30(17.1)                    78(44.6)                  
 21(33.9)                    21(33.9)         
 46(14.6)                    99(31.3)                     
 55(24.1)                    89(39)                            
 
  19(31.1)   
  67(38.3) 
  20(32.3)                 
167(52.8) 
  83(36.4)                                   
                           1                            
1(1.6)     
0  
0           
4(1.3)   































Reported not serious freq Reported serious freq
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7.3.4.6  Section summary  
 22 extracts providing details of the physical symptoms; the drug and 
reason for taking drug; the impact and severity and previous knowledge of 
SE  
 21 patient reports and one parent report 
 9 reports for males; 12 for females; 1 unknown with ages ranged from 8-
83 years 
 Free text severity levels are 2 mild, 11 moderate and 9 severe effects 
 Nine drugs linked to CNS; 3 to Respiratory; 3 to Infections; 2 CVS; 2 
Endocrine; 2 Obstetrics/Gynaecological and 1 Anaesthesia 
 Comments composed of 6 scant; 13 moderately elaborate and 3 elaborate 
narratives 
 Overall comments covered descriptions of SE, their impact and severity   
 
7.3.4.7 Impact of SE ± multidimensional influences on patient lives  
Descriptions of the impact of SE were divided into physical, psychological and social 
impacts with overlap between these classifications. Social impacts were derived from a 
number of criteria which included the combination of both physical and psychological 
impacts. In total 2098 reports reported the impact of the SE as follows:  
- physical impact described by 1261 (60%)   
- physical and psychological impact reported by 101 (5%)  
- physical and social impact by 345 (16%) 
- physical, psychological and social impact by 391 (19%) 
Associations between type of impact of SE by gender, reporter type and drug class were 
explored. Physical impact was reported for similar proportions of males (418; 62%) and 
females (835; 59%). A majority of reporters ± over 60% - described physical impacts with 
a combination of physical, psychological and social impacts reported by carers (24; 26%). 
The highest proportion of physical impact was reported for GI drugs (84: 72%) with a 
combination of physical, psychological and social impacts linked to CNS drugs (145; 
30%). A Kruskal-Wallis test indicated the relationship between the type of impact and drug 
class was significant: X2 (1, N = 1953) = 75.79, p <0.001. 7KH&RKHQ¶VHIIHFWVL]HYDOXe (d
 











7.3.4.7.1 Physical impact of SE 
The explicit impact was primarily related to physical symptomology - described 
by 2099 patients (93%): 
 
³Felt unwell, cold, I had the most severe headache like a helmet of pain, 
indescribable. I will not take them again. I went out but felt cold and tired so 
came home. Within two hours I had a headache which got progressively worse as 
the evening wore on. The back of my hands, including fingers, were very blue 
YHLQHG,IHOWDV,I,ZRXOGKDYHDVWURNH«WKHSDLQZDVVWLOOGUHDGIXODQGKDGWR
JHWXSSPDQGWRRNDSDUDFRGRO´ 
Patient, female, age not supplied, Isoket, I-Net. 
 
 
³5HGLWFK\UDVKRQLQVLGHRIUight arm at the wrist. Rash on both underarms. 
Strange feeling in head and neck. Severe headache across forehead and back of 
KHDG´ 
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          Gender 
             Male 
          Female 
 
 418(61.6)                   34(5)         
 835(59.4)                   67(4.8)                                   
 
 
  109(15.9) 
236(16.8) 
         
                                     0.87                  
123(18)                    
267(19) 
 
       Reporter        
          Patient 
            Carer 
           Parent 
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                                     0.3 
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BNF chapter 
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              CVS 
             Resp 
             CNS 
     Infections 
 
     
 84(72.4)                     2(1.7)              
145(55.3)                  15(5.7)                  
  59(71.1)                    3(3.6)         
 238(48.8)                 31(6.4)                     
 239(64.6)                 19(5.1)                           
 
   
 19(16.4)   
 58(22.6) 
 10(12)                 
 74(15.2) 
 67(18.1)                             
                                       
                                  1 
11(9.5)     
44(16.8)  
11(13.3)           
145(29.7)   
 45(12.2)    
 




7.3.4.7.2  Psychological impact of SE 
However the explicit psychological impact of SE was frequently experienced as 
increased anxiety, depression, irrational thoughts and aberrant behaviours were 




Patient, male, 46 years, citalopram, I-Net. 
 
³7LUHGQHVVUDVKDQGLWFKLQHVV,ZRXOGOLNHWRVWRSWDNLQJWKHVHWDEOHWV,IHHOEDG
taking them, headaches, severe aches in my legs and very sore hips, swollen 
fingers and the feeling of being constantly depressed. 
Patient, male, 58 years, ramipril, I-Net. 
 
³%DODQFHZHQWFUDPSVLQOHJ- muscles in leg torn, ruptured achilles, feeling 
irritated..Very depressed and angry all the time, constant rage. Increased blood 
pressure. Headaches. Rage was worst. Stopped because of cramps..I also had a 
rather terrible irritation and a bizarre reaction were [sic] I could not stop 
VZHDULQJ,HYHQXVHGVZHDULQJZRUGVWKDW,GLGQ¶WHYHQNQRZWKDW,NQHZ´ 





feeling of impending doom, headaches, got up every morning with a very anxious 
upset stomach, family and friends noticed. I cannot begin to tell you how dreadful 
I felt. I thought I was losing the plot and worried about the effect it was having on 
my life, my family and friends. Everyone noticed the difference in me and would 
ask what was wrong as I became a completely irrational anxious person who 
dreaded every single day. I only realised it was the nasal spray when I stopped it 
for a couple of days as I had a horrendous nose bleed, it took two days and I 
VXGGHQO\IHOWPHDJDLQ,FDQ
WWHOO\RXKRZPXFKEHWWHU,IHHO´ 
Patient, female, 53 years, Nasonex, I-Net. 
 
One patient describes her fears that she would harm her family as a result of the 





whilst suffering from insomnia. My head was racing, similar to if I'd drunk a lot 
of caffeine or was suffering from stress. I couldn't stop being scared that I might 
WXUQSV\FKRWLFDQGNLOOP\IDPLO\,WVFDUHGWKHKHOORXWRIPH´ 
Patient, female, 37 years, Selincro, I-Net. 
 
Patients described the extreme psychological impact and distress of the SE. In 
many cases these effects were persistent and had significant impact on their ability 
to function normally. The negative impact was multifaceted and experienced 
across numerous aspects of their lives including their concentration levels, which 




³3KRELFDQ[LHW\Ongoing high anxiety with phobias, panic, etc. Therapy and 
cognitive behavioural therapy for anxiety disorder with phobias (claustrophobia) 
and anxiety-UHODWHGV\PSWRPVOLNHSDOSLWDWLRQVWKDWUHVXOWHGLQGRFWRU
VYLVLWV´ 
Patient, female, 27 years, Implanon, I-Net. 
 
³$EQRUPDOEHKDYLRXUDQ[LHW\GHSUHVVLRQVXLFLGDOWKRXJKWVXQDEOHWRWKLQNRU
judge, allergic skin reaction. I feel alone and hurt and depressed. I cry a lot and 
QHHGSURIHVVLRQDOKHOS´ 




suicidal and I had massive highs and lows. Couldn't sleep or eat and couldn't 
concentrate on simple tasks. Was very, very low and nearly made a suicide 
DWWHPSW´ 
Patient, female, 27 years, topiramate, I-Net. 
 
 
7.3.4.7.3  Social impact of SE 
Seven hundred and sixty patients (34%) also described the social impact of their 
SE and its implicit impact on their QoL:  
 
³6HYHUHPXVFXODUZHDNQHVVDQGSDLQLQERWKDUPV)HHOVOLNHEXUQLQJDQG
muscular spasms..Affecting my everyday life - hard to housework, pick things up.  
Lack of sleep due to pain in arms.  PaiQLVVWLOOWKHUHZKLOVWUHVWLQJ´ 




remember anything from a night out whatsoever, it never happened ever before in 
my whole life of drinking. So I stopped my social life until I come off the tablets 
DOWRJHWKHU´ 
Patient, male, 52 years, sertraline, I-Net. 
 
 
One patient reported the significant negative impact of the SE on their normal 
functioning at work. He experienced difficulties in concentration and stress as a 
result of his impaired work performance: 
 
³,WVWDUWHGZKHQ,ZDVLQDPHHWLQJDWZRUN- I started to get tunnel vision and 
eventually lost consciousness for a split second then I found it very difficult to 
concentrate and I felt panicky. This has got worse and worse despite my 
discontinuation of the drug. I constantly have blurred vision, I feel panicky and 
agitated in social situations (I have never suffered with panic or anxiety before), I 
get dizzy, I find it incredibly hard to focus and think analytically, as a result I'm 
developing stress and worry as it is affecting my work. I feel constantly spaced 
RXWDQGVOLJKWO\UHPRYHGIURPP\VHOI´ 




Another perspective is offered by a report from a carer which describes the 
GLVDEOLQJLPSDFWRIWKH6(RQWKHTXDOLW\RIKLVZLIH¶VOLIH 
³Her body began to inflate like a balloon. Her body became numb, two deep 
scars appeared at two ends of her mouth, other lines also appeared on her face 
and her face became flat with her high cheekbones disappearing. Such changes 
in her body and face made her very distressed. She could not bear her physical 
changes and numbness. She became disabled from her distress and lost her 
independence. I had to become her full-WLPHFDUHU´ 
Carer, female, age not supplied, Seroxat, paper. 
 
7.3.4.7.4  Section summary 
 14 extracts providing details of the physical, psychological and social 
impacts of SE 
 13 patient reports and one carer report 
 5 reports for males; 9 for females with ages ranged from 26-65 years 
 Free text severity levels are 3 moderate and 10 with severe effects 
 Eight drugs linked to CNS; 2 to CVS; 1 to Infections; 1 to 
Obstetrics/Gynaecological and 1 to Ear/Nose 
 Comments are composed of 6 moderately elaborate and 7 elaborate 
narratives 
 Overall comments are related to the multidimensional impact of SE on 
SDWLHQWV¶lives 
 
7.3.4.8  Identification of SE ± strategies and information sources 
Strategies and information sources used to identify SE were described by 679 
(30%) reports. These reports described effects for 155 males (22.83%) and 524 
females (77.17%) in 635(93.52%) patient, 33(4.86%) carer and 11 (1.62%) parent 
reports. The highest proportions of these reports were for those in older age 
categories aged 51-60 (150; 22.09%); 61-70 years (128; 18.85%) and aged over 
80 (25; 3.68%). The strategies employed in identifying SE included the timing 
sequence of SE; differential diagnosis and confirmation with information sources. 
Information sources included HCPs, PILs, the Internet and family/friends. 









Table 7.14: Frequency table of Subcategories 11-22# 
Sub category Frequency % total % of 
Hierarchical 
category 6 
Timing sequence of SE 
 
313 13.88 46.1 
Challenge/dechallenge 
 
40 1.77 5.89 
Reduction in dose 
 
21 0.93 3.09 
 HCP confirmed 
 
136 6.03 20.03 
Used PILs to identify SE 
 
52 2.31 7.66 
Used family/friends to identify SE 
 
12 0.53 1.77 
 Used internet to identify SE 
 
28 1.24 4.12 
 Prior SE history 
 
54 2.39 7.95 
 Change in general health status 
 
54 2.39 7.95 
 Change in brand 47 2.08 6.92 
 Patient makes a differential 
diagnosis 
102 4.52 15.02 
Suspected possible interaction 
effects 
 
40 1.77 5.89 
 
#Includes use of multiple strategies/sources per report 
 
7.3.4.8.1  Timing sequence 
Three hundred and thirteen reports - 14% of the total population - used temporal 
associations including de-challenge, re-challenge, changes in dose to identify their 
SE: 
 
³:LWKLQ an hour of taking the medication I have extremely uncomfortably 
sweating which lasts for about 4 hours which I never had in the past. I have tried 
varying the times I take it to no available [sic]. I have even tried not taking it for 
one day and found that I did not get the sweating. And as soon as I started it 
DJDLQWKHQH[WGD\WKHVZHDWLQJFDPHEDFN´ 
Patient, female, 63 years, propranolol, I-Net. 
 
³1DXVHDIURPVWDUWRIWUHDWPHQWQGGD\,VWUXJJOHGWRGULQNDQ\WKLQJUGGD\
unable to eat or drink anGVWDUWHGKDYLQJYLVXDOKDOOXFLQDWLRQV´ 





premenstrual syndrome (PMS) symptoms. The effects of these tablets were 
readily increasing ever\GD\,WRRNRQH´ 
Patient, female, 46 years, Cerazette, I-Net. 
 
7.3.4.8.2  Differential diagnosis 
It was found that 5% or 102 patients assessed the possible causes of their SE and 
made a differential diagnosis:   
 
³+HDUWEXUQSDUWLFXODUO\EDGDWQLJKWSevere enough to interrupt sleep.  Only 
started after a couple of days of taking the medicine. I don't normally get 
KHDUWEXUQ´ 




Patient, male, 27 years, citalopram, I-Net.  
 
³$ERXW-5 hours after taking the medication I was yawning at least 4 times a 
minute for about 15-20 minutes and this happened almost everyday but had not 
happened befRUHWDNLQJWKHPHGLFDWLRQ´ 
Patient, female, 34 years, sertraline, I-Net.  
 
 
7.3.4.8.3  Confirmed with HCPs 
Just over 6% or 136 reports confirmed their SE with a HCP. Effects in 64 males 
(49.23%) and 72 females (52.94 %) were confirmed, with the most common of 
these reports being for those in age categories 21-40 years (28;20.59%); 51-60(32; 
23.53%); 61-70 years (20; 14.71%) and aged over 80 (25; 18.38%). 
Patients confirmed with their GPs:  
 
³,KDGEHHQWDNLQJDWRUYDVWDWLQPJIRU\HDUV7KHVWDWLQGRse was increased 
to 20mg because my total cholesterol had increased to 5.4. The skin rash started 
to develop approximately two weeks after starting the 20mg dose. At the 
IROORZLQJYLVLWWRP\*3KHWROGPHWRVWRSWDNLQJWKHDWRUYDVWDWLQPJ´ 
Patient, male,65 years, atorvastatin, I-Net.  
 
³&KDQJHWRVHQVHVPHOO7KHVPHOOZDVVRSURIRXQG,IHOWVLFNZLWKLW(YHQWXDOO\
it dissipated but later it returned but not so bad. Spoke to GP who advised to not 
WDNHDQ\PRUH´ 
Patient, female, 59 years, doxycycline, I-Net.  
 
³1LJKWWHUURUV«+DYLQJKDGDVLPLODUUHDFWLRQZKHQJLYHQ&DOSROLQWKHSDVW,
took my son to see the GP for advice. She suggested offering tablet form of 
SDUDFHWDPRO´ 






Others used hospital doctors:  
 
³+Hart attack and triple bypass. Was informed by a surgeon at hospital that he 
was fairly certain the diclofenac had caused some or all of the cardiovascular 
LVVXHVDQGVWRSSHGP\WDEOHWVDWRQFH´ 
Patient, male, 52 years, diclofenac, I-Net. 
 
Some patients used pharmacists as an initial point of contact: 
 
³9HU\LWFK\VNLQIRUDIHZKRXUVDIWHUWDNLQJ«,spoke to the pharmacist at 
[anonymised] ZKRKDVVXJJHVWHG,DVNIRUDQRWKHUSUHVFULSWLRQ´ 
Patient, female, 65 years, Actavis levothyroxine, I-Net. 
 
³,QFUHased hair loss, easy bruising and muscle twitches..Mentioned to general 
practitioner (GP) and to pharmacist. Pharmacist suggested I report side effects 
KHUH´ 
Patient, female, 53 years,vVenlafaxine, I-Net.  
 




subsequently developed crusts. After seeing the pharmacist I made an 
appointment to see my GP the following day who prescribed an antibiotic cream 
DQGFRQILUPHGWKDW,VKRXOGQRWUHDSSO\WKHJHO«,ZDQWHGWRDVNDSKDUPDFLVW
ZKHWKHU,VKRXOGFRQWLQXHDSSO\LQJWKHJHODQGZDVWROGQRWWR´ 
Patient, male, 78 years, Picato, I-Net.  
 
 However another patient highlighted the lack of privacy that can be part of 
pharmacy interactions: 
 
³I went to the pharmacy to collect my prescription, I receive my medications weekly. When 
collecting my last prescription one of my medications, ramipril capsules were 5mg and 
previously were in a red and yellowish capsule. This week it was a green and grey capsule. 
I have memory problems at the best of times and when sorting my many medications into 
my weekly planner pill boxes I was getting further confused. My prescriptions are on 
electronic repeat yet the pharmacy states at times that my prescription has not been filled 
by the general practitioners [sic] surgery and expect me to have an explanation of why this 
is. I find it difficult not to lose my temper with the staff as this treatment is degrading and 
I'm expected to discuss my private medical details in front of other customers.´ 
Patient, male unknown, ramipiril, MHRA. 
  
 
7.3.4.8.4  Confirmed with PILs 





 ³$OWKRXJK,DPVRPHZKDWSURQHWRPRXWKXOFHrs, this is usually after a specific event such 
as abrasion. After the third ulcer without obvious cause, I checked the patient information 
leaflet (PIL) for naproxen, which I had been taking for about a week, and noted it was a 
SRVVLEOHVLGHHIIHFW´ 
Patient, male, 64 years, naproxen, I-Net.  
 
7.3.4.8.5  Confirmed with the Internet 
It was found that just 28 patients (1%) used the Internet to identify their SE:  
³,VXIIHUHGVHYHUHLUUDWLRQDOWKRXJKWVDVZHOODVDQ[LHW\FRXOGQ
WHDWYHU\
PXFK«,ZHQWRQLQWHrnet to see side effects and couldn't believe the amount of 
SHRSOHZKRIHOWH[DFWO\KRZ,GLG´ 
Patient, female, 53 years, Nasonex, I-Net. 
 
7.3.4.8.6  Confirmed with family/friends 
However reporters were least likely to use family or friends to confirm their SE ± 
just 0.5%:  
 
³'LDUUKRHDJRWSURJUHVVLYHO\ZRUVHDVWKHZHHNVZHQWRQ,ZDVXQVXUHLILWZDV
related to my sensitive stomach..I was advised to stop the cough syrup by a friend 
who is a physiotherapist who knows my medical history and suspected I was 
KDYLQJDUHDFWLRQ´ 
  
Patient, female, 34 years, Robitussin chesty cough, I-Net.  
 
7.3.4.8.7 Confirmed with multiple sources 
Reporters also used multiple information sources to assist them in identifying 
their SE: 
 
³(UHFWLOHG\VIXQFWLRQGLVFRYHUHGRQVWDrting new relationship. Not really made 
aware of this possible side effect when put on tablets but it is in the leaflet but not 
listed with other side effects. Search on internet immediately flagged up the 
LVVXH´ 
Patient, male, 64 years, simvastatin, I-Net.  
 
³9HU\VHYHUHDSODVWLFDQDHPLD+DGH\HGURSVSUHVFULEHGE\JHQHUDO
practitioner and used them for 2 days only..The leaflet enclosed in drops stated in 
rare cases can cause aplastic anaemia. It states on some research on the internet 
that it should QRWEHXVHGLQFKLOGUHQXQGHU\HDUVRIDJH´ 
Parent, male 1 year, chloramphenicol, I-Net. 
 
³'L]]LQHVVGURZVLQHVVKDOOXFLQDWLRQVKHDGDFKHUDSLGKHDUWUDWHVKDNLQJ
sleep disturbance, vertigo, vomiting. After speaking to a nurse and basic searches 
on the internet, the patient was told they should never have been given such a 
KLJKGRVH´ 
 






7.3.4.8.8  Section summary 
 20 extracts providing details of the timing sequence; differential diagnosis 
and information sources used to identify SE 
 17 patient reports, one carer and 2 parent reports 
 9 reports for males; 11 for females with ages ranged from 1-78 years 
 Free text severity levels are 5 mild, 7 moderate and 8 severe effects 
 Seven drugs linked to CNS; 3 to CVS; 3 to Infections; 2 
Obstetrics/Gynaecological; 1 Muskoloskeletal; 1 Eye; 1 Ear/Nose; 1 Skin 
and 1 Anaesthesia 
 Comments composed of 2 scant; 13 moderately elaborate and 5 elaborate 
narratives 




7.3.4.9   Managing SE ± behaviours and outcomes 
Overall 990 (41%) reports provided details of their behaviours as they sought to 
manage their SE. These details were present in reports for 282 (28.48%) of males 
and 708 females (71.52%), in 810(81.82%) patient, 95(9.6%) carer and 85 
(8.59%) parent reports. The highest proportions of these reports were for those in 
older age categories aged 51-60 (378; 38.18%); 61-70 years (277; 28%); 71-80 (9; 
9.2%) and aged over 80 (38; 3.84%).  
Behaviours were described in 334 (61%) reports with severe effects, with the 
highest proportions of reports linked to Endocrine drugs (101; 58%). These are 
followed by CVS drugs (146; 53%); drugs for malignant disease (25; 50%) and 
respiratory drugs (43; 48%). The behaviours included HCP consultation, self-












Table 7.15: Frequency table of Subcategories 26-36# 
 
Sub category Frequency % of total % of 
hierarchical 
category 8 
 Stopping meds 
 
354 15.7 35.76 
 Adhered to meds 
 
64 2.84 6.46 
Reducing dose 
 
30 1.33 3.03 
 OTC remedies to counteract 
symptoms 
 
95 4.21 9.6 
 Prescription remedies to 
counteract symptoms 
 
157 6.96 15.86 
 Finished course 
 
27 1.2 2.73 
  Reverting to original brands 
 
23 1.02 2.32 
 HCP consultation 
 
671 29.76 67.78 
 Self directed medicine 
management 
 
164 7.27 16.57 
 Self directed non medicine 
management 
26 1.15 2.63 
HCP medicine management 
 
260 11.53 26.26 
 
#Includes multiple behaviours per report 
 
7.3.4.9.1 Patient behaviours 
Analysis found that 671 patients (30%) consulted with a HCP. These reports were 
composed of 615 (91.65%) patient, 29 (4.32%) carer and 27 (4.02%) parent 
reports. Among 196 males (29.21%) and 475 females (70.79%) the highest 
proportion described severe effects (249; 37.11%). Consultation with HCP was 
linked to the following drug classes: endocrine (78; 44%); malignant disease (19; 
38%); CVS (95; 35%); muskoskeletal (80; 31%) and CNS (146; 28%). Those in 
the older age categories were more likely to consult with HCPs ± 132 (37%) aged 










ciprofloxacin. GP not so sure but to stop taking medicine anyway. Have been 
UHIHUUHGIRUQHXURORJLFDORSLQLRQ´ 
Patient, female, 67 years, ciprofloxacin, I-Net. 
 
Within HCP interactions 315 patients (14% of the total sample) had multiple 
contacts with HCPs:  
³,QFUHDVHGEOXUUHGYLVLRQLQFUHDVHGVZHDWLQJDQGKHDWHGERG\,KDYHW\SH
diabetes controlled by metformin 500mg twice daily and Zicron 40mg twice 
GDLO\,DPDOVRRQUDPLSULOPJGDLO\«,KDYHVHHQWZRGHUPDWRORJLVWVIURPWZR
GLIIHUHQWKRVSLWDOVDQHXURORJLVWDQGPRVWUHFHQWO\DQHQGRFULQRORJLVW´ 
Patient, male, 76 years, ramipril, I-Net.  
 
Analysis of the reports indicate that over 380 patients (17%) interact with GPs. 





following uptake of drug. Worsened cognition, significantly reduced mobility and 
inability to hold items..Asked general practitioner who prescribed medication to 
VWRSXVHRIWKHGUXJ´ 
Carer, male, 75 years, gabapentin, I-Net.  
 
However these HCP consultations do not always appear to result in corresponding 
medicine management by HCPs. Just 260 patients (12%) described a HCP 
managed medicine intervention:  
 
³7LQJOLQJRIIDFLDOPXVFOHVDQGLQFUHDVLQJWZLWFKLQJRIWKHULJKWVLGHRI
face...prescribed the medication by diabetic specialist nurse by phone. Side 
HIIHFWVGHYHORSHGE\VHFRQGGD\WHOHSKRQHGKHUDQGWROGWRVWRSWDNLQJLW´ 
Patient, female, 70 years, Januvia, I-net.  
³%UHDWKOHVVQHVVVSRNHWRJHQHUDOSUDFWLWLRQHUDERXWWKHVLGHHIIHFW- was 
particularly concerned as I am asthmatic. general practitioner removed me from 
WKHPHGLFDWLRQZLWKLPPHGLDWHHIIHFWDQGVZLWFKHGPHWRJDEDSHQWLQ´ 
Patient, female, 33 years, topiramate, I-net.  
 
 
Analysis of the reports indicated that overall 190 (8%) of patients engaged in 
independent behaviours to manage their SE. These behaviours included self-







Been on statins for years. General practitioner took me off tablets but when 
restarted symptoms recurred. I have taken myself off tablets after several restarts 
RQDUHGXFHGOHYHO´ 
Patient, male, 72 years, atorvastatin, I-Net. 
 
³7KHFRQVHTXHQFHVRIVWRSSLQJWKHVWDWLn were immediately noticeable. I lost 
most of my aches and pains that I suffer overnight and the pain in my elbows 
FOHDUHGXS«,KDYHVWD\HGRIIDWRUYDVWDWLQIRUZHHNVDQG,KDYHQRPRUHDFKHV
RUSDLQV´ 
Patient, male, 60 years, atorvastatin, I-Net.  
 
Patients also engaged in self-directed behaviours to manage their SE that did not 
not involve medicines (26;1%). One patient described a simple intervention to 
manage her SE which did not require medicine: 
 
³$IWHUWKHVHFRQGGRVHRQP\ILUVWGD\RIWUHDWPHQWI experienced moderate to 
severe heart burn that lasted all evening. I drank milk to neutralise the acid and 
this did make the burning sensation less painful however it still felt very 
XQFRPIRUWDEOH´ 
Patient, female, 24 years, co-codamol, I-Net. 
 
It was found that when patients experienced SE, 354 (16%) of them stopped 
taking their medicine or removed the medical device. Analysis indicated that the 
majority of these were female (238; 67.23%) compared to 116 (32.77%) males. 
Those more likely to stop their medicine were aged 21±40 (80; 22.6%); 51-60 (66; 
18.64%) and 61-70 years (74; 20.9%). Analysis indicated that 235 (35.02%) of 
those who consulted HCPs stopped their medicines (235; 35.02%). Non-adherent 
behaviours were linked to the following drug classes: CNS (74; 22%); infections 
(65; 19%) and CVS (62; 19%).  
 
³&RQVWDQWXUJHWRXULQDWHDQGLUULWDWLRQUDVKRQIDFHDQGORZHUOHJVSOXVRYHU
torso to a lesser extent, intermittent explosive diarrhoea and swelling of face (eye 
lids, brow, lips)..I realised that all the symptoms probably related to taking 
RPHSUD]ROHDVWKH\DUHOLVWHGVLGHHIIHFWV,VWRSSHGWDNLQJWKHGUXJ´ 








half of my field of vision lasting about 15 minutes. I stopped taking the 
DPORGLSLQHLQFDVHWKH\ZHUHFDXVLQJWKHSUREOHP´ 






terrible infection, paracetamol did not work, had to stay in bed all day. This was 
very upsetting, so I also felt emotionally low..Lots of little blister like spots. Then 
several painful large ones appeared..I should also have mentioned that I found 
WKHVLGHHIIHFWVVRXQEHDUDEOHWKDW,WRRNWKH0LUHQDRXWP\VHOI´ 
 
Patient, female, 43 years, Mirena, I-Net. 
 
7.3.4.9.2  Behavioural outcomes 
Overall 233 patients (10%) provided details of the results of their SE 
management. These outcome details were for 131(56.22%) females and 
102(43.78%) males contained outcome details in 218 (93.56%) patient, 9 (3.86%) 
carer and 6 (2.58%) parent reports. Those aged 61-70 years (51; 21.89%) and 71-
80 (21; 9.01%) were more likely to provide details on outcomes. Outcomes were 
described in 73 (13%) reports with severe effects, with the highest proportions of 
reports linked to CVS drugs (46;17%) 27 (15%) with Endocrine and 15(13%) GI 
drugs. The outcomes described in these reports included de-challenge, taking 
counteracting medicine and recording SE in medical records.  
 
Table 7.16: Frequency table of Subcategories 37-42# 





Dechallenge and SE went away 
 
124 5.5 53.22 
Took counteracting med and 
masked SE 
40 1.77 17.17 
Med taken to treat SE leads to 
more SE 
 
21 0.93 9.01 
Used cams to treat SE 
 
29 1.29 12.45 
Recorded suspect ADR in medical 
records 
16 0.71 6.87 
Used coping strategies to deal 
with SE 
 
22 0.98 9.44 
#Includes multiple outcomes per report 
 
A positive dechallenge was undertaken by 124 (6%) patients with the SE 
disappearing:  
 
³)LUVWPXVFOHSDLQWKHQWHUULEOHSDLQLQDEGRPHQGXULQJWKHOast year of 
WDNLQJDIWHU,VWRSSHGWDNLQJLWDOPRVWVWUDLJKWDZD\WKLQJVFDOPHGGRZQ´ 




³6ZHOOLQJRINQHHVJURLQVZHOOLQJVZHOOLQJRIOHJVDnd throbbing pain. I didn't 
realise the effects were from the naproxen until I stopped taking them. As soon as 
I stopped taking it the swelling, throbbing, heavy sensation stopped and my legs 
UHWXUQHGWRQRUPDOVL]H´ 
Patient, female, 55 years, naproxen, I-Net. 
 
³3DLQLQP\OHJPXVFOHVSDLQLQP\VKRXOGHUVDQGUHGXFHGmovability in 
shoulder also couldn¶t raise my arm above my head..When I came off the 
atorvastatin the pain in my legs disappeared and muscle wastage stopped and the 
SDLQLQVKRXOGHUVDOVRGLVDSSHDUHGDQGLQWLPHWKHPRYDELOLW\LPSURYHG´ 
 
Patient, male, 54 years, Lipitor, I-Net.  
 
Forty patients (2%) took counteracting medicine aimed at masking the SE:  
 
³'U\PRXWKHVSHFLDOO\GXULQJH[HUFLVH,QGLJHVWLRQ- taking omeprazole to 
counter. Two instances of cystitis requiring antibiotics. The difference the 
medication has made to my quality of life is such that I am prepared to put up 
with the side effects. 
Patient, female, 57 years, Betmiga, I-Net. 
 
³1DXVHDVHYHUHPLJUDLQHSDLQLQOHJVDQGSHOYLFDUHDDQ[LHW\SHUVLVWHQW
vomiting unable to stop for 3 days..a practice nurse made a home visit and 
prescribed prochlorperazine 3mg to stop the vomiting and paracetamol 
VXSSRVLWRULHVIRUWKHSDLQ´ 
Patient, female, 48years, Esmya, I-Net.  
 






Patient, female, 22 years, doxycycline, I-Net.  
 
³8QFRQWUROODEOHFRXJKYRPLWEHKDYLRXUDOWHration, worsening as medicine kept 
EHLQJWDNHQVWRSSHGDVGHWR[ZLWKKRPHRSDWK\´ 
Parent, female, 2 years, montelukast, I-Net. 
 
A small number of patients - 16 - (1%) describe wanting to record their SE in their 
medical records, to prevent it from happening again in future: 
 
³,QHHGWKLVGUXJWRKHOSZLWKWKHUHIOX[SUREOHPVFDXVHGE\XVLQJGUXJVIRUP\
arthritis..I have also written to my doctor to add to my notes that I need to have 
WKH-HQVRQ3URGXFWWRNHHSP\EORRGSUHVVXUHDQGSDLQDWED\´ 
Patient, female, 67 years, omeprazole, I-Net.  
 
7.3.4.9.3  Section summary 
 21 extracts providing details of behaviours for managing SE such as HCP 
consultation, self-directed interventions and stopping medicines 
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 19 patient reports, one carer and one parent report 
 6 reports for males; 15 for females with ages ranged from 2-76 years 
 Severity levels are 3 mild, 4 moderate and 14 severe effects 
 Eight drugs linked to CVS; 6 to CNS; 2 to Infections; 2 to Endocrine and 2 
to Obstetrics/Gynaecological 
 Comments composed of 2 scant, 14 moderately elaborate and 5 elaborate 
narratives 
 Overall comments related to the behaviours used to manage SE and the 
outcomes of these behaviours 
 
7.3.5 Consequences of SE  
Analysis of the reports also identified the long term results of the SE for patients 
with over 263 patients (12%) describing the consequences of the SE. Within 229 
(11%) patient, 11 (12%) carer and 23 (16%) parent reports for 175 (12%) females 
and 88 (12%) males consequences were mentioned. The highest proportions of 
these reports were for those in the younger and older age categories ± infants (9; 
33%); 61-70 (43; 12%) and those aged over 80 (10; 16%). Outcomes were 
described in 141 (26%) reports with severe effects with the highest proportions of 
reports linked to malignant disease (12; 24%); skin (19; 23%); 
obstetrics/gynaecological (25; 15%); CNS drugs (68; 13%) and CVS (30; 11%). 
These consequences included accepting the SE, persistent physical, psychological, 
















Table 7.17: Frequency table of Subcategories 54-62# 
 




category  11  
Accepts SE 
 
11 0.49 4.18 
Reluctant to take related med 7 0.31 2.66 
Will not use med again 
 
14 0.62 5.32 
 Prolonged/persistent physical 
effects 
 
207 9.18 78.7 
Prolonged/persistent 
psychological effects 
65 2.88 24.71 
Prolonged/persistent social effects 
 




22 0.98 8.37 
 Prolonged/persistent economic 
effects 
 




60 2.66 22.81 
#Includes multiple consequences per report 
 
7.3.4.8.1  Consequences for patients 
A small number of reporters ± 0.5% - accepted the SE: 
 
³7KHPRXWKXOFHUVRFFXUHYHU\WLPH,KDYHWKHLQMHFWLRQDERXW on to three weeks after. 
Sometimes they last for a few days but they have lasted for three weeks. Each time I take 
the medicine which I've been on for two years I get one of the side effects. The mouth 
ulcers have been seen by my dermatologist but I had plaque psoriasis covering 85% of my 
body including my hair and face so I am more than happy to suffer with the occasional side 
HIIHFW´ 
Patient, female, 36 years, Stelara, I-Net 
 
³6SRNHZLWKQXUse regarding suicidal thoughts. Asked if I wished to continue. Advantages 
outweigh issues so remain on the treatment. I know the thoughts are hormone related and 
am able to fight them. Acne, acute depression, bone pain, excess sweating, hot flushes, 
mood swings, painful breasts, sleep disturbance and suicidal depressLRQ´ 
Patient, female, 33 years, Decapeptyl SR, I-Net. 
 
As a result of the SE seven reporters (0.3%) indicated their reluctance to take a 




³Severe constipation and abdominal pain whilst starting dexamethasone and head was 
worse. Upon finishing 10 day course was followed by severe diarrhoea and abdominal 
pain and sought help at accident and emergency. Suspected inflammatory bowel disease 
and reluctantly started budesonide 9mg as previous side effects of steroids. Same 
happened, headache got worse and constipation gas started again. The minute started 
GH[DPHWKDVRQH,KDGVHYHUHFRQVWLSDWLRQDQGDEGRPLQDOSDLQ´ 
Patient, female, 24 years, dexamethasone, I-Net 
 
³I have had a strong reaction to nitrofurantoin, felt like I was going to pass out 
in the shower. I got out and sat on the toilet seat, was then very sick. I have 
VWRSSHGWDNLQJWKHPDQGQRZIHHOILQH,ZRXOGQRWWDNHWKHVHWDEOHWVDJDLQ´ 
   Patient, female, unknown, nitrofurantoin, Patient(MHRA) 
 
7.3.5.2  Persistent physical effects  




irregular. My husband and I are trying for a baby and it is slowing the whole 
process down, as instead of 12 attempts a year (for someone with a 28/30-day 
cycle), we will have fewer..If I had known, I would not have started using the pill 
or would have stopped it a couple of months earlier. Currently, I cannot be sure 
that they will ever get back to normal´.   
Patient, female, 35 years, Gedarel, I-Net.  
 
³)X]]\KHDGKHDGDFKHQDXVHDORVVRIDSSHWLWHOEVZHLJKWORVVLQGD\V
weakness and loss of energy, sore throat and mouth, nasal congestion. I believe 
the side effects I experienced are mostly common place, and this medicine should 
be discontinued.  It did clear up the cystitis quite quickly but the side effects are 
still being experienced aftHUWKHFRXUVHKDVEHHQILQLVKHG´    
Patient, female, 74 years, trimethoprim, I-Net.    
 
³+DLUWKLQQLQJDQGKDLUORVV7KLVVLGHHIIHFWZDVQRWEURXJKWWRP\DWWHQWLRQ\HW
when I search on the internet, hundreds of women are complaining about it and 
have no information on whether the hair growth will return or what the longer 
WHUPHIIHFWVDUH«0\KDLULVQRZLQWHUULEOHFRQGLWLRQDQGIDOOLQJRXW´ 
   
Patient, female, 56 years, omeprazole, I-NET.  
 
7.3.5.3  Persistent psychological effects 
Patients (65; 3%) also described the long-term psychological consequences of 
their SE:  
³,KDYHIDFHGVHYHUHHIIHFWVIURP3URSHFLDILQDVWHULGH,ZDVSUHVFULEHGLWIRU
hair loss and I used it for 1 week, but suffered a string of side effects, including 
genital pain, weak and discoloured discharge, inept, and low libido. However, 
more seriously I took a pill and within 90 minutes I suffered acute depression and 
VXLFLGDOWKRXJKWV«6RPHVLGHHIIHFWVKDYHVWRSSHGVXFKDVJHQLWDODFKLQJDQG
poor discharge [sic], but others have persisted 9 months in..No suitable advice or 
referral has been offered to me, and I am at a loss of what to do. It has 
FRPSOHWHO\FKDQJHGP\OLIHIRUWKHZRUVH´ 






anything, apathy, loss of friends. Loss of jobs. The antipsychotics have nearly 
completely destroyed my life. I am no longer able to function like I once did. My 
PLQGLVQRZLQDWRWDOPHVV´ 
Patient, male, 20 years, Risperdal Consta, I-Net.  
.  
 
³7HQGRQGDPDJHWR$FKLlles tendon, musculoskeletal pain, electric shocks in 
arms and legs, behind eyes, in fingers, toes, coldness numbness in legs and feet, 
anxiety disorder, regular panic attacks and butterflies in stomach, anxiety 
induced nausea, constant dizziness, crushing pressure in head, subjective visual 
disturbances, perception altered, pain behind eyes, electric shocks behind eyes 
DQGGHSUHVVLYHHSLVRGHV«'HYHORSHGPRUHDQGPRUHWHUULI\LQJV\PSWRPVDVWLPH
SURJUHVVHG7KHPHQWDOVLGHHIIHFWVDUHFULSSOLQJ´ 
Patient, male, 34 years, Avelox, I-Net.  
 
7.3.5.4 Persistent social effects 
Fifty patients (2%) described the negative social effects they experienced as a 
result of their SE. Patients provided vivid accounts of significant changes to their 
normal social functioning:    
 
³Acute depression, hot flushes, weeping, insomnia. 3 nights of approximately 3 hours 
sleep, irritable legs syndrome, depression causing dysfunction of daily life, weeping for no 
significant reason.´ 
Patient, female, 67 years, Quinoric, I-Net 
 
 
One patient describes the significant psychological problems he experienced 
including severe depression which led to a suicide attempt on his part:  
 
³,ZDVRNZKLOHWDNLQJWKHPHGLFDWLRQDQG,RQO\KDGVHYHUDORIWKHFRPPRQVLGH
effects like dry lips, nosebleeds, tiredness and aching joints. But after completing 
my 6 month course I have never felt right and gradually became severely 
depressed and made an attempt on my life around 5 years ago. I have been with 
the psychiatric department since then and have been diagnosed with agitated 
depression and severe anxiety, obsessive compulsive disorder and have recently 
had a relapse in my mental health. I also take medication for my mental health. I 
was completely different before taking this medication and was very outgoing 
DQGVRFLDEOHEXWQRZ,DPXQDEOHWRZRUNDQG,GRQRWJRRXW´ 
Patient, male, 23 years, Roaccutane, I-Net 
 
 
7.3.5.5  Persistent life changing effects  






³'LDJnosed Cushing¶s syndrome caused by Nasonex/Mometasone spray. High 
blood pressure, weight gain of 4 stones, muscle weakness, breathless, nose 
EOHHGVILEXODIUDFWXUHEORRGVXJDUV«,DPH[WUHPHO\DQJU\WKDWP\*3
prescribed this drug to me for 9 years. I am left with a list of debilitating health 
problems after stopping the nasal spray, needing repeat x-ray of my left ankle as 
it became swollen after normal activity; I am still breathless and despite a 
healthy diet my weight is still 4 stones heavier than it should be, I have muscle 
ZHDNQHVVDQGYHU\UHGXFHGVWDPLQDDQGHQHUJ\OHYHOV´ 




vision which remains so today. I was prescribed one daily pill of quinine 
sulphate...I am now totally convinced that quinine sulphate was responsible for 
the original diagnosis of atrial fibrillation and, after ceasing to take it, my heart 
rhythm returned to normal. It is also my conviction that although I was not 
diagnosed with atrial fibrillation until earlier this year I think it had been present 
for some time before and especially last year when my eye occlusion occurred.  
/RJLFDOO\TXLQLQHVXOSKDWHFRXOGDJDLQKDYHEHHQWKHFXOSULW³ 
  Patient, male, 85 years, quinine sulphate, I-Net. 
 
³6HYHUHORQJ-term depression, anxiety disorder, suicidal ideation and suicide 
attempts. I was admitted to hospital after attempting suicide. I struggled for many 
years, but eventually had to give up my job as a civil servant. I am now on quite a 
high dose of medication to get me through each day. I suffered a complete mental 
breakdown, at which point my husband took me to hospital. I have been under the 
FDUHRIWKH$GXOW0HQWDO+HDOWK6HUYLFHVHYHUVLQFH´ 
Patient, female, 40 years, Roaccutane, I-Net.  
 
7.3.5.6 Persistent economic and work related effects  
Over 40 patients experienced long term work related (22; 1%) and economic 
effects (19; 1%) as a consequence of their SE: 
 
³,EHOLHYH,KDYHVXIIHUHGDURXQGVLGHeffects ranging from tooth grinding in 
sleep, ruining teeth to major anger problems, general pain, intense tight 
chest/breathing problems, ringing in ears and loss of my job and career due to 
VKRUWWHUPPHPRU\ORVVDQGFRQIXVLRQFRQFHQWUDWLRQ´ 
Patient, male, 27 years, citalopram, I-Net. 
 
7.3.5.7 Section summary 
 10 extracts providing details of the consequences of SE which included 
persistent physical, psychological, social, economic, work-related and life 
changing effects 
 10 patient reports 
 2 reports for males; 8 for females with ages ranged from 26-78 years 
 Severity levels are 2 mild, 5 moderate and 3 severe effects 
 Two drugs linked to CNS; 2 to CVS; 2 to Infections; 1 to Endocrine; 1 to 
Obstetrics/Gynaecological; 1 to Eye and 1 to Skin 
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 Comments composed of 7 moderately elaborate and 3 elaborate narratives 




7.3.6 Patient concerns  
Patients (344; 15%) described issues of particular concern to them in 297 (14%) 
patient, 24 (25%) carer and 23 (26%) parent reports for 217 (14%) females and 
127 (17%) males who reported particular issues. In 159 (29%) reports with severe 
effects concerns were reported, with the highest proportions of reports linked to 
eye drugs (10; 30%); endocrine (38; 22%); GI (23;19%) and CNS drugs 
(93;18%).  Reports for infants (10; 37%); 41-50 years (57; 17%) and those aged 
over 80 (15; 25%) were more likely to describe particular concerns. These 
concerns included negative experiences with HCPs, disagreement with +&3V¶
treatment/diagnoses and specific concerns about the suitability of medicine. 
 
Table 7.18: Frequency table of Subcategories 63-70# 
Sub category Frequency % of 
total 
% within  
Hierarchical 
category 12  
 Licensing issues 
 
26 1.15 7.56 
Issues with prescribers 51 2.26 14.82 
Issues with pharmaceutical 
industry 
 
 45       2.0 13.08 
Negative experience in HCP 
interaction 
 
 203 9.0 59.0 
Specific concerns about 
quality/suitability of med 
 74 3.28 21.51 
Disagrees with HCP 
diagnosis/treatment 
 
 92 4.08 26.74 
  HCP ignored allergy history 
 
 20 0.89 5.81 
 Perceives themselves as sensitive 
to meds 
 
 31  1.37 9.01 
#Includes multiple concerns per report 
 
7.3.6.1  YC reporter concerns 
Over 200 patients (9%) described their HCP interaction in negative terms:  
244 
 
³$cne and itching face. The acne started on my neck (it was similar to the hot, 
fizzy type rash you get from a reaction to antibiotics if allergic). The acne then 
spread to my face and continued to itch. It took more than two weeks after 
stopping the drops before my skin cleared up. The fact medical professionals 
discarded my concerns and told me to continue the treatment, led me to question 
their expertise and whether they knew what they were doing at all, so I 
GLVFRQWLQXHGWDNLQJWKHGURSV´ 
Patient, female, 30 years, FML eye drops, I-Net.  
 
³$WWKHWLPHRIWDNLQJ5RDFFXWDQH,ZDVXQDZDUHRIWKHSRVVLEOHOLQNWR
depression. I remember being informed that it was a 'trial' for the drug and that 
there were possible side effects. However, I do not recall my attention being 
drawn to this particular link. Therefore, I had no idea that my subsequent 
depression, anxiety and suicidal ideation were anything to do with Roaccutane, 
VR,GLGQRWUHSRUWLWDWWKHWLPH´ 
Patient, female, 40 years, Roaccutane, I-Net 
 
³5educed sexual drive. Inability to maintain erection. I spoke to a General 
Practitioner (GP) at my local practice. She said that as I was in my fifties it was 
probably not something to worry about - whilst inconvenient, she said, it was 
better than being depressed.   
Patient, male, 50 years, fluoxetine, I-Net.  
 
 
Analysis found that 92 patients (4%) of patients disagreed with the 
treatment/diagnosis of the HCP: 
 
³3DSLOOHGHPDGLVFRYHUHGGXHWRGHYHORSLQJLGLRSDWKLFLQWUDFUDQLDOK\SHUWHQVLRQ
after taking metformin. Have permanent damage to sight. Constant headaches 
experienced. Approached out of hours general practitioner in Accident and 
(PHUJHQF\ZKRZURQJO\GLDJQRVHGSDLQDVPLJUDLQH´ 
Patient, female, 26 years, metformin, I-Net.  
 
 
³,WFKLQJRIJHQLWDODUHDvery bad itch, yeast infection genitals, oral thrush and 
swollen glands. I am known to get vaginal imbalances after antibiotics as well as 
having penicillin allergies so this medicine should had been avoided to prescribe 
DQGDPRUHVXLWDEOH«SLFNHGIRUP\FKHVWLQIHFWLRQ´ 
Patient, female, 41 years, doxycycline, I-Net.  
 
³:HLJKWJDLQGHVSLWHGRLQJGLHW6NLQEOLVWHUVRQSHQLVWLUHGDOOWKHWLPH
severe eczema on hands, increased bruising, skin infections that dont [sic] go 
away. Dosage raised several times to current 1400mg. I am not convinced I am 
suffering epileptic seizures since I remain conscious. I think the problem is 
FDXVHGE\DEORFNDJHLQP\OHIWFDURWLGDUWHU\´ 
Patient, male, 61 years sodium valproate, I-Net.  
 
Seventy-four patients (3%) had specific concerns about the suitability of their 





³3KRWRVHQVLWLYHUHDFWLRQLWFKLQJEXUQLQJKRWOXPS\VNLQDIIHcted sleep because 
of itching. Has tried to avoid sun..Leaflet says that it is not suitable for over 65's 
and patient feels this should be printed on the box as she did not read this until 
DIWHUVKHRSHQHGLW´ 
Patient, female, 68 years, tetracycline, telephone.          
 
³2QO\HUURULVWKDWWKHUHDUHQRZDUQLQJVWRJHQHUDOSUDFWLWLRQHUVRURQWKH
leaflet) about the medication causing systemic lupus erythematosus (lupus) so as 
P\GRFWRUVDLGLWVKRXOGQHYHUEHJLYHQWRVRPHRQHZLWKWKHFRQGLWLRQ´ 
 
Patient, female, 68 years, amlodipine, I-Net.  
 
 
7.3.6.2  Section summary 
 
 8 extracts providing details of UHSRUWHUV¶Foncerns such as negative 
H[SHULHQFHVZLWK+&3VGLVDJUHHPHQWZLWK+&3V¶WUHDWPHQWGLDJQRVHVDQG
specific concerns about the suitability of medicine 
 8 patient reports 
 2 reports for males; 6 for females with ages ranged from 26-68 years 
 Severity levels are 2 mild, 5 moderate and 1 severe effects 
 Two drugs linked to CNS; 2 to Infections; 1 to CVS; 1 to 
Obstetrics/Gynaecological; 1 to Eye and 1 to Skin 
 Comments composed of 7 moderately elaborate and 1 elaborate narrative 
 Overall comments related to the specific concerns of YC reporters on a 
range of issues 
 
7.3.4.10  Other aspects of YC Reports 
Analysis indicated that 175 patients (8%) submitted reports with specific 
characteristics/attributes including motivations to report, evidence to support their 
report (medical records/photos) and seeking advice. There were 150 (85.71%) 
patient, 12 (6.86%) carer and 13 (7.42%) parent reports for 119 (68%) females 
and 56 (32%) males. Reports with severe effects (73; 13%) were the most likely 
to display these characteristics when compared with other severity levels. The 
highest proportions of these reports were linked to ear/nose drugs (5; 16%); eye 
(4; 12%); malignant disease (5; 10%) and respiratory drugs (9; 10%). Reports for 
infants (5; 19%); 51-60 years (29; 8%); 71-80 (14; 8%) and those aged over 80 (5; 






Table 7.19: Frequency table of Subcategories 71-74# 
 
Sub category Frequency % total % of 
subcategory  
 Motivation to report described 
 
99 4.39 56.57 
Supporting documents supplied 14 0.62 8 
 Advice requested   
       
 51  2.26 29.14 
Awareness of sensitivity exhibited 
 
 37 1.64 21.14 
 
#Includes multiple characteristics per report 
 
7.3.4.10.1  Motivation to report 
Approximately 90 patients (4%) described the motivating factors that led to their 
reporting the SE.  
One patient identified the importance of reporting SE even if they are well-
known. She believes that common SE such as insomnia can have serious negative 





sedated and I didn't recover my sleep pattern whilst being treated on this drug. 
The consequences of that, along with other unfortunate circumstances, were 
positively harmful for me. Once I was out of hospital and saw my own 
psychiatrist again, I suggested to him that I might report the drug for this 
negative effect under the yellow card system. He dissuaded me however, saying 
that it was already a well-known effect so no need to report it. However, I feel 
that insomnia is such a serious and harmful effect to be experienced by someone 
with psychosis, that there absolutely ought to be high profile guidelines on how to 
PRQLWRUIRUWKLVDQGZKDWDFWLRQLVUHTXLUHGLILWFRQWLQXHV´ 
Patient, female, no age supplied, aripiprazole, paper.  
 
Another patient highlights the overwhelming effects she experienced in the 
following extract. Her motivation for submitting the YC is to increase patient 
awareness of a potentially debilitating SE:  
³6\PSWRPVGHYHORSHGRYHUWUHDWPHQWIURPWKHPLOGV\PSWRPRIUHVWOHVVOHJV
painful feet and joints in my feet and legs..Started treatment of mirtazapine 
15mgs...Hit a crisis point due to being in constant pain, in feet legs knees, muscle 
stiffness causing reduced mobility, which in turn was affecting my work, 
combined with other stress my depression was getting worse..I feel that the 
symptoms of pain in feet, knees, muscle spasms and muscle weakness should be 
highlighted more on the drug information and doctors made aware of it. It may 
be a rare side effect but it is a debilitating one, if it had not been for the support 
of my family the pain would have eventually driven me to take my own lifH´ 






since taking Nefopam Hydrochloride. I was put on this medication seven weeks 
ago when l dislocated my new hip replacement. l was having increased sweats, 
feeling queasy & had awful headaches. This culminated with me starting 
vomiting yesterday with diarrhoea, this has continued today. I thought to check 
the information sheet inside the Nefopam box and alongside the side effects that 
may occur less frequently l am actually experiencing: being sick, diarrhoea, 
blurred vision, sweating,& headaches, which are actually 5 of the 9 side effects. 
Needless to say l am stopping taking the Nefopam immediately as its hard enough 
coping with the problems l have without these extra problems. I hope my 
H[SHULHQFHPD\KHOSRWKHUVQRWJRWKURXJKWKHVDPH´ 
Patient, female, age not supplied, nefopam hydrochloride, paper.  
 
7.3.7.2  Supporting evidence 
Some reports included evidence to support their experiences. This evidence was 
provided in 14 reports (1%) and included photographs, medical records and letters 
from consultants: 
 
³My hair density has decreased by approximately one-third within months and it 
is now approximately half of its density; thus the hair loss has been sudden and 
dramatic. I have attached photos prior to Mirena insertion and photos taken a 
year ago to givH\RXDQLGHDRIWKHKDLUORVV´ 
Patient, female, 35 years, Mirena, Yellow card 
 
³The spironolactone was started and developed symptoms ten days later (was in 
the surgery as attended for an electrocardiogram (ECG)). This is the description 
of the reaction documented by our practice nurse: Attended for ECG - recently 
commenced on spironolactone for heart failure, during consult began spasming, 
rapidly became more violent and commenced on oxygen, with good effect for a 
short whiOHYLROHQWVSDVPVRQJRLQJ´ 
Patient, female, 78 years, spironolactone, I-Net 
 
 
7.3.7.3 Advice requested 
Analysis of reports found that 51 patients (2%) requested advice, as potential 
motives for submitting a YC report:  
 
³+DLUORVVWell I want to find out if there's anything I can do to combat the hair 
loss without reducing/stoSSLQJGRVDJH´ 
Patient, male, 27 years, Lamictal, I-Net.  
 
³0\VH[GULYHKDVJRQHGRZQDQG,DPXQDEOHWRDOZD\V maintain and get an 
erection. Everything was normal before I started taking this medicine and want 
to know anything I can take to help me. I cannot obtain and get an erection and 
its affecting my sexual relationship.´  





Experienced a severe skin rash 8 weeks after all over body..Liver readings 
doubled. Mother would like to know if this was first stage of Stevens-Johnson 
syndrome. She would also like to know if Stevens-Johnson syndrome presents 
LWVHOIDVDVNLQUDVKLQLWLDOO\DQGLILWLVSURJUHVVLYH´ 
Parent, female, age not supplied, lamotrigine, paper.  
 
 
7.3.7.4  Awareness of sensitivity exhibited 
Thirty seven reporters (1.6%) made explicit reference to their sensitivity to 
medicines: 
³,DPVHQVLWLYHWRDOLVWRIPHGLFDWLRQVWKH\DUHFOHDUO\ZULWWHQRQP\1DWLRQDO+HDOWK
Service (NHS) notes, I often have to remind consultants of them. I made this very clear to 
the consultant that prescribed pregabalin to me, but he still prescribed it. I also wear a 
medical bracelet due to high level allergies´ 
     Patient, female, 41 years, pregabalin, I-Net 
 
 ³([WUHPHLUULWDWLRQRIWKHH\HUHGQHVVLWFKLQJLQIODPPDWLRQDQGEXUQLQJVHQVDWLRQRQ
the skin.  I was originally prescribed antibiotic drops, but those did not improve my 
condition and made it worse. Because of that I went to the accident and emergency which 
I had been advised to do in that event and was given the ointment. The ointment has had 
a definite adverse effect which was almost instant. I applied the ointment at night when I 
returned from the hospital and again in the morning. Some ointment got on to my cheek 
and this had a burning sensation for a short time. At this present time, about four hours 
since the last application, my eye is very inflamed, red and painful.I am allergic to 
ampicillin and septrin having had very severe reaction to the same following surgery. I 
have to avoid these penicillins and have not been prescribe them for years.   
Patient, female 66 years, chloramphenicol, I-Net. 
 
7.3.7.5  Section summary 
 8 extracts providing details of the specific characteristics of YC reports 
such as motivations to report, supporting documentation and advice 
seeking 
 7 patient reports and 1 parent report 
 2 reports for males; 6 for females with ages ranged from 26-78 years 
 Severity levels are 1 mild, 1 moderate and 6 severe effects 
 Three drugs linked to CNS; 2 to CVS; and 3 to Endocrine system 
 Comments composed of 1 scant, 1 moderately elaborate and 6 elaborate 
narratives 
 Overall comments related to the specific characteristics of YC reports 
 
7.3.8 Reports of positive SE 
In addition to these specific attributes analysis of the YC reports also revealed five 




³Rapid weight gain (24kg in 3 months) so asked general practitioner to reduce 
dose from 600 to 300mg/day. Weight stabilised after reducing dose, at 15 kg 
heavier than normal weight. A positive side effect is a complete reduction in 
migraines, used to suffer 3-5/month but have not had any since starting 
pregabalin.´ 
Patient, female, 30 years, pregabalin, I-Net 
 
³The side effect I am reporting is a positive one. Not only has erectile 
dysfunction (ED) been treated, the chronic pain I have suffered is much reduced.  
Markedly reduced pain from my right hand, following a reverse flow radial arm 
flap surgery.´ 
Patient, male, 63 years, sildenafil, I-Net 
 
 
³Did feel a bit light headed. More important fact is that this medicine had a 
rapid, confirmed, successful additional effect on ending a dystonic storm. The 
storm started as I got into bed. It's a deep neurological crisis. I felt it happening 
in my nervous system and I lost control of limbs and entered a state of panic and 
utterly intolerable pain.  I was in a state of forced squirming unable to sit or lie 
still and unable to control body properly. Other pains from my myalgia, 
paresthesia were exacerbated by the storm. Taking one 5 mg zolpidem in EU/ UK 
Stilnoct film coated tablet had a moderate effect but merely took it down from cat 
4 to cat 1-2. Systems were still all involved and head, neck, back, chest, legs, feet, 
arms, hands, face, voice, and a deep sense of profound unease/ terror. So I took 
one more and it pretty much nailed the storm.  The dystonia continues in its usual 
semi manageable way so I look forward to sleeping now. I would be delighted to 
explain my experience as my experience confirms that of others. This drug and 
similar ones of the class may be novel treatments for status dystonia: an acute 
flare of chronic focal and generalised dystonia.´ 
 Patient, male, 39 years, Stilnoct, I-Net 
 
³2QWDNLQJWUDPDGRO,KDGPXFKPRUHHQHUJ\On further investigation it was 
found that 1 tablet 50mg extended release lowered my standing heart rate by 20 
beats per minute. This is great if you have postural orthostatic tachycardia 
syndrome (POTS). Continued use to prevent daily spikes in heart rate for POTS 
could be a possible treatment for those with asthma WKDWFDQ¶WWDNHEHWD
EORFNHUV"´ 
        Patient, female, 34 years, tramadol hydrochloride, I-Net 
 
 
³I suffer from myelofibrosis and have been having regular blood transfusion, 
every 3 - 4 weeks. Since being diagnosed with temporal arteritis and being 
prescribed prednisolone my haemoglobin is much improved and seems to hold at 
around 90. I only need transfusions now at extended intervals, around 8 weeks. 
Improved production of red cells. Is this one of the (beneficial) side effects of 
prednisolone? None of the professionals seems to know.´ 
           Patient, male, 76 years, prednisolone, I-Net 
7.3.9 Template analysis of selected free text narratives 
A range of extracts have been used to demonstrate the results of the template 
analysis. These extracts represent severe effects to a variety of drugs across 
different reporters. The findings are illustrated by verbatim quotations and the 
extracts identified by reporter type, patient age, gender, drug type and method of 
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reporting. The analysis was conducted on 12 patient, 12 carer and 12 parent 
reports. These reports described severe reactions across a range of drug classes - 
GI(3); CVS(4); respiratory(3); CNS(7); infections(4); endocrine(3); obstetrics(3); 
malignant(1); muskoloskeletal (2); eye(1); ear/nose(1); skin(2); and OTC(2). The 
focus of the analysis is on the multi-dimensional impact of severe SE. Five main 
themes were identified with eight subthemes. The analysis is divided into these 
main themes and is composed of five sections as follows: 
 Reconstruction of event 
 Impact of SE 
 Coping with SE 
 Seeking meaning 




Figure 7.11: Final template of main themes and subthemes  
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7.3.9.1  Reconstruction of event 
Description and evaluation of effects 
The elaborate narratives had detailed descriptions and evaluations of SE. They 
relate information on the onset, progression, severity and outcomes of SE: 
 
³,DPH-mailing on behalf of my friend who is staying with me for a few days. She became 
unwell yesterday evening with a bad head cold and as she felt worse this morning she took 
two of the above caplets which she claims she has had before. Within a very short while 
she suffered from swelling of the inside of her mouth and lips, thankfully just on the left 
side. I took her to my local pharmacy and the pharmacist there advised that she saw a 
doctor. Thankfully my medical centre were able to see her and she was told that she was 
suffering an allergic reaction to the caffeine which obviously is RQHRIWKHLQJUHGLHQWV´ 




the arms, pins and needles throughout the body. Dry mouth, headache and nausea. 
General exhaustion. He has been given antihistamine and steroid cream. Seek Advice 
Details: My son woke up in the night with itching and the rash burning. We called NHS 
Direct due to severity of the rash and places. The doctor called 3am and then we saw a 
doctor twice for medication.´ 
Parent, male, 14 years, Buscopan, I-Net 
 
7.3.9.2 Impact of SE 
Analysis indicated that the impact of SE manifested themselves across a range of 
domains ± physical, psychological, social and economic.  
Physical, psychological, social, economic and family effects 
Reporters indicated the effects had significant negative physical, psychological 
and economic effects: 
³Severe acute respiratory syndrome, acute digestive discomfort, persistent 
chronic nausea, very tight chest and diaphragm pain ("like a 3-hour heart 
attack"). The effects all peaked and continued at a high level for 4.5 hours, 
tailing off until 3.5 hours later. I was reluctant to involve the ambulance service, 
and it was obviously not a time when I could consult a pharmacy or my own 
general practitioner. Had this happened during daylight hours, I would have 
probably sought professional advice or intervention. The chest tightness and 
breathing difficulties were extremely difficult and painful, and the chronic nausea 
ZDVTXLWHGLVWUHVVLQJ´ 
  




eventually had to sell her house to pay some debts. Having been told by the 
neurologist 'it was not her fault', and that gradually decreasing the dose of the 
agonist, changing to a levodopa drug Sinemet and having deep brain surgery the 
addiction would stop, but it continued in secret for some time. We were never told 
this is known to be a possibility. Her attempted suicide and depression was as a 
result of her desperate financial situation. This has led to a breakdown in family 
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relationships (she is widowed with two teenage sons). She has told so many lies 
to so many people, there is now a total lack of trust.´  
Parent, female, 40 years, Requip, I-Net, 
 
Reporters also expressed concerns about the particularly significant negative 
impact of effects on the family of patients: 
 
³Aggression, agitation, anxiety, paranoia, passive suicidal ideation and violence. 
I am writing to report this on behalf of my deceased father. I believe that he 
should never have been prescribed this drug in the first place given its side 
effects, I feel it exacerbated problems my father already had and the GP should 
have flagged this when prescribing. My father was on this medication for 6 
months before his death and day to day life for himself and his wife and my 
sisters was awful. He became aggressive, violent and suffered severe anxiety and 
paranoid thought. He mentioned suicide on moUHWKDQRQHRFFDVLRQ´ 
Carer, male, 50 years, Champix, I-Net 
 
³Ruptured post tibial tendon. Joint and tendon, muscle pain. Anxiety. Fatigue. 
Pins and needles. Right post tibial tendon ruptured after three days on 
ciprofloxacin. Left post tibial tendon also affected after three days on 
ciprofloxacin. All other symptoms mentioned happened gradually. From a fit and 
active person to disabled in three days. I rode horses and was able to do all the 
associated work. I am only just able to walk without crutches for short distances 
and still need them for rough ground. My husband had to take over the running 
of the house, the horses and dogs and caring for elderly relatives. This had had a 
catastrophic effeFWRQRXUOLYHVDVDIDPLO\´ 
Patient, female, 62 years, ciprofloxacin, I-Net 
 
7.3.9.3 Coping with SE 
2YHUDOOUHSRUWHUV¶GHVFULSWLRQVRIFRSLQJSURFHVVHVLQYROYHGWZRVXEWKHPHVWKDW
divided into cognitive and behavioural responses. Effective coping strategies 
generally involved both cognition and adaptive health behaviours. 
Cognitive and behavioural responses 
These sub-themes were linked and most reporters engaged in combinations of 
these responses. Regardless of reporter type, coping involved cognitive and 
behavioural responses such as non-adherence, information seeking, differential 
diagnosis and social support seeking behaviours: 
 
³Dizziness, drowsiness, hallucinations, headache, rapid heart rate, shaking, 
sleep disturbance, vertigo, vomiting.  After speaking to a nurse and basic 
searches on the internet, the patient was told they should never have been given 
such a high dose as they have never taken this before, and should have started 
ORZHUDQGEXLOWXSRYHUWLPH´ 





³Bumps on arms a day after taking omeprazole, followed by rash spreading over 
body from the back.  Doctor thought it was eczema but it didn't cause my child to 
itch and didn't respond to prescribed eczema lotions and creams. I suspected it 
was the medicine as I saw this was a rare side effect so I decided to stop the 
medicine.´ 
Parent, female 0 years, omeprazole, I-Net 
 
³I received a letter from a medical centre making a strong recommendation to 
discontinue taking quinine sulphate which I complied with shortly after my first 
24 hour electrocardiogram (ECG).  At that time my only thought was what could 
I now take to relieve my leg cramps at night. Your letter confirming your 
diagnosis of atrial fibrillation came as a great shock but also encouraged me and 
my wife to carry out detailed research into the side effects of quinine sulphate on 
the regular rhythm of the heart and I discovered there existed a great deal of 
evidence of which I am sure you are aware. At the same time I tried to convince 
myself into taking your recommended regime of medication but I did not succeed.  
After weeks of discussion with my wife, who has been a tower of strength 
throughout, I continued to take only my usual medication of perindopril, 
clopidogrel and amlodipine.´  
Patient, male, 85 years, quinine sulphate, Patient(MHRA) 
 
7.3.9.4  Seeking meaning 
Several processes were identified by reporters as fundamental to finding clear 
meaning and understanding their experiences. These included seeking to 
clarify/making sense of their SE event. In addition, reporters frequently tried to re-
establish control with health-related decisions such as non-adherence; reporting 
their SE or accessing appropriate feedback: 
³7KUHHPRQWKVDJRP\JUDQGGDGSDVVHGDZD\LWZDVVXGGHQDQGXQH[SHFWHG,Q
2007 he suffered a stroke in result of this he was prescribed the drug warfarin. 
He also had an irregular heartbeat. He was doing fine on the warfarin. I was 
taking him for his regular blood tests. A few years later we discovered that he 
was losing his memory we didn't think anything of it until it started getting worse. 
He had dementia for 6 years prior to his death, me and my mother were looking 
after him. I was his full time carer and my mother helped me out. He had arthritis 
on his hip and knee so he had trouble walking. His dementia and arthritis rapidly 
went down hill so we could no longer take him to the clinic for his blood tests, 
meaning we had to get district nurses to come out to the house. This was fine 
until they started having problems extracting blood. They suggested putting him 
on this drug where he wouldn't need as many blood tests, the drug in question is 
rivaroxaban. We didn't know that rivaroxaban could cause bleeding to the brain, 
this is what my granddad died of. At the hospital they explained that with 
dementia your brain shrinks and any sudden jolt, fall or knock to the head could 
cause a bleed. We put my granddad in respite, went away and on arrival back we 
received the call from the hospital, they couldn't operate because of his dementia, 
age and heart condition. I don't know exactly what happened in the care home 
but you don't just suddenly get a bleed on the brain, something must have caused 
it. We were there with him in the hospital and we saw him take his final breath, 
this will live with in my memory for the rest of my life. Please I want your help to 
try and get rivaroxaban banned for good, there must be another way to thin the 
blood, another medicine that won't cause death. I want to leave end this email 
with this, warfarin is used in rat poison, it may just be in small doses but it is still 
a poison. Thank you for taking the time to read this´. 





that I suffered has been reported. I had the intravenous medication at the hospital 
and almost died as a result of a severe reaction resulting in liver failure, 
pneumonia and development of lupus. This was confirmed by severe jaundice, 
long stay in hospital and two liver biopsies etc. Unfortunately, the hospital office 
has refused to let me know if this was reported. This is a very serious incident 
that almost resulted in my death and should have been reported..I developed 
itching prior to the infusion. I explained to the rheumatology nurses who checked 
with the doctor who dismissed it as dermatitis although I told them I have never 
had dermatitis or any skin problems. He gave the nurses the go-ahead to give the 
infusion despite my concerns that I had the itching and my alanine 
aminotransferase were elevated which the same doctor also dismissed as a blip. I 
became extremely unwell and had to admit myself via accident and emergency to 
hospital with serious liver damage and close to death. I was unable to walk, 
became extremely jaundiced, lost my sense of tasting (was unable to taste any 
kind of salt or sugar totally; lost my appetite completely), became extremely 
swollen with cellulitis, numbness and pins and needles to both legs which were 
very swollen with fluid retention, the steroids burnt a hole in the side of my 
tongue, muscle weakness, fainting, fatigue, tinnitus, shortness of breath among 
other symptoms. None of the medications were working and my liver became 
more damaged. Following on from the liver damage, I had atelectasis and 
subsequently suffered from serious pneumonia. This unit does not have a liver 
specialist department yet I was not referred to a specialist unit and suffered 
unnecessarily and unduly. I have made some degree of recovery but have 
ongoing problems with my health generally and my liver. My alanine 
aminotransferase fluctuate and are presently deranged also my gamma-
glutamyltransferase. I continue to suffer tremendously from ongoing problems 
with my health and emotional state. I was never offered any debriefing or 
counselling as this has had a major impact on my young family and myself. Over 
the last few days I have been diagnosed with possible narrowing of the carotid 
arteries due to syncope (continue to feel faint even when sitting and suffering 
from serious fatigue and exhaustion). The side effects are still ongoing as my 
liver function remains abnormal and I am suffering from liver pain etc. I am 
disappointed to learn that such a serious, adverse medication-induced liver 
injury occurred and almost resulted in my death yet it was not reported to the 
MHRA´ .   
Patient, female, 47 years infliximab, MHRA 
 
³My son commented three weeks into the treatment that this was affecting his 
sexual libido and he had noticed the change over the past few weeks following 
commencement of this tablet course. He has now stopped taking this medication 
prior to seeking further medical advice. We were aware of the listed side effects 
before commencement and my son experienced some headaches in the first week 
and the drying of skin and lips, nose, which he had expected. This was reported 
to the pharmacist and the skin clinic. Paracetamol x 2 were taking at the onset of 
a headache and emollients for the dry skin. He was not taking any other 
medicines. Prior to commencing with this medication we carefully read the 
leaflet Information for the user containing all the listed side-effects. He has later 
said to me that his emotions were also more emphasised. Which we were aware 
of as they were listed. This clearly does not mention or list male low libido or 
impotence condition in your leaflet. My son was concerned and searched the side 
effects of isotretinoin on the internet in relation to his new complaint of a low 
libido. Only to find this was listed and commented on frequently of sexual libido 
being affected as a common side effect of this drug. Prior to my son taking this 
medication, he had a normal sexual relationship with his girlfriends. Why was 
this side effect not listed on your leaflet? I cannot begin to say what implications 
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this can have on my child at this very important development age. Do you have 
any trials of testosterone levels taken before and after isotretinoin use? My son 
feels so sure of this side effect of impotence with the taking of isotretinoin and is 
willing to have the testosterone blood test to prove clinically that this is a side 
effect of this drug.  I will be taking this matter further and await your early 
response.  He felt he had to stop taking this medication prior to seeking further 
PHGLFDODGYLFH´ 
Parent, male, 17 years, isotretinoin, I-Net 
 
7.3.9.5 Attitudinal change 
A recurrent theme amongst the narratives was the change that occurred in health 
beliefs/perceptions. As a result of SE, beliefs about medicines; about their ability 
to manage effects; attitudes towards their general health and perceptions of HCPs 
were subject to change.  
This report highlights a change in belief about medicine with specific concerns 
about future use of antibiotics: 
 
³Felt giddy and sick. When you feel ill you don't want a drug that makes you feel 
sicker.  Now afraid of using antibiotics.´ 
Carer, female, 81 years, amoxicillin, I-Net 
 
 
This patient is afraid to try any new medicines as a result of her effects: 
 
³1RZ, just over 2 months later, the pain and weakness have continued to 
improve slowly, but I am by no means fully recovered. I find that if I overdo 
things, which could simply be a session of ironing or a shopping trip, the pains 
become more severe and the feeling of weakness in all my muscles returns. I still 
sometimes wake up from sleep screaming in pain and unable to move to a more 
comfortable position, but this is now less frequent. My doctor, whilst sympathetic, 
offered me no help for my symptoms. I am now afraid to try any new medications 
and am trying to control my blood sugar with diet.´ 
Patient, female, 59 years, Januvia, I-Net 
 
This patient describes a change in her health beliefs - the severe effects she 
experienced have led her to now believe she is addicted to her medicine: 
 
³<HVWHUGD\,IRUJRWWRWDNHP\WDEOHWVLHYHQODID[LQHOLVRQRSULODQGVLPYDVWDWLQ 
all of which I take in the morning).  I went to bed and woke at 1am thinking I was 
getting a migraine - I had at that time not remembered that I had missed a dose.. 
I took 50mg sumatriptan. Very shortly afterwards I suffered from severe vivid 
migraines with wakefulness/paralysis/trying to scream from which I was unable 
to rouse myself. I had no headache or nausea. The nightmares continued through 
the night, although later turned to less frightening but extremely vivid dreams. I 
had great difficulty waking up at my usual time, but managed it. It is now 11.22 
and I still feel peculiar and extremely tired, although I have now taken my 
medication at 8.30am. I think that this incident was caused by either missing my 
venlafaxine, or otherwise by this and by subsequently taking the sumatriptan. I 
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hope this information is useful. It isn't pleasant to realise that one is addicted to 
ones [sic] PHGLFDWLRQ´ 
Patient, female, 53 years, sumatriptan succinate, I-Net 
 
7KH6(KDYHKDGDQHJDWLYHLPSDFWRQWKLVSDWLHQW¶VGaily life and her confidence to cope 
with the onset of unpredictable effects:  
 
³7KHUHLVGHILQLWHO\JRRGFDXVHWRSUHYHQWH-lites being smoked near people on 
lithium. I went shopping not so long ago and basically suddenly had to stop 
walking as felt terrible. My partner looked up and saw someone passing by 
smoking an e-lite in close proximity. I luckily always have water on me and also 
paused red faced and hot for a minute till I felt better and vowed never to go near 
the e-lites and their open air users again..The e-lite nearby must have rocketed 
WKURXJKP\V\VWHPDQGFKDQJHGP\OHYHODV,FRXOGQ¶WHYHQFDUU\RQZDONLQJ
Lithium also affects heart rhythms which could be very serious. I think it is very 
unfair that random passers-by have the power to make others feel ill this way 
albeit accidentally. It still makes you ill whether they do it on purpose or not. I 
FDQ¶WJRWRWKHVKRSWKHFLQHPDRUDQ\FDIHVHWFEHFDXVH,GUHDGDVXGGHQKHDOWK
FKDQJHSURPSWHGE\XQSUHGLFWDEOHFLUFXPVWDQFH´ 
Patient, female, unknown, E-lite - electronic cigarette, MHRA  
 
This patient believes that her medicine is necessary and worries about the impact 
of non-adherence on her general health. However she is unable to accept the 
resulting SE and has to stop taking the medicine: 
 
³40mg atrovastatin-anxiety and depression. Tried simvastatin provastatin, now 
rosuvastatin reduce dose each time same problem. Took medicines for 
approximately 3 months. I felt unwell on them, nothing specific informed GP then 
woke one morning with no warning and was unable to go to work, very tearful, 
did not want to leave the house..Went back to 5 mg been on for nearly 4 months 
but have had to stopped again as I was getting the anxiety and depression coming 
back. I have no issues taking the medication if tKDW¶VZKDW,QHHGWRVWD\ZHOOEXW
constantly feeling like this is not good and every time I have to stopped [sic] 
taking them I start to worry about having a heart attack or stroke.  Each dose 
was lowered, but side effects occurred quicker, and have taken longer to get 
over.´ 
Patient, female, 60 years, rosuvastatin, I-Net 
 
7KLVSDWLHQW¶VKHDOWKEHOLHIVQRZLQFOXGHKLVFRQYLFWLRQWKDWKLVSE were 
unnecessary and that his long term health may have been negatively affected by 
his medicine: 
´7KH&UHR3KDUPDlofepramine has given me severe and lingering side effects from 1 
tablet taken at night-time and one tablet taken on the following morning.. The dispensing of 
the lofepramine was a matter of some discussion between the pharmacist and myself, when 
I discovered that the brand I've had two days of misery and totally unnecessary side effects 
from the Creo lofepramine, and with now unknown future repercussions on my already 
frail system by ingesting what was, to my body, nothing but utter poison in the form of 
CUHRORIHSUDPLQH´ 




These attitudinal changes were apparent across all reporter types and often were 
linked to negative interactions with HCPs or the SE being downplayed by HCPs: 
 
³,HYHQWXDOO\JRWWDNHQWR the local hospital to wait for ages to see a doctor. This doctor 
then referred me on to the new specialist emergency hospital, where I was admitted for 
tests.  My blood was found to be ok and the doctor was off with me and acted like I was 
wasting his time! I repeated my concerns about the bad side-effects I'd experienced since 
taking the clarithromycin antibiotic- he didn't seem to know anything about these side-
HIIHFWV´ 
Patient, female, 42 years, clarithromycin, I-Net 
 
 
³$IWHUWDNLQJ=DPDGROWKH\ZHUHXnable to return to work for over a week as they felt so 
dizzy and had a headache. When the patient tried to report this at the chemist they were 
told they had never heard of yellow card and go to see the doctor. The doctors surgery also 
told them they had never heard of yellow card so a complaint form was taken. The next day 
the doctor phoned to tell them that they had caused a commotion asking for the yellow 
card. They are reporting this effect so that no one else suffers the same as them. They were 
not veU\NHHQWRUHSRUWWKHVHHIIHFWVDQG,DPILOOLQJWKLVLQIRUWKHSDWLHQWDV,¶PQRWVure if 
the doctor has done one. The patient contacted the doctor but was told the reaction had 
nothing to do with tablet prescribed. They did not suffer from this before they took the 
WDEOHWDQGDIWHUDGYLFHIURPDVFLHQWLVWDQGDQXUVHWKH\ZHUHDGYLVHGWRUHSRUWWKLV´ 
Carer, female, 49 years, Zamadol SR, I-Net 
 
³Was prescribed trimethoprim for a suspected urine infection, within an hour of taking I 
started to feel unwell, short of breath, dizzy, heart racing. Called my general practitioner 
(GP) who said call an ambulance. I was admitted to hospital and kept in for 4 days but 
they did not believe it was connected to the Trimethoprim. Within a month I had another 
water infection and despite me talking through my concerns about taking trimethoprim I 
was prescribed again and assured I would be ok. Within 1 hour I became increasingly 
unwell, my vision was very blurred and I had severe pain in my legs. I immediately went to 
my GP. I was in agony, still my GP refused to accept it was connected. I left my GP and 
started severely vomiting and collapsed. An ambulance was called and I was rushed to 
KRVSLWDO´ 






The aim of this phase of the study was to investigate how YC reporters identify and 
manage ADRs, what type of information sources were used to aid identification, as well as 
the impact of ADRs. It analysed 2285 patient YC reports received by the MHRA in a six 




Results indicated a pattern in YC reports - the majority submitted for females with 
more younger females and older males reported to have experienced SE. Over 
30% of reports were for females aged 21-40 and over 20% for males aged 61-70. 
Previous YC research found a similar pattern of greater proportions of reports for 
females (Avery et al., 2011). ADR research which indicated that females and 
older patients are at higher risk of developing ADRs also supports thLVVWXG\¶V
findings (Martin et al., 2013; Moen et al., 2009; Zopf et al., 2008). 
Data from this study shows that the majority of reports were submitted by patients 
themselves, particularly among females (94%). Over 90% of reports concerning those aged 
41-50 and 51-60 years were submitted by patients. As expected most parent reports were 
for infants and those 1-20 years; while most carer reports were for those in the oldest age 
categories (71-80 years and over). Although past research has suggested that older people 
were at greater risk of developing ADRs due to factors such as such as co-morbidity and 
polypharmacy (Alhawassi  et al., 2014; Hefner et al., 2015; Martin et al., 2013), the 
distribution of reports did not reflect this. 
The Internet was the most commonly used method of reporting for both genders, all age 
groups  and for all reporter types (over 90%). These findings are consistent with previous 
research which found that the Internet was commonly used for health information (Clarke 
et al., 2016; Harvey et al., 2017). However Internet reporting dropped to 66% for those 
aged over 80. This finding is consistent with that of Medlock (2015) who identified HCPs 
as the preferred information source for older seniors seeking additional information on side 
effects. In contrast to this study previous YC research identified the YC form as the most 
frequently used method of patient reporting with just 14% using the Internet (Avery et al., 
2011). Possible explanations could include increased Internet use amongst the general 
population. In general research has also indicated that increased numbers of patients are 
accessing health information online (Clarke et al., 2016).  Research has also been 
conducted which suggested changes to the Internet form to reduce its complexity 
(Anderson et al., 2011). These changes may have led to enhanced Internet reporting. 
Frequently online health forums provide details on the YC scheme which could also result 
in increased Internet reporting.   
This study identified over 70% of overall reports for serious effects with a higher 
proportion in females. These results reflect previous research which also found 
that more serious ADRs were reported for females and females reported greater 
impact on QDL (Lucca et al., 2017; Skilving et al., 2016). Consistent with 
previous research this study found that severe effects were more likely to be 
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reported for older age categories (Hefner et al., 2015). Over 60% of those aged 
14-50 reported serious effects, increasing to over 70% in those aged 61-80 and 
over. Serious effects were not confirmed by HCPs in the majority of YC reports 
(90%) regardless of reporter type. The current study also found that unresolved 
reactions did not result in increased reporting of severity. Only a small proportion 
of reports described effects that caused incapacity (5%), hospitalisation (8%) or 
threatened life (11%). In contrast, earlier YC research found higher rates of 
hospitalisation (13%) and lower rates (6%) of life threatening outcomes for UK 
patients (Avery et al., 2011; Inch et al., 2012). It seems possible that several 
factors could explain these different findings including general improvements in 
pharmacovigilance, increased availability of health information on ADRs, 
increased drug potency or simply variation in indiYLGXDOV¶H[SHULHQFHVGXHWR
chance. Many extreme outcomes such as hospitalisation/life threatening events 
were experienced by the vulnerable populations - younger and older patients. The 
most interesting findings relate to severity and suggest that YC repoUWHUV¶
assessment of SE as serious, are not linked to consultation with HCPs, unresolved 
reactions, or outcomes such as hospitalisation/incapacity. Further research is 
UHTXLUHGWRH[DPLQHZKDWIDFWRUVLQIOXHQFH<&UHSRUWHUV¶VHYHULW\DVVHVVPHQWV 
A high proportion of severe reactions and polypharmacy reports were linked to 
multiple reactions and multiple outcomes. Older patients were more likely to have 
resolved reactions which could be explained by effective medical interventions. In 
general older patients are more likely to attend HCPs than younger patients which 
could in turn result in better recovery outcomes.  This explanation is supported by 
survey findings in Phase One of this study which found that retirees were more 
likely to attend their GPs when experiencing SE. The findings from all the phases 
of this study will be compared and discussed in the following chapter ± Chapter 8: 
Discussion.   
Pattern of medicine use amongst YC reports 
This study revealed a pattern of medicine use amongst YC reports. The number of reported 
drugs ranged from 1-12, although the majority of reports were for one drug regardless of 
gender or age, with most reports being linked to CNS, infections and CV systems. These 
findings are not unexpected - NHS statistics which examined the number of prescription 
items dispensed in England indicate that the top three system drugs prescribed in the 
community in 2015 were as follows: 98.5% were for drugs in infections; 97% for drugs in 
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CVS with 90% for drugs in CNS (NHS, 2016). It is reasonable therefore the YC reports 
would reflect this pattern of prescribing and that a large number of reported SE would be 
related to these systems. CNS drugs were the most commonly reported regardless of 
gender. They were also linked to four age categories and were highest in those aged 21-40 
and 51-60 indicating similar use across age ranges. CNS drugs are used for a wide range of 
conditions such as anxiety, depression, nausea, pain, epilepsy, dementia and substance 
dependence. It is therefore not unexpected that CNS drugs were regularly reported to the 
YCS. In addition NHS statistics indicate that there has been an increase of 5.7 million in 
CNS items dispensed since 2014 (NHS, 2016). The greatest increase in prescribing in 2015 
was for antidepressant drugs such as amitriptyline, mirtazapine and citalopram (NHS, 
2016). Increased volume of prescribing CNS drugs could reasonably be expected to result 
in more SE and more YC reports. As expected CNS drugs were also linked to severe 
effects followed by infections and CVS. 
 A pattern of SE outcomes was identified as follows:  incapacity was reported for CNS and 
CVS drugs; hospitalisation was linked to GI, CVS and CNS drugs; while life threatening 
events were reported for CNS drugs. An interesting finding was that reported severity 
levels were not influenced by the number of drugs cited. The overall profile of effects in 
YC reports was also indicative of certainty in the association - nearly half of reports 
concerned only one or two effects and were linked to one drug. The most common effects 
were physical ± pain, abdominal discomfort, headache and fatigue. These findings are 
broadly supported by previous YC research which identified the top five drugs in 270 
patient reports as CNS, CVS and skin system drugs. The most frequently reported 
reactions were also physical ± nausea, headache and dizziness. (Avery et al., 2011). A 
pattern of high frequency and complex impacts was identified amongst GI and CNS drugs 
respectively. Over 70% of physical impact was reported for GI drugs ± this may be related 
to the variety of drugs within this class which are used in multiple treatments and different 
conditions. A combination of physical, psychological and social impacts were found to be 
linked to CNS drugs (30%). Again these findings are not unexpected as there is significant 
diversity within the CNS class in terms of the type of drugs. Overall GI and CNS drugs can 
be used to treat numerous diseases which would reflect the findings of common and 
complicated impacts for these specific BNF classes.  
 Value of free text comments 
This study indicated that many of the free text comments provided vivid and rich 
GHVFULSWLRQVRISDWLHQWV¶H[SHULHQFHVAn interesting finding was the 
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comprehensive information, frequently rich in detail, which was supplied by 
reporters. This information reflected the range and complexity of SE. Many of the 
LOOQHVVEHOLHIVSHUFHSWLRQVLGHQWLILHGHQFRPSDVV/HYHQWKDO¶VGLPHQVLRQVRILOOQHVV
representations. Over 90% of reports contained descriptions of physical 
symptoms, highlighting the importance of somatic sensations in YC reports. Drug 
details and reasons for taking the drug were supplied by over half of reporters - 
33% and 21% respectively. These findings are supported by previous YC research 
which found that patient reports included symptom and history information 
(Avery et al., 2011). Previous ADR research has also found that patient reports 
frequently relate descriptions of physical effects (De Smedt et al.,2012; Gandhi et 
al., 2003; McLernon et al., 2010). Focus on physical sensations as displayed in the 
YC reports is a key element of the CSM of Self-Regulation (Hagger & Orbell, 
2003; Leventhal et al., 2011). 
Impact and severity of SE 
Regardless of reporter type, elaborate narratives were frequently provided on the 
VHYHULW\DQGLPSDFWRI6(RQSDWLHQWV¶OLYHV2YHUDOORIUHSRUWVUHODWHGD
range of effects; mild (13%), moderate (24%) and severe (25%). A combination 
of explicit and implicit impacts was described in 95% of reports; physical (93%), 
psychological (24%) and social (34%). These findings illustrate the serious 
GLVUXSWLRQWRPDQ\DVSHFWVRISDWLHQWV¶OLYHV- emotional, social and occupational 
± which can be a feature of SE (Asseray et al., 2013). A striking finding was the 
prolonged consequences of effects for just under 20% of YC patients. These 
included persistent negative physical (9%), psychological (3%), social (2%) and 
life changing (3%) effects. Previous YC research found similar patterns of 
impaired emotional (34%) and social (27%) functioning in patients (Avery et al., 
2011).  
Another important finding was the subjective experience of SE, over half of 
UHSRUWVGHVFULEHGHIIHFWVDVµVHYHUH¶ZKLFKLQFOXGHGHIIHFWVFRPPRQO\ODEHOOHGDV
mild such as rash, muscle pain. These results can be explained by research which 
has identified the role of individual perceptions and attentional biases in health 
behaviours (Lee et al., 1997). Patients with heighted health anxiety have negative 
perceptions about their symptoms and illness in general. These beliefs can lead to 
vigilance to symptoms and increased somatosensory perceptions. Attentional 
biases are therefore associated with increased pain reports and elevated 
perceptions of severity (Chapman, 2011). Overall the information on SE impact 
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highlight the value of YC free text comments and highlight their potential to 
contribute knowledge to health research. 
Identification of SE 
This study found that 30% of reports provided details on how individuals 
identified experiences as suspected side effects. The most commonly reported 
method was related to the timing of effects ± 13% - followed by differential 
diagnoses in 5% of reports. These findings are supported by previous research 
which also identified the use of timing relationships by patients to assess SE 
(Chaipichit et al., 2014; Krska et al., 2011). However, these levels are below those 
observed by Avery et al., (2011) who found over 60% of patients reported 
temporal associations. In terms of information sources an interesting pattern 
emerged with the use of multiple sources by many reporters. Surprisingly low 
proportions - just 6% - confirmed effects with HCPs while just 1% used the 
Internet and 2% reported they used PILs. Previous research of reporters to the 
YCS found similarly low proportions of HCP use (9%); but higher proportions of 
Internet use (5%) and use of  PILs (16%) (Krska et al., 2011). A possible 
explanation for the findings of this study might be that that Internet or PILs were 
used by the YC reporters but not specifically reported. However this result could 
also link to an evolving pattern of information use in YC reporters and thus 
indicate a focus for future research. Survey data from Phase One of this study 
found a contrasting pattern of information use with over 60% of survey 
respondents using GPs or PILs to confirm their SE. These findings will be 
compared and fully discussed in the following chapter ± Chapter 8.  
Behaviours and outcomes 
Over 40% of reports described a variety of patient behaviours such as HCP 
consultation (30%); non-adherence (16%) and counteracting SE symptoms with 
medicines (8%). These findings contrast with previous research which identified 
coping behaviours in patients with heart failure (De Smedt et al., 2012). A higher 
proportion of these patients consulted HCPs (49%) and used additional medicines 
to alleviate the SE (14%) when compared to YC reports. In contrast to the 
findings from this study non-adherence was reported in just 7% of heart failure 
patients. However it is not unexpected that patients with a chronic condition such 
as heart failure would display different patterns of health behaviours to those of 
general YC reporters. The former have different health concerns and would be 
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medicines. There has been extensive research into non-adherence which has 
identified its risk factors (Martin et al., 2005; Van Dulmen, 2007). Non-adherence 
studies have found that patients with concerns about their medicines who receive 
conflicting similar information are more likely to be non-adherent. In addition, 
patients who sought information from non-HCPs were more likely to be non-
adherent (Carter et al.,2013; Nunes et al., 2009). These findings contrast with this 
study which found that over half of those who consulted with HCPs engaged in 
non-adherent behaviours. The levels for non-adherence were higher in this study 
than those of the Omnibus survey (2009) which found just 5% of respondents 
stopped their medicine.  
It is noteworthy that just 1% of YC reports described recording the suspected 
effects in medical records. This indicates some cognitive dissonance amongst 
reporters who report to the YCS yet did not make contact with their HCP to get 
their medical records updated. These findings may be explained by issues of 
accessibility or time constraints with HCPs.  It may also be related to dismissive 
attitudes among HCPs towards SE.    
YC reporters and reports 
This study found that patients had specific issues including concerns about HCPs. 
Just under 10% reported negative experiences with HCPs with 4% disagreeing 
with the diagnosis and/or treatment. Previous YC research supports these findings 
± 8% of reporters to the YCS described dismissive attitudes to ADRs amongst 
HCPs with 4% of patients stating a HCP had refused to make a report when 
requested (Avery et al., 2011). These negative HCP interactions are an important 
finding as 33% of reports described interactions across a range of HCPs: GPs 
(17%); pharmacists (4%); hospital admissions (4%) and multiple HCP contacts 
(14%). Engaging with HCPs is a key component for many patients who 
experience SE. Therefore, this may be a useful result in indicating a focus for 
future research.  
Previous YC research identified that many patients reported their ADRs for 
altruistic reasons (Avery et al., 2011). Research in the Netherlands found that over 
90% of patient reporters expressed altruistic motives for reporting ± to share their 
experience, prevent harm to others and benefit research (Van Hunsel et al., 2010). 
A later review of the factors which influence patient reporting in the UK, 
Australia and the Netherlands found that altruism was identified as the primary 
motivation to report in 21 studies (Al Dweik et al.,2016). This research study 
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found that the altruistic motivations which underlined reporting to the YCS were 
described in 4% of reports. These findings support previous research - that in 
common with other patient reporters YC reporters also wish to share their 
experiences and prevent others from suffering similar reactions (Al Dweik et al., 
2016).   
A characteristic identified by this study were the reports which included 
supporting evidence in the form of medical documents, letters, photos (1%). 
Advice was requested by 2% of reports and was frequently linked to severe 
effects. Research has illustrated the advantages that accrue in adaptive health 
behaviours when effective feedback is provided to patients (Morrison et al., 2014; 
Pu et al., 2015). This indicates the importance of developing appropriate feedback 
channels for YC reporters ± further research is required to identify the benefits of 
such tailored feedback which was found to be desired in the evaluation of patient 
reporting (Avery et al 2011). 
Individual free text narratives 
A novel finding of this study was the results of the template analysis undertaken 
of selected narratives. The focus was to explore and conceptualise the relationship 
between YC reporters and the multidimensional impact of SE. Five major themes 
were identified: reconstruction; impact of SE; coping; attitudinal change and 
meaning seeking. 
Reconstruction of SE event 
Research has proposed that memory retrieval is a process of reconstruction greatly 
influenced by cognitive schema. These schemas affect both memory encoding and 
retrieval processes (Bower et al., as cited in Chan et al, 2009). An interesting 
finding was the subthemes of description and evaluation that occurred as part of 
the reconstruction of SE.  Reporters frequently used their cognitive schema to 
evaluate their effects as they retrieved the SE event from their stored memory. 
This raises the issue that this process of reconstruction may be strongly influenced 
by mental representations such as illness beliefs/attitudinal changes. This suggests 
WKDWUHSRUWHUV¶DFFRXQWVVKRXOd be considered as the filtered output of memory 
retrieval which may not accurately reflect the actual SE event.  However, it can 
also be argued that these additional schemas are essential for comprehensive 
reconstruction of the SE event and can result in informative and comprehensive 
narratives.  
Multidimensional impact of SE 
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As expected there was a sense amongst reporters that SE could negatively impact 
RQPDQ\DVSHFWVRISDWLHQWV¶OLYHV([DPSOHVRIDGYHUVHSK\VLFDOSV\FKRORJLFDO
social and economic effects were related. Previous research supports these 
findings with patients describing physical, psychological and social effects as 
distressing and persistent in nature (Avery et al., 2011; Judd et al., 2014). These 
findings are also consistent with the Interview findings in Phase Two of this 
study. Interviewees described the significant and debilitating impact of SE on 
their lives. An interesting finding was the emphasis that was placed on the 
negative effects on family life. This focus was apparent for all reporters and may 
be characteristic of severe reports in general. It suggests possible avenues for 
future research as impact on family life may be a key component in assessments 
of severity.     
Coping with SE 
As expected effective coping strategies amongst YC reporters are primarily 
composed of both cognitive and behavioural responses. These strategies included 
information seeking, social support seeking and non-adherent behaviours. 
Previous research supports this pattern of coping with social support seeking and 
information seeking being common coping strategies (de Smedt et al., 2009; de 
Smedt et al., 2012). 
Seeking meaning 
An interesting finding from these narratives was the process of seeking meaning 
and understanding SE. Reporters identified essential components such as 
clarifying/making sense of their SE event, re-establishing control and accessing 
feedback. This desire to re-establish control is supported by previous research. 
The health locus of control is an important element in theories of health 
behaviours. Its three dimensions are internal locus, external (others) and external 
(chance) loci (Levenson, 1974; Wallston et al., 1978). Research has established 
that a strong internal locus is related to positive health behaviours, while the 
chance locus is related to maladaptive health behaviours (Grotz et al., 2011; 
Sarafino, 2002). Some YC reporters indicated their desire for feedback stipulating 
that this desire had motivated them to report. The narratives also illustrated that 
reporters who did receive feedback via the YCS found it beneficial and often 
expressed gratitude for the contact. As mentioned effective feedback has been 
found to contribute to positive health behaviours (Morrison et al., 2014; Pu et al., 
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2015). The importance attached to sense making processes across reporter types 
suggest an area for future research.   
Attitudinal change 
Reporters frequently indicated that their health beliefs and perceptions were 
affected by their SE experience. Changes occurred in their attitudes towards their 
medication, their confidence in ability to manage side effects and their perceptions 
about their general health. The narratives suggest that these changes might be a 
cconsequence of negative interactions with HCPs. These findings of attitudinal 
change are supported by the interview findings from Phase Two of this study. As 
mentioned the findings from earlier phases will be compared to the YC findings in 
the following chapter.  
 
4.6 Strengths and Limitations 
Overall the objectives for this phase of the study were largely met: 
 The free-text comments of YC reports were investigated. 
 When the information was available within the YC reports, analysis identified the 
different sources of information used by YC reporters and their assessment of the 
value of these sources.  
 When the information was available within the YC reports, analysis identified the 
LPSDFWRI$'5VRQSHRSOHV¶GDLO\OLYHVDQGWKHFRQVHTXHQFHV of ADRs on 
medicines use in a large sample of YC reporters.  
A considerable strength was the use of a previously untapped resource, the free text 
comments from YC reports. These findings proved that the comments were valuable 
sources of information that contribute novel findings to the body of health research. 
Another advantage of this research is that it has highlighted numerous areas which merit 
future research ± such as the role of feedback; positive HCP interactions and non-
adherence. The large number of reports ensured a large sample size which contributed to 
the statistical power of the findings. The main limitation of this phase was time constraints 
which impacted negatively on the scope of the analysis. Data were available on the 
reaction outcomes, the duration of the reaction the method of administration, where the 
patient obtained the drug and in VRPHFDVHVGHWDLOVRIWKHSDWLHQW¶VPHGLFDOKLVWRU\
Analysis could have been conducted to identify associations between specific drugs and 
reaction outcomes, reaction duration and drug administration. Future research could be 
undertaken which could investigate potential relationships between medical history and 
reaction outcomes and reported severity of SE. In addition the free text comments are a 
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rich data source which could be subjected to future analysis. This might include creating 
narrative profiles for specific drug types; reaction outcomes and reaction types. The 
application to access YC data and the demands of working with the large dataset all 
contributed to these time pressures. A large component of this phase involved qualitative 
analysis which may have been subject to researcher bias. However, attempts were made to 
address this possible limitation through techniques such as inter-rater coding. 
       
4.7 Summary 
YC reports were examined to gather information on how YC reporters identify and manage 
their SE. In addition to quantitative analysis of the reports, this phase of the study focused 
on the novel use of free text in YCs to examine SE experiences.    
 Quantitative analysis of the 2285 reports was divided into description of YC 
reports; causative drugs; identification of SE; impact and SE behaviours and outcomes. 
Some key findings are as follows: most YC reports for females; patient reports; commonly 
one drug with one/two effects; linked to CNS drugs. Severity levels do not increase with 
number of drugs; not linked to unresolved outcomes; linked to CNS drugs.  
 The in-depth qualitative analysis of free text comments illustrated their value as 
sources of information about the SE experience. Thirteen hierarchical categories were 
identified with the main categories being identification of SE, management, impact and 
consequences of SE 
 Individual narratives provided details on the multidimensional impact of SE. Five 












































The primary purposes of this PhD study were to explore how people identify and 
manage SE from their medicines and examine the impact and consequences these 
SE have in their lives. An explanatory mixed method design was used to address 
the range of research questions in varied ways. This approach was chosen so that 
data could be generated from different sources and subjected to different analysis.  
Phase One of the study involved the development of a questionnaire to gather 
JHQHUDOLQIRUPDWLRQRQSHRSOHV¶H[SHULHQFHVRI6(DQGUHFUXLWSRWHQWLDO
interviewees for Phase Two. For Phase Two a phenomenological approach was 
selected to explore the opinions and experiences of people who had recently 
experienced a SE, through in-depth interviews. Phase One and Phase Two of the 
study overlapped and analysis of the interviews from Phase Two informed the 
following phase ± Phase Three. For Phase Three a novel assessment tool for the 
general public to use to assess suspected side effects was developed, the Side 
Effects Patient Assessment Tool (SE-PAST). This assessment tool was validated 
amongst members of the general public known to have experienced side effect(s) 
and in a larger online population. Finally, in Phase Four data was elicited from a 
large sample of YC reports - submitted to the YCS by patients, parents and carers. 
7KLVSKDVHSURYLGHGIXUWKHULQVLJKWLQWRSHRSOHV¶H[SHULHQFHVRI6(DQGH[DPLQHG
the potential value of data within YC reports from non-HCPs. It also facilitated 
comparison of YC reporters and the wider general public. 
Health research has slowly come to recognise the potential of a patient-centred approach 
which moves past the clinical aspects of SE. There is genuine value to be gained by 
exploring the alternative viewpoint that patients can provide to SE reporting. As part of 
WKLVWKHVLVDOLWHUDWXUHUHYLHZZDVFRQGXFWHGZKLFKH[DPLQHGFXUUHQWUHVHDUFKRQSDWLHQWV¶
identification and management of SE. This review avoided repeat of the literature and 
identified a lack of knowledge surrounding how people cope with and manage SE. This 
study attempted to address these deficits. A mixed methods study, which used data from 
multiple sources, was employed to explore the following key areas:  KRZSDWLHQWV¶
H[SHULHQFH6(DQGWKHSHUVSHFWLYHVRISDWLHQWUHSRUWVKRZ6(LPSDFWRQSDWLHQWV¶OLYHV
KRZSDWLHQWV¶FRSHZLWK6(ZKDWLQIRUPDWLRQVRXUFHVDUHXVHGE\SDWLHQWVWRLGHQWLI\6(
and finally, the value of a cDXVDOLW\DVVHVVPHQWWRROIRUSDWLHQWV¶XVH7KLVVWXG\XVHGD




comparing noteworthy results from the four phases of the study, and describes how they 
answer the research questions. 
 
8.2 Primary findings  
The principal findings of this study relate to the complexity of SE and the need to 
conceive of SE as distinctly subjective experiences. The thesis provided a unique 
DQGLQVLJKWIXOSHUVSHFWLYHRQSDWLHQWV¶SHUVRQDOH[SHULHQFHVRISE. It found that 
6(FDQIUHTXHQWO\KDYHRYHUZKHOPLQJLPSDFWVRQPDQ\DVSHFWVRISDWLHQWV¶OLYHV
Descriptions of adverse physical, psychological, social and economic effects were 
provided across all phases of the research.  
This study also provided information on the strategies employed by patients to manage SE. 
These strategies varied greatly and included both cognitive and behavioural responses such 
as non-adherence; HCP consultation; seeking information from a range of sources and 
seeking social support. Decisions made by patients were influenced by a range of factors 
including established health beliefs; previous SE experiences; cognitive biases; perceived 
sHYHULW\RI6(LQGLYLGXDOV¶FRSLQJVW\OHVDQG+&3LQWHUDFWLRQV 
As expected the study data showed that females and older patients were more likely to 
have experienced SE and also more likely to report them as severe. These findings are 
consistent with previous research and indicate some of the healthcare challenges faced by 
policy makers. The UK population continues to age with 18% aged 65 years and older 
(Office for National Statistics, 2016).  Aspects of this ageing population are the 
corresponding increases in multimorbidity and polypharmacy which in turn leads to 
increased risks of SE in older patients. The implications of these findings are discussed 
further in Section 8.6. Research into gender differences have indicated that females 
frequently use data more comprehensively than males. In stressful situations ± such as 
experiencing SE ± females engage in more extensive cognition than males who tend to rely 
more on heuristics when assessing stimuli/cues (Meyers-Levy & Loken, 2015). These 
studies have also found that females are more likely to express anxiety/fear and also report 
more physical symptoms and psychological distress than males (McLean & Anderson, 
2009; Meyers-Levy & Loken, 2015). Electrophysiological research into gender differences 
in attentional processing suggests that gender could be an important factor in regulating 
attentional biases. Females showed greater engagement with and more elaborate 
processing of threat-related stimuli (Pintzinger et al., 2017). These findings are supported 
by the study data as female respondents were more likely than males to have experienced 
SE and also more likely to report them as severe. It is suggested that gender differences in 
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SE experience could be influenced by the different cognitive resources which females 
allocate to processing their SE (Thompson et al., 2016).  Research has also identified 
gender differences in relation to pain with pain-related health conditions and symptoms 
more frequent in females than males (Fillingim et al., 2009; Vambheim & Flaten, 2017).  
A pattern of medicine use was evident in YC reports and users of the SE-PAST.  The 
majority of YC reports were for one drug regardless of gender or age, with most reports 
being linked to CNS, infections and CV systems. SE-PAST respondents most commonly 
reported causative medicines linked to CN and CV systems as well as Infection drugs. 
These findings have implications for prescribers and are discussed in Section 8.6  
There were also several key findings related to the type of information sources patients 
used to identify SE and their assessment of these sources. GPs and PILs were identified as 
the most commonly used sources in general, irrespective of coping styles. GPs were 
assessed as the most trustworthy and PILs as the most accessible sources respectively. This 
study indicated that a hierarchy of source characteristics could exist, where individual 
components such as accessibility, trustworthiness, ease of understanding and relevance are 
ranked in importance by patients seeking health information. The data also suggested that 
predominantly positive assessments of pharmacists were not reflected in their actual use as 
information sources. Just 28% of survey respondents used pharmacists to find out about the 
SE. These findings on information sources present opportunities for future research and are 
discussed in Section 8.8.  
 
8.3 Addressing the research questions 
The central research question of this study was:  
How do people identify and manage ADRs from their medicines and what impact 
and consequences do these ADRs have in their lives? 
This was developed into four sub-questions: 
1. What are the personal experiences of people in managing ADRs? 
a. What are the impact(s) and consequences of their ADR experiences? 
b. What coping strategies do people use when they experience ADRs? 
2. What types of information sources do people use to find out about ADRs? 
a. What are the factors contributing to the use of these different 
information sources? 
3. What would be the essential characteristics of a reliable assessment tool 
for patients to use to assess ADRs? 
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a. Would patients consider such an assessment tool to be valuable and 
useful to them?    
4. What is the value of patient reports within pharmacovigilance?  
a. Are there differences between people who report ADRs and the 
general public in terms of impact of ADRs and information sources 
used? 
 
What are the personal experiences of people in managing ADRs? 
There were important findings about the SE experience across the phases of this study. A 
pattern of multiple medicine use was evident in both survey and SE-PAST respondents. 
Overall medicine use increased with age among survey respondents ± over 30% of those 
aged 61-70 used five-eight medicines, increasing to over 40% of those aged 71-80 years 
and 50% of those over 80.  Survey data indicated that the majority ± over 70% - who had 
experienced one or more SE used more than one medicine, while 65% of SE-PAST 
respondents used more than one medicine. Analysis of YC reports added to this 
information and indicated that reports linked to CVS drugs increased for older age 
categories. This finding is not unexpected as CVS drugs are the most commonly prescribed 
medicines for older patients. Similar proportions of CNS drugs were evident across age 
categories - indicating widespread use for a variety of conditions.  
The data collected from SE-PAST respondents and YC reports also indicated a pattern of 
causative drugs. The most commonly reported causative drugs by online respondents to 
SE-PAST were CNS, cardiovascular system and infection medicines. Similarly, most YC 
reports were linked to CNS, infections and CV systems. There were important findings 
concerning knowledge about causality ± linking confidence in causality to use of 
information sources and medicine use. Analysis of survey data indicated that using 
multiple information sources could increase confidence in causality assessment. YC 
reports linked certainty about causality to number of drugs, with nearly half of reports 
describing one/two effects which were linked to one drug. In addition, the finding that 95% 
of YC reports overall cited only one drug suggests a degree of certainty in identifying a 
causative drug among this population, regardless of the number of symptoms reported. 
Data from SE-PAST respondents confirmed this link, displaying decreased causality 
knowledge with increased medicine use.  
An overall profile of effects was found across the study phases which indicated that the 
most common effects were physical.  Over 80% of survey and SE-PAST respondents 
described the physical effects of SE, while over 90% of YC reports described physical 
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effects. The most frequently reported effects in both survey responses and YC reports were 
pain, abdominal discomfort, headache and fatigue.   
In terms of severity, data from survey, SE-PAST respondents and YC reports 
suggested that severe SE were most commonly reported for females and older 
patients. These findings supported previous research but also provided additional 
information on the association between SE severity and coping style. Analysis of 
the survey data demonstrated that more Monitors ± over 50% - reported their SE 
DVµXQSOHDVDQW¶than either of the other two coping styles.  
The impact of nocebo and placebo susceptibility amongst survey, SE-PAST 
respondents and YC reports should also be considered. Nocebo and placebo 
effects are generally defined as a worsening or improvement in clinical symptoms 
in response to the administration of an inert substance. However nocebo and 
placebo effects are also used to describe unexpected reactions to active 
medicine/treatments which are not linked to the pharmacological action of the 
medicine/treatment (Dodd et al., 2017). These effects occur within a physiological 
and psychological context - psychological mechanisms include expectancy and 
classical conditioning. (Belcher et al., 2017). Respondents susceptible to these 
effects might experience an unexpected reaction/nocebo response to their 
medicine. These responses could be the result of expectations created by their pre-
existing health beliefs or direct information they received prior to taking their 
medicine/reporting their SE (Dodd et al., 2017). Placebo and nocebo research has 
suggested that medication information from PILs, could LQIOXHQFHSDWLHQWV¶
expectations and cause the nocebo effect (Schmitz et al., 2017; Tan et al., 2014; 
Verdu & Costello, 2004). Nocebo effects can also occur when patients experience 
an association between their medicine and previous negative experiences (Dodd et 
al., 2017). Adverse effects such as SE which are purely symptomatic can therefore 
be difficult to verify at an individual level in patients, as they may be nocebo 
effects (Chavarria et al., 2017).  
 
What are the impact and consequences of their ADR experiences? 
 Data from all phases of this study add considerably to research findings 
concerning the impact of SE. Analysis of survey and SE-PAST data showed that 
IHPDOHVZHUHPRUHOLNHO\WRGHVFULEHWKHLPSDFWRQ4'/DVµVHULRXV¶¶VHYHUH¶$
majority of survey respondents focused primarily on the physical impact of SE ± 
over 80%. Psychological and social effects were less frequently described, by 
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12% and 10% respectively. These findings from the general public can be 
compared with YC reports, many of which provide more detail of the SE 
experience. A majority of YC reporters also described physical impacts, but 
higher proportions of reports described both psychological (24%) and social 
impacts (34%). In particular, a combination of physical, psychological and social 
impacts was reported by many carers (just under 30%). This finding suggests that 
carers could provide a comprehensive insight into the complexity of SE. It also 
provides support for the potential benefits of carer engagement in reporting SE. 
Most of the physical effects in YC reports were linked to GI drugs, while the 
combination of physical, psychological and social impacts was most common in 
relation to CNS drugs. This is supported by SE-PAST data which linked 
severe/moderate impacts to CNS and CVS medicines. 
When interview data and YC reports are compared, similar examples of adverse 
and debilitating physical, psychological, social and economic effects are found. 
Data from interviewees and YC reports suggest that a wide range of SE had both 
explicit and implicit impact on their lives. For interviewees, the explicit impact 
was primarily related to physical symptomology such as stiffness, headaches, or 
rashes. They also linked their SE to explicit economic impacts. The implicit 
impact of SE was linked to psychological effects which were described as less 
obvious but significant in impact. A combination of explicit and implicit impacts 
was also described in the majority of YC reports ± over 90%. These included 
physical, psychological and social effects which could result in serious disruption 
to many aspects of patiHQWV¶OLYHV$VWULNLQJILQGLQJZDVWKHDGGLWLRQDOGHWDLO
supplied by YC reports on the prolonged consequences of effects for patients (just 
under 20%). These included persistent negative physical, psychological, social 
and life changing effects. 
Both the survey and YC reports also provided consistent findings on the 
consequences of SE. Analysis of survey and YC data showed that females and 
older respondents were more likely to experience negative consequences. Survey 
respondents with monitoring coping styles were also more likely to require a GP 
visit/hospitalisation. Data from YC reports indicated that severe SE resulted in 
negative consequences such as incapacity, hospitalisation and life threatening 




What coping strategies do people use when they experience ADRs? 
A pattern of coping styles was identified in survey respondents and YC reports. 
Data were obtained from survey respondents about predicted coping strategies 
such as information seeking, social support seeking and non-adherent behaviours, 
from the amended SECope scale. The findings suggest that the most frequent 
predicted behaviours were based on positive information seeking strategies in 
around 70% of respondents, but also negative adherence strategies in almost 40%. 
Moreover, a majority of respondents who predicted non-adherence engaged in 
actual non-adherence behaviours. Those with monitoring coping styles were more 
likely to engage in non-adherent behaviours than those with other coping styles. 
These findings contrast with YC reports - coping strategies were described by just 
over 40% of YC reporters. Just under 10% of YC reports described information 
seeking behaviours across a range of sources which included HCPs, 
family/friends and the Internet. Non-adherent behaviours ± stopping/reducing 
medicines - were described in just under 20% of reports. This difference can be 
explained since the survey specifically sought information about coping strategies, 
while there is no requirement to provide information on YC reports. It is thus 
possible that coping strategies such as seeking information/social support were 
used by the YC reporters but not specifically reported. However these findings 
could also indicate a difference in coping strategies between people who report 
ADRs and the general public, with more YC reporters engaging in non-adherence 
behaviours.   
The 0LOOHU¶V0RQLWRULQJDQGEOXQWLQJPRGHORIFRSLQJ is based on categorisation of coping 
behaviours (Miller, 1989). The MBSS was used to categorise survey respondents into those 
with monitoring, blunting and neutral coping styles and blunting coping styles. However 
there are disadvantages to taking this approach as coping styles can frequently exist along a 
FRQWLQXXPUDWKHUWKDQDQµDOO-or-QRQH¶SKHQRPHQRQZLWKGLVWLQFWSDUDPHWHUV5RVVOHU
2013). It should also be acknowledged that coping styles are not stable across situations 
and DQLQGLYLGXDO¶VFRSLQJVW\OHcan change over time and particularily with context. The 
MBSS measures coping with scenarios that differ in their predictability and perceived 
controllability.  Research has found that situations with a combination of high 
predictability and high controllability promote monitoring behaviours while those with low 
predictability and controllability promote blunting behaviours (Van Zuuren et al., 1996 as 
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cited in Bijttebier et al., 2001).  A conceptualisation of coping styles as a continuum of 
behaviours may address the disadvantages associated with a categorial approach to coping. 
Qualitative analysis does suggest that there could be a pattern of coping strategies 
specific to YC reporters. In order to find meaning and understand the SE 
experience so they could report it, it was necessary for reporters to engage in 
appraisal and coping processes. Reporters described factors such as 
clarifying/making sense of their SE event, re-establishing control and accessing 
feedback. These cognitive and behavioural factors suggest a link to Lazarus and 
Folkman's theory of Stress and Coping (Lazarus & Folkman, 1984). This theory 
identifies coping as a response to stress - stress-related problems lead to coping 
strategies which are influenced by personal and environmental factors. Within this 
theoretical framework stressful events trigger appraisal and coping processes 
which can vary greatly across patient groups. The coping process is composed of 
problem focused actions and emotion focused actions. These findings have 
implication for HCPs and are discussed further in Section 8.6.  
 
What types of information sources do people use to find out about ADRs? 
Phases One, Two, Three and Four elicited important findings on the information 
sources that patients use and the factors that contribute to their use. Analysis of 
survey and interview data show that factors such as the timing of the side effect, 
eliminatory thinking, previous health experiences and knowledge (from a range of 
sources) were used to identify SE. A similar use of timing relationships is evident 
in YC data - the most common method of identifying SE was related to the timing 
of effects. These findings reflect previous research which established that patients 
use temporal associations to link the medicine to SE.   
Acquisition of knowledge through a variety of information sources was 
investigated amongst survey respondents, interviewees and YC reporters. This 
resulted in novel findings with regard to information sources, as it can be 
acknowledged that differences exist between people who report ADRs and the 
general public.  
Survey and interview data found that HCPs or PILs were most commonly used to confirm 
SE. This contrasts with surprisingly low use of HCPs or PILs by YC reporters, although 
these were the most commonly cited methods. Again, one possible explanation might be 
that these sources were used but not reported. An interesting finding was that multiple 
sources were reported as being used by YC reporters, which was also noted in survey 
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respondents, 52% of whom used multiple sources to confirm causality. From analysis of 
the survey data a picture of predicted use and actual use of information sources was 
created. The majority of survey respondents maintained their predictions and actually used 
*3VDQG3,/V7KLVUHIOHFWHGWKHUHVSRQGHQWV¶DVVHVVPHQWRI*3s as the most trustworthy, 
and easy to understand information sources; with PILs as the most accessible source. Both 
survey respondents and interviewees had reservations about the Internet and considered it 
the least trustworthy source, although it was used by a high proportion of respondents in 
practice, probably due to its accessibility. Interview data added depth to this pattern of 
Internet use and showed that specific sites ± such as NHS Choices 
(http://www.nhs.uk/pages/home.aspx)- were deemed high in quality and therefore 
trustworthy sources. Interestingly, a low proportion of YC reporters (7%) cited using the 
Internet to confirm their SE. High proportions of survey respondents assessed pharmacists 
as trustworthy and easy to understand. These findings are supported by previous research - 
however, an important finding was that the positive assessments of pharmacists across the 
four source characteristics did not correspond with actual use (under 30%). This indicates 
that perceptions of information sources can be very influential factors in source selection. 
These perceptions may in turn be mediated by a hierarchical order of characteristics. 
Pharmacists were not used - despite positive assessments - however, PILs which received 
mixed assessments were actually used by a majority of survey respondents. These findings 
have implications for future research and are discussed further in Section 8.7.   
 
What would be the essential characteristics of a reliable assessment tool for 
patients to use to assess ADRs? 
This study developed and validated a novel assessment tool ± the SE-PAST - for the 
general public to use to assess suspected SE. A theoretical framework is provided by the 
Self-Regulation Model/CSM. It is based on survey and interview data with additional 
criteria data from the Thai questionnaire (Jarernsiripornkul et al., 2015) and the gold 
standard Naranjo algorithm (Naranjo et al., 1981). As outlined in Chapter Two there are 
some existing assessment tools for patients to use to assess SE causality. A patient-reported 
adverse drug event (ADE) questionnaire intended for postmarketing studies and clinical 
trials was developed by researchers in the Netherlands (De Vries et al., 2013). A 
questionnaire for patient self-assessment of ADRs was later developed and validated in 
Thailand (Jarernsiripornkul et al., 2015).  
Structure of assessment tools 
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These three instruments were based on previous research and existing questionnaires. In 
addition all were developed with iterative processes and patient input. Both the ADE 
questionnaire and the Thai ADR questionnaire used expert opinion to assess the 
instruments.   
The ADE questionnaire was composed of four sections: 
Section 1 - questions about general patient characteristics. 
Section 2 ± questions about drug use in the past 4 weeks, details of diseases for which 
drugs were used and any other diseases. 
Section 3 ± checklists for ADEs experienced in the past 4 weeks. 
Section 4 - GHVFULEHWKH$'(LQWKHSDWLHQW¶VRZQZRUGVDQGTXHVWLRQVDERXWQDWXUHDQG
causality of ADE. ADEs coded according to body categories. 
This structure led to some problems ± the main one was over reporting of ADEs. The 
checklists created confusion in respondents as there was no distinction between related and 
unrelated ADEs. In addition the recall period for ADEs ± set at four weeks ± was identified 
as too short and insufficient to capture ADEs that vary over time.  
The Thai ADR questionnaire was composed of two sections as follows: 
Section 1 - Questions to obtain demographic data on gender, age, education level, career 
and income, plus an additional question to obtain information on underlying chronic 
diseases. 
Section 2 - Details of ADR experiences were sought and a checklist of information sources 
used to confirm suspected ADR. Open and closed questions were used to obtain details of 
timing, symptoms, causative medicines, severity and confidence in causality. Drugs  
were classified according to anatomical therapeutic chemical classification system (ATC) 
and ADRs were classified by system organ class (SOC) according to MedDRA 
terminology. 
The majority of respondents were able to complete the questionnaire without assistance. 
The instrument had some of the characteristics essential for an effective tool. Its structure 
ensured it was clear, consistent and easy for patients to use. A large amount of detailed 
information was gathered on ADR experiences, use of information sources and causative 
drugs. However no weightings were given to the causality assessment tool, in contrast to 
standard methods, such as the Naranjo method, on which it was based. 
As described in Chapter Six the SE-PAST was composed of two sections: 
Section A ± questions to obtain background information including demographic 




Section B ± the Assessment Tool (ten item scale), Scoring Box, which used weightings for 
key items, and SE Probability Key. Additional information about the four causality levels 
was provided, accompanied by advice for respondents. 
This structure ensured the instrument was simple, easy to use and helped achieve study 
objectives. It assisted respondents to fully recall a particular event - their SE - before they 
assessed it using the AT. A majority of respondents found the SE-PAST useful, but also 
indicated that it was potentially helpful ± it would encourage them to report their side 
effect or talk to a HCP about it.  
Validation of assessment tools 
These three instruments were validated using different methods. Cognitive debriefing 
interviews of twenty-eight patients were used to test the content validity of the ADE 
questionnaire. Tests of feasibility and reliability were also conducted ± however problems 
with low kappa values arose as a result of an unbalanced sample. A clearer analytical 
picture was gained by reporting of the proportions of positive agreement. The researchers 
concluded that the ADE questionnaire was not a reliable instrument. It was suggested that 
improving the questionnaire could increase reliability. 
 The Thai ADR questionnaire was validated by HCP experts with experience of ADRs 
identification and reporting. Index of consistency (IOC) scores were generated by these 
raters to assess content validity. The IOC scores were considered acceptable and an overall 
indication of good content validity.  
Initial and online validation of the SE-PAST involving people with ADR experiences 
indicated good face and content validity.  Exploratory factor analysis was conducted to 
investigate the factor structure of the instrument and correlations between its variables. 
PCA and parallel analysis identified the number of factors/components and which 
variables were linked to these factors/components. The PCA was deemed effective as the 
criterion of 5-10 respondents per statement was met. $ORZ&URQEDFK¶VDOSKD- below 0.7 ± 
was obtained suggesting poor construct validity. However the SE-PAST assessed the 
probability of SE for respondents. It gathered information on SE ± a defined construct - 
and was not measuring an underlying theoretical trait/construct. This suggests that there 
was no requirement for construct validity for this instrument.  
When the three instruments are critically reviewed it can be argued that more robust 
validation methods were used to assess the Thai ADR questionnaire and the SE-PAST. 
Comparison of the techniques indicate that the assessment of the ADE questionnaire for 
reliability and validity was compromised by its unbalanced sample. Reliability analysis and 
expert raters were employed to validate the Thai ADR questionnaire. This analysis was 
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sufficient to identify the reliable psychometric properties of the instrument. Validation of 
the SE-PAST also included common measures of internal reliability and validity. However 
additional factor analysis furWKHULQYHVWLJDWHGWKHLQVWUXPHQW¶VVWUXFWXUHDQGLQFUHDVHGWKH
robustness of the analysis. Overall the Thai ADR questionnaire and the SE-PAST display 
some of the essential characteristics of a reliable assessment tool. The SE-PAST is shorter 
and is available online with automatically calculated weightings which may be less 
onerous for patients/the public and thus increase its uptake and usability. Unlike the Thai 
ADR questionnaire, it does not contain questions about additional medicines used or 
medical conditions, which could be used by an assessor to help assess causality, but are not 
essential for supporting patients to self-assess. 
 
What is the value of patient reports within pharmacovigilance?  
This study found that YC reports provide a unique and significant perspective on 
SE.  In particular the free text comments are valuable sources of information 
SURYLGLQJYLYLGDQGULFKGHVFULSWLRQVRISDWLHQWV¶H[SHULHQFHVComprehensive 
information is provided which reflects the range and complexity of SE. A pattern 
RIVLJQLILFDQWGLVUXSWLRQWRPDQ\DVSHFWVRISDWLHQWV¶OLYHVKDVEHHQHVWDEOLVKHG
These problems can include prolonged consequences of SE with persistent 
negative physical, psychological, social and life changing effects. Another 
important finding was the subjective experience of SE - many reports described 
severe effects commonly labelled by HCPs as mild. Such findings could indicate a 
disconnect between the perceptions of patients and HCPs in relation to SE 
severity. Analysis of the YC reports suggest they are valuable data sources that 
can contribute to PV and more widely to health research. 
 
8.4 Strengths and limitations 
Health research can produce controversial scientific evidence however the great 
benefit of such evidence is that it can be both checked and challenged. A 
fundamental strength of this study is that it provides information on side effects 
from medicines which can be examined and assessed for reliability. It is perhaps 
LQHYLWDEOHWKDWWKLVVWXG\ZDVLQIOXHQFHGE\WKHUHVHDUFKHU¶VSHUVRQDl 
characteristics, previous experiences and knowledge. Attempts were made to 
minimise this researcher bias by a basic strategy of systematic study design. Study 
records and documentation of the analytical processes were carefully maintained 
throughout the research. In addition, collaboration with supervisors throughout 
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this study ensured rigour and lessened bias. The studies within this body of work 
have several limitations, but also many strengths, which are described within 
Chapters Four to Seven. A significant strength of the overall thesis was its 
explanatory mixed method design that combined the strengths of both qualitative 
and quantitative research. This design also enabled the triangulation and 
confirmation of results across the different phases of the study. Overall this study 
contributes to the knowledge surrounding how people cope with and manage SE. 
There are no published studies which have explored this topic through thematic 
analysis of free text comments from YC reports. This PhD study also developed a 
reliable assessment tool for assessing SE, specifically designed for patient use. 
The most significant limitation of this study was the problem of self-selecting 
bias. The respondents who chose to participate in Phases One, Two and Three, 
may have been particularly interested in SE. Their high levels of interest in the 
research topic may not have represented the opinions and experiences of the wider 
general population and contributed to a high proportion of survey respondents 
being categorised as Monitors.  In addition the opinions and experiences of HCPs 
in relation to SE were not sought which could have resulted in a limited/skewed 
perspective. In Phase One of this study (Chapter Four) the survey was distributed 
in numerous small to medium sized pharmacies. The use of these multiple 
distribution sites across several geographical regions facilitated diversity in the 
data collection. This diversity may have helped to correct self-selection distortions 
and thus generate representative data. In Phase Two (Chapter Five) the interviews 
relied on participants who believed they had experienced significant SE. They 
may have wished to portray their SE as uncommon and their interpretations of 
questions may have been highly subjective. However, the IPA approach to the 
LQWHUYLHZVDFNQRZOHGJHGDQGDOORZHGLQWHUSUHWDWLRQRISDUWLFLSDQWV¶VXEMHFWLYH
experience of SE. The interviews led to interesting results which provided insight 
into how people identify and manage their SE. In Phase Three (Chapter Six) a 
novel causality scale was developed and validated for use by the general public to 
assess suspected SE.  Respondents from this phase confirmed the value of a 
simple, useful assessment tool which could motivate people to report and/or 
discuss their SE with a HCP. In Phase Four (Chapter Seven) a current picture of 
the experiences of SE amongst YC reporters was established. The findings are 
limited to YC reports but developed previous YC research by focusing on in-
depth analysis of free text comments. This analysis was strengthened by using a 
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specifically developed coding frame which revealed the multidimensional impact 
of SE. A wide range of physical, psychological, social and economic issues 
related to SE were identified. This research had incremental value and developed 
previous YC studies. The key strength of the research was the value in including 
SDWLHQWV¶H[SHULHQFHVDQGSHUVSHFWLYHVLQ6(UHVHDUFK 
 
8.5 Novel findings 
$UHYLHZRIWKHOLWHUDWXUHVXUURXQGLQJSDWLHQWV¶H[SHULHQFHRI6(LGHQWLILHG
deficits in knowledge and understanding of the subject. A central aim of this 
thesis was to contribute to current knowledge by providing a more comprehensive 
picture of the side effects experience for patients. The research resulted in several 
novel findings: 
 information on the impact of coping styles on the overall SE experience of 
patients (Phase One) 
 the identification of a pattern of information use across coping styles in 
patients with SE (Phase One) 
 the novel finding on the concept of body awareness in those who have 
experienced SE (Phase Two)  
 the development and validation of a novel causality assessment tool for 
patient use (Phase Three)  
 the novel findings that arose from analysis of the free-text responses in a 
large unselected sample of YC reports (Phase Four)  
 
Coping styles    
The survey phase gathered information on the impact of coping styles on the 
experience of SE. This was facilitated by the use of a gold standard psychological 
scale ± the MBSS ± in a novel population. The results were original findings as 
the MBSS had not been previously used in SE research. It was found that 
respondents with monitoring coping styles perceived greater risks from their SE 
while blunting coping styles were associated with non-adherence to medicines. 
Another important novel finding was that PILs and GPs are influential 
information sources which are commonly used across different coping styles. 
These findings could have implications for effective communication of health 




The interviews identified ERG\DZDUHQHVVDVDNH\SURFHVVLQSDWLHQWV¶H[SHULHQFH
of SE. This is a novel research finding as the concept of body awareness had not 
been previously identified as a significant aspect of ADR research. Interviewees 
who had experienced SE indicated that attending to body signals was an essential 
element of positive self-care health behaviours. This phase of the study found that 
body awareness and an appreciation of how the body reacts in differing 
circumstances is important in the context of SE from medicines. These findings 
suggest that further research should be undertaken to investigate the role of body 
awareness in the SE experience. 
SE-PAST (Side Effects ± Patient ASsessment Tool) 
A review of ADR research was conducted as part of this research and indicated 
the limited numbers of assessment tools for assessing causality available for 
patients. It was suggested that a standardised assessment method could have 
multiple benefits and facilitate improved reporting of SE by patients. A novel 
assessment tool was developed for use by the general public to assess suspected 
SE. This tool underwent two processes of validation ± by people known to have 
experienced SE and further validation in a larger online population. The SE-PAST 
is a novel research instrument which addressed current deficits within patient 
causality tools and had some promising findings for practice. A majority of 
respondents considered it a useful tool which could empower them to discuss their 
experiences of suspected SE with health professionals.  
In-depth qualitative analysis of free text comments  
The in-depth qualitative analysis of free text comments provided novel and interesting 
findings covering identification, impact and consequences of SEs in a large UK-wide 
sample. In general, this study illustrated the value of YC free text as sources of information 
about the SE experience. The findings reflect the range and complexity of SE and 
contribute novel findings to the body of health research. 
 
8.6 Implications for practice and policy 
There are a variety of key stakeholders interested in side effects from medicines ± 
these include policy makers; government agencies; national and international 
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organisations; healthcare professionals; pharmaceutical industry; academic 
researchers and patients who use medicines. These stakeholders have distinct 
perspectives and health research can thus present different implications for them.  
Policy makers and agencies/organisations  
Policy makers focus on improving policy making, by identifying effective 
practice. Agencies and organisations, both national and international - such as the 
MHRA, the Commission on Human Medicines (CHM), the European Medicines 
Agency (EMA) and the WHO - attempt to improve standards and ensure good 
practice. A recent report from the Academy of Medical Sciences has explored 
how to improve the generation, trustworthiness and communication of scientific 
evidence to strengthen its role in decisions by patients about the benefits and 
harms of medicines (Tooke et al., 2017). The concept of patient-centred care has 
been established within the NHS. The Department of Health in England has stated 
that patients should be positively involved in their care ± with access to the 
information they need, greater choice and control over their care and shared 
decision making at the centre of NHS services:  
³7KHV\VWHPZLOOIRFXVRQSHUVRQDOLVHGFDUHWKDWUHIOHFWVLQGLYLGXDOV¶KHDOWKDQGFDUHQHHGV
supports carers and encourages strong joint arrangements and local partnHUVKLSV´ 
 (Department of Health, 2010).  
This research study has explored SDWLHQWV¶SHUVRQDOH[SHULHQFHVRI SE and 
provided a picture on the impact and consequences these SE have in their lives. It 
has demonstrated the complexity of SE and highlighted the overwhelming impacts 
6(FDQKDYHRQPDQ\DVSHFWVRISDWLHQWV¶OLYHV$VSDUWRIWKHµLQIRUPDWLRQ
UHYROXWLRQ¶DGYRFDWHGE\WKH1+6WKLVUHVHDUFKKDVLPSOLFDWLRQVIRUDJHQFLHV
which want to plan and improve quality dialogue with patients and HCPs.  
Patient Information Leaflets (PILs) 
PILs are highly regulated by the EU and the MHRA approves all packaging and labelling 
information for medicinal products sold in the UK (Directive 2001/83/EC).  A review of 
PILs was conducted in 2014 which made a number of recommendations to increase their 
clarity and readability (Van Dijk et al., 2014). These included better guidelines and sharing 
of best practice, increased involvement of patients in developing PILs and an increased 
role for electronic media. It highlighted the improvements in practice made by the MHRA 
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in making good PILs examples - which had been tested by users - available to the 
pharmaceutical industry (Van Dijk et al., 2014). The present research study found that PILs 
are commonly used information sources which were assessed by 80% of survey 
respondents as accessible. However just over 50% of respondents considered that PILs 
were easy to understand and under 50% considered PILs to be relevant to them. These 
findings indicate a significant problem with patientV¶XQGHUVWDQGLQJDQGSHUFHSWLRQVRI
PILs. It supports the previous review which also found that patients had reservations about 
WKHRYHUDOOTXDOLW\RI3,/VDQGFKDQJHVFRXOGEHPDGHWRLPSURYHSDWLHQWV¶XQGHUVWDQGLQJ
of PILs (Van Dijk et al., 2014).  Perhaps more importantly, only 60% of respondents 
considered PILs to be trustworthy, which suggests more work is required to ensure that the 
LQIRUPDWLRQWKH\SURYLGHLVIRFXVHGRQSDWLHQWV¶QHHGV 
The Internet 
The study also found that websites such as NHS Choices which were identified as 
quality trustworthy sources were frequently used by survey respondents and 
interviewees. This study found that many respondents perceived the Internet as 
untrustworthy and were cautious in accessing healthcare information online. 
However more respondents used the Internet to find out about SE than used 
SKDUPDFLVWV7KLVPD\EHUHODWHGWRSDWLHQWV¶SHUFHSWLRQVWKDWWKHLQWHUQHWLVDQ
accessible and relevant information source. These findings indicate that clear risk 
communication could be facilitated by an increased focus on high quality trusted 
sites. A recent report recommended that NHS Choices should be used as a central 
repository of clear up-to-date, evidence-based information on the potential 
benefits and harms of medicines. In addition reputable online information sources 
could facilitate informed health decisions by describing and providing links to 
XVHIXOHYLGHQFHEDVHGGHFLVLRQWRROVIRUSDWLHQWV¶XVH7RRNHHWDO7KH
SE-PAST was identified in this study as a useful assessment tool which can 
facilitate engagement with HCPs and is available in an online format. This finding 
could help to progress these recommendations, prove beneficial to patients and 
assist their active involvement in their healthcare.  
Healthcare Professionals (HCPs) 
There are a number of findings in this study that are relevant to HCPs. A recent report by 
WKH5R\DO&ROOHJHRI*HQHUDO3UDFWLWLRQHUVKLJKOLJKWHG*3V¶FRQFHUQVabout the challenges 
DVVRFLDWHGZLWKDQDJHLQJ8.SRSXODWLRQ3DWLHQWV¶Zith numerous long-term conditions 
can have complicated treatment regimens with multiple medicines. This polypharmacy can 
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in turn lead to increased risks of SE (Royal College of General Practitioners, 2016). This 
research study found that GPs were widely used by the general public but infrequently 
cited by YC reporters as information sources. There were 9% of YC reports which 
described negative interactions with HCPs, including some relating to GPs. The YCS 
provides the opportunity for patients to report their experiences without interpretation by a 
health professional, hence this could be a factor contributing to the low use of HCPs as 
information sources. In contrast, survey respondents assessed both GPs and pharmacists as 
trusted information sources which were easy to understand, although pharmacists were 
used less frequently than GPs to confirm SE  
These findings highlight the important role that HCPs can play in providing accurate, 
consistent and useful health information. A recent report recommended training HCPs to 
ensure they can clearly communicate the potential benefits and risks of medicines to 
patients (Tooke et al., 2017) a need which is borne out by the negative experiences 
described by some YC reporters. The survey also found that using GPs as information 
sources could mediate the influence of coping styles. In general this study suggests that 
comprehensive information for medicine users should include both the risks and potential 
impact of SE from medicines. Although prescribers and dispensers of medicine do have a 
good understanding of adverse effects from medicines, perhaps more in-depth training is 
needed in how to communicate risks more effectively to their patients. Research indicates 
that information about medicines and SE influence how people take their medicines. It is 
essential therefore that the information provided is both accurate and easy to understand. 
Complex health information is more effectively communicated through effective use of 
language ± using simple language and terms (Sawant et al., 2016). Verbal descriptors have 
been identified as a manageable and appealing format for communicating risks from 
medicines to patients. (Berry et al., 2003; Carrigan et al., 2008; Dickinson et al., 2016; 
Knapp et al., 2009). However patients can frequently overestimate the risk of SE by 
misinterpretation of verbal and numerical descriptors (Carrigan et al., 2008; Knapp et al., 
2010). Using frequencies to communicate risks to patients could increase the accuracy and 
effectiveness of SE risk information (Knapp et al., 2009; Knapp et al., 2010). 
Improvements in education and training in patient counselling could therefore address the 
challenges associated with communicating SE risk. The consequences of experiencing 
some ADRs which could have a significant impact on an individual may be more difficult 
WRFRQYH\SHUKDSVQHHGLQJDSHUVRQDOLVHGDSSURDFKDQGDZDUHQHVVRIDQLQGLYLGXDO¶VOLIH
situation. Health services increasingly advocate patient-centred approaches to care, which 
could include information tailored to the individual. Communication training for HCPs 
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which focuses on providing such tailored information would be an evidence based 
intervention with beneficial outcomes for patient-centred healthcare. 
   
Prescribers 
The pattern of medicine use which was evident in YC reports and SE-PAST respondents 
was unsurprising. The most commonly reported drugs were linked to CNS, infections and 
CV systems. These reports reflect a pattern of prescribing in England - NHS statistics 
indicate that the top three system drugs prescribed in the English community in 2015 were 
for drugs in infections; followed by CVS and CNS drugs (NHS, 2016). NHS statistics also 
show that the greatest recent increase in prescribing was for antidepressant drugs. These 
included increased use of amitriptyline, mirtazapine and citalopram. There were also 
significant increases in prescribing antisecretory drugs and mucosal protectants - with 
increased use of omeprazole and lansoprazole. An increased volume of prescribing was 
evident for drugs used in diabetes, with increased use of metformin hydrochloride, 
gliclazide and sitagliptin. Lipid regulating drugs, were also increasingly prescribed with 
increased use of atorvastatin (NHS, 2016). It is reasonable to assume that increased 
prescribing results in more SE and therefore more patient reports. Data from SE-PAST 
respondents and YC reporters suggest that this is indeed the case - the most commonly 
reported drugs included citalopram, omeprazole, atorvastatin and metformin.  
The aging UK population - with its complex prescribing needs - ensure that rational 
prescribing by HCPs is an area of interest in healthcare (Royal College of General 
Practitioners 2016). Research has indicated that GPs must keep up to date on current 
prescribing practice as well as displaying an awareness of their prescribing profile (Vægter 
et al.,2012). These findings indicate that even though drugs are commonly prescribed, their 
impact can be significant ± as was shown in this study. Patient experiences of SE should 
therefore not be dismissed by HCPs. HCPs need to ensure they are aware of potential SE 
and the consequences these may have for their patients, therefore the findings could 
contribute to the education of GPs.  
Pharmacists 
The findings of this study also suggest that patients who experience SE do not use 
pharmacists as information sources as consistently as GPs. NHS policy ± the Five Year 
Forward View ± haVLGHQWLILHGD³KHDOWKDQGZHOO-EHLQJUROH´IRUFRPPXQLW\SKDUPDFLHVLQ
patient-centred healthcare. Progression has been made with a series of practical steps such 
as increasing numbers of clinical pharmacists in GP surgeries, increased use of Medicines 
Use Reviews and Prescription Intervention Services (Twigg et al., 2017). A role has been 
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identified for pharmacists in responding to patients with multimorbidity and complicated 
medical needs. This requires them to be µWUDQVODWRUV¶RIFRPSOH[health information and 
conduct medication reviews in collaboration with GPs (Royal College of General 
Practitioners 2016). However, it is noteworthy from this study that the positive perceptions 
about pharmacists which patients exhibited did not result in actual use. In light of the 
central role which community pharmacies have been assigned in NHS policy this is of 
potential concern to the pharmacy profession and suggests a need for greater publicity 
about how they can support medicines use.     
Academic researchers 
This study is also of potential interest to researchers in the areas of 
pharmacovigilance and medicines information. Unlike many studies, it employed 
a flexible mixed methods approach that combined the strengths of both qualitative 
DQGTXDQWLWDWLYHUHVHDUFKWRFUHDWHDIXOOHUSLFWXUHRISDWLHQWV¶6(H[SHULHQFHVDQG
also involved both YC reporters and the wider population of medicine users. This 
approach resulted in some significant findings and identified several areas which 
require further investigation. It can be hoped that this research study will help to 
increase awareness among health researchers of the multidimensional impact of 
SE; the variation in SE experience for patients and the unique perspective that can 
be gained from patient reports.  
Patients who use medicines 
From the beginning this study sought to place patients and their SE experience at 
its centre. As a result of this patient-centred approach its findings have 
implications for patients who use medicines. Research has identified the 
beneficial health outcomes that result from patient engagement in decisions 
related to their health (Tooke et al., 2017).  A recent study made recommendations 
to support shared decision making about medicine use between HCPs and patients  
(Tooke et al., 2017). These included the development of decision tools/aids to 
assist in the decision making process. This study developed and validated a side 
HIIHFWVDVVHVVPHQWWRROIRUSDWLHQWV¶XVH6(-PAST). Most on-line users of the SE-
PAST agreed it was a useful instrument and would encourage them to report their 
side effect or talk to a healthcare professional about it. These findings suggest that 
the SE-PAST could play a valuable role in helping patients to clarify their 
concerns and priorities in relation to their medicines. It could empower patients in 
their HCP consultations and facilitate genuine shared decision making about their 
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health. It is also noteworthy from this study that the YCS makes a valuable 
contribution to patient wellbeing when they experience SE. This scheme provides 
patients with an opportunity to describe their SE experiences. Research has 
suggested that adaptive coping behaviours can be facilitated/influenced by outlets 
such as the YCS which assist patients in understanding their SE experience 
(Lazarus, 1993;1999). 
 
8.7 Implications for future research 
The findings of this study indicate that further research may be warranted in 
several areas. These include investigation of information source characteristics; 
coping styles; body awareness; SE-PAST; a review of SE impact according to 
established SE profiles and the sense making processes of the SE experience.  
Future research on source characteristics is recommended. Phase One of this study 
indicated that perceptions of information sources can be a key factor in their use. 
The survey data suggested that source characteristics of accessibility and 
relevance can be significant predictors of information use. It was found that 
perceptions of information sources may be influenced by a hierarchical order of 
source characteristics. Further research is required to examine the important 
characteristics of information sources in information seeking behaviours. Such 
research could identify if a hierarchy of source characteristics exists which may 
mediate perceptions. In addition, research is needed to determine how to increase 
the understandability and trustworthiness of PILs from the patient perspective. 
The results of this study indicated that PILs and GPs are information sources 
which are commonly used across different coping styles. Previous research has 
found that providing information to patients which is consistent with their coping 
style can have beneficial outcomes. These findings could therefore have 
implications for effective communication of health information and suggest 
further research is required. In particular, more research involving those with 
Blunting coping styles is required. 
Another focus for future research is body awareness/sensitivity in the context of 
SE. Previous research has identified adaptive body awareness as a response to 
immediate sensations/effects which occurs in combination with non-judgemental 
attention to such effects. The novel interview findings indicate that body 
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awareness is a key process in the SE experience, which merits continued 
investigation. SE could be mediated by adopting a self-focus that directs attention 
to the effects in a mindful, non-judgmental manner. Research therefore could 
examine if mindfulness training in patients who are most likely to experience SE 
could be beneficial.  
The SE-PAST also offers an avenue for further research and development. A 
recent study identified the importance of shared decision making about medicine 
use between HCPs and patients (Tooke et al., 2017). Organisations such as Age 
UK are developing tool-kits for older patients to use in HCP consultations, with 
the intention of facilitating effective decision-making processes. The SE-PAST 
was validated in this thesis as a useful tool which motivated patients to discuss 
their SE with HCPs. It may be a valuable addition to a tool-kit that supports 
shared decision making, contributing to patient knowledge and self-confidence.  
Findings from YC reports indicated that a review of the impact of SE according to 
SE profile could be warranted. Psychological impact was reported for drugs which 
did not specifically describe psychological effects in their SE profiles. These 
reported psychological effects are therefore unexpected and may simply be a 
consequence of illness. Future research could investigate these discrepancies 
between reported effects for drugs and the known safety profiles for these drugs. 
The potential for using material from patient YC reports to contribute to HCP 
education is also worthy of consideration. 
The results of this study found that SE can be a predominantly subjective 
experience, with potential to impact future decisions about using medicines. An 
interesting finding related to the sense making processes which patients engage in 
to facilitate their understanding of the SE experience. This is an important area for 
future research. Further investigation could assist in developing a model of these 
processes and confirm the role of influential components such as re-establishing 
control and beneficial feedback in the SE experience.   
 
8.8 Conclusion  
ADRs are a significant public health problem worldwide, which affect patient outcomes 
and future behaviours. This thesis IRFXVHGRQSDWLHQWV¶SHUVSHFWLYHVLQLGHQWLI\LQJDQG
managing side effects from medicines and its findings have implications for both HCPs 
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and government organisations. The studies which comprise the thesis have provided a 
comprehensive picture of how patients identify, seek to understand and engage in a variety 
of strategies to manage their effects. It has also demonstrated the noteworthy impact which 
6(FDQKDYHRQSDWLHQWV¶OLYHVRIWHQZLWKSURORQJHGFRQVHTXHQFHVHealth professionals, 
particularly GPs, PILs and the Internet are frequently used sources of information about 
PHGLFLQH6(EXWVRPHWLPHVIDOOVKRUWRISDWLHQWV¶H[SHFWDWLRQV7KLVWKHVLVIRXQGWKDWGPs 
and PILs were widely used by the public but less regularly by YC reporters as information 
sources. This frequent use of PILs by the public was notwithstanding their assessment of 
PILs as not relevant or easy to understand sources. These findings indicate that the 
information provided by PILs do not appear to fully address patienWV¶QHHGV,WVXJJHVWV
that changes to PILs may be required to increase the comprehension and relevance of PILs. 
It is also noteworthy that negative interactions with HCPs were described by just under 
10% of YC reporters. Patient engagement in heath decisions requires reliable, clear 
information about the benefits and harms of medicines. The use of a self-assessment tool, 
such as the SE-PAST, could empower patients to have more effective communication with 
HCPs about their SE experiences. Improved communication between patients and HCPs 
could reduce uncertainty and lead to informed choices/decisions by patients. Further 
research is required to establish how best information on SE can be tailored to patients¶
needs and communicated in a clear, consistent, reliable and useful manner and how a 
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APPENDIX 1: Literature searches, search terms and paper selection 
Key search terms and appropriate Medical Subject Headings (MeSH) terms were identified 
by searching relevant ADR research literature. The following words were used as search 
terms: adverse drug reactions; side effects; pharmacovigilance; patients; reporting/patient 
reporting; information sources; causality assessment and patient experience. The MeSH 
WHUPVµFRQVXPHUSDUWLFLSDWLRQ¶DQGµ$'5UHSRUWLQJV\VWHPV¶ZHUHDOVRXVHG. Multiple 
databases were searched: Cochrane Database of Systematic Reviews (CDSR); EBSCO 
Host database (MEDLINE, PsychARTICLES, PsychINFO) PubMed, SAGE Journals 
online and ScienceDirect. 
Search 1      Search 2    
    
 
 





# Searches Results 
1  Adverse drug reactions 79,494 
2 Side effects  10,630 
3 1 AND 2 1,038 
4 Pharmacovigilance 5850 
5 Patient reporting  1328 
6 4 AND 5 116 
7 3 AND 6 60 
8 Kept by title 38 
9 Kept by abstract 4 
10 Included in review 42 
# Searches Results 
1  Adverse drug reactions 79,494 
2 Side effects  10,630 
3 1 AND 2 1,038 
4 Pharmacovigilance 5850 
5 Patient reporting  1328 
6 4 AND 5 116 
7 3 AND 6 60 
8 Information sources  218,512 
9 Causality assessment 720 
10 3 AND 6 AND 7 3 
11 Kept by title 3 
12 Kept by abstract 3 
13 Included in review 3 
# Searches Results 
1  Adverse drug reactions 79,494 
2 Side effects  10,630 
3 1 AND 2 1,038 
4 Pharmacovigilance 5850 
5 Patients 4,877,499 
6 4 AND 5 2622 
7 Causality assessment 720 
8 3 AND 6  44 
9 Kept by title 28 
10 Kept by abstract 28 
11 Included in review 28 
# Searches Results 
1  Adverse drug reactions 79,494 
2 Side effects  10,630 
3 1 AND 2 1,038 
4 Patient Experience 78,340 
5 3 AND 4 393 
6 Kept by title 65 
7  Kept by abstract 65 
8 Included in review 65 
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Your application for ethical approval for the project entitled Validation and testing of an 
assessment tool for use by the general public in identifying suspected side effects from their 
medicines (REF 0116/2) has now been considered on behalf of the Medway School of Pharmacy 
School Research Ethics Committee (SREC).  
I am pleased to inform you that your study will be approved, subject to the following minor 
amendments; 
x A number of the documents show the Birmingham logo, however there is no reference to 
the collaboration with Birmingham within the text of the documents. Please include 
information of the connection 
x The committee felt that destroying the consent forms after one month was too soon. Please 
scan the consent forms on to an encrypted memory stick and keep for 12 months 
x Please explain reason for collating postcode data on the information leaflet or the 
questionnaire 
 
Please resubmit your documents with track changes to J.Mowbray@kent.ac.uk 
 
I must also remind you of the following:  
1. that if you are intending to work unaccompanied with children or with vulnerable adults, 
you will need to apply for a DBS check; the project must be conducted under the 
supervision of someone who has an up-to-date DBS check; you must not be in the presence 
of children alone except if you have completed a DBS check;  
2. that you must comply with the Data Protection Act (1998);  
3. that you must comply throughout the conduct of the study with good research practice 
standards;  
4. If you are completing this project off site, you must obtain prior approval from relevant 
authorities and adhere to the MSOP off site protocol.  
5. to refer any amendment to the protocol to the School Research Ethics Committee (SREC) 
for approval.  
6. You are required to complete an annual monitoring report or end of project report and 
submit to j.mowbray@kent.ac.uk  
 
 
Yours sincerely  
 
 







MHRA 151 Buckingham Palace Road Victoria London SW1W 9SZ United Kingdom www.mhra.gov.uk  
 
 %HUQDGLQH2¶'RQRYDQ 
Sent via email:  
bo77@kent.ac.uk  
Date 14th December 2015  




Application: ACYD042  
 
The Independent Scientific Advisory Committee for MHRA database research (ISAC) considered 
the above application by electronic review. The Committee considered that your application was an 
appropriate use of Yellow Card data and that the proposed methodology is appropriate for the 
objectives of the study. The Committee advised that the application should be granted provided 
you comply with the following conditions:  
,WLVRXUXQGHUVWDQGLQJWKDWWKHWKUHHFRPPHQWER[HVUHIHUUHGWRLQVHFWLRQ'DUHthe narrative, 
reporter comment and free text medical history boxes.  
 
,QDGGLWLRQDV\RXUSURSRVDOZLOOLQYROYHWKHUHOHDVHRI&DWHJRU\,,GDWD,VKRXOGUHPLQG\RXRI
the undertakings you agreed to when you completed the application form. These are included at 
Annex A.  
 
<RXPXVWDELGHE\WKHGuidelines for Safe Disposal of Electronic Yellow Card Data for External 
Users included at Annex B.  
 
3OHDVHQRWHWKHHQFORVHGLQIRUPDWLRQDW$QQH[&RQWKH1DWLRQDO5HVHDUFK5HJLVWHU155:H
strongly recommend that you register with the NRR.  
 
The MHRA has accepted the advice of the ISAC. If you are willing to accept the above conditions, 
please let me know as soon as possible and no later than 28 days after the date of service of this 
letter.  
Yours sincerely,  
Yours sincerely,  
 
Rebecca Owen  
Signal Management Co-ordinatior / Yellow Card Secretary to the ISAC  


















































































































APPENDIX 5: R&D emails 
 km rmgconsortium (MAIDSTONE AND TUNBRIDGE WELLS NHS TRUST) 
<rmgconsortium.km@nhs.net>                                           Fri 05/12/2014 10:02 
Dear Bernadine 
 
 The last thing that we will need before you can start on your research 
project is for us to issue you with a Letter Of Access.  In order for us to so 
this please can you let us have a Research Passport (with DBA and 
Occupational health checks).  Your university HR department will be familiar 
with the Research Passport process & will be able to help you with this. 
  
As we will probably be the first site to review you Research Passport please 
can you supply original copies of all the documents. 




RM&G Consortium for Kent and Medway 
No 6 The Courtyard 
Campus Way 
Gillingham Business Park 
Kent ME8 0NZ 
 
km rmgconsortium (MAIDSTONE AND TUNBRIDGE WELLS NHS TRUST) 




I have looked into this a little PRUH	EHFDXVHRIWKHDEROLWLRQRIWKH3&7·V,
am sorry but we are no longer able to issue Letters Of Access in primary care 
& you will have to ask the pharmacies on an individual basis to do this.  I would 






RM&G Consortium for Kent and Medway 
No 6 The Courtyard 
Campus Way 
Gillingham Business Park 











































































From: Denig, P (med) [p.denig01@umcg.nl] 
Sent: 28 May 2014 20:42 
To: B.O'Donovan 
Subject: RE: Request to use MBSS in PhD project (UK) 
  
Dear Bernadine O'Donovan, 
 
First, my apologies for not reacting sooner. I have asked within our organisation whether there 
would be any restriction regarding the use of our revised version of the SECope questionnaire. As 
far as I understand, there is no restriction. This implies that you are free to use our revised version 
as presented in Table 2 of our publication, using the following reference: Coping with adverse drug 
events in patients with heart failure: Exploring the role of medication beliefs and perceptions.  
De Smedt RH, Jaarsma T, Ranchor AV, van der Meer K, Groenier KH, Haaijer-Ruskamp FM, Denig 
P. 
Psychol Health. 2012;27(5):570-87.  
 
I would, however, be interested in the results from using our revised SECope questionnaire in 
another population. Maybe we could conduct some additional (construct) validity testing together, 





























PARTICIPANT INFORMATION SHEET 
Title of Project: A study exploring how people identify and manage side effects from 
medicines. 
 
Name of Researcher (s):  ĞƌŶĂĚŝŶĞK ?ŽŶŽǀĂn, Dr R. Rodgers, Dr A Cox and Professor J 
Krska. 
 
You are being invited to take part in a study. It is being carried out by the Medway School 
of Pharmacy, University of Kent and the University of Birmingham. You have been chosen 
because you have experienced side effect(s) from your medicine. Before you decide if you 
want to take part, you must understand why the study is being done and what it involves. 
Please take time to read the following information. Ask if anything is not clear or if you 
would like more information. Take time to decide if you want to take part or not. 
 
Why is the study being done?  
This ƐƚƵĚǇŝƐĚĞƐŝŐŶĞĚƚŽĞǆƉůŽƌĞƉĞŽƉůĞƐ ?ĞǆƉĞƌŝĞŶĐĞƐŽĨŝĚĞŶƚŝĨǇŝŶŐƐŝĚĞĞĨĨĞĐƚƐĨƌŽŵ
medicines and an assessment tool has been developed to help people do this. This study 
seeks to confirm the validity of this assessment tool.  
 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. Even if you agree to take part, you 
can change your mind at any time without giving any reason. If you decide not to take part 
in the study, your legal rights will not be affected in any way.  
 
If I do take part, what would I have to do and what would be done to me? 
You will be invited via email to provide feedback on the assessment tool. If you decide you 
would like to do so, you will be sent a copy of the assessment tool by post with a consent 
form and a prepaid envelope. If you agree to take part, you will be asked to sign a consent 
form and return it to the Medway School of Pharmacy in the prepaid envelope. I will contact 
you and arrange a telephone interview at a time and date that suits you. The interview will 
take no more than 30 minutes and you can change your mind and end the interview at any 
time. During this interview I will ask you to review and comment on the assessment tool. I 
will also ask you for any suggestions you may have for its possible improvement. 
 
Are there any risks if I take part? 
The telephone interview will be conducted at a date and time which is convenient for you 
and it will take no more than 30 minutes. There are no risks to taking part in the study. 
 
 
Are there any benefits if I take part? 




We will not tell anyone that you have taken part in the study.  
 
What will happen to the results? 
If you decide to take part in the interview, the information you provide will be treated in 
the strictest confidence in accordance with the Data Protection Act 1998 and used only 
for the purpose of arranging the interview. Consent forms will be scanned on an 
encrypted memory stick and will be held for no longer than 12 months after the 
completion of the project.  Research data will be securely stored in a secure filing cabinet 
and on password protected computers. All the data collected will be fully anonymised 
and digital records will be destroyed five years after the final report has been written. 
This project forms part of a larger PhD project, which will be published as a PhD thesis. A 
ĐŽƉǇŽĨƚŚŝƐƉƌŽũĞĐƚ ?ƐƌĞƉŽƌƚǁŝůůďĞƉƌŽĚƵĐĞĚĂŶĚĚŝƐƐĞŵŝŶĂƚĞĚƚŽƚŚĞDĞĚǁĂǇ^ĐŚŽŽůŽĨ
Pharmacy. The findings will also be disseminated through conferences, and in the writing 
of research papers. 




Who is Organising and Funding the study? 
This study is being carried out by students and staff at Medway School of Pharmacy.  It is 
being funded by the Medway School of Pharmacy, University of Kent.  
 
Who should I contact if I want to know more about the study? 
ĞƌŶĂĚŝŶĞK ?ŽŶŽǀĂŶ 
Medway School of Pharmacy 
Chatham Maritime 
Kent ME4 4TB 
Phone 0163420 Ext 2920 
Email bo77@kent.ac.uk 
 
Who should I contact if I have any concerns about the study or the way it has been 
conducted? 
If you have concerns about how this research study has been conducted please contact 
the Chair of the MSoP Research Ethics Committee on S.A.Corlett@kent.ac.uk 




This project has been looked at and approved by the MSoP Research Ethics Committee 












I found this Assessment tool easy to read. 
Strongly Disagree  Disagree  Agree   Strongly Agree 
                                                                                                                                    
I found this Assessment tool easy to understand. 
Strongly Disagree  Disagree  Agree   Strongly Agree 
                                                                                                                                    
I found this Assessment tool was clearly laid out. 
Strongly Disagree  Disagree  Agree   Strongly Agree 
                                                                                                                                    
I found this Assessment tool had a logical structure. 
Strongly Disagree  Disagree  Agree   Strongly Agree 
                                                                                                                                    
I found this Assessment tool easy to complete. 
Strongly Disagree  Disagree  Agree   Strongly Agree 
                                                                                                                                    









This Assessment tool asks you about your past experiences of side effects. Did you find it difficult 








Are there any suggestions you can make on how to improve this questionnaire? 






















































Dear pharmacist  
PhD project: Exploring how people identify and manage side effects from medicines. 
DǇ ŶĂŵĞ ŝƐ ĞƌŶĂĚŝŶĞ K ? ŽŶŽǀĂŶ ĂŶĚ / Ăŵ Ă WŚ ƐƚƵĚĞŶƚ Ăƚ ƚŚĞ DĞĚǁĂǇ ^ĐŚŽŽů ŽĨ
WŚĂƌŵĂĐǇ ? / Ăŵ ŝŶǀĞƐƚŝŐĂƚŝŶŐ ƉĞŽƉůĞƐ ? ĞǆƉĞƌŝĞŶĐĞƐ ŽĨƐǇŵƉƚŽŵƐ ƚŚĞǇ ƉĞƌĐĞŝǀĞ ƚŽ ďĞ
medicine side effects and how they have identified these as potential adverse drug 
reactions, for example using information in PILs, the internet or from health professionals.  
I am writing to ask if you would kindly support this study in a small way. I have developed 
a questionnaire which I would like to give out to as many people as possible, not just those 
who are collecting prescriptions from pharmacies. A copy of this questionnaire is enclosed 
and an information sheet with more details. Please take time to read this and decide if you 




I will not: 
x Interfere in the day-day running of your pharmacy 
x Coerce any customer to take a questionnaire  
x Access any confidential medical information of any pharmacy customer.  
I have many years of customer service experience within pharmacies and will adhere to 
established research ethical and confidentiality guidelines.  
I will call you within the next week to see whether you are willing to participate. Thank you 
for reading this letter. 

















APPENDIX 11: Topic Guide for interviews 
,QWURGXFWLon ± 5 mins 
[Cover purpose, confidentiality, format, duration and recording of interview; contact 
information; any questions from interviewee.] 
)DFWXDODFFRXQWRIVLGHHIIHFWVH[SHULHQFH± 5 mins 
³6R\RXUHFHQWO\H[SHULHQFHGDVLGHHIIHFWIURPDPHGLcine that you had been 
taking...could you tell me what happened? You were.....(raised questioning tone & 
SDXVH´ 
Cognitive processes involved in identification ± 15 mins 
- Symptoms 
- Timeline 
- Sequence  
- Aided/unaided decision 
 ³:H¶YHEHHQWDONLQJLQJHQHUal DERXW\RXUVLGHHIIHFWV,¶d now like to ask you what 
PDGH\RXVXVSHFWSDXVHWKDWWKHPHGLFLQHQDPHGGUXJKDGFDXVHGWKHVLGHHIIHFWV´ 
 ³6R\RXGHFLGHGWKHPHGLFLQHQDPHGGUXJKDGFDXVHGWKHVLGHHIIHFWEHFDXVH[[[´ (echo) 
,PSDFWRIVLGHHIIHFWRQdaily functioning ± 10 mins 
- Physical elements 
- Psychological elements 
- Social elements 
³1RZLI,FRXOGMXVWDVN\RXSDXVHWRWKLQNEDFNVRPHPRUHWRWKHWLPHWKDW\RXKDGWKLV
side effect(s)....would you say that the side effect(s) affected your daily life"´ 
 ³&RXOG\RXWHOOPHVRPHPRUHDERXWWKDW"´ (probing q) 
&RSLQJVWUDWHJLHV± 10 mins 
- Behaviours (action) 
- Social support 
³6RZH¶YHWDONHGDERXWWKHLPSDFWWKHVLGHHIIHFWVKDGRQWKHTXDOLW\RI\RXUGDLO\
OLIH,¶OGOLNHWRDVN\RXWRWKLQNEDFNDJDLn to the time that you had this side 
effect(s).......People who experience a side effect(s)....generally they deal with it in 
382 
 
many different ways......Could you tell me about what happened in your 
VLWXDWLRQKRZ\RXFRSHGZLWKWKLVVLGHHIIHFWV"´ 



























APPENDIX 12: MBSS scoring key 
Monitor/Blunter Style Scale  W Scoring Key 
1.    Vividly imagine that you are afraid of the dentist and have to get some dental work done.  
Which of the following would you do?  Check all of the statements that might apply to you. 
    M     I would ask the dentist exactly what work was going to be done. 
    B     I would take a tranquilizer or have a drink before going. 
    B     I would try to think about pleasant memories. 
    M     I would want the dentist to tell me when I would feel pain. 
    B     I would try to sleep. 
    M     I would watch all the dentist's movements and listen for the sound of the drill. 
    M     I would watch the flow of water from my mouth to see if it contained blood. 
    B     I would do mental puzzles in my mind. 
3.    Vividly imagine that, due to a large drop in sales, it is rumored that several people in your 
department at work will be laid off. Your supervisor has turned in an evaluation of your work for 
the past year.  The decision about lay-offs has been made and will be announced in several days.  
Check all of the statements that might apply to you. 
    M     I would talk to my fellow workers to see if they knew anything about what the  
            supervisor's evaluation of me said. 
    M     I would review the list of duties for my present job and try to figure out if I had fulfilled  
             them all. 
    B     I would go to the movies to take my mind off things 
  M     I would try to remember any arguments or disagreements I might have had that would   
            have resulted in the supervisor having a lower opinion of me 
    B     I would push all thoughts of being laid off out of my mind. 
    B     I would tell my spouse that I'd rather not discuss my chances of being laid off. 
    M     I would try to think which employees in my department the supervisor might have  
                        thought had done the worst job. 












APPENDIX 14: Interview notes 
Initial reflections on the interviews: 
Int1 Short interview ended at request of interviewee as was tired. 
Int2  Interview takes place in quiet apartment. Interviewee recalls SE experience in 
detail.  
Int3 Interview difficult as interviewee focused on her negative experiences with 
HCPs. 
Int4 Interview takes place in noisy surroundings. Interviewee recalls SE clearly 
and describes their impact on him.  
Int5 Interview takes place in quiet sitting room. Interviewee fully engaged 
throughout.  
Int6 Interview takes place in private house. Excellent rapport with interviewee. 
Int7 Interview takes place in quiet sitting room. Interviewee experiences chronic 
pain and talks in detail about his SE. 
Int8 Interview takes place in café so background noise throughout. Interviewee 
speaks in detail about his SE and coping strategies. 
Int9 Interviewee engaged with questions and was keen to share his experiences of 
both mild and severe SE. 
Int10 Good rapport established with interviewee. 
Int11 Interviewee was elderly with a soft voice. 
Int12 Interviewee engaged with questions and was keen to share her SE experiences. 
Int13 Interview takes place in quiet kitchen. Good rapport established and SE 
clearly described. 
Int14 Interview conducted in café so background noise on recording fluctuates. 
Good rapport established with interviewee. 
Int15 Interviewee engaged fully and was keen to share her SE experiences. Some 

















Title of Project: A study exploring how people identify and manage side effects from 
medicines. 
 
Name of Researcher (s):  ĞƌŶĂĚŝŶĞK ?ŽŶŽǀĂŶ ?ƌZ ?ZŽĚŐĞƌƐ ?ƌŽǆĂŶĚWƌŽĨĞƐƐ ƌ:
Krska. 
 
You are being invited to take part in a study. It is being carried out by the Medway School 
of Pharmacy, University of Kent and the University of Birmingham. You have been chosen 
because you have experienced side effect(s) from your medicine. Before you decide if you 
want to take part, you must understand why the study is being done and what it involves. 
Please take time to read the following information. Ask if anything is not clear or if you 
would like more information. Take time to decide if you want to take part or not. 
 
Why is the study being done?  
This ƐƚƵĚǇŝƐĚĞƐŝŐŶĞĚƚŽĞǆƉůŽƌĞƉĞŽƉůĞƐ ?ĞǆƉĞƌŝĞŶĐĞƐŽĨŝĚĞŶƚŝĨǇŝŶŐƐŝĚĞĞĨĨĞĐƚƐĨƌŽŵ
medicines and an assessment tool has been developed to help people do this. This study 
seeks to confirm the validity of this assessment tool.  
 
Do I have to take part? 
No. It is up to you to decide whether or not to take part. Even if you agree to take part, you 
can change your mind at any time without giving any reason. If you decide not to take part 
in the study, your legal rights will not be affected in any way.  
 
If I do take part, what would I have to do and what would be done to me? 
You will be invited via email to provide feedback on the assessment tool. If you decide you 
would like to do so, you will be sent a copy of the assessment tool by post with a consent 
form and a prepaid envelope. If you agree to take part, you will be asked to sign a consent 
form and return it to the Medway School of Pharmacy in the prepaid envelope. I will contact 
you and arrange a telephone interview at a time and date that suits you. The interview will 
take no more than 30 minutes and you can change your mind and end the interview at any 
time. During this interview I will ask you to review and comment on the assessment tool. I 
will also ask you for any suggestions you may have for its possible improvement. 
 
Are there any risks if I take part? 
The telephone interview will be conducted at a date and time which is convenient for you 
and it will take no more than 30 minutes. There are no risks to taking part in the study. 
 
 




Are there any benefits if I take part? 
If you are interviewed you will be offered a shopping voucher to the value of £10. 
tŝůůĂŶǇŽŶĞŬŶŽǁƚŚĂƚ/ ?ǀĞƚĂŬĞŶƉĂƌƚ ?
We will not tell anyone that you have taken part in the study.  
 
What will happen to the results? 
If you decide to take part in the interview, the information you provide will be treated in 
the strictest confidence in accordance with the Data Protection Act 1998 and used only 
for the purpose of arranging the interview. Consent forms will be scanned on an 
encrypted memory stick and will be held for no longer than 12 months after the 
completion of the project.  Research data will be securely stored in a secure filing cabinet 
and on password protected computers. All the data collected will be fully anonymised 
and digital records will be destroyed five years after the final report has been written. 
This project forms part of a larger PhD project, which will be published as a PhD thesis. A 
ĐŽƉǇŽĨƚŚŝƐƉƌŽũĞĐƚ ?ƐƌĞƉŽƌƚǁŝůůďĞƉƌŽĚƵĐĞĚĂŶĚĚŝƐƐĞŵŝŶĂƚĞĚƚŽƚŚĞDĞĚǁĂǇ^ĐŚŽŽůŽĨ
Pharmacy. The findings will also be disseminated through conferences, and in the writing 
of research papers. 




Who is Organising and Funding the study? 
This study is being carried out by students and staff at Medway School of Pharmacy.  It is 
being funded by the Medway School of Pharmacy, University of Kent.  
 
Who should I contact if I want to know more about the study? 
ĞƌŶĂĚŝŶĞK ?ŽŶŽǀĂŶ 
Medway School of Pharmacy 
Chatham Maritime 
Kent ME4 4TB 
Phone 0163420 Ext 2920 
Email bo77@kent.ac.uk 
 
Who should I contact if I have any concerns about the study or the way it has been 
conducted? 
If you have concerns about how this research study has been conducted please contact 
the Chair of the MSoP Research Ethics Committee on S.A.Corlett@kent.ac.uk 




This project has been looked at and approved by the MSoP Research Ethics Committee 









   
 
 
A study exploring how people identify and manage side effects from medicines. 
1DPHRIUHVHDUFKHU%HUQDGLQH2¶'RQRYDQ 
 
I have read and understand the information provided for the above 
study. I have had the opportunity to consider the information, ask 





I understand that my participation is voluntary and that I am free to 
withdraw at any time, without giving a reason and that this will not 






I understand that any personal information collected during the study 
will be anonymised and remain confidential 
 








Name of Participant (Print) 
 
 
Signature        Date 
 
Name of Researcher (Print) 
 
 
Signature        Date          
 
                Version 2.0 07/12/15 












APPENDIX 16: Online statement for AT 
Welcome, 
You are invited to WDNHSDUWLQDUHVHDUFKVWXG\ZKLFKORRNVDWSHRSOHV¶
experiences of identifying side effects from medicines. The research is conducted 
by the Medway School of Pharmacy and the University of Birmingham.  
 
This study will take approximately 15 minutes of your time. You will be asked to 
participate by completing an on-line survey about your experience of the 
suspected side effect(s). For questions where you are asked to describe your 
experience in your own words, the boxes will expand as you type. The survey will 
include questions which will help you to assess the event you suspect may be a 
side effect from a medicine (Side Effects - Patient Assessment Tool). 
 
You must be at least 18 years old and a UK resident to take this survey.  
The decision to participate in this research is voluntary. You do not have to 
participate and you may skip any questions you do not wish to answer. If you do 
not wish to complete this survey just close your browser. 
 
Your part in this study is anonymous to the researcher. However, because it is 
web based, by completing it you will leave behind an electronic record. Neither the 
researcher nor anyone else involved with this survey will be capturing this 
information. 
 
To find out more about the study please read the Participant Information Sheet 
which can be accessed on the following page. 
 
If you have any questions about this study, please feel free to contact Bernadine 
2¶'RQRYDQ0HGZD\6FKRRORI3KDUPDF\&KDWKDP0DULWLPH.HQW0(7%
Phone 0163420 Ext 2920, Email bo77@kent.ac.uk 
The study was approved by the Medway School of Pharmacy Research 
Ethics  Committee. If you have concerns about how this research study has been 
conducted please contact the Chair of this Committee: S.A.Corlett@kent.ac.uk 
 
By clicking on the Submit button at the end of the page you confirm that you have 
read and understand this page.   
  











































APPENDIX 19: Invitation email to potential assessors 
Mr X/Ms X 
My name is Bernadine O' Donovan and I am a PhD student at the Medway School of Pharmacy. I 
ŚĂǀĞƌĞĐĞŝǀĞĚǇŽƵƌĚĞƚĂŝůƐĨƌŽŵ ?ZĞƐĞĂƌĐŚƚĞĂŵŵĞŵďĞƌ ?s name] who has been in touch with you 
to let you know that I would be contacting you regarding our project. 
  
As you are aware we are ĞǆƉůŽƌŝŶŐƉĞŽƉůĞƐ ?ĞǆƉĞƌŝĞŶĐĞƐŽĨŝĚĞŶƚŝĨǇŝŶŐƐŝĚĞĞĨĨĞĐƚƐĨƌŽŵŵĞĚŝĐŝŶĞƐ
and an assessment tool has been developed to help people do this. This study seeks to confirm 
the validity of this assessment tool.  
 You are being invited to take part in a study, to provide feedback on the assessment tool. You have 
been chosen because you have experienced side effect(s) from your medicine. Before you decide if 
you want to take part, you must understand why the study is being done and what it involves. I 
have attached a Participant Information Sheet which provides this information. 
If you decide you would like to provide feedback on the tool, I will send you a copy of the assessment 
tool by post with a consent form and a prepaid envelope. If you agree to take part, you will be asked 
to sign a consent form and return it to the Medway School of Pharmacy in the prepaid envelope. I 
will contact you and arrange a telephone interview at a time and date that suits you. The interview 
will take no more than 30 minutes and you can change your mind and end the interview at any 
time. 
I will be in touch within the next few days to see whether you can help us. 
Thank you for reading this email. 
Regards  
Bernadine O' Donovan (PhD student) 















APPENDIX 20: Invitation email to patient support groups and organisations 
Dear Sir/Madam, 
DǇŶĂŵĞŝƐĞƌŶĂĚŝŶĞK ?ŽŶŽǀĂŶĂŶĚ/ĂŵĂƉŽƐƚŐƌĂĚƵĂƚĞƐƚƵĚĞŶƚĂƚƚŚĞDĞĚǁĂǇ
School of Pharmacy. I would like to invite XX to take part in a research study that is being 
carried out by the Medway School of Pharmacy, University of Kent and the University of 
Birmingham. 
dŚŝƐƌĞƐĞĂƌĐŚŝƐůŽŽŬŝŶŐĂƚƉĞŽƉůĞƐ ?ĞǆƉĞƌŝĞŶĐĞƐŽĨŝĚĞŶƚŝĨǇŝŶŐƐŝĚe effects from their 
medicine(s). We have developed an assessment tool to help people who suspect they 
may have experienced side effects. This assessment tool has been specially designed 
based on interviews with people who have had side effects from their medicine(s). At this 
stage of the research we would very much like to check if people find this assessment tool 
useful. 
I am aware that XX patients can experience problems with generic medication. 
Your website has the link to the Yellow Card Scheme, but some of your members may find 
our assessment tool helpful in clarifying their suspected side effect/effects.  
If XX is willing, we would like you to help us distribute a link to our anonymous online 
assessment tool through your website, for up to three months.  
Below is a link to the Side Effects - Patient Assessment Tool (SE - PAST) 
 https://msp.eu.qualtrics.com/SE/?SID=SV_8Jq61lhD9OoUPT7 
I hope that XX will consider posting this link on your website as it would greatly help our 
research. 
If you would like more information about this research you can contact me: 
ĞƌŶĂĚŝŶĞK ?ŽŶŽǀĂŶ ? 
Medway School of Pharmacy, 
Chatham Maritime 
Kent ME4 4TB 





























APPENDIX 22: ISAC application for access to YC data 
` 
 
ACCESS TO YELLOW CARD DATA  




Applicants must read the Access to Yellow Card Data Guidance Notes before completing 
this form. These notes give relevant advice on each individual question in the Access to 
Yellow Card Data application form, as well as the conditions of use which applicants will 




Undertakings by the MHRA in relation to information provided by applicants 
 
The information submitted on this form will be considered by the Independent Scientific Advisory 
Committee on MHRA database research (ISAC) established by the Medicines and Healthcare products 
Regulatory Agency (MHRA) to advise on applications for access to Yellow Card data. Any personal 
data provided in an application will be used only for statistical analysis, management, planning and 
in the provision of services by the MHRA. In accordance with the Data Protection Act 1998, the ISAC 
and the MHRA will respect the confidentiality of all personal information, but reserve the right to 
publish in an anonymous and unidentifiable form summary data about applications received (via the 
internet or in its annual report) for reference and audit purposes. 
 
Yellow Card data requests fall into the following categories: 
 
Category Ia ± Anonymised aggregated adverse drug reaction (ADR) data in the format 
of Drug Analysis Prints (DAPs). Drug Analysis Prints contain complete listings of all 
suspected adverse drug reactions or side effects, which have been reported to the MHRA 
via the Yellow Card Scheme. These are freely available from our website at 
www.mhra.gov.uk/daps 
 
Category Ib ± A list of data fields which exclude any information that can identify the 
patient and reporter and therefore can be released without the need for ISAC 
401 
 
consideration. A list of all the data fields that can be provided is given on the next page.  
Details of your request should be sent to Pharmacovigilanceservice@mhra.gsi.gov.uk 
 
Category II ± If you require more than the Ib data fields then your request will be classed 
as a category II request (see section D.2 for the list of category II data fields). Applicants 
should complete this form and then send to isacyellowcarddata@mhra.gsi.gov.uk 
 




Category I releasable data fields (Category Ib data) 
 
Category Ib data case details listed below are releasable under the Freedom of Information 
Act (FOIA) without consideration by the ISAC. These are known as Category Ib data. 
Provision of these data will depend on the number of cases held by the Agency. The MHRA 
will not release any data subset in which there are five or fewer cases per cell. This is 
necessary to prevent identification of patients and/or reporters. Where there are less than 
five cases per cell the data will be aggregated with adjacent cells. Any aggregation will be 
clearly marked on the dataset. 
 
Data fields 
Patient age categories 
Patient gender 
Suspect drug(s) 
Dose of suspect drug(s) 
Route of administration 
Duration of treatment 
Suspected adverse drug reaction(s) 
Adverse drug reaction outcome(s)  
Time to onset 
Past medical history 








For ISAC use only: 
Protocol Number: .......................... 
Date submitted: ............................. 
IMPORTANT 
If you have any queries, please contact ISAC 
Secretariat: isacyellowcarddata@mhra.gsi.gov.uk 
 
Section A ± Personal details 
A.1: Principal applicant (full name, job title, organisation, address, e-mail address for correspondence 
regarding this protocol) 
%HUQDGLQH2¶'RQRYDQ3K'VWXGHQW0HGZD\6Fhool of Pharmacy, Anson Building, Universities of 
Greenwich & Kent, Central Avenue, Chatham Maritime, Kent ME4 4TB.  
bo77@kent.ac.uk 
 
A.2: List of all co-applicants / collaborators (Please list the names, job title, organisation, address and 
email addresses of all collaborators) 
Professor Krska, Professor of Pharmacy Practice, Medway School of Pharmacy, The Universities of 
Greenwich and Kent, Central Avenue, Chatham ME4 4TB  
j.krska@kent.ac.uk 
 
Dr Rodgers, Senior Clinical Lecturer, Medway School of Pharmacy, The Universities of Greenwich and 
Kent, Central Avenue, Chatham ME4 4TB  
r.m.rodgers@kent.ac.uk 
 
Dr Cox, Lecturer in Clinical Pharmacy, Institute of Clinical Sciences, College of Medical and Dental 




Section B ± Title and summary of the proposal 
B.1: Title of proposal for use of Yellow Card data 
Investigation of Yellow CDUGUHSRUWVWRHYDOXDWHUHSRUWHUV¶XVHRILQIRUPDWLRQVRXUFHVSOXVRWKHUPHWKRGV
of identifying ADRs, and the impact of their experiences 
 
B.2: Name and address of the department / institution / place at which the research / analysis will be 
conducted 




B.3: Proposed start date 01/01/16                                Proposed duration (if known) 30/11/16 
 
Section C ± Use of other databases 
C.1 Are you intending to use Yellow Card data in combination with another database or other data 
sources1 (local, national, international or personal data archive).  
Yes    No   
If yes, please specify  
      
 
Section D ± Details of proposal 
D.1: Would your research involve contacting the reporter and/or patient via the MHRA? 
Yes    No   
If yes, please specify (Note you will need to include with your application any documentation to be 
provided to reporters/patients regarding the proposed research project (e.g. information sheets, 
invitations letters, consent forms) 
      
 
D.2: The main data fields that are usually provided as Category II are listed below. Only tick the fields 
that you require to meet the needs of the study. 
Data fields Yes No If yes give further details as 
necessary 
Patient age         
Patient gender         
Suspect drug(s)         
Dose of suspect drug(s)         
Route of administration         
Drug start / stop dates         
Indication for suspect drug         
Suspected adverse drug reaction(s)         
                                                          




Reaction outcome         
Reaction start / stop dates         
Reaction details (including description of 
reaction as provided by the reporter, action 
taken with the suspect drug as a result of the 
reaction) 
        
Test results         
Past medical history         
Previous drug history         
Other ± List any other fields you require Name of the drug(s) 
Where drug(s) were obtained 
Severity of the side effect  
Free text comments from 3 comment boxes 
    
 Yes No If yes, please give details 
D.3: Have you applied for or received ethical 
approval for your request? Please provide a 
copy of any ethics committee approval and 
the reference number.  
        
D.4: Is the proposal subject to any 
agreement with any academic, commercial or 
other organisations? 
        
D.5: Is the proposal likely to lead to any 
patentable or commercially exploitable 
results 
        
D.6: Do you consider that the consequences 
of your research may have implications for 
public health? 
  This research may have potential benefits 
for public health as it will offer important 
and useful insight into what information 
sources people may use in identifying 
$'5VDVZHOODVLQIRUPDWLRQRQSHRSOHV¶
experiences of side effects in general. 
 
Section E ± Relevant applications and publications 
 Yes No If yes, please give details 
E.1: Have you used Yellow Card data 
previously? 
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E.2: Is this application a resubmission of a 
previous application? 
        
E.3: Have you previously submitted other 
applications to the ISAC or its predecessor, 
the Interim Committee on Yellow Card Data? 
        
 
Section F ± Security & confidentiality 
F.1: Please confirm that you will abide by the principles of the DPA 1998 as detailed in the guidance notes 
on Applications for Access to Yellow Card Data 
Yes    No   
F.2: How long do you intend to retain the Yellow Card data? If longer than 12 month, please provide 
justification. 
Retention period of 5 years is proposed. This retention period is in line with University of Kent Research 
Data Management Policy. The UK Data Archive also supports a method of managing data based on a 
Research Data Lifecycle (http://www.data-archive.ac.uk/create-manage/life-cycle). This Lifecycle suggests 
that retaining data for extended periods can provide increased opportunities for future research.  
 
F.3: Please confirm all Yellow Card data provided will be confidentially and securely held on 
networks/laptops and that data will be appropriately destroyed once the research has been completed. 
(Please refer back to the guidance notes for further details) 
      Yes    No   
 
Section G ± Publication  
G.1: How do you intend to disseminate the findings and results of your proposal? Please specify  
In peer reviewed scientific journals, at relevant conferences and published as a PhD thesis. The findings 
will also submitted to the MHRA Group Manager of the Vigilance Intelligence and Research Group. Study 
results will uploaded to suitable research data repositories and also uploaded for public access to the Kent 
Academic Repository. The research will also be voluntarily registered with a suitable registry as 
epidemiological research which is utilising MHRA databases.  
The results of the study will also be disseminated to the public through presentations to the MHRA Patient 
and Public Engagement Expert Advisory Group (PPEEAG), the Medway School of Pharmacy public 
engagement group (Public Involvement in Pharmacy Studies Group; PIPS) and to the Patient Safety 
Congress 2016.   
 
G.2: Please confirm that you will submit any draft abstracts / papers / presentations or publications to the 
MHRA for necessary regulatory action and review at least four calendar weeks prior submission. 




Section H ± Relevant research history 
H.1: All applicants (principal and co-applicants) who will have access to any Yellow card data must list a 
brief summary of relevant research history. Any recent experience and/or publications which are of particular 
relevance to the current application should be highlighted. 
%HUQDGLQH2¶'RQRYDQ 
Experience in Masters level research involving qualitative and quantitative analysis of survey data  (MSc 
Cognitive Neuropsychology & MSc Neuropharmacology)  
See attached CV for additional information  
 
Professor Krska 
Member of research team in previous large study evaluating Yellow Card data 
See attached CV for additional information 
 
Dr Rodgers 
Research into use of information sources  
Research into public views on NHS services 
See attached CV for additional information 
 
Dr Cox 
Member of the Advisory group for UK Yellow Card study  
Senior pharmacist at the West Midlands Centre for Adverse Drug Reactions 
See attached CV for additional information 
 
 
Section I ± Supplementary Information 
I.1: If you have any comments on this application form please provide feedback: 
 
 
Section J ± Undertakings by the applicant(s) in relation to the application 
 
1. I confirm that I have read, understood and agreed to comply with the Data Protection Statement and 
the Guidance Notes on Applications for Access to Yellow Card Data (see annex B). 
2. I agree to use the data only for the intended purpose for which access was granted.  
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3. I will submit in writing any change to the proposed research methodology as soon as they are identified 
or communicated to me, and will await approval by ISAC before proceeding.  
4. I will submit in writing any amendment to the principal applicant and/or co-applicants to the MHRA for 
approval by ISAC. 
5. I understand data will only be provided if Yellow Card data is considered feasible for the research being 
conducted. 
6. I will submit any draft articles to the MHRA for approval at least four calendar weeks before submission. 
7. I will ensure that any Yellow Card data is maintained securely and confidentially at all times.  
8. I will inform the MHRA of any new drug safety issues identified at the time of recognition.   
9. I understand that I will be required to sign a contract detailing the terms under which the Yellow Card 
data is provided (including the conditions of release listed in section 2.2 of the Guidance Notes on 
Applications for Access to Yellow Card Data) before any data will be released by the MHRA. 

























Please also complete the following protocol check list on the next page to ensure all the 
necessary information has been included as part of your application. Then add your protocol 




PROTOCOL CONTENT CHECKLIST 
 
In order to help ensure that protocols submitted for review contain adequate information for protocol 
evaluation, ISAC have produced instructions on the content of protocols for research using Yellow 
Card data. Applicants must complete the checklist below to confirm that the protocol being submitted 
includes all the areas required by ISAC, or to provide justification where a required area is not 
considered to be relevant for a specific protocol.  Protocols will not be circulated to ISAC for review 
until the checklist has been completed by the applicant.  
 
 Included in 
protocol? 
 
Required area Yes No If no, reason for omission 
Lay Summary          
Objectives, specific aims and rationale         
Study Type (Descriptive, Hypothesis Generating 
Hypothesis Testing,) 
        
Study Design         
Statistical Analysis Plan (including how you will 
address missing data) 
        
Selection of any comparison group(s) or 
controls 
  No comparison group(s) or 
controls will be used 
Plans for contacting Yellow Card reporters 
(include information sheets, invitation letters, 
consent forms, copy of ethics committee 
approval letter, etc) 
  No plans for contacting 
Yellow Card reporters 
Patient group involvement   No patient group involvement 
Potential limitations of the study          
Plans for disseminating and communicating 
study results 
        
Relevant research history         
 
Voluntary registration of ISAC approved studies 
Epidemiological studies are increasingly being included in registries of research around the world, 
including those primarily set up for clinical trials. To increase awareness amongst researchers of 
ongoing research, ISAC encourages voluntary registration of epidemiological research conducted 
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using MHRA databases. This will not replace information on ISAC approved protocols that may be 
published in its summary minutes or annual report. It is for the applicant to determine the most 
appropriate registry for their study. Please inform the ISAC secretariat that you have registered a 
protocol and provide the location. 
 
 Please add your protocol here (aim for no more than 5 pages) 
   
Investigation of Yellow Card reports to evaluate ƌĞƉŽƌƚĞƌƐ ?use of information sources, plus 
other methods of identifying ADRs, and the impact of their experiences 
Research team: ĞƌŶĂĚŝŶĞK ?ŽŶŽǀĂŶ ?Professor J. Krska, Dr R. Rodgers and Dr A. Cox.  
Lay summary 
Side effects from medicines can have a significant negative impact on peoƉůĞƐ ?ĚĂŝůǇůŝǀĞƐ ?dŚŝƐ
impact can extend into many areas with physical, economic, social and/or psychological effects. 
This study is gathering information on how people identify and manage side effects, and is looking 
at the different types of information sources people may use to find out about side effects (e.g. 
pharmacists, patient information leaflets (PILs), the internet, family/friends).  
Around 2,000 people each year report their experience of a side effect to the Medicines & 
Healthcare products Regulatory Agency (MHRA), using Yellow Card reports. These Yellow Card 
reports allow people to describe in detail what happened to them, how it has impacted on their 
lives and how they managed the side effect. Some earlier work has shown that many people also 
describe how they came to realise the experience was a side effect and where they found 
information about it.  
The experiences which people who submit Yellow Cards is used by the MHRA in deciding whether 
ĂƐŝĚĞĞĨĨĞĐƚŚĂƐŽĐĐƵƌƌĞĚĂŶĚŝƚƐ ?ƐĞƌŝŽƵƐŶĞƐƐ ?,Žwever the MHRA does not conduct any in-depth 
ĂŶĂůǇƐŝƐŽĨƚŚĞ ?ƐŽŵĞƚŝŵĞƐůĞŶŐƚŚǇ ?ĚĞƐĐƌŝƉƚŝŽŶƐŽĨƌĞƉŽƌƚĞƌƐ ?ĞǆƉĞƌŝĞŶĐĞƐ ?tĞƉƌŽƉŽƐĞƚŽ
conduct an analysis of all the text written on Yellow Card reports (both paper and electronic 
reports) sent to the MHRA in the last year, to determine how people who report suspected side 
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effect have identified and managed them, the impact on their lives and the different types of 
information sources they have used. We will not have any personal details about the reporters or 
their doctors, so the text will all be anonymous. 
We have already carried out a study with members of the public to learn about how they identify 
and manage side effects and the impact of these, but we wish to find out whether the 
experiences of people who report their side effect to the MHRA are different in any way. This is 
ĂŶĞǆƉůŽƌĂƚŽƌǇƐƚƵĚǇǁŚŝĐŚǁŝůůĂůƐŽŚĞůƉƵƐƚŽƐĞĞŚŽǁŵƵĐŚǁĞĐĂŶůĞĂƌŶĂďŽƵƚƉĞŽƉůĞƐ ?
experiences of side effects by using Yellow Card reports.  
Background 
The large evaluation of patient reporting of adverse drug reactions (ADRs) to the Yellow Card 
Scheme ?ǁŚŝĐŚƌĞƉŽƌƚĞĚŝŶ ? ? ? ? ?ƌĞĐŽŵŵĞŶĚĞĚƚŚĂƚĨƵƚƵƌĞƌĞƐĞĂƌĐŚƐŚŽƵůĚ “ŝŶǀĞƐƚŝŐĂƚĞthe 
ďƵƌĚĞŶŽĨZƐŝŶƚĞƌŵƐŽĨŝŵƉĂĐƚŽŶƉĂƚŝĞŶƚƐ ?ůŝǀĞƐ ?ĂŶĚĞǀĂůƵĂte the extent to which ƉĂƚŝĞŶƚƐ ? 
views and experiences of the seriousness of ADRs concur with those of regulatory bodies, such as 
the MHRA ? ?ǀĞƌǇĞƚĂů ? ? ? ? ? ? ? 
 As part of a PhD study investigating the personal experiences and opinions of the general public 
in identifying and managing side effects from medication, I am exploring how people cope with 
and manage ADRs, the consequences of ADRs, in terms of use of medicines and impact on daily 
lives. In addition, this study is investigating different types of information sources people use to 
find out about ADRs (e.g. pharmacists, patient information leaflets (PILs), the internet, 
family/friends), factors contributing to the use of these different information sources and how 
they are used by people to inform their experiences of adverse drug reactions (ADRs). An output 
of this work is the development of a tool for patients to use to assist them in identifying potential 
ADRs, which could encourage reporting. Other such tools are in development elsewhere (De Vries 
et al., 2013; Jarernsiripornkul et al., 2015). 
It is well known that some ADRs ĐĂŶŚĂǀĞĐŽŶƐŝĚĞƌĂďůĞŶĞŐĂƚŝǀĞŝŵƉĂĐƚŽŶƉĞŽƉůĞƐ ?ĚĂŝůǇůŝǀĞƐ 
(Anderson et al., 2011; Anson, 2006; Butt et al., 2011; De Langen et al., 2008; Krska et al., 2011; 
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Shet et al., 2014). However relatively little is known about how people cope with and manage 
ADRs and the consequences of their experience for their future use of medicines, including the 
suspected medicine. The present study is using questionnaires distributed to patients using 
community pharmacies, followed by in-depth interviews with a sub-sample, to explore these 
questions, in addition to use of information sources on ADRs. 
Over 4,000 people, including parents and carers, submit Yellow Card reports to the MHRA 
annually. Free-text questions on YC reporting forms cover: symptoms and how the event 
happened; details of the outcome including use of medicines, and other relevant information. 
Previous work has shown that reporters to the Yellow Card Scheme may include information on 
their reports about how they identified ADRs, the information sources they use and the impact on 
their lives (Anderson et al., 2011; Krska et al., 2011).  However this study was able to utilise only a 
small, purposively selected sample of YCs involving only 4.4% of the YCs received during the study 
ƉĞƌŝŽĚ P ? ? ?ĐŽǀĞƌĞĚƚŚĞĨŝǀĞĚƌƵŐƐŵŽƐƚĐŽŵŵŽŶůǇƌĞƉŽƌƚĞĚďǇƉĂƚŝĞŶƚƐĂŶĚ ? ?ĐŽǀĞƌĞĚ ‘ďůĂĐŬ
ƚƌŝĂŶŐůĞ ?ĚƌƵŐƐ ?dŚĞĨƌĞĞ-text data were analysed qualitatively and were found to cover: a 
description of the problem, the impact of the adverse reaction on the patient, descriptions of the 
possible association between the drug and adverse effects, the patient's background medical 
history, actions taken by the patient and involvement of health professionals (Avery et al 2011). 
Given the small size and purposive selection of this sample, it is not known how many YC reports 
overall include information about how reporters identified ADRs or the impact of the ADR within 
free-text responses. An opportunity thus exists to study the free-text data on a larger, unselected 
sample of YC reports to determine the frequency with which reporters describe information 
sources used, the types of information sources, how these contribute to ADR identification and 
the consequences of ADRs.  
The previous study suggested that Yellow Card reports frequently provide explicit detail of the 
ĞĨĨĞĐƚƐŽĨZƐŽŶƚŚĞƉĂƚŝĞŶƚ ?ƐůŝĨĞ ?ĨĂŵŝůǇĂŶĚ ?ŽƌĐĂƌĞƌƐ ?ǁŚŝĐŚĐŽƵůĚďĞƵƐĞĚƚŽĐƌĞĂƚĞĂƌŝĐŚ
ŶĂƌƌĂƚŝǀĞ ?ĞŶĂďůŝŶŐĂĐŽŵƉƌĞŚĞŶƐŝǀĞƉŝĐƚƵƌĞŽĨĞĂĐŚŝŶĚŝǀŝĚƵĂů ?ƐĞǆƉĞƌŝĞŶĐĞƐŽĨƚŚĞŝƌR and 
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their subsequent use of medicines (Avery et al., 2011). The previous study also showed that both 
ƚŚĞƚŝŵŝŶŐŽĨĞǀĞŶƚƐĂŶĚŝŶĨŽƌŵĂƚŝŽŶƐŽƵƌĐĞƐǁĞƌĞŬĞǇĨĂĐƚŽƌƐŝŶĨůƵĞŶĐŝŶŐƌĞƉŽƌƚĞƌƐ ?ƐƵƐƉŝĐŝŽŶƐŽĨ
their ADR. A larger sample, depending on the data contained in the reporting forms, could not 
only confirm these findings, but also facilitate evaluation of the assessment tool currently in 
ĚĞǀĞůŽƉŵĞŶƚ ?/ŶĂĚĚŝƚŝŽŶ ?ƚŚĞĚĂƚĂŵĂǇƉƌŽǀŝĚĞŵŽƌĞƵƐĞĨƵůůĞĂƌŶŝŶŐĂďŽƵƚƌĞƉŽƌƚĞƌƐ ?ƵƐĞŽĨ
information sources in general. A large study of YC data is thus warranted. 
Evaluating the free-text and other content of a large sample of YC reports will not only provide an 
overall picture of the type of data and its potential value, it will also permit a comparison to be 
made between YC reporters and the wider general public, recruited through the survey currently 
ƵŶĚĞƌǁĂǇ ?K ?ŽŶŽǀĂŶĞƚĂů ? ?ƵŶƉƵďůŝƐŚĞĚĚĂƚĂ ? ?dŚĞƉŽƐƐŝďŝůŝƚǇĞǆŝƐƚƐƚŚĂƚŵĂŶǇzƌĞƉŽƌƚĞƌƐ
may have a higher educational level than the general population, therefore may differ in how they 
identify or manage ADRs (McLernon et al., 2011). 
 Aim: 
The aim of this study is to investigate the value of YC reports in determining how people use 




 To determine the different sources of information used by YC reporters in finding 
out about ADRs and their perceived value for this purpose.  
 7RDVVHVVWKHLPSDFWRI$'5VRQSHRSOHV¶GDLO\OLYHVDQGWKHFRQVHTXHQFHVRI
ADRs on medicines use in a large sample of YC reporters. 
 To confirm the methods used by a large sample of YC reporters to identify ADRs.  
 To compare use of information sources and impact of ADRs among YC reporters 





This study will involve the analysis of both free-text comments and responses to closed questions 
derived from a large sample of Yellow Card data. It will thus use both qualitative and quantitative 
analysis. As a study primarily involving analysis of free-text data using qualitative and semi-
quantitative methods, it is seeking to generate hypotheses about the information sources 
reporters use, how they are used and the impact of ADRs on their daily lives. It will seek to 
determine the extent to which different information is included by YC reporters on reporting 
forms and the potential usefulness of these data in addressing the objectives. 
Methodology: 
Yellow Card data 
This project will require access to a sample of recent patient reports to the Yellow Card Scheme. It 
will analyse all patient reports submitted to the scheme over a 6 month period  W estimated at a 
sample size of approx. 2000 reports. MHRA staff will extract and clean the YC data. This data will 
then be delivered in a passport protected CD format for analysis. Category II data fields are required 
for this study and a Category II request will be made to the ISAC. All data fields listed in Section D.2 
of the ISAC application form except test results are required for this study. Additional details are 
also required from Sections 1, 2 and 3 of the Yellow Card report, which will include all responses to 




Table 1: Required data fields 
Patient age Reaction outcomes 
Patient gender Reaction start/stop dates 
Suspect drug(s) Reaction details 




The research methodology will not utilise controls or comparison groups. There are no plans for 
contacting Yellow Card reporters as part of this research. 
Inclusion criteria for Yellow Card data 
ඵ Yellow Card reports from the general public. 
ඵ Yellow card reports generated from July  W December 2015. 
ඵ Yellow card data fields as specified above. 
Data Analysis 
The Yellow Card data will be transferred into SPSS and checked using simple frequencies to assess 
completeness of all data fields, remove any duplicate cases, detect and remove any errors and 
inconsistencies and ensure missing data are accounted for. The cleaned data will be subjected to 
both qualitative and quantitative analysis. Content analysis will be used to code the free-text 
responses and identify points of commonality, in addition to a semi-quantitative analysis of coded 
data. For the latter, free-text responses will be analysed using Excel to develop a coding frame as 
follows: two researchers will initially independently read 100 different responses to identify and 
agree emergent themes, these will be used to code a further 100 responses, to determine the 
need for further themes, then the final agreed themes will be used to code the entire dataset, by 
two researchers independently ensuring there is reliability in the coding process. Any 
Route of administration Previous drug history 
Drug start/stop dates Other: Where drug(s) were obtained 
Severity of the side effect 
Suspected adverse drug reaction(s) Other: Full free text comments provided in 
response to questions covering: symptoms 
and how it happened, more details of the 
outcome, any other relevant information. 
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discrepancies will be discussed and agreed. This method has been used previously for quantitative 
analysis of free-text responses to questionnaires from YC reporters (Avery et al., 2011).   
Secondly, the data management program NVivo will be used to further analyse the free-text 
responses from individual reporters qualitatively, combining them with responses to closed 
questions, to create narratives of individual experiences, which can then be subjected to 
phenomenological analysis. 
 The quantitative data from responses to closed questions within the YC reports will be analysed 
using SPSS software. Descriptive statistics will be generated covering suspect drug, indication, 
whether or not stopped after the ADR, reported seriousness and outcome, in relation to age and 
gender. It is our intention to also combine the categorised free-text data with these data, 
depending on the information available within the free-text responses. This will potentially enable 
an analysis of the information sources used, methods used to identify ADR and its impact in 
relation to suspect drug, indication, whether stopped, reported seriousness and outcome.  
Ethical considerations  
We believe that accessing anonymised Yellow Card data can be considered of minimal risk. We 
wilůŶŽƚďĞƐĞĞŬŝŶŐĂŶǇŝŶĨŽƌŵĂƚŝŽŶĂďŽƵƚƚŚĞƌĞƉŽƌƚĞƌŽƌƚŚĞƌĞƉŽƌƚĞƌ ?ƐĚŽĐƚŽƌ ? 
The Research Ethics and Governance Officer at the University of Kent has been consulted in 
relation to ethical approval for this study. Her opinion is that as the data will be anonymised, the 
study does not require ethical approval. Access to this data will be limited to named members of 
the research team (the Principal applicant and co-applicants. The Yellow Card data will be safely 
stored on university computers and memory sticks which are password protected. The Yellow 
Card data will be extracted and cleaned by MHRA staff  and passed to us in passport protected CD 
format for analysis. These digital records will be retained for five years after the final report has 
been written and subsequently securely destroyed. The data will be retained for this period of 
time in keeping with University of Kent Research Data Management Policy. University of Kent 
policies covering the management of research data support the retention of data for public 
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consultation and re-use. The Research Data Management Policy supports data archiving principles 
and therefore it is anticipated that the data will be placed in suitable repositories. DataCite the 
global registry of research data repositories will provide a list of suitable repositories. In line with 
University of Kent policy once uploaded to a recommended repository the data will be linked to 
the Kent Academic Repository. 
Potential limitations 
As indicated, at present little is known about the overall content of material available in free-text 
sections of YC reports, other than was reported in a previous, small study, involving only 230, 
purposively selected reports (Krska et al., 2011). Our analysis plan must therefore be subject to 
the availability of the data. We propose to use methods similar to those used in previous work, 
but may need to adapt these, depending on the amount and type of written data obtained. 
Regardless of the eventual detailed analysis, the study will provide learning about the potential 
value of free-text data available on patient reporting forms, both for future research and for use 
by the MHRA in their own analyses. 
Dissemination 
The results of the study will be reported and disseminated in peer reviewed scientific journals, 
(such as Drug Safety, Pharmacoepidemiology and Drug Safety) at relevant conferences (such as 
ISPE) and published within a PhD thesis, available electronically from the University of Kent. Study 
results will be uploaded to a recommended repository. A list of suitable research data repositories 
will therefore be generated via DataCite. In line with University of Kent policy once uploaded to a 
recommended repository the data will also be uploaded for public access to the Kent Academic 
Repository. The findings will also be submitted to Mick Foy, Group Manager of the Vigilance 
Intelligence and Research Group at the MHRA. The research will also be voluntarily registered 
with a suitable registry as epidemiological research which is utilising MHRA databases. The results 
of the study will also be disseminated to the public through presentations to the MHRA Patient 
and Public Engagement Expert Advisory Group (PPEEAG), the Medway School of Pharmacy public 
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engagement group (Public Involvement in Pharmacy Studies Group; PIPS) and to the Patient 
Safety Congress 2016.   
Relevant research experience  
I have previous experience at Masters and undergraduate level of conducting research 
projects.As part of these projects I have distributed screening questionnaires, recruited and 
debriefed participants as well as conducting in-depth interviews, focus groups and telephone 
interviews. I have previously worked on research studies which required the analysis of both 
quantitative and qualitative data. I also have experience of presenting my research to lay 
audiences in an uncomplicated and understandable manner. My co-applicants have considerable 
relevant research experience in the general area of ADRs and in particular in direct patient 
reporting. Prof Krska was part of the team which conducted a large evaluation of patient 
reporting of ADRs through the UK's Yellow Card Scheme. Dr Anthony Cox was a member of the 
Advisory group for this large study and is also senior pharmacist at the West Midlands Centre for 
Adverse Drug Reactions. Both have investigated patient experiences of NHS healthcare services 
and the impact of ADRs on patients and their views on reporting. Dr Ruth Rodgers has conducted 
research into public views of NHS services and use of information sources. These histories are 
outlined in Section H of the ISAC application form and also in supporting documents (see 
summary CVs for Principal and Co-applicants). 
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Once your application is complete please email this along with any other relevant 
documents to the following mailbox  
isacyellowcarddata@mhra.gsi.gov.uk 
 
 
 
 
